US20220298254A1 - Cd47 antigen-binding molecules - Google Patents

Cd47 antigen-binding molecules Download PDF

Info

Publication number
US20220298254A1
US20220298254A1 US16/760,899 US201816760899A US2022298254A1 US 20220298254 A1 US20220298254 A1 US 20220298254A1 US 201816760899 A US201816760899 A US 201816760899A US 2022298254 A1 US2022298254 A1 US 2022298254A1
Authority
US
United States
Prior art keywords
amino acid
acid sequence
seq
region
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US16/760,899
Inventor
Jerome Douglas Boyd-Kirkup
Dipti Thakkar
Piers Ingram
Zhihao Wu
Konrad Paszkiewicz
Peter BRAUER
Siyu Guan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hummingbird Bioscience Holdings Ltd
Original Assignee
Hummingbird Bioscience Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1718101.7A external-priority patent/GB201718101D0/en
Priority claimed from GBGB1720425.6A external-priority patent/GB201720425D0/en
Priority claimed from GBGB1720426.4A external-priority patent/GB201720426D0/en
Application filed by Hummingbird Bioscience Holdings Ltd filed Critical Hummingbird Bioscience Holdings Ltd
Assigned to HUMMINGBIRD BIOSCIENCE HOLDINGS PTE. LTD. reassignment HUMMINGBIRD BIOSCIENCE HOLDINGS PTE. LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BRAUER, PETER, INGRAM, Piers, GUAN, Siyu, BOYD-KIRKUP, Jerome, DIPTI, THAKKAR, PASZKIEWICZ, Konrad, WU, Zhihao
Assigned to Hummingbird Bioscience Holdings Limited reassignment Hummingbird Bioscience Holdings Limited CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: HUMMINGBIRD BIOSCIENCE HOLDINGS PTE. LTD.
Assigned to Hummingbird Bioscience Pte. Ltd. reassignment Hummingbird Bioscience Pte. Ltd. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: Hummingbird Bioscience Holdings Limited
Publication of US20220298254A1 publication Critical patent/US20220298254A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

Definitions

  • the present invention relates to the fields of molecular biology, more specifically antibody technology.
  • the present invention also relates to methods of medical treatment and prophylaxis.
  • CD47 is the “don't-eat-me” signal and is ubiquitously expressed on normal cells where binding to SIRP ⁇ on macrophages inhibits phagocytosis. CD47 is commonly over-expressed in tumors where it correlates with immune evasion and poor prognosis. Blocking CD47-SIRPalpha interaction restores macrophage phagocytosis of tumor cells and anti-CD47 mAbs have shown anti-tumor efficacy in mouse models of solid tumors and hematological malignancies.
  • WO 2014/087248 A2 discloses monospecific anti-CD47 antibodies having an affinity for human CD47 as high as ⁇ 23.6 nM.
  • the high-affinity CD47 antibodies disclosed therein induce substantial hemagglutination (see e.g. Example 8 of WO 2014/087248 A2).
  • the present invention provides an antigen-binding molecule, optionally isolated, which is capable of binding to CD47.
  • an antigen-binding molecule optionally isolated, which is capable of binding to CD47 in extracellular region 1.
  • the antigen-binding molecule is capable of binding to the V-type Ig-like domain of CD47. In some embodiments the antigen-binding molecule is capable of binding to a polypeptide comprising or consisting of the amino acid sequence shown in SEQ ID NO:9. In some embodiments the antigen-binding molecule is capable of inhibiting interaction between CD47 and SIRP ⁇ . In some embodiments the antigen-binding molecule is capable of increasing phagocytosis of CD47-expressing cells.
  • the antigen-binding molecule is capable of binding to a peptide or polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO:21. In some embodiments the antigen-binding molecule comprises:
  • the antigen-binding molecule is capable of binding to a peptide or polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO:22.
  • the present invention provides an antigen-binding molecule, optionally isolated, comprising (i) an antigen-binding molecule according to the invention, and (ii) an antigen-binding molecule capable of binding to an antigen other than CD47.
  • the antigen-binding molecule is capable of binding to cells expressing CD47 at the cell surface.
  • the antigen-binding molecule is capable of inhibiting interaction between CD47 and SIRP ⁇ .
  • the antigen-binding molecule is capable of increasing phagocytosis of CD47-expressing cells.
  • the present invention provides a chimeric antigen receptor (CAR) comprising an antigen-binding molecule according to the invention.
  • CAR chimeric antigen receptor
  • the present invention provides a nucleic acid, or a plurality of nucleic acids, optionally isolated, encoding an antigen-binding molecule or a CAR according to the invention.
  • the present invention provides an expression vector, or a plurality of expression vectors, comprising a nucleic acid or a plurality of nucleic acids according to the invention.
  • the present invention provides a cell comprising an antigen-binding molecule, a CAR, a nucleic acid or a plurality of nucleic acids, or an expression vector or a plurality of expression vectors according to the invention.
  • the present invention provides a method comprising culturing a cell comprising a nucleic acid or a plurality of nucleic acids, or an expression vector or a plurality of expression vectors according to the invention, under conditions suitable for expression of the antigen-binding molecule or CAR from the nucleic acid(s) or expression vector(s).
  • the present invention provides a composition comprising an antigen-binding molecule, a CAR, a nucleic acid or a plurality of nucleic acids, an expression vector or a plurality of expression vectors, or a cell according to the invention.
  • the present invention provides an antigen-binding molecule, a CAR, a nucleic acid or a plurality of nucleic acids, an expression vector or a plurality of expression vectors, a cell, or a composition according to the invention for use in a method of medical treatment or prophylaxis.
  • the present invention provides an antigen-binding molecule, a CAR, a nucleic acid or a plurality of nucleic acids, an expression vector or a plurality of expression vectors, a cell, or a composition according to the invention for use in a method of treatment or prevention of a cancer.
  • the present invention provides the use of an antigen-binding molecule, a CAR, a nucleic acid or a plurality of nucleic acids, an expression vector or a plurality of expression vectors, a cell, or a composition according to the invention in the manufacture of a medicament for use in a method of treatment or prevention of a cancer.
  • the present invention provides a method of treating or preventing a cancer, comprising administering to a subject a therapeutically or prophylactically effective amount of an antigen-binding molecule, a CAR, a nucleic acid or a plurality of nucleic acids, an expression vector or a plurality of expression vectors, a cell, or a composition according to the invention.
  • the present invention provides a method for increasing phagocytosis of CD47-expressing cells, comprising contacting CD47-expressing cells with an antigen-binding molecule according to the invention.
  • the present invention provides an in vitro complex, optionally isolated, comprising an antigen-binding molecule according to the invention bound to CD47.
  • the present invention provides a method comprising contacting a sample containing, or suspected to contain, CD47 with an antigen-binding molecule according to the invention, and detecting the formation of a complex of the antigen-binding molecule with CD47.
  • the present invention provides a subject for treatment with a CD47-targeted agent, the method comprising contacting, in vitro, a sample from the subject with an antigen-binding molecule according to the invention and detecting the formation of a complex of the antigen-binding molecule with CD47.
  • the present invention provides the use of an antigen-binding molecule according to the invention as an in vitro or in vivo diagnostic or prognostic agent.
  • the cancer is selected from: a hematologic malignancy, a myeloid hematologic malignancy, a lymphoblastic hematologic malignancy, myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma (NHL), multiple myeloma (MM), bladder cancer, brain cancer, glioblastoma, ovarian cancer, breast cancer, colon cancer, liver cancer, hepatocellular carcinoma, prostate cancer, lung cancer, Non-small Cell Lung Cancer (NSCLC), skin cancer and melanoma.
  • MDS myelodysplastic syndrome
  • AML acute myeloid leukemia
  • CML chronic myeloid leukemia
  • ALL acute lymphoblastic leukemia
  • NHL non-Hodgkin's lymphoma
  • MM multiple myeloma
  • bladder cancer brain cancer, gli
  • the present invention provides antigen-binding molecules having combinations of desirable biophysical and/or functional properties as compared to antigen-binding molecules disclosed in the prior art.
  • aspects of the present invention relate to antigen-binding molecules capable of binding to CD47.
  • antigen-binding molecules which bind to human CD47 with high affinity, which are cross-reactive with non-human primate CD47, and which display potent inhibition of interaction between CD47 and SIRP ⁇ .
  • the antigen-binding molecules described herein bind to CD47 with greater affinity than prior art anti-CD47 antibodies, and are more potent as a CD47-targeted therapeutic agents.
  • the antigen-binding molecules described herein bind to a particular epitope of CD47 that provides for more effective inhibition of the interaction between CD47 and SIPR ⁇ as compared to prior art anti-CD47 antibodies.
  • the antigen-binding molecules described herein are thus more effective at enhancing phagocytosis of cells expressing CD47 than prior art anti-CD47 antibodies.
  • Human CD47 (also known as IAP, MERG and OA3) is the protein identified by UniProt Q08722. Alternative splicing of mRNA encoded by the human CD47 gene yields four isoforms which differ in the sequence of the C-terminal cytoplasmic tail region: isoform OA3-323 (UniProt: Q08722-1, v1; SEQ ID NO:1); isoform OA3-293 (UniProt: Q08722-2; SEQ ID NO:2), which lacks the amino acid sequence corresponding to positions 293 to 323 of SEQ ID NO:1; isoform OA3-305 (UniProt: Q08722-3; SEQ ID NO:3), which comprises the substitutions K304N and A305N relative to SEQ ID NO:1, and which lacks the amino acid sequence corresponding to positions 306 to 323 of SEQ ID NO:1; and isoform OA3-312 (UniProt: Q08722-4; SEQ ID NO:4), which lacks the amino
  • the N-terminal 18 amino acids of SEQ ID NOs:1 to 4 constitute a signal peptide, and so the mature form of isoforms OA3-323, OA3-293, OA3-305 and OA3-312 (i.e. after processing to remove the signal peptide) have the amino acid sequences shown in SEQ ID NOs:5 to 8, respectively.
  • CD47 The structure and function of CD47 is reviewed e.g. in Sick et al., Br J Pharmacol. (2012) 167(7): 1415-1430 and Willingham et al. Proc Natl Acad Sci USA. (2012) 109(17): 6662-6667, both of which are hereby incorporated by reference in its entirety.
  • CD47 is a ubiquitously-expressed ⁇ 50 kDa multi-pass membrane receptor that belongs to the immunoglobulin superfamily, comprising an N-terminal extracellular region (SEQ ID NO:10) having a V-type Ig-like domain (SEQ ID NO:9), five transmembrane domains (SEQ ID NOs:11, 13, 15, 17 and 19), and a short C-terminal intracellular tail (SEQ ID NO:20).
  • CD47 is involved in cell-to-cell communication through ligating to the transmembrane signal-regulatory proteins (SIRPs) SIRP ⁇ and SIRP ⁇ and integrins (e.g. ⁇ v ⁇ 3 integrin), and also mediates cell-extracellular matrix interactions through binding to thrombospondin-1 (TSP-1).
  • SIRPs transmembrane signal-regulatory proteins
  • integrins e.g. ⁇ v ⁇ 3 integrin
  • TSP-1 thrombospondin-1
  • CD47 is the ligand for SIRP ⁇ , which expressed on macrophages and dendritic cells. Binding of CD47 to SIRP ⁇ on the surface of phagocytic cells, triggers SIRP ⁇ ITIM signalling, inhibiting phagocytosis of the CD47 expressing cell.
  • CD47 is a multi-pass transmembrane protein, whereas SIRP ⁇ consists of 4 extracellular domains and an intracellular ITIM-domain. The terminal V-set domain of SIRP ⁇ interacts with the Ig V-like domain of CD47.
  • SIRP ⁇ Upon binding CD47, SIRP ⁇ initiates a signalling cascade that results in the inhibition of phagocytosis of the CD47-expressing cell.
  • This “don't eat me” signal is transmitted by phosphorylation by Src kinases of immunoreceptor tyrosine-based inhibitor motifs (ITIMs) in the cytoplasmic domain of SIRP ⁇ .
  • ITIMs immunoreceptor tyrosine-based inhibitor motifs
  • SH2 Src homology-2
  • SHP-1 and SHP-2 blocks phagocytosis, potentially through preventing the accumulation of myosin-IIA at the phagocytic synapse.
  • Disrupting the interaction along the antiparallel beta sheets of CD47 prevents downstream ITIM-mediated signalling, enabling phagocytes to ‘eat’ and destroy cancer cells.
  • CD47 expression/activity is implicated in the development and progression of many cancers, and accumulating evidence suggests that cell-surface expression of CD47 is a common mechanism by which cancer cells protect themselves from phagocytosis.
  • CD47 refers to CD47 from any species and includes CD47 isoforms, fragments, variants or homologues from any species.
  • a “fragment”, “variant” or “homologue” of a protein may optionally be characterised as having at least 60%, preferably one of 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of the reference protein (e.g. a reference isoform).
  • fragments, variants, isoforms and homologues of a reference protein may be characterised by ability to perform a function performed by the reference protein.
  • a “fragment” generally refers to a fraction of the reference protein.
  • a “variant” generally refers to a protein having an amino acid sequence comprising one or more amino acid substitutions, insertions, deletions or other modifications relative to the amino acid sequence of the reference protein, but retaining a considerable degree of sequence identity (e.g. at least 60%) to the amino acid sequence of the reference protein.
  • An “isoform” generally refers to a variant of the reference protein expressed by the same species as the species of the reference protein (e.g. OA3-323, OA3-293, OA3-305 and OA3-312 are all isoforms of one another).
  • a “homologue” generally refers to a variant of the reference protein produced by a different species as compared to the species of the reference protein.
  • human CD47 isoform OA3-323 (Q08722-1, v1; SEQ ID NO:1) and Rhesus macaque CD47 (UniProt: F7F5Y9-1, v2; SEQ ID NO:117) are homologues of one another.
  • Homologues include orthologues.
  • a “fragment” of a reference protein may be of any length (by number of amino acids), although may optionally be at least 25% of the length of the reference protein (that is, the protein from which the fragment is derived) and may have a maximum length of one of 50%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the length of the reference protein.
  • a fragment of CD47 may have a minimum length of one of 10, 20, 30, 40, 50, 100, 150, 200, 250 or 300 amino acids, and may have a maximum length of one of 20, 30, 40, 50, 100, 150, 200, 250 or 300 amino acids.
  • the CD47 is CD47 from a mammal (e.g. a primate (rhesus, cynomolgous, non-human primate or human) and/or a rodent (e.g. rat or murine) CD47).
  • Isoforms, fragments, variants or homologues of CD47 may optionally be characterised as having at least 70%, preferably one of 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of an immature or mature CD47 isoform from a given species, e.g. human.
  • Isoforms, fragments, variants or homologues may optionally be functional isoforms, fragments, variants or homologues, e.g. having a functional property/activity of the reference CD47 (e.g. human CD47 isoform OA3-323), as determined by analysis by a suitable assay for the functional property/activity.
  • an isoform, fragment, variant or homologue of CD47 may display association with one or more of: SIRP ⁇ , SIRP ⁇ , TSP-1 and ⁇ v ⁇ 3 integrin.
  • the CD47 comprises, or consists of, an amino acid sequence having at least 70%, preferably one of 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to one of SEQ ID NOs:1 to 8.
  • a fragment of CD47 comprises, or consists of, an amino acid sequence having at least 70%, preferably one of 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to one of SEQ ID NOs:9 or 10.
  • CD47 is an attractive therapeutic target.
  • CD47 is usually expressed on the surface of normal healthy cells and migrating hematopoietic stem cells to prevent phagocytosis, and is upregulated in nearly all hematological and solid tumors, to evade immune surveillance and escape phagocytosis. Disrupting the interaction between CD47 and SIRP ⁇ enables phagocytes to “eat” and destroy cancer cells.
  • CD47 blockade repolarises tumor-associated macrophages into a pro-inflammatory, anti-tumor state, and clearance of malignant cells by phagocytic cells offers an additional route for neo-antigen presentation to adaptive immune system.
  • the present invention provides antigen-binding molecules capable of binding to CD47.
  • an “antigen-binding molecule” refers to a molecule which is capable of binding to a target antigen, and encompasses monoclonal antibodies, polyclonal antibodies, monospecific and multispecific antibodies (e.g., bispecific antibodies), and antibody fragments (e.g. Fv, scFv, Fab, scFab, F(ab′) 2 , Fab 2 , diabodies, triabodies, scFv-Fc, minibodies, single domain antibodies (e.g. VhH), etc.), as long as they display binding to the relevant target molecule(s).
  • monospecific and multispecific antibodies e.g., bispecific antibodies
  • antibody fragments e.g. Fv, scFv, Fab, scFab, F(ab′) 2 , Fab 2 , diabodies, triabodies, scFv-Fc, minibodies, single domain antibodies (e.g. VhH), etc.
  • the antigen-binding molecule of the present invention comprises a moiety or moieties capable of binding to a target antigen(s).
  • the moiety capable of binding to a target antigen comprises an antibody heavy chain variable region (VH) and an antibody light chain variable region (VL) of an antibody capable of specific binding to the target antigen.
  • the moiety capable of binding to a target antigen comprises or consists of an aptamer capable of binding to the target antigen, e.g. a nucleic acid aptamer (reviewed, for example, in Zhou and Rossi Nat Rev Drug Discov. 2017 16(3):181-202).
  • the moiety capable of binding to a target antigen comprises or consists of a antigen-binding peptide/polypeptide, e.g. a peptide aptamer, thioredoxin, monobody, anticalin, Kunitz domain, avimer, knottin, fynomer, atrimer, DARPin, affibody, nanobody (i.e. a single-domain antibody (sdAb)) affilin, armadillo repeat protein (ArmRP), OBody or fibronectin—reviewed e.g. in Reverdatto et al., Curr Top Med Chem.
  • a antigen-binding peptide/polypeptide e.g. a peptide aptamer, thioredoxin, monobody, anticalin, Kunitz domain, avimer, knottin, fynomer, atrimer, DARPin, affibody, nanobody (i.e. a single-domain
  • the antigen-binding molecules of the present invention generally comprise an antigen-binding domain comprising a VH and a VL of an antibody capable of specific binding to the target antigen.
  • the antigen-binding domain formed by a VH and a VL may also be referred to herein as an Fv region.
  • An antigen-binding molecule may be, or may comprise, an antigen-binding polypeptide, or an antigen-binding polypeptide complex.
  • An antigen-binding molecule may comprise more than one polypeptide which together form an antigen-binding domain.
  • the polypeptides may associate covalently or non-covalently.
  • the polypeptides form part of a larger polypeptide comprising the polypeptides (e.g. in the case of scFv comprising VH and VL, or in the case of scFab comprising VH-CH1 and VL-CL).
  • An antigen-binding molecule may refer to a non-covalent or covalent complex of more than one polypeptide (e.g. 2, 3, 4, 6, or 8 polypeptides), e.g. an IgG-like antigen-binding molecule comprising two heavy chain polypeptides and two light chain polypeptides.
  • polypeptide e.g. 2, 3, 4, 6, or 8 polypeptides
  • IgG-like antigen-binding molecule comprising two heavy chain polypeptides and two light chain polypeptides.
  • the antigen-binding molecules of the present invention may be designed and prepared using the sequences of monoclonal antibodies (mAbs) capable of binding to CD47.
  • Antigen-binding regions of antibodies such as single chain variable fragment (scFv), Fab and F(ab′)2 fragments may also be used/provided.
  • An “antigen-binding region” is any fragment of an antibody which is capable of binding to the target for which the given antibody is specific.
  • Antibodies generally comprise six complementarity-determining regions CDRs; three in the heavy chain variable (VH) region: HC-CDR1, HC-CDR2 and HC-CDR3, and three in the light chain variable (VL) region: LC-CDR1, LC-CDR2, and LC-CDR3.
  • the six CDRs together define the paratope of the antibody, which is the part of the antibody which binds to the target antigen.
  • VH region and VL region comprise framework regions (FRs) either side of each CDR, which provide a scaffold for the CDRs.
  • FRs framework regions
  • VH regions comprise the following structure: N term-[HC-FR1]-[HC-CDR1]-[HC-FR2]-[HC-CDR2]-[HC-FR3]-[HC-CDR3]-[HC-FR4]-C term; and VL regions comprise the following structure: N term-[LC-FR1]-[LC-CDR1]-[LC-FR2]-[LC-CDR2]-[LC-FR3]-[LC-CDR3]-[LC-FR4]-C term.
  • the CDRs and FRs of the VH regions and VL regions of the antibody clones described herein were defined according to the international IMGT (ImMunoGeneTics) information system (LeFranc et al., Nucleic Acids Res. (2015) 43 (Database issue):D413-22), which uses the IMGT V-DOMAIN numbering rules as described in Lefranc et al., Dev. Comp. Immunol. (2003) 27:55-77.
  • the antigen-binding molecule comprises the CDRs of an antigen-binding molecule which is capable of binding to CD47. In some embodiments, the antigen-binding molecule comprises the FRs of an antigen-binding molecule which is capable of binding to CD47. In some embodiments, the antigen-binding molecule comprises the CDRs and the FRs of an antigen-binding molecule which is capable of binding to CD47. That is, in some embodiments the antigen-binding molecule comprises the VH region and the VL region of an antigen-binding molecule which is capable of binding to CD47.
  • the antigen-binding molecule comprises a VH region and a VL region which is, or which is derived from, the VH/VL region of a CD47-binding antibody clone described herein (i.e. anti-CD47 antibody clones 1-1-A1_BM, 1-1-A1, 5-48-A6, 5-48-D2, 11A1H1, 11A1H2, 11A1H3, 11A1H4, 11A1H5, 11A1H6, 11A1H7, 11A1H8, 11A1H9, 11A1H10 or 11A1H11).
  • a CD47-binding antibody clone described herein i.e. anti-CD47 antibody clones 1-1-A1_BM, 1-1-A1, 5-48-A6, 5-48-D2, 11A1H1, 11A1H2, 11A1H3, 11A1H4, 11A1H5, 11A1H6, 11A1H7, 11A1H8, 11A1H9, 11A1H10 or
  • the antigen-binding molecule comprises a VH region according to one of (1) to (4) below:
  • the antigen-binding molecule comprises a VH region according to one of (6) to (15) below:
  • the antigen-binding molecule comprises a VH region comprising the CDRs according to one of (1), (2), (3), (4) or (5) above, and the FRs according to one of (5), (6), (7), (8), (9), (10), (11), (12), (13), (14) or (15) above.
  • the antigen-binding molecule comprises a VH region according to one of (16) to (25) below:
  • a VH region comprising the CDRs according to (1) and the FRs according to (6).
  • a VH region comprising the CDRs according to (1) and the FRs according to (7).
  • a VH region comprising the CDRs according to (2) and the FRs according to (8).
  • a VH region comprising the CDRs according to (3) and the FRs according to (9).
  • a VH region comprising the CDRs according to (4) and the FRs according to (10).
  • a VH region comprising the CDRs according to (1) and the FRs according to (12).
  • the antigen-binding molecule comprises a VH region according to one of (26) to (34) below:
  • a VH region comprising an amino acid sequence having at least 70% sequence identity more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO:23.
  • a VH region comprising an amino acid sequence having at least 70% sequence identity more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO:39.
  • a VH region comprising an amino acid sequence having at least 70% sequence identity more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO:49.
  • a VH region comprising an amino acid sequence having at least 70% sequence identity more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO:65.
  • a VH region comprising an amino acid sequence having at least 70% sequence identity more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO:178.
  • a VH region comprising an amino acid sequence having at least 70% sequence identity more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO:127.
  • a VH region comprising an amino acid sequence having at least 70% sequence identity more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO:129.
  • a VH region comprising an amino acid sequence having at least 70% sequence identity more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO:130.
  • a VH region comprising an amino acid sequence having at least 70% sequence identity more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO:131.
  • a VH region comprising an amino acid sequence having at least 70% sequence identity more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO:132.
  • the antigen-binding molecule comprises a VL region according to one of (36) to (43) below:
  • the antigen-binding molecule comprises a VL region according to one of (44) to (50) below:
  • the antigen-binding molecule comprises a VL region comprising the CDRs according to one of (36), (37), (38), (39), (40), (41), (42) or (43) above, and the FRs according to one of (44), (45), (46), (47), (48), (49) or (50) above.
  • the antigen-binding molecule comprises a VL region according to one of (51) to (60) below:
  • the antigen-binding molecule comprises a VL region according to one of (61) to (70) below:
  • a VL region comprising an amino acid sequence having at least 70% sequence identity more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO:31.
  • a VL region comprising an amino acid sequence having at least 70% sequence identity more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO:44.
  • a VL region comprising an amino acid sequence having at least 70% sequence identity more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO:57.
  • a VL region comprising an amino acid sequence having at least 70% sequence identity more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO:73.
  • a VL region comprising an amino acid sequence having at least 70% sequence identity more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO:179.
  • a VL region comprising an amino acid sequence having at least 70% sequence identity more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO:128.
  • a VL region comprising an amino acid sequence having at least 70% sequence identity more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO:133.
  • a VL region comprising an amino acid sequence having at least 70% sequence identity more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO:134.
  • a VL region comprising an amino acid sequence having at least 70% sequence identity more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO:135.
  • a VL region comprising an amino acid sequence having at least 70% sequence identity more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO:136.
  • the antigen-binding molecule comprises a VH region according to any one of (1) to (35) above, and a VL region according to any one of (36) to (70) above.
  • substitutions may conservative substitutions, for example according to the following Table.
  • amino acids in the same block in the middle column are substituted.
  • amino acids in the same line in the rightmost column are substituted:
  • substitution(s) may be functionally conservative. That is, in some embodiments the substitution may not affect (or may not substantially affect) one or more functional properties (e.g. target binding) of the antigen-binding molecule comprising the substitution as compared to the equivalent unsubstituted molecule.
  • the VH and VL region of an antigen-binding region of an antibody together constitute the Fv region.
  • the antigen-binding molecule according to the present invention comprises, or consists of, an Fv region which binds to CD47.
  • the VH and VL regions of the Fv are provided as single polypeptide joined by a linker region, i.e. a single chain Fv (scFv).
  • the antigen-binding molecule of the present invention comprises one or more regions of an immunoglobulin heavy chain constant sequence.
  • the immunoglobulin heavy chain constant sequence is, or is derived from, the heavy chain constant sequence of an IgG (e.g. IgG1, IgG2, IgG3, IgG4), IgA (e.g. IgA1, IgA2), IgD, IgE or IgM.
  • the immunoglobulin heavy chain constant sequence is human immunoglobulin G 1 constant (IGHG1; UniProt: P01857-1, v1; SEQ ID NO:118). Positions 1 to 98 of SEQ ID NO:118 form the CH1 region (SEQ ID NO:119). Positions 99 to 110 of SEQ ID NO:118 form a hinge region between CH1 and CH2 regions (SEQ ID NO:120). Positions 111 to 223 of SEQ ID NO:118 form the CH2 region (SEQ ID NO:121). Positions 224 to 330 of SEQ ID NO:118 form the CH3 region (SEQ ID NO:122).
  • the exemplified antigen-binding molecules were prepared using pFUSE-CHIg-hG1, which comprises the substitutions D356E, L358M (positions numbered according to EU numbering) in the CH3 region relative to SEQ ID NO:118.
  • the amino acid sequence of the CH3 region encoded by pFUSE-CHIg-hG1 is shown in SEQ ID NO:123. It will be appreciated that CH3 regions may be provided with further substitutions in accordance with modification to an Fc region of the antigen-binding molecule as described herein.
  • a CH1 region comprises or consists of the sequence of SEQ ID NO:119, or a sequence having at least 60%, preferably one of 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:119.
  • a CH1-CH2 hinge region comprises or consists of the sequence of SEQ ID NO:120, or a sequence having at least 60%, preferably one of 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:120.
  • a CH2 region comprises or consists of the sequence of SEQ ID NO:121, or a sequence having at least 60%, preferably one of 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:121.
  • a CH3 region comprises or consists of the sequence of SEQ ID NO:122 or 123, or a sequence having at least 60%, preferably one of 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:122 or 123.
  • the antigen-binding molecule of the present invention comprises one or more regions of an immunoglobulin light chain constant sequence.
  • the immunoglobulin light chain constant sequence is human immunoglobulin kappa constant (IGKC; C ⁇ ; UniProt: P01834-1, v2; SEQ ID NO:124).
  • the immunoglobulin light chain constant sequence is a human immunoglobulin lambda constant (IGLC; C ⁇ ), e.g. IGLC1, IGLC2, IGLC3, IGLC6 or IGLC7.
  • a CL region comprises or consists of the sequence of SEQ ID NO:124, or a sequence having at least 60%, preferably one of 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:124.
  • the VL and light chain constant (CL) region, and the VH region and heavy chain constant 1 (CH1) region of an antigen-binding region of an antibody together constitute the Fab region.
  • the antigen-binding molecule comprises a Fab region comprising a VH, a CH1, a VL and a CL (e.g. C ⁇ or C ⁇ ).
  • the Fab region comprises a polypeptide comprising a VH and a CH1 (e.g. a VH-CH1 fusion polypeptide), and a polypeptide comprising a VL and a CL (e.g. a VL-CL fusion polypeptide).
  • the Fab region comprises a polypeptide comprising a VH and a CL (e.g. a VH-CL fusion polypeptide) and a polypeptide comprising a VL and a CH (e.g. a VL-CH1 fusion polypeptide); that is, in some embodiments the Fab region is a CrossFab region.
  • the VH, CH1, VL and CL regions of the Fab or CrossFab are provided as single polypeptide joined by linker regions, i.e. as a single chain Fab (scFab) or a single chain CrossFab (scCrossFab).
  • the antigen-binding molecule of the present invention comprises, or consists of, a Fab region which binds to CD47.
  • the antigen-binding molecule described herein comprises, or consists of, a whole antibody which binds to CD47.
  • whole antibody refers to an antibody having a structure which is substantially similar to the structure of an immunoglobulin (Ig). Different kinds of immunoglobulins and their structures are described e.g. in Schroeder and Cavacini J Allergy Clin Immunol. (2010) 125(202): S41-S52, which is hereby incorporated by reference in its entirety.
  • Immunoglobulins of type G are ⁇ 150 kDa glycoproteins comprising two heavy chains and two light chains. From N- to C-terminus, the heavy chains comprise a VH followed by a heavy chain constant region comprising three constant domains (CH1, CH2, and CH3), and similarly the light chain comprise a VL followed by a CL.
  • immunoglobulins may be classed as IgG (e.g. IgG1, IgG2, IgG3, IgG4), IgA (e.g. IgA1, IgA2), IgD, IgE, or IgM.
  • the light chain may be kappa ( ⁇ ) or lambda ( ⁇ ).
  • the antigen-binding molecule described herein comprises, or consists of, an IgG (e.g. IgG1, IgG2, IgG3, IgG4), IgA (e.g. IgA1, IgA2), IgD, IgE, or IgM which binds to CD47.
  • IgG e.g. IgG1, IgG2, IgG3, IgG4
  • IgA e.g. Ig. IgA1, IgA2
  • IgD IgE
  • IgM which binds to CD47.
  • multispecific antigen-binding molecules By “multispecific” it is meant that the antigen-binding molecule displays specific binding to more than one target.
  • the antigen-binding molecule is a bispecific antigen-binding molecule.
  • the antigen-binding molecule comprises at least two different antigen-binding domains (i.e. at least two antigen-binding domains, e.g. comprising non
  • the antigen-binding molecule binds to CD47 and an antigen other than CD47, and so is at least bispecific.
  • the term “bispecific” means that the antigen-binding molecule is able to bind specifically to at least two distinct antigenic determinants.
  • an antigen-binding molecule according to the present invention may comprise antigen-binding molecules capable of binding to the targets for which the antigen-binding molecule is specific.
  • an antigen-binding molecule which is capable of binding to CD47 and an antigen other than CD47 may comprise: (i) an antigen-binding molecule which is capable of binding to CD47, and (ii) an antigen-binding molecule which is capable of binding to an antigen other than CD47.
  • an antigen-binding molecule which is capable of binding to CD47 and an antigen other than CD47 may comprise (i) an antigen-binding molecule which is capable of binding to CD47, (e.g. a CD47-binding Fab or scFv), and (ii) an antigen-binding molecule which is capable of binding to an antigen other than CD47 (e.g. a Fab or scFv specific for the antigen other than CD47).
  • an antigen-binding molecule which is capable of binding to CD47 e.g. a CD47-binding Fab or scFv
  • an antigen-binding molecule which is capable of binding to an antigen other than CD47 e.g. a Fab or scFv specific for the antigen other than CD47.
  • an antigen-binding molecule according to the present invention may comprise antigen-binding polypeptides or antigen-binding polypeptide complexes capable of binding to the targets for which the antigen-binding molecule is specific.
  • a component antigen-binding molecule of a larger antigen-binding molecule may be referred to e.g. as an “antigen-binding domain” or “antigen-binding region” of the larger antigen-binding molecule.
  • the antigen-binding molecule comprises an antigen-binding molecule capable of binding to CD47, and an antigen-binding molecule capable of binding to an antigen other than CD47.
  • the antigen other than CD47 is an immune cell surface molecule.
  • the antigen other than CD47 is a cancer cell antigen.
  • the antigen other than CD47 is a receptor molecule, e.g. a cell surface receptor.
  • the antigen other than CD47 is a cell signalling molecule, e.g. a cytokine, chemokine, interferon, interleukin or lymphokine.
  • the antigen other than CD47 is a growth factor or a hormone.
  • a cancer cell antigen is an antigen which is expressed or over-expressed by a cancer cell.
  • a cancer cell antigen may be any peptide/polypeptide, glycoprotein, lipoprotein, glycan, glycolipid, lipid, or fragment thereof.
  • a cancer cell antigen's expression may be associated with a cancer.
  • a cancer cell antigen may be abnormally expressed by a cancer cell (e.g. the cancer cell antigen may be expressed with abnormal localisation), or may be expressed with an abnormal structure by a cancer cell.
  • a cancer cell antigen may be capable of eliciting an immune response.
  • the antigen is expressed at the cell surface of the cancer cell (i.e. the cancer cell antigen is a cancer cell surface antigen).
  • the part of the antigen which is bound by the antigen-binding molecule described herein is displayed on the external surface of the cancer cell (i.e. is extracellular).
  • the cancer cell antigen may be a cancer-associated antigen.
  • the cancer cell antigen is an antigen whose expression is associated with the development, progression or severity of symptoms of a cancer.
  • the cancer-associated antigen may be associated with the cause or pathology of the cancer, or may be expressed abnormally as a consequence of the cancer.
  • the cancer cell antigen is an antigen whose expression is upregulated (e.g. at the RNA and/or protein level) by cells of a cancer, e.g.
  • the cancer-associated antigen may be preferentially expressed by cancerous cells, and not expressed by comparable non-cancerous cells (e.g. non-cancerous cells derived from the same tissue/cell type).
  • the cancer-associated antigen may be the product of a mutated oncogene or mutated tumor suppressor gene.
  • the cancer-associated antigen may be the product of an overexpressed cellular protein, a cancer antigen produced by an oncogenic virus, an oncofetal antigen, or a cell surface glycolipid or glycoprotein.
  • An immune cell surface molecule may be any peptide/polypeptide, glycoprotein, lipoprotein, glycan, glycolipid, lipid, or fragment thereof expressed at or on the cell surface of an immune cell.
  • the part of the immune cell surface molecule which is bound by the antigen-binding molecule of the present invention is on the external surface of the immune cell (i.e. is extracellular).
  • the immune cell surface molecule may be expressed at the cell surface of any immune cell.
  • the immune cell may be a cell of hematopoietic origin, e.g. a neutrophil, eosinophil, basophil, dendritic cell, lymphocyte, or monocyte.
  • the lymphocyte may be e.g. a T cell, B cell, natural killer (NK) cell, NKT cell or innate lymphoid cell (ILC), or a precursor thereof (e.g. a thymocyte or pre-B cell).
  • the antigen other than CD47 is an antigen expressed by cells of a hematologic malignancy, a myeloid hematologic malignancy, a lymphoblastic hematologic malignancy, myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), chronic myeloid leukemia, acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma, multiple myeloma, bladder cancer or brain cancer.
  • MDS myelodysplastic syndrome
  • AML acute myeloid leukemia
  • ALL acute lymphoblastic leukemia
  • NHL acute lymphoblastic leukemia
  • the antigen other than CD47 is an antigen expressed by cells of AML, e.g. as described in Hoseini and Cheung Blood Cancer J. (2017) 7(2):e522, which is hereby incorporated by reference in its entirety.
  • the antigen other than CD47 is selected from: CD33, CD123, Wilms' tumor protein (WT1), CD13, CD15, CD30, CD45, C-type lectin-like molecule 1 (CLL1), Fms-like tyrosine kinase 3 (FLT-3), VEGF and angiopoietin-2 (Ang-2).
  • WT1 Wilms' tumor protein
  • CD13 CD13
  • CD15 CD15
  • CD30 CD45
  • CLL1 C-type lectin-like molecule 1
  • FLT-3 Fms-like tyrosine kinase 3
  • VEGF angiopoietin-2
  • Ang-2 angiopoietin-2
  • Multispecific antigen-binding molecules described herein display at least monovalent binding with respect to CD47, and also display at least monovalent binding with respect to the antigen other than CD47.
  • the antigen-binding molecule comprises an antigen-binding region (e.g. an Fv, Fab or antibody) capable of binding to CD47, and an antigen-binding region (e.g. an Fv, Fab or antibody) capable of binding to an antigen other than CD47.
  • the antigen-binding molecule comprises the VH and VL of an antibody capable of binding to CD47, and the VH and VL of an antibody capable of binding to an antigen other than CD47.
  • Binding valency refers to the number of binding sites in an antigen-binding molecule for a given antigenic determinant.
  • the anti-CD47 antibody is bivalent with respect to binding to CD47.
  • Multispecific antigen-binding molecules according to the invention may be provided in any suitable format, such as those formats described in described in Brinkmann and Kontermann MAbs (2017) 9(2): 182-212, which is hereby incorporated by reference in its entirety.
  • Suitable formats include those shown in FIG. 2 of Brinkmann and Kontermann MAbs (2017) 9(2): 182-212: antibody conjugates, e.g. IgG2, F(ab′) 2 or CovX-Body; IgG or IgG-like molecules, e.g. IgG, chimeric IgG, ⁇ -body common HC; CH1/CL fusion proteins, e.g.
  • scFv2-CH1/CL, VHH2-CH1/CL ‘variable domain only’ bispecific antigen-binding molecules, e.g. tandem scFv (taFV), triplebodies, diabodies (db), dsDb, db(kih), DART, scDB, dsFv-dsFv, tandAbs, triple heads, tandem dAbNHH, tertravalent dAb.VHH;
  • Non-Ig fusion proteins e.g.
  • scFv2-albumin scDb-albumin, taFv-albumin, taFv-toxin, miniantibody, DNL-Fab2, DNL-Fab2-scFv, DNL-Fab2-IgG-cytokine 2 , ImmTAC (TCR-scFv); modified Fc and CH3 fusion proteins, e.g.
  • Fab-scFv (bibody), Fab-scFv 2 (tribody), Fab-Fv, Fab-dsFv, Fab-VHH, orthogonal Fab-Fab; non-Ig fusion proteins, e.g. DNL-Fab 3 , DNL-Fab 2 -scFv, DNL-Fab 2 -IgG-cytokine 2 ; asymmetric IgG or IgG-like molecules, e.g.
  • DAF two-in one-IgG
  • bispecific antigen-binding molecules The skilled person is able to design and prepare bispecific antigen-binding molecules.
  • Methods for producing bispecific antigen-binding molecules include chemically crosslinking of antigen-binding molecules or antibody fragments, e.g. with reducible disulphide or non-reducible thioether bonds, for example as described in Segal and Bast, 2001. Production of Bispecific Antigen-binding molecules. Current Protocols in Immunology. 14:IV:2.13:2.13.1-2.13.16, which is hereby incorporated by reference in its entirety.
  • SPDP N-succinimidyl-3-(-2-pyridyldithio)-propionate
  • SPDP N-succinimidyl-3-(-2-pyridyldithio)-propionate
  • SPDP N-succinimidyl-3-(-2-pyridyldithio)-propionate
  • SPDP N-succinimidyl-3-(-2-pyri
  • bispecific antigen-binding molecules include fusing antibody-producing hybridomas e.g. with polyethylene glycol, to produce a quadroma cell capable of secreting bispecific antibody, for example as described in D. M. and Bast, B. J. 2001. Production of Bispecific Antigen-binding molecules. Current Protocols in Immunology. 14:IV:2.13:2.13.1-2.13.16.
  • Bispecific antigen-binding molecules according to the present invention can also be produced recombinantly, by expression from e.g. a nucleic acid construct encoding polypeptides for the antigen-binding molecules, for example as described in Antibody Engineering: Methods and Protocols, Second Edition (Humana Press, 2012), at Chapter 40: Production of Bispecific Antigen-binding molecules: Diabodies and Tandem scFv (Hornig and Farber-Schwarz), or French, How to make bispecific antigen-binding molecules, Methods Mol. Med. 2000; 40:333-339, the entire contents of both of which are hereby incorporated by reference.
  • a DNA construct encoding the light and heavy chain variable domains for the two antigen-binding fragments i.e. the light and heavy chain variable domains for the antigen-binding fragment capable of binding CD47, and the light and heavy chain variable domains for the antigen-binding fragment capable of binding to another target protein
  • sequences encoding a suitable linker or dimerization domain between the antigen-binding fragments can be prepared by molecular cloning techniques.
  • Recombinant bispecific antibody can thereafter be produced by expression (e.g. in vitro) of the construct in a suitable host cell (e.g. a mammalian host cell), and expressed recombinant bispecific antibody can then optionally be purified.
  • the antigen-binding molecules of the present invention comprise an Fc region.
  • An Fc region is composed of CH2 and CH3 regions from one polypeptide, and CH2 and CH3 regions from another polypeptide. The CH2 and CH3 regions from the two polypeptides together form the Fc region.
  • the antigen-binding molecule of the present invention comprises an Fc region comprising modification in one or more of the CH2 and CH3 regions promoting association of the Fc region.
  • Recombinant co-expression of constituent polypeptides of an antigen-binding molecule and subsequent association leads to several possible combinations.
  • modification(s) promoting association of the desired combination of heavy chain polypeptides.
  • Modifications may promote e.g. hydrophobic and/or electrostatic interaction between CH2 and/or CH3 regions of different polypeptide chains. Suitable modifications are described e.g. in Ha et al., Front. Immnol (2016) 7:394, which is hereby incorporated by reference in its entirety.
  • the antigen antigen-binding molecule of the present invention comprises an Fc region comprising paired substitutions in the CH3 regions of the Fc region according to one of the following formats, as shown in Table 1 of Ha et al., Front. Immnol (2016) 7:394: KiH, KiH s-s , HA-TF, ZW1, 7.8.60, DD-KK, EW-RVT, EW-RVT s-s , SEED or A107.
  • the Fc region comprises the “knob-into-hole” or “KiH” modification, e.g. as described e.g. in U.S. Pat. No. 7,695,936 and Carter, J Immunol Meth 248, 7-15 (2001).
  • one of the CH3 regions of the Fc region comprises a “knob” modification
  • the other CH3 region comprises a “hole” modification.
  • the “knob” and “hole” modifications are positioned within the respective CH3 regions so that the “knob” can be positioned in the “hole” in order to promote heterodimerisation (and inhibit homodimerisation) of the polypeptides and/or stabilise heterodimers.
  • Knobs are constructed by substituting amino acids having small chains with those having larger side chains (e.g. tyrosine or tryptophan). Holes are created by substituting amino acids having large side chains with those having smaller side chains (e.g. alanine or threonine).
  • one of the CH3 regions of the Fc region of the antigen-binding molecule of the present invention comprises the substitution (numbering of positions/substitutions in the Fc, CH2 and CH3 regions herein is according to the EU numbering system as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991) T366W, and the other CH3 region of the Fc region comprises the substitution Y407V.
  • one of the CH3 regions of the Fc region of the antigen-binding molecule comprises the substitution T366W, and the other CH3 region of the Fc region comprises the substitutions T3665 and L368A. In some embodiments, one of the CH3 regions of the Fc region of the antigen-binding molecule comprises the substitution T366W, and the other CH3 region of the Fc region comprises the substitutions Y407V, T3665 and L368A.
  • the Fc region comprises the “DD-KK” modification as described e.g. in WO 2014/131694 A1.
  • one of the CH3 regions comprises the substitutions K392D and K409D, and the other CH3 region of the Fc region comprises the substitutions E356K and D399K. The modifications promote electrostatic interaction between the CH3 regions.
  • the antigen-binding molecule of the present invention comprises an Fc region modified as described in Labrijn et al., Proc Natl Acad Sci USA. (2013) 110(13):5145-50, referred to as ‘Duobody’ format.
  • one of the CH3 regions comprises the substitution K409R
  • the other CH3 region of the Fc region comprises the substitution K405L.
  • the antigen-binding molecule of the present invention comprises an Fc region comprising the “EEE-RRR” modification as described in Strop et al., J Mol Biol. (2012) 420(3):204-19.
  • one of the CH3 regions comprises the substitutions D221E, P228E and L368E
  • the other CH3 region of the Fc region comprises the substitutions D221R, P228R and K409R.
  • the antigen-binding molecule comprises an Fc region comprising the “EW-RVT” modification described in Choi et al., Mol Cancer Ther (2013) 12(12):2748-59.
  • one of the CH3 regions comprises the substitutions K360E and K409W
  • the other CH3 region of the Fc region comprises the substitutions Q347R, D399V and F405T.
  • one of the CH3 regions comprises the substitution S354C
  • the other CH3 region of the Fc region comprises the substitution Y349C.
  • Introduction of these cysteine residues results in formation of a disulphide bridge between the two CH3 regions of the Fc region, further stabilizing the heterodimer (Carter (2001), J Immunol Methods 248, 7-15).
  • the Fc region comprises the “KiH S-S ” modification.
  • one of the CH3 regions comprises the substitutions T366W and S354C, and the other CH3 region of the Fc region comprises the substitutions T3665, L368A, Y407V and Y349C.
  • the antigen-binding molecule of the present invention comprises an Fc region comprising the “SEED” modification as described in Davis et al., Protein Eng Des Sel (2010) 23(4):195-202, in which ⁇ -strand segments of human IgG1 CH3 and IgA CH3 are exchanged.
  • one of the CH3 regions comprises the substitutions S364H and F405A
  • the other CH3 region of the Fc region comprises the substitutions Y349T and T394F (see e.g. Moore et al., MAbs (2011) 3(6):546-57).
  • one of the CH3 regions comprises the substitutions T350V, L351Y, F405A and Y407V
  • the other CH3 region of the Fc region comprises the substitutions T350V, T366L, K392L and T394W (see e.g. Von Kreudenstein et al., MAbs (2013) 5(5):646-54).
  • one of the CH3 regions comprises the substitutions K360D, D399M and Y407A
  • the other CH3 region of the Fc region comprises the substitutions E345R, Q347R, T366V and K409V (see e.g. Leaver-Fay et al., Structure (2016) 24(4):641-51).
  • one of the CH3 regions comprises the substitutions K370E and K409W
  • the other CH3 region of the Fc region comprises the substitutions E357N, D399V and F405T (see e.g. Choi et al., PLoS One (2015) 10(12):e0145349).
  • the present invention also provides polypeptide constituents of antigen-binding molecules.
  • the polypeptides may be provided in isolated or substantially purified form.
  • the antigen-binding molecule of the present invention may be, or may comprise, a complex of polypeptides.
  • a polypeptide comprises more than one domain or region
  • the plural domains/regions are preferably present in the same polypeptide chain. That is, the polypeptide comprises more than one domain or region is a fusion polypeptide comprising the domains/regions.
  • a polypeptide according to the present invention comprises, or consists of, a VH as described herein. In some embodiments a polypeptide according to the present invention comprises, or consists of, a VL as described herein.
  • the polypeptide additionally comprises one or more antibody heavy chain constant regions (CH). In some embodiments, the polypeptide additionally comprises one or more antibody light chain constant regions (CL). In some embodiments, the polypeptide comprises a CH1, CH2 region and/or a CH3 region of an immunoglobulin (Ig).
  • CH antibody heavy chain constant regions
  • CL antibody light chain constant regions
  • the polypeptide comprises a CH1, CH2 region and/or a CH3 region of an immunoglobulin (Ig).
  • the polypeptide comprises one or more regions of an immunoglobulin heavy chain constant sequence. In some embodiments the polypeptide comprises a CH1 region as described herein. In some embodiments the polypeptide comprises a CH1-CH2 hinge region as described herein. In some embodiments the polypeptide comprises a CH2 region as described herein. In some embodiments the polypeptide comprises a CH3 region as described herein.
  • the polypeptide comprises a CH3 region comprising any one of the following amino acid substitutions/combinations of amino acid substitutions (shown e.g. in Table 1 of Ha et al., Front. Immnol (2016) 7:394, incorporated by reference hereinabove): T366W; T3665, L368A and Y407V; T366W and S354C; T3665, L368A, Y407V and Y349C; S364H and F405A; Y349T and T394F; T350V, L351Y, F405A and Y407V; T350V, T366L, K392L and T394W; K360D, D399M and Y407A; E345R, Q347R, T366V and K409V; K409D and K392D; D399K and E356K; K360E and K409W; Q347R,
  • the CH2 and/or CH3 regions of the polypeptide comprise one or more amino acid substitutions for promoting association of the polypeptide with another polypeptide comprising a CH2 and/or CH3 region.
  • polypeptide comprises one or more regions of an immunoglobulin light chain constant sequence. In some embodiments the polypeptide comprises a CL region as described herein.
  • polypeptide according to the present invention comprises a structure from N- to C-terminus according to one of the following:
  • antigen-binding molecules composed of the polypeptides of the present invention.
  • the antigen-binding molecule of the present invention comprises one of the following combinations of polypeptides:
  • the antigen-binding molecule comprises more than one of a polypeptide of the combinations shown in (A) to (I) above.
  • the antigen-binding molecule comprises two polypeptides comprising the structure VH-CH1-CH2-CH3, and two polypeptides comprising the structure VL-CL.
  • the antigen-binding molecule of the present invention comprises one of the following combinations of polypeptides:
  • VH(anti-CD47) refers to the VH of an antigen-binding molecule capable of binding to CD47 as described herein, e.g. as defined in one of (1) to (35); and “VL(anti-CD47)” refers to the VL of an antigen-binding molecule capable of binding to CD47 as described herein, e.g.
  • the polypeptide comprises or consists of an amino acid sequence having at least 70%, preferably one of 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of one of SEQ ID NOs:23, 31, 39, 44, 49, 57, 65, 73, 178, 179, 127, 128, 129, 130, 131, 132, 133, 134, 135 or 136.
  • the polypeptide comprises or consists of an amino acid sequence having at least 70%, preferably one of 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of one of SEQ ID NOs:107, 108, 109, 110, 111, 112, 113, 114, 159, 160, 161, 162, 163, 164, 165, 166, 167 or 168.
  • the antigen-binding molecules and polypeptides of the present invention comprise a hinge region.
  • a hinge region is provided between a CH1 region and a CH2 region.
  • a hinge region is provided between a CL region and a CH2 region.
  • the hinge region comprises, or consists of, an amino acid sequence having at least 70%, preferably one of 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:120.
  • the antigen-binding molecules and polypeptides of the present invention comprise one or more linker sequences between amino acid sequences.
  • a linker sequence may be provided at one or both ends of one or more of a VH, VL, CH1-CH2 hinge region, CH2 region and a CH3 region of the antigen-binding molecule/polypeptide.
  • Linker sequences are known to the skilled person, and are described, for example in Chen et al., Adv Drug Deliv Rev (2013) 65(10): 1357-1369, which is hereby incorporated by reference in its entirety.
  • a linker sequence may be a flexible linker sequence.
  • Flexible linker sequences allow for relative movement of the amino acid sequences which are linked by the linker sequence.
  • Flexible linkers are known to the skilled person, and several are identified in Chen et al., Adv Drug Deliv Rev (2013) 65(10): 1357-1369. Flexible linker sequences often comprise high proportions of glycine and/or serine residues.
  • the linker sequence comprises at least one glycine residue and/or at least one serine residue. In some embodiments the linker sequence consists of glycine and serine residues. In some embodiments, the linker sequence has a length of 1-2, 1-3, 1-4, 1-5 or 1-10 amino acids.
  • the antigen-binding molecules and polypeptides of the present invention may additionally comprise further amino acids or sequences of amino acids.
  • the antigen-binding molecules and polypeptides may comprise amino acid sequence(s) to facilitate expression, folding, trafficking, processing, purification or detection of the antigen-binding molecule/polypeptide.
  • the antigen-binding molecule/polypeptide may comprise a sequence encoding a His, (e.g. 6 ⁇ His), Myc, GST, MBP, FLAG, HA, E, or Biotin tag, optionally at the N- or C-terminus of the antigen-binding molecule/polypeptide.
  • the antigen-binding molecule/polypeptide comprises a detectable moiety, e.g. a fluorescent, lunminescent, immuno-detectable, radio, chemical, nucleic acid or enzymatic label.
  • the antigen-binding molecules and polypeptides of the present invention may additionally comprise a signal peptide (also known as a leader sequence or signal sequence).
  • Signal peptides normally consist of a sequence of 5-30 hydrophobic amino acids, which form a single alpha helix. Secreted proteins and proteins expressed at the cell surface often comprise signal peptides.
  • the signal peptide may be present at the N-terminus of the antigen-binding molecule/polypeptide, and may be present in the newly synthesised antigen-binding molecule/polypeptide.
  • the signal peptide provides for efficient trafficking and secretion of the antigen-binding molecule/polypeptide. Signal peptides are often removed by cleavage, and thus are not comprised in the mature antigen-binding molecule/polypeptide secreted from the cell expressing the antigen-binding molecule/polypeptide.
  • Signal peptides are known for many proteins, and are recorded in databases such as GenBank, UniProt, Swiss-Prot, TrEMBL, Protein Information Resource, Protein Data Bank, Ensembl, and InterPro, and/or can be identified/predicted e.g. using amino acid sequence analysis tools such as SignalP (Petersen et al., 2011 Nature Methods 8: 785-786) or Signal-BLAST (Frank and Sippl, 2008 Bioinformatics 24: 2172-2176).
  • SignalP Protein et al., 2011 Nature Methods 8: 785-786
  • Signal-BLAST Frank and Sippl, 2008 Bioinformatics 24: 2172-2176.
  • the signal peptide of the antigen-binding molecule/polypeptide of the present invention comprises, or consists of, an amino acid sequence having at least 80%, 85% 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of one of SEQ ID NOs:81 to 86.
  • the antigen-binding molecules of the present invention additionally comprise a detectable moiety.
  • the antigen-binding molecule comprises a detectable moiety, e.g. a fluorescent label, phosphorescent label, luminescent label, immuno-detectable label (e.g. an epitope tag), radiolabel, chemical, nucleic acid or enzymatic label.
  • a detectable moiety e.g. a fluorescent label, phosphorescent label, luminescent label, immuno-detectable label (e.g. an epitope tag), radiolabel, chemical, nucleic acid or enzymatic label.
  • the antigen-binding molecule may be covalently or non-covalently labelled with the detectable moiety.
  • Fluorescent labels include e.g. fluorescein, rhodamine, allophycocyanin, eosine and NDB, green fluorescent protein (GFP) chelates of rare earths such as europium (Eu), terbium (Tb) and samarium (Sm), tetramethyl rhodamine, Texas Red, 4-methyl umbelliferone, 7-amino-4-methyl coumarin, Cy3, and Cy5.
  • GFP green fluorescent protein
  • Radiolabels include radioisotopes such as lodine 123 , lodine 125 , lodine 126 , lodine 131 , lodine 133 , Bromine 77 , Technetium 99m , Indium 111 , Indium 113m , Gallium 67 , Gallium 68 , Ruthenium 95 , Ruthenium 97 , Ruthenium 103 , Ruthenium 105 , Mercury 207 , Mercury 203 , Rhenium 99m , Rhenium 101 , Rhenium 105 , Scandium 47 , Tellurium 121m , Tellurium 122m , Tellurium 125m , Thulium 165 , Thuliuml 167 , Thulium 168 , Copper 67 , Fluorine 18 , Yttrium 90 , Palladium 100 , Bismuth 217 and Antimon 211 .
  • Luminescent labels include as radioluminescent, chemiluminescent (e.g. acridinium ester, luminol, isoluminol) and bioluminescent labels.
  • Immuno-detectable labels include haptens, peptides/polypeptides, antibodies, receptors and ligands such as biotin, avidin, streptavidin or digoxigenin.
  • Nucleic acid labels include aptamers.
  • Enzymatic labels include e.g. peroxidase, alkaline phosphatase, glucose oxidase, beta-galactosidase and luciferase.
  • the antigen-binding molecules of the present invention are conjugated to a chemical moiety.
  • the chemical moiety may be a moiety for providing a therapeutic effect.
  • Antibody-drug conjugates are reviewed e.g. in Parslow et al., Biomedicines. 2016 September; 4(3):14.
  • the chemical moiety may be a drug moiety (e.g. a cytotoxic agent).
  • the drug moiety may be a chemotherapeutic agent.
  • the drug moiety is selected from calicheamicin, DM1, DM4, monomethylauristatin E (MMAE), monomethylauristatin F (MMAF), SN-38, doxorubicin, duocarmycin, D6.5 and PBD.
  • the antigen-binding molecule comprises, or consists of:
  • the antigen-binding molecule comprises, or consists of:
  • the antigen-binding molecule comprises, or consists of:
  • the antigen-binding molecule comprises, or consists of:
  • the antigen-binding molecule comprises, or consists of:
  • the antigen-binding molecule comprises, or consists of:
  • the antigen-binding molecule comprises, or consists of:
  • the antigen-binding molecule comprises, or consists of:
  • the antigen-binding molecule comprises, or consists of:
  • the antigen-binding molecule comprises, or consists of:
  • the antigen-binding molecule comprises, or consists of:
  • the antigen-binding molecule comprises, or consists of:
  • the antigen-binding molecule comprises, or consists of:
  • the antigen-binding molecule comprises, or consists of:
  • the antigen-binding molecule comprises, or consists of:
  • the antigen-binding molecules described herein may be characterised by reference to certain functional properties.
  • the antigen-binding molecule described herein may possess one or more of the following properties:
  • the antigen-binding molecules and antigen-binding domains described herein preferably display specific binding to the relevant target antigen(s) (e.g. CD47).
  • target antigen(s) e.g. CD47
  • specific binding refers to binding which is selective for the antigen, and which can be discriminated from non-specific binding to non-target antigen.
  • An antigen-binding molecule/domain that specifically binds to a target molecule preferably binds the target with greater affinity, and/or with greater duration than it binds to other, non-target molecules.
  • the ability of a given polypeptide to bind specifically to a given molecule can be determined by analysis according to methods known in the art, such as by ELISA, Surface Plasmon Resonance (SPR; see e.g. Hearty et al., Methods Mol Biol (2012) 907:411-442), Bio-Layer Interferometry (see e.g. Lad et al., (2015) J Biomol Screen 20(4): 498-507), flow cytometry, or by a radiolabeled antigen-binding assay (RIA) enzyme-linked immunosorbent assay.
  • SPR Surface Plasmon Resonance
  • RIA radiolabeled antigen-binding assay
  • the extent of binding of the antigen-binding molecule to an non-target molecule is less than about 10% of the binding of the antibody to the target molecule as measured, e.g. by ELISA, SPR, Bio-Layer Interferometry or by RIA.
  • binding specificity may be reflected in terms of binding affinity where the antigen-binding molecule binds with a dissociation constant (KD) that is at least 0.1 order of magnitude (i.e. 0.1 ⁇ 10 n , where n is an integer representing the order of magnitude) greater than the KD of the antigen-binding molecule towards a non-target molecule.
  • KD dissociation constant
  • This may optionally be one of at least 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.5, or 2.0.
  • the antigen-binding molecule described herein binds to CD47 with a K D of 10 ⁇ M or less, preferably one of ⁇ 5 ⁇ M, ⁇ 2 ⁇ M, ⁇ 1 ⁇ M, ⁇ 500 nM, ⁇ 100 nM, ⁇ 75 nM, ⁇ 50 nM, ⁇ 40 nM, ⁇ 30 nM, ⁇ 20 nM, ⁇ 15 nM, ⁇ 12.5 nM, ⁇ 10 nM, ⁇ 9 nM, ⁇ 8 nM, ⁇ 7 nM, ⁇ 6 nM, ⁇ 5 nM, ⁇ 4 nM ⁇ 3 nM, ⁇ 2 nM, ⁇ 1 nM or ⁇ 500 ⁇ M.
  • the antigen-binding molecules of the present invention may bind to a particular region of interest of the target antigen(s).
  • the antigen-binding region of an antigen-binding molecule according to the present domain may bind to linear epitope of a target antigen (e.g. CD47), consisting of a contiguous sequence of amino acids (i.e. an amino acid primary sequence).
  • the antigen-binding region molecule may bind to a conformational epitope of a target antigen (i.e. CD47), consisting of a discontinuous sequence of amino acids of the amino acid sequence.
  • the antigen-binding molecule of the present invention is capable of binding to CD47. In some embodiments, the antigen-binding molecule is capable of binding to CD47 in an extracellular region of CD47. In some embodiments, the antigen-binding molecule is capable of binding to CD47 in extracellular region 1 of CD47 (e.g. the region shown in SEQ ID NO:10). In some embodiments, the antigen-binding molecule is capable of binding to the V-type Ig-like domain of CD47 (e.g. the region shown in SEQ ID NO:9).
  • the antigen-binding molecule is capable of binding to a polypeptide comprising or consisting of the amino acid sequence shown in SEQ ID NO:10. In some embodiments the antigen-binding molecule is capable of binding to a polypeptide comprising or consisting of the amino acid sequence shown in SEQ ID NO:9. In some embodiments the antigen-binding molecule is capable of binding to a polypeptide comprising or consisting of the amino acid sequence shown in SEQ ID NO:9. In some embodiments the antigen-binding molecule is capable of binding to a peptide or polypeptide comprising or consisting of the amino acid sequence shown in SEQ ID NO:21. In some embodiments the antigen-binding molecule is capable of binding to a peptide or polypeptide comprising or consisting of the amino acid sequence shown in SEQ ID NO:22.
  • a “peptide” refers to a chain of two or more amino acid monomers linked by peptide bonds.
  • a peptide typically has a length in the region of about 2 to 50 amino acids.
  • a “polypeptide” is a polymer chain of two or more peptides. Polypeptides typically have a length greater than about 50 amino acids.
  • an antigen-binding molecule to bind to a given peptide/polypeptide can be analysed by methods well known to the skilled person, including analysis by ELISA, immunoblot (e.g. western blot), immunoprecipitation, surface plasmon resonance and biolayer interferometry.
  • the antigen-binding molecule is capable of binding the same region of CD47, or an overlapping region of CD47, to the region of CD47 which is bound by an antibody comprising the VH and VL sequences of one of clones 1-1-A1_BM, 1-1-A1, 5-48-A6, 5-48-D2, 11A1H1, 11A1H2, 11A1H3, 11A1H4, 11A1H5, 11A1H6, 11A1H7, 11A1H8, 11A1H9, 11A1H10 or 11A1H11.
  • the region of a peptide/polypeptide to which an antibody binds can be determined by the skilled person using various methods well known in the art, including X-ray co-crystallography analysis of antibody-antigen complexes, peptide scanning, mutagenesis mapping, hydrogen-deuterium exchange analysis by mass spectrometry, phage display, competition ELISA and proteolysis-based ‘protection’ methods. Such methods are described, for example, in Gershoni et al., BioDrugs, 2007, 21(3):145-156, which is hereby incorporated by reference in its entirety.
  • the antigen-binding molecule of the present invention displays cross-reactivity with CD47 of a non-human primate. That is, in some embodiments the antigen-binding molecule binds to both human CD47 and CD47 from a non-human primate. In some embodiments the non-human primate is rhesus macaque ( Macaca mulatta ).
  • the antigen-binding molecule of the present invention binds to CD47 in a region which is accessible to an antigen-binding molecule (i.e., an extracellular antigen-binding molecule) when CD47 is expressed at the cell surface (i.e. in or at the cell membrane).
  • the antigen-binding molecule is capable of binding to CD47 expressed at the cell surface of a cell expressing CD47.
  • the antigen-binding molecule is capable of binding to CD47-expressing cells (e.g. myeloid cells, myeloid leukemia cells, HL-60 cells, HMC-1 cells, HEL cells or Raji cells).
  • the ability of an antigen-binding molecule to bind to a given cell type can be analysed by contacting cells with the antigen-binding molecule, and detecting antigen-binding molecule bound to the cells, e.g. after a washing step to remove unbound antigen-binding molecule.
  • the ability of an antigen-binding molecule to bind to immune cell surface molecule-expressing cells and/or cancer cell antigen-expressing cells can be analysed by methods such as flow cytometry and immunofluorescence microscopy.
  • the antigen-binding molecule of the present invention may be an antagonist of CD47.
  • the antigen-binding molecule is capable of inhibiting a function or process (e.g. interaction, signalling or other activity) mediated by CD47.
  • inhibition refers to a reduction, decrease or lessening relative to a control condition.
  • the antigen-binding molecule of the present invention is capable of inhibiting interaction between CD47 and a ligand for CD47. In some embodiments the antigen-binding molecule of the present invention is capable of inhibiting interaction between CD47 and SIRP ⁇ .
  • an antigen-binding molecule to inhibit interaction between two factors can be determined for example by analysis of interaction in the presence of, or following incubation of one or both of the interaction partners with, the antibody/fragment.
  • An example of a suitable assay to determine whether a given antigen-binding molecule is capable of inhibiting interaction between two interaction partners is a competition ELISA assay.
  • An antigen-binding molecule which is capable of inhibiting a given interaction is identified by the observation of a reduction/decrease in the level of interaction between the interaction partners in the presence of—or following incubation of one or both of the interaction partners with—the antigen-binding molecule, as compared to the level of interaction in the absence of the antigen-binding molecule (or in the presence of an appropriate control antigen-binding molecule).
  • Suitable analysis can be performed in vitro, e.g. using recombinant interaction partners or using cells expressing the interaction partners. Cells expressing interaction partners may do so endogenously, or may do so from nucleic acid introduced into the cell.
  • one or both of the interaction partners and/or the antigen-binding molecule may be labelled or used in conjunction with a detectable entity for the purposes of detecting and/or measuring the level of interaction.
  • the ability of an antigen-binding molecule to inhibit interaction between two binding partners can also be determined by analysis of the downstream functional consequences of such interaction.
  • downstream functional consequences of interaction between CD47 and SIRP ⁇ may include SIRP ⁇ -mediated signalling.
  • the ability of an antigen-binding molecule to inhibit interaction of CD47 and SIRP ⁇ may be determined by analysis of SIRP ⁇ ITIM phosphorylation, or analysis of phagocytosis of CD47-expressing cell by a SIRP ⁇ -expressing cell.
  • the antigen-binding molecule of the present invention is capable of inhibiting interaction between CD47 and SIRP ⁇ to less than less than 1 times, e.g. ⁇ 0.99 times, ⁇ 0.95 times, ⁇ 0.9 times, ⁇ 0.85 times, ⁇ 0.8 times, ⁇ 0.75 times, ⁇ 0.7 times, ⁇ 0.65 times, ⁇ 0.6 times, ⁇ 0.55 times, ⁇ 0.5 times, ⁇ 0.45 times, ⁇ 0.4 times, ⁇ 0.35 times, ⁇ 0.3 times, ⁇ 0.25 times, ⁇ 0.2 times, ⁇ 0.15 times, ⁇ 0.1 times, ⁇ 0.05 times, or ⁇ 0.01 times the level of interaction between CD47 and SIRP ⁇ in the absence of the antigen-binding molecule (or in the presence of an appropriate control antigen-binding molecule).
  • the antigen-binding molecule inhibits interaction between CD47 and SIRP ⁇ with an IC50 (e.g. as determined by ELISA) of 100 ⁇ g/ml or less, preferably one of ⁇ 90 ⁇ g/ml, ⁇ 80 ⁇ g/ml, ⁇ 70 ⁇ g/ml, ⁇ 60 ⁇ g/ml, ⁇ 50 ⁇ g/ml, ⁇ 40 ⁇ g/ml, ⁇ 30 ⁇ g/ml, ⁇ 20 ⁇ g/ml, ⁇ 10 ⁇ g/ml, ⁇ 9 ⁇ g/ml, ⁇ 8 ⁇ g/ml, ⁇ 7 ⁇ g/ml, ⁇ 6 ⁇ g/ml, ⁇ 5 ⁇ g/ml, ⁇ 4 ⁇ g/ml, ⁇ 3 ⁇ g/ml, ⁇ 2 ⁇ g/ml, ⁇ 1.5 ⁇ g/ml, ⁇ 1 ⁇ g/ml, ⁇ 0.5 ⁇ g/ml,
  • the antigen-binding molecule inhibits SIRP ⁇ -mediated signalling.
  • SIRP ⁇ -mediated signalling can be analysed using SIRP ⁇ -expressing cells e.g. using an assay for detecting and/or quantifying SIRP ⁇ ITIM phosphorylation, or using in vitro assay of phagocytosis of CD47-expressing cells (e.g. Raji cells) by SIRP ⁇ -expressing cells (e.g. macrophages).
  • an in vitro assay of phagocytosis of CD47-expressing cells by SIRP ⁇ -expressing cells may be performed as described in Feng et al., Proc Natl Acad Sci USA. (2015) 112(7): 2145-2150 (hereby incorporated by reference in its entirety), or as described in the experimental examples herein.
  • the antigen-binding molecule of the present invention is capable of inhibiting SIRP ⁇ -mediated signalling to less than 1 times, e.g. ⁇ 0.99 times, ⁇ 0.95 times, ⁇ 0.9 times, ⁇ 0.85 times, ⁇ 0.8 times, ⁇ 0.75 times, ⁇ 0.7 times, ⁇ 0.65 times, ⁇ 0.6 times, ⁇ 0.55 times, ⁇ 0.5 times, ⁇ 0.45 times, ⁇ 0.4 times, ⁇ 0.35 times, ⁇ 0.3 times, ⁇ 0.25 times, ⁇ 0.2 times, ⁇ 0.15 times, ⁇ 0.1 times, ⁇ 0.05 times, or ⁇ 0.01 times the level of SIRP ⁇ -mediated signalling in the absence of the antigen-binding molecule (or in the presence of an appropriate control antigen-binding molecule).
  • the antigen-binding molecule of the present invention is capable of increasing phagocytosis of CD47-expressing cells. In some embodiments, the antigen-binding molecule of the present invention is capable of increasing phagocytosis of CD47-expressing cells (e.g. Raji cells) by SIRP ⁇ -expressing cells (e.g. macrophages).
  • CD47-expressing cells e.g. Raji cells
  • SIRP ⁇ -expressing cells e.g. macrophages
  • An antigen-binding molecule which is capable of increasing phagocytosis of CD47-expressing cells by SIRP ⁇ -expressing cells is identified by the observation of an increased level of phagocytosis of the CD47-expressing cells by the SIRP ⁇ -expressing cells in the presence of—or following incubation of the CD47-expressing cells with—the antigen-binding molecule, as compared to the level of phagocytosis detected in the absence of the antigen-binding molecule (or in the presence of an appropriate control antigen-binding molecule).
  • the antigen-binding molecule of the present invention is capable of increasing phagocytosis of CD47-expressing cells (e.g. Raji cells) by SIRP ⁇ -expressing cells (e.g. macrophages) to more than 1 times, e.g.
  • the antigen-binding molecule of the present invention is capable of increasing the number/proportion of cancer antigen-specific immune cells (e.g. CD8+ T cells or CD8+ CTLs) relative to a negative control condition, e.g. in an appropriate in vitro assay, or in vivo.
  • cancer antigen-specific immune cells e.g. CD8+ T cells or CD8+ CTLs
  • Tseng et al., Proc Natl Acad Sci USA. (2013) 110(27): 11103-11108 (hereby incorporated by reference in its entirety) demonstrated that increased phagocytosis of CD47-expressing cancer cells by macrophages in the presence of an anti-CD47 antibody was associated with increased priming of cancer antigen-specific CD8+ T cells.
  • Antigen-binding molecules capable of causing an increase in the number/proportion of cancer antigen-specific immune cells can be identified using a T cell priming assay e.g. as described in Tseng et al., Proc Natl Acad Sci USA. (2013) 110(27): 11103-11108.
  • the antigen-binding molecule of the present invention does not cause substantial hemagglutination (e.g. at concentrations of up to 400 ⁇ g/ml).
  • Hemagglutination refers to agglutination of red blood cells (erythrocytes).
  • an agent which causes hemagglutination may be referred to as a hemagglutinin.
  • the antigen-binding molecule of the present invention is not a hemagglutinin.
  • hemagglutination The ability of an antibody to cause hemagglutination can be analysed e.g. using an in vitro hemagglutination assay.
  • a suitable assay of hemagglutination for the purposes of such analysis is described e.g. in Example 5 of WO 2013/119714 A1 (hereby incorporated by reference in its entirety), or the assay of hemagglutination described in the experimental examples herein.
  • “Substantial” hemagglutination may be a level of hemagglutination which is more than 2 times, e.g. more than 3, 4, 5, 6, 7, 8, 9 or 10 times the level of hemagglutination detected in the absence of the antigen-binding molecule (or in the presence of an appropriate control antigen-binding molecule which does not cause hemagglutination).
  • the antigen-binding molecule of the present invention causes less hemagglutination as compared to a reference anti-CD47 antibody (e.g. a prior art anti-CD47 antibody). In some embodiments, the antigen-binding molecule of the present invention causes less than 1 times, e.g.
  • a reference anti-CD47 antibody e.g. a prior art anti-CD47 antibody
  • the antigen-binding molecule of the present invention increases killing of cancer cells. In some embodiments the antigen-binding molecule of the present invention causes a reduction in the number of cancer cells in vivo, e.g. as compared to an appropriate control condition.
  • the cancer may be a cancer expressing CD47, or may comprise cells expressing CD47 (e.g. the CD47+ AML cell line, HL-60).
  • the antigen-binding molecule of the present invention may be analysed for anticancer activity in an appropriate in vivo model, e.g. an AML cell line-derived xenograft model.
  • the antigen-binding molecule of the present invention causes a greater reduction of the number of cancer cells in vivo in a AML cell line-derived xenograft model as compared to a reference anti-CD47 antibody (e.g. a prior art anti-CD47 antibody).
  • administration of an antigen-binding molecule according to the present invention may cause one or more of: inhibition of the development/progression of the cancer, a delay to/prevention of onset of the cancer, a reduction in/delay to/prevention of tumor growth, a reduction in/delay to/prevention of metastasis, a reduction in the severity of the symptoms of the cancer, a reduction in the number of cancer cells, a reduction in tumour size/volume, and/or an increase in survival (e.g. progression free survival), e.g. as determined in an AML cell line-derived xenograft model.
  • survival e.g. progression free survival
  • the present invention also provides Chimeric Antigen Receptors (CARs) comprising the antigen-binding polypeptides or polypeptides of the present invention.
  • CARs Chimeric Antigen Receptors
  • CARs are recombinant receptors that provide both antigen-binding and T cell activating functions.
  • CAR structure and engineering is reviewed, for example, in Dotti et al., Immunol Rev (2014) 257(1), hereby incorporated by reference in its entirety.
  • CARs comprise an antigen-binding region linked to a cell membrane anchor region and a signalling region.
  • An optional hinge region may provide separation between the antigen-binding region and cell membrane anchor region, and may act as a flexible linker.
  • the CAR of the present invention comprises an antigen-binding region which comprises or consists of the antigen-binding molecule of the present invention, or which comprises or consists of a polypeptide according to the invention.
  • the cell membrane anchor region is provided between the antigen-binding region and the signalling region of the CAR and provides for anchoring the CAR to the cell membrane of a cell expressing a CAR, with the antigen-binding region in the extracellular space, and signalling region inside the cell.
  • the CAR comprises a cell membrane anchor region comprising or consisting of an amino acid sequence which comprises, consists of, or is derived from, the transmembrane region amino acid sequence for one of CD3- ⁇ , CD4, CD8 or CD28.
  • a region which is ‘derived from’ a reference amino acid sequence comprises an amino acid sequence having at least 60%, e.g. one of at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the reference sequence.
  • the signalling region of a CAR allows for activation of the T cell.
  • the CAR signalling regions may comprise the amino acid sequence of the intracellular domain of CD3-, which provides immunoreceptor tyrosine-based activation motifs (ITAMs) for phosphorylation and activation of the CAR-expressing T cell.
  • ITAMs immunoreceptor tyrosine-based activation motifs
  • Signalling regions comprising sequences of other ITAM-containing proteins such as Fc ⁇ RI have also been employed in CARs (Haynes et al., 2001 J Immunol 166(1):182-187).
  • Signalling regions of CARs may also comprise co-stimulatory sequences derived from the signalling region of co-stimulatory molecules, to facilitate activation of CAR-expressing T cells upon binding to the target protein.
  • Suitable co-stimulatory molecules include CD28, OX40, 4-1BB, ICOS and CD27.
  • CARs are engineered to provide for co-stimulation of different intracellular signalling pathways.
  • signalling associated with CD28 costimulation preferentially activates the phosphatidylinositol 3-kinase (P13K) pathway, whereas the 4-1BB-mediated signalling is through TNF receptor associated factor (TRAF) adaptor proteins.
  • TNF receptor associated factor (TRAF) adaptor proteins TNF receptor associated factor
  • the CAR of the present invention comprises one or more co-stimulatory sequences comprising or consisting of an amino acid sequence which comprises, consists of, or is derived from, the amino acid sequence of the intracellular domain of one or more of CD28, OX40, 4-1BB, ICOS and CD27.
  • an optional hinge region may provide separation between the antigen-binding domain and the transmembrane domain, and may act as a flexible linker. Hinge regions may be derived from IgG1.
  • the CAR of the present invention comprises a hinge region comprising or consisting of an amino acid sequence which comprises, consists of, or is derived from, the amino acid sequence of the hinge region of IgG1.
  • a cell comprising a CAR according to the invention.
  • the CAR according to the present invention may be used to generate CAR-expressing immune cells, e.g. CAR-T or CAR-NK cells.
  • Engineering of CARs into immune cells may be performed during culture, in vitro.
  • the antigen-binding region of the CAR of the present invention may be provided with any suitable format, e.g. scFv, scFab, etc.
  • the present invention provides a nucleic acid, or a plurality of nucleic acids, encoding an antigen-binding molecule, polypeptide or CAR according to the present invention.
  • the nucleic acid is purified or isolated, e.g. from other nucleic acid, or naturally-occurring biological material.
  • the nucleic acid(s) comprise or consist of DNA and/or RNA.
  • the present invention also provides a vector, or plurality of vectors, comprising the nucleic acid or plurality of nucleic acids according to the present invention.
  • the nucleotide sequence may be contained in a vector, e.g. an expression vector.
  • a “vector” as used herein is a nucleic acid molecule used as a vehicle to transfer exogenous nucleic acid into a cell.
  • the vector may be a vector for expression of the nucleic acid in the cell.
  • Such vectors may include a promoter sequence operably linked to the nucleotide sequence encoding the sequence to be expressed.
  • a vector may also include a termination codon and expression enhancers. Any suitable vectors, promoters, enhancers and termination codons known in the art may be used to express a peptide or polypeptide from a vector according to the invention.
  • operably linked may include the situation where a selected nucleic acid sequence and regulatory nucleic acid sequence (e.g. promoter and/or enhancer) are covalently linked in such a way as to place the expression of nucleic acid sequence under the influence or control of the regulatory sequence (thereby forming an expression cassette).
  • a regulatory sequence is operably linked to the selected nucleic acid sequence if the regulatory sequence is capable of effecting transcription of the nucleic acid sequence.
  • the resulting transcript(s) may then be translated into a desired peptide(s)/polypeptide(s).
  • Suitable vectors include plasmids, binary vectors, DNA vectors, mRNA vectors, viral vectors (e.g. gammaretroviral vectors (e.g. murine Leukemia virus (MLV)-derived vectors), lentiviral vectors, adenovirus vectors, adeno-associated virus vectors, vaccinia virus vectors and herpesvirus vectors), transposon-based vectors, and artificial chromosomes (e.g. yeast artificial chromosomes).
  • viral vectors e.g. gammaretroviral vectors (e.g. murine Leukemia virus (MLV)-derived vectors), lentiviral vectors, adenovirus vectors, adeno-associated virus vectors, vaccinia virus vectors and herpesvirus vectors
  • lentiviral vectors e.g. murine Leukemia virus (MLV)-derived vectors
  • lentiviral vectors e.g. murine Leukemia virus (ML
  • the vector may be a eukaryotic vector, e.g. a vector comprising the elements necessary for expression of protein from the vector in a eukaryotic cell.
  • the vector may be a mammalian vector, e.g. comprising a cytomegalovirus (CMV) or SV40 promoter to drive protein expression.
  • CMV cytomegalovirus
  • Constituent polypeptides of an antigen-binding molecule according to the present invention may be encoded by different nucleic acids of the plurality of nucleic acids, or by different vectors of the plurality of vectors.
  • the present invention also provides a cell comprising or expressing an antigen-binding molecule, polypeptide or CAR according to the present invention. Also provided is a cell comprising or expressing a nucleic acid, a plurality of nucleic acids, a vector or a plurality of vectors according to the invention.
  • the cell may be a eukaryotic cell, e.g. a mammalian cell.
  • the mammal may be a primate (rhesus, cynomolgous, non-human primate or human) or a non-human mammal (e.g. rabbit, guinea pig, rat, mouse or other rodent (including any animal in the order Rodentia), cat, dog, pig, sheep, goat, cattle (including cows, e.g. dairy cows, or any animal in the order Bos), horse (including any animal in the order Equidae), donkey, and non-human primate).
  • rodent including any animal in the order Rodentia
  • cat, dog, pig, sheep, goat, cattle including cows, e.g. dairy cows, or any animal in the order Bos
  • horse including any animal in the order Equidae
  • donkey and non-human primate
  • the present invention also provides a method for producing a cell comprising a nucleic acid(s) or vector(s) according to the present invention, comprising introducing a nucleic acid, a plurality of nucleic acids, a vector or a plurality of vectors according to the present invention into a cell.
  • introducing an isolated nucleic acid(s) or vector(s) according to the invention into a cell comprises transformation, transfection, electroporation or transduction (e.g. retroviral transduction).
  • the present invention also provides a method for producing a cell expressing/comprising an antigen-binding molecule, polypeptide or CAR according to the present invention, comprising introducing a nucleic acid, a plurality of nucleic acids, a vector or a plurality of vectors according to the present invention in a cell.
  • the methods additionally comprise culturing the cell under conditions suitable for expression of the nucleic acid(s) or vector(s) by the cell.
  • the methods are performed in vitro.
  • the present invention also provides cells obtained or obtainable by the methods according to the present invention.
  • Antigen-binding molecules and polypeptides according to the invention may be prepared according to methods for the production of polypeptides known to the skilled person.
  • Polypeptides may be prepared by chemical synthesis, e.g. liquid or solid phase synthesis.
  • peptides/polypeptides can by synthesised using the methods described in, for example, Chandrudu et al., Molecules (2013), 18: 4373-4388, which is hereby incorporated by reference in its entirety.
  • antigen-binding molecules and polypeptides may be produced by recombinant expression.
  • Molecular biology techniques suitable for recombinant production of polypeptides are well known in the art, such as those set out in Green and Sambrook, Molecular Cloning: A Laboratory Manual (4th Edition), Cold Spring Harbor Press, 2012, and in Nat Methods. (2008); 5(2): 135-146 both of which are hereby incorporated by reference in their entirety.
  • Methods for the recombinant production of antigen-binding molecules are also described in Frenzel et al., Front Immunol. (2013); 4: 217 and Kunert and Reinhart, Appl Microbiol Biotechnol. (2016) 100: 3451-3461, both of which are hereby incorporated by reference in their entirety.
  • the antigen-binding molecule of the present invention are comprised of more than one polypeptide chain.
  • production of the antigen-binding molecules may comprise transcription and translation of more than one polypeptide, and subsequent association of the polypeptide chains to form the antigen-binding molecule.
  • any cell suitable for the expression of polypeptides may be used.
  • the cell may be a prokaryote or eukaryote.
  • the cell is a prokaryotic cell, such as a cell of archaea or bacteria.
  • the bacteria may be Gram-negative bacteria such as bacteria of the family Enterobacteriaceae, for example Escherichia coli .
  • the cell is a eukaryotic cell such as a yeast cell, a plant cell, insect cell or a mammalian cell, e.g. CHO, HEK (e.g. HEK293), HeLa or COS cells.
  • the cell is not a prokaryotic cell because some prokaryotic cells do not allow for the same folding or post-translational modifications as eukaryotic cells.
  • very high expression levels are possible in eukaryotes and proteins can be easier to purify from eukaryotes using appropriate tags.
  • Specific plasmids may also be utilised which enhance secretion of the protein into the media.
  • polypeptides may be prepared by cell-free-protein synthesis (CFPS), e.g. according using a system described in Zemella et al. Chembiochem (2015) 16(17): 2420-2431, which is hereby incorporated by reference in its entirety.
  • CFPS cell-free-protein synthesis
  • Production may involve culture or fermentation of a eukaryotic cell modified to express the polypeptide(s) of interest.
  • the culture or fermentation may be performed in a bioreactor provided with an appropriate supply of nutrients, air/oxygen and/or growth factors.
  • Secreted proteins can be collected by partitioning culture media/fermentation broth from the cells, extracting the protein content, and separating individual proteins to isolate secreted polypeptide(s).
  • Culture, fermentation and separation techniques are well known to those of skill in the art, and are described, for example, in Green and Sambrook, Molecular Cloning: A Laboratory Manual (4th Edition; incorporated by reference herein above).
  • Bioreactors include one or more vessels in which cells may be cultured. Culture in the bioreactor may occur continuously, with a continuous flow of reactants into, and a continuous flow of cultured cells from, the reactor. Alternatively, the culture may occur in batches.
  • the bioreactor monitors and controls environmental conditions such as pH, oxygen, flow rates into and out of, and agitation within the vessel such that optimum conditions are provided for the cells being cultured.
  • the polypeptide(s) of interest may be isolated. Any suitable method for separating proteins from cells known in the art may be used. In order to isolate the polypeptide it may be necessary to separate the cells from nutrient medium. If the polypeptide(s) are secreted from the cells, the cells may be separated by centrifugation from the culture media that contains the secreted polypeptide(s) of interest. If the polypeptide(s) of interest collect within the cell, protein isolation may comprise centrifugation to separate cells from cell culture medium, treatment of the cell pellet with a lysis buffer, and cell disruption e.g. by sonification, rapid freeze-thaw or osmotic lysis.
  • polypeptide(s) of interest may be isolated from the supernatant or culture medium, which may contain other protein and non-protein components.
  • a common approach to separating protein components from a supernatant or culture medium is by precipitation. Proteins of different solubilities are precipitated at different concentrations of precipitating agent such as ammonium sulfate. For example, at low concentrations of precipitating agent, water soluble proteins are extracted. Thus, by adding different increasing concentrations of precipitating agent, proteins of different solubilities may be distinguished. Dialysis may be subsequently used to remove ammonium sulfate from the separated proteins.
  • precipitating agent such as ammonium sulfate
  • polypeptide(s) of interest may be desired or necessary to concentrate the polypeptide(s).
  • a number of methods for concentrating proteins are known in the art, such as ultrafiltration or lyophilisation.
  • the present invention also provides compositions comprising the antigen-binding molecules, polypeptides, CARs, nucleic acids, expression vectors and cells described herein.
  • the antigen-binding molecules, polypeptides, CARs, nucleic acids, expression vectors and cells described herein may be formulated as pharmaceutical compositions or medicaments for clinical use and may comprise a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.
  • the composition may be formulated for topical, parenteral, systemic, intracavitary, intravenous, intra-arterial, intramuscular, intrathecal, intraocular, intraconjunctival, intratumoral, subcutaneous, intradermal, intrathecal, oral or transdermal routes of administration which may include injection or infusion.
  • Suitable formulations may comprise the antigen-binding molecule in a sterile or isotonic medium.
  • Medicaments and pharmaceutical compositions may be formulated in fluid, including gel, form.
  • Fluid formulations may be formulated for administration by injection or infusion (e.g. via catheter) to a selected region of the human or animal body.
  • composition is formulated for injection or infusion, e.g. into a blood vessel or tumor.
  • such methods of production may comprise one or more steps selected from: producing an antigen-binding molecule, polypeptide, CAR, nucleic acid (or plurality thereof), expression vector (or plurality thereof) or cell described herein; isolating an antigen-binding molecule, polypeptide, CAR, nucleic acid (or plurality thereof), expression vector (or plurality thereof) or cell described herein; and/or mixing antigen-binding molecule, polypeptide, CAR, nucleic acid (or plurality thereof), expression vector (or plurality thereof) or cell described herein with a pharmaceutically acceptable carrier, adjuvant, excipient or diluent.
  • a further aspect the invention described herein relates to a method of formulating or producing a medicament or pharmaceutical composition for use in the treatment of a disease/condition (e.g. a cancer), the method comprising formulating a pharmaceutical composition or medicament by mixing an antigen-binding molecule, polypeptide, CAR, nucleic acid (or plurality thereof), expression vector (or plurality thereof) or cell described herein with a pharmaceutically acceptable carrier, adjuvant, excipient or diluent.
  • a disease/condition e.g. a cancer
  • antigen-binding molecules polypeptides, CARs, nucleic acids, expression vectors, cells and compositions described herein find use in therapeutic and prophylactic methods.
  • the present invention provides an antigen-binding molecule, polypeptide, CAR, nucleic acid (or plurality thereof), expression vector (or plurality thereof), cell or composition described herein for use in a method of medical treatment or prophylaxis. Also provided is the use of an antigen-binding molecule, polypeptide, CAR, nucleic acid (or plurality thereof), expression vector (or plurality thereof), cell or composition described herein in the manufacture of a medicament for treating or preventing a disease or condition.
  • the methods may be effective to reduce the development or progression of a disease/condition, alleviation of the symptoms of a disease/condition or reduction in the pathology of a disease/condition.
  • the methods may be effective to prevent progression of the disease/condition, e.g. to prevent worsening of, or to slow the rate of development of, the disease/condition.
  • the methods may lead to an improvement in the disease/condition, e.g. a reduction in the symptoms of the disease/condition or reduction in some other correlate of the severity/activity of the disease/condition.
  • the methods may prevent development of the disease/condition a later stage (e.g. a chronic stage or metastasis).
  • the articles of the present invention may be used for the treatment/prevention of any disease/condition that would derived therapeutic or prophylactic benefit from a reduction in the number and/or activity of cells expressing CD47.
  • the disease/condition may be a disease/condition in which cells expressing CD47 are pathologically implicated, e.g. a disease/condition in which an increased number/proportion of cells expressing CD47 is positively associated with the onset, development or progression of the disease/condition, and/or severity of one or more symptoms of the disease/condition, or for which an increased number/proportion of cells expressing CD47, is a risk factor for the onset, development or progression of the disease/condition.
  • the disease/condition to be treated/prevented in accordance with the present invention is a disease/condition characterised by an increase in the number/proportion/activity of cells expressing CD47, e.g. as compared to the number/proportion/activity of cells expressing CD47 in the absence of the disease/condition.
  • the disease/condition to be treated/prevented is a cancer.
  • CD47 has been proposed to be a cell-surface marker expressed by all human cancers (Willingham et al. Proc Natl Acad Sci USA. (2012) 109(17): 6662-6667)
  • the cancer may be any unwanted cell proliferation (or any disease manifesting itself by unwanted cell proliferation), neoplasm or tumor.
  • the cancer may be benign or malignant and may be primary or secondary (metastatic).
  • a neoplasm or tumor may be any abnormal growth or proliferation of cells and may be located in any tissue.
  • the cancer may be of tissues/cells derived from e.g. the adrenal gland, adrenal medulla, anus, appendix, bladder, blood, bone, bone marrow, brain, breast, cecum, central nervous system (including or excluding the brain) cerebellum, cervix, colon, duodenum, endometrium, epithelial cells (e.g.
  • kidney oesophagus
  • glial cells heart, ileum, jejunum, kidney, lacrimal glad, larynx, liver, lung, lymph, lymph node, lymphoblast, maxilla, mediastinum, mesentery, myometrium, nasopharynx, omentum, oral cavity, ovary, pancreas, parotid gland, peripheral nervous system, peritoneum, pleura, prostate, salivary gland, sigmoid colon, skin, small intestine, soft tissues, spleen, stomach, testis, thymus, thyroid gland, tongue, tonsil, trachea, uterus, vulva, white blood cells.
  • Tumors to be treated may be nervous or non-nervous system tumors.
  • Nervous system tumors may originate either in the central or peripheral nervous system, e.g. glioma, medulloblastoma, meningioma, neurofibroma, ependymoma, Schwannoma, neurofibrosarcoma, astrocytoma and oligodendroglioma.
  • Non-nervous system cancers/tumors may originate in any other non-nervous tissue, examples include melanoma, mesothelioma, lymphoma, myeloma, leukemia, Non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma, chronic myelogenous leukemia (CML), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), cutaneous T-cell lymphoma (CTCL), chronic lymphocytic leukemia (CLL), hepatoma, epidermoid carcinoma, prostate carcinoma, breast cancer, lung cancer, colon cancer, ovarian cancer, pancreatic cancer, thymic carcinoma, NSCLC, hematologic cancer and sarcoma.
  • NHL Non-Hodgkin's lymphoma
  • CML chronic myelogenous leukemia
  • AML acute myeloid leukemia
  • MDS myelodysplastic syndrome
  • CTCL
  • the treatment/prevention may be aimed at one or more of: delaying/preventing the onset/progression of symptoms of the cancer, reducing the severity of symptoms of the cancer, reducing the survival/growth/invasion/metastasis of cells of the cancer, reducing the number of cells of the cancer and/or increasing survival of the subject.
  • the cancer to be treated/prevented comprises cells expressing CD47.
  • the cancer to be treated/prevented is a cancer which is positive for CD47.
  • the cancer over-expresses CD47. Overexpression of CD47 can be determined by detection of a level of expression of CD47 which is greater than the level of expression by equivalent non-cancerous cells/non-tumor tissue.
  • CD47 expression may be determined by any suitable means. Expression may be gene expression or protein expression. Gene expression can be determined e.g. by detection of mRNA encoding CD47, for example by quantitative real-time PCR (qRT-PCR). Protein expression can be determined e.g. by detection of CD47, for example by antibody-based methods, for example by western blot, immunohistochemistry, immunocytochemistry, flow cytometry, or ELISA.
  • qRT-PCR quantitative real-time PCR
  • a patient may be selected for treatment described herein based on the detection of a cancer expressing CD47, or overexpressing CD47, e.g. in a sample obtained from the subject.
  • CD47 has been shown to suppress innate macrophage and NK cell-mediated anticancer responses (Soto-Pantoja et al., Expert Opin Ther Targets. (2013) 17(1): 89-103, which is hereby incorporated by reference in its entirety).
  • CD47 is expressed by acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma (NHL), multiple myeloma (MM), bladder cancer, brain cancer and ovarian cancer cells.
  • AML acute myeloid leukemia
  • CML chronic myeloid leukemia
  • ALL acute lymphoblastic leukemia
  • NHL non-Hodgkin's lymphoma
  • MM multiple myeloma
  • CD47 has recently been shown to promote tumor invasion and metastasis in Non-small Cell Lung Cancer (NSCLC; Zhao et al., Sci Rep. (2016) 6: 29719) and melanoma (Ngo et al., Cell Reports (2016) 16, 1701-1716).
  • the cancer to be treated/prevented in accordance with the present invention is selected from: a hematologic malignancy, a myeloid hematologic malignancy, a lymphoblastic hematologic malignancy, myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma (NHL), multiple myeloma (MM), bladder cancer, brain cancer, glioblastoma, ovarian cancer, breast cancer, colon cancer, liver cancer, hepatocellular carcinoma, prostate cancer, lung cancer, Non-small Cell Lung Cancer (NSCLC), skin cancer and melanoma.
  • MDS myelodysplastic syndrome
  • AML acute myeloid leukemia
  • CML chronic myeloid leukemia
  • ALL acute lymphoblastic leukemia
  • NHL non-Hodgkin's lymphoma
  • MM multiple my
  • CD47 is a particularly attractive therapeutic targets for AML because it is highly expressed in all characterised AML cell lines, and play functional roles which therefore reduce risk of antigen loss.
  • the large population of tissue-resident macrophages in the liver (Kupffer cells) represents an attractive therapeutic mechanism for hematological malignancies, and macrophage-driven clearance of malignant cells offers a further route for neo-antigen presentation to adaptive immune system.
  • CD47 is also implicated in the pathogenesis of autoimmune diseases, inflammatory diseases, ischemia-reperfusion injury (IRI) and cardiovascular diseases (see e.g. Soto-Pantoja et al., Expert Opin Ther Targets. (2013) 17(1): 89-103).
  • the CD47-SIRP ⁇ axis has been implicated in type I diabetes (Dugas et al., J Autoimmun. (2010) 35(1):23-32).
  • Thrombospondin-1 has been shown to act via CD47 to inhibit nitric oxide signaling throughout the vascular system, and blocking TSP1-CD47 interaction alleviates tissue ischemia (Isenberg et al., Arterioscler Thromb Vasc Biol. (2008) 28(4): 615-621) and reduces ischemia-reperfusion injury (IRI) (Xiao et al., Liver Transpl. (2015) 21(4): 468-477).
  • the disease/disorder to be treated/prevented is a cancer, an autoimmune disease (e.g. type I diabetes), an inflammatory disease, ischemia-reperfusion injury (IRI) or cardiovascular disease.
  • an autoimmune disease e.g. type I diabetes
  • an inflammatory disease e.g. ischemia-reperfusion injury (IRI) or cardiovascular disease.
  • IRI ischemia-reperfusion injury
  • Administration of the articles of the present invention is preferably in a “therapeutically effective” or “prophylactically effective” amount, this being sufficient to show therapeutic or prophylactic benefit to the subject.
  • the actual amount administered, and rate and time-course of administration will depend on the nature and severity of the disease/condition and the particular article administered. Prescription of treatment, e.g. decisions on dosage etc., is within the responsibility of general practitioners and other medical doctors, and typically takes account of the disease/disorder to be treated, the condition of the individual subject, the site of delivery, the method of administration and other factors known to practitioners. Examples of the techniques and protocols mentioned above can be found in Remington's Pharmaceutical Sciences, 20th Edition, 2000, pub. Lippincott, Williams & Wilkins.
  • Administration may be alone or in combination with other treatments, either simultaneously or sequentially dependent upon the condition to be treated.
  • the antigen-binding molecule or composition described herein and a therapeutic agent may be administered simultaneously or sequentially.
  • the methods comprise additional therapeutic or prophylactic intervention, e.g. for the treatment/prevention of a cancer.
  • the therapeutic or prophylactic intervention is selected from chemotherapy, immunotherapy, radiotherapy, surgery, vaccination and/or hormone therapy.
  • the therapeutic or prophylactic intervention comprises leukapheresis.
  • the therapeutic or prophylactic intervention comprises a stem cell transplant.
  • the antigen-binding molecules of the present invention are particularly suitable for use in conjunction with radiotherapy.
  • Antagonism of CD47 has previously been shown to help maintain the viability of normal tissues after irradiation, while increasing the radiosensitivity of tumors (Maxhimer et al., Science Translational Medicine (2009) 1(3): 3ra7).
  • Simultaneous administration refers to administration of the antigen-binding molecule, polypeptide, CAR, nucleic acid (or plurality thereof), expression vector (or plurality thereof), cell or composition and therapeutic agent together, for example as a pharmaceutical composition containing both agents (combined preparation), or immediately after each other and optionally via the same route of administration, e.g. to the same artery, vein or other blood vessel.
  • Sequential administration refers to administration of one of the antigen-binding molecule/composition or therapeutic agent followed after a given time interval by separate administration of the other agent. It is not required that the two agents are administered by the same route, although this is the case in some embodiments.
  • the time interval may be any time interval.
  • Chemotherapy and radiotherapy respectively refer to treatment of a cancer with a drug or with ionising radiation (e.g. radiotherapy using X-rays or ⁇ -rays).
  • the drug may be a chemical entity, e.g. small molecule pharmaceutical, antibiotic, DNA intercalator, protein inhibitor (e.g. kinase inhibitor), or a biological agent, e.g. antibody, antibody fragment, aptamer, nucleic acid (e.g. DNA, RNA), peptide, polypeptide, or protein.
  • the drug may be formulated as a pharmaceutical composition or medicament.
  • the formulation may comprise one or more drugs (e.g. one or more active agents) together with one or more pharmaceutically acceptable diluents, excipients or carriers.
  • a treatment may involve administration of more than one drug.
  • a drug may be administered alone or in combination with other treatments, either simultaneously or sequentially dependent upon the condition to be treated.
  • the chemotherapy may be a co-therapy involving administration of two drugs, one or more of which may be intended to treat the cancer.
  • the chemotherapy may be administered by one or more routes of administration, e.g. parenteral, intravenous injection, oral, subcutaneous, intradermal or intratumoral.
  • routes of administration e.g. parenteral, intravenous injection, oral, subcutaneous, intradermal or intratumoral.
  • the chemotherapy may be administered according to a treatment regime.
  • the treatment regime may be a pre-determined timetable, plan, scheme or schedule of chemotherapy administration which may be prepared by a physician or medical practitioner and may be tailored to suit the patient requiring treatment.
  • the treatment regime may indicate one or more of: the type of chemotherapy to administer to the patient; the dose of each drug or radiation; the time interval between administrations; the length of each treatment; the number and nature of any treatment holidays, if any etc.
  • a single treatment regime may be provided which indicates how each drug is to be administered.
  • Chemotherapeutic drugs may be selected from: Abemaciclib, Abiraterone Acetate, Abitrexate (Methotrexate), Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation), ABVD, ABVE, ABVE-PC, AC, Acalabrutinib, AC-T, Adcetris (Brentuximab Vedotin), ADE, Ado-Trastuzumab Emtansine, Adriamycin (Doxorubicin Hydrochloride), Afatinib Dimaleate, Afinitor (Everolimus), Akynzeo (Netupitant and Palonosetron Hydrochloride), Aldara (Imiquimod), Aldesleukin, Alecensa (Alectinib), Alectinib, Alemtuzumab, Alimta (Pemetrexed Disodium), Aliqopa (Copanlisib Hydrochloride), Alkeran for
  • the chemotherapeutic agent is selected from one or more of: cytarabine, 5-azacytidine (5-AZA), valproic acid (VPA), all-trans retinoic acid (ATRA), decitabine, sodium phenylbutyrate, hydrozyurea, 6-mercaptopurine (6-MP), 6-thioguanine (6-TG), Mocetinostat (MGCD0103), Panobinostat (LBH-589), romidepsin, an antracycline, daunorubicin, daunomycin, idarubicin, cladribine (Leustatin, 2-CdA), midostaurin, fludarabine (Fludara) and topotecan.
  • cytarabine 5-azacytidine
  • VPA valproic acid
  • ATRA all-trans retinoic acid
  • decitabine sodium phenylbutyrate
  • hydrozyurea 6-mercaptopurine (6-MP), 6-thioguan
  • the chemotherapeutic agent is histone deacetylase (HDAC) inhibitor, e.g. a HDAC inhibitor described in Fredly et al., Clin Epigenetics. (2013) 5(1):12 (hereby incorporated by reference in its entirety).
  • HDAC histone deacetylase
  • the chemotherapeutic agent is cytarabine.
  • Multiple doses of the producing an antigen-binding molecule, polypeptide, CAR, nucleic acid (or plurality thereof), expression vector (or plurality thereof), cell or composition may be provided.
  • One or more, or each, of the doses may be accompanied by simultaneous or sequential administration of another therapeutic agent.
  • Multiple doses may be separated by a predetermined time interval, which may be selected to be one of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or 31 days, or 1, 2, 3, 4, 5, or 6 months.
  • doses may be given once every 7, 14, 21 or 28 days (plus or minus 3, 2, or 1 days).
  • the invention also provides the articles of the present invention for use in methods for detecting, localizing or imaging CD47, or cells expressing CD47.
  • the antigen-binding molecules described herein may be used in methods that involve the antigen-binding molecule to CD47. Such methods may involve detection of the bound complex of the antigen-binding molecule and CD47.
  • a method comprising contacting a sample containing, or suspected to contain, CD47, and detecting the formation of a complex of the antigen-binding molecule and CD47. Also provided is a method comprising contacting a sample containing, or suspected to contain, a cell expressing CD47, and detecting the formation of a complex of the antigen-binding molecule and a cell expressing CD47.
  • Suitable method formats are well known in the art, including immunoassays such as sandwich assays, e.g. ELISA.
  • the methods may involve labelling the antigen-binding molecule, or target(s), or both, with a detectable moiety, e.g. a fluorescent label, phosphorescent label, luminescent label, immuno-detectable label, radiolabel, chemical, nucleic acid or enzymatic label as described herein.
  • Detection techniques are well known to those of skill in the art and can be selected to correspond with the labelling agent.
  • Methods of this kind may provide the basis of methods for the diagnostic and/or prognostic evaluation of a disease or condition, e.g. a cancer. Such methods may be performed in vitro on a patient sample, or following processing of a patient sample. Once the sample is collected, the patient is not required to be present for the in vitro method to be performed, and therefore the method may be one which is not practised on the human or animal body. In some embodiments the method is performed in vivo.
  • Detection in a sample may be used for the purpose of diagnosis of a disease/condition (e.g. a cancer), predisposition to a disease/condition, or for providing a prognosis (prognosticating) for a disease/condition, e.g. a disease/condition described herein.
  • the diagnosis or prognosis may relate to an existing (previously diagnosed) disease/condition.
  • Such methods may involve detecting or quantifying one or more of CD47 or cells expressing CD47, e.g. in a patient sample. Where the method comprises quantifying the relevant factor, the method may further comprise comparing the determined amount against a standard or reference value as part of the diagnostic or prognostic evaluation. Other diagnostic/prognostic tests may be used in conjunction with those described herein to enhance the accuracy of the diagnosis or prognosis or to confirm a result obtained by using the tests described herein.
  • a sample may be taken from any tissue or bodily fluid.
  • the sample may comprise or may be derived from: a quantity of blood; a quantity of serum derived from the individual's blood which may comprise the fluid portion of the blood obtained after removal of the fibrin clot and blood cells; a tissue sample or biopsy; pleural fluid; cerebrospinal fluid (CSF); or cells isolated from said individual.
  • the sample may be obtained or derived from a tissue or tissues which are affected by the disease/condition (e.g. tissue or tissues in which symptoms of the disease manifest, or which are involved in the pathogenesis of the disease/condition).
  • the present invention also provides methods for selecting/stratifying a subject for treatment with a CD47-targeted agent.
  • a subject is selected for treatment/prevention in accordance with the invention, or is identified as a subject which would benefit from such treatment/prevention, based on detection/quantification of CD47, or cells expressing CD47, e.g. in a sample obtained from the individual.
  • the subject in accordance with aspects the invention described herein may be any animal or human.
  • the subject is preferably mammalian, more preferably human.
  • the subject may be a non-human mammal, but is more preferably human.
  • the subject may be male or female.
  • the subject may be a patient.
  • a subject may have been diagnosed with a disease or condition requiring treatment (e.g. a cancer), may be suspected of having such a disease/condition, or may be at risk of developing/contracting such a disease/condition.
  • a disease or condition requiring treatment e.g. a cancer
  • the subject is preferably a human subject.
  • the subject to be treated according to a therapeutic or prophylactic method of the invention herein is a subject having, or at risk of developing, a cancer.
  • a subject may be selected for treatment according to the methods based on characterisation for certain markers of such disease/condition.
  • kit of parts may have at least one container having a predetermined quantity of an antigen-binding molecule, polypeptide, CAR, nucleic acid (or plurality thereof), expression vector (or plurality thereof), cell or composition described herein.
  • the kit may comprise materials for producing an antigen-binding molecule, polypeptide, CAR, nucleic acid (or plurality thereof), expression vector (or plurality thereof), cell or composition described herein.
  • the kit may provide the antigen-binding molecule, polypeptide, CAR, nucleic acid (or plurality thereof), expression vector (or plurality thereof), cell or composition together with instructions for administration to a patient in order to treat a specified disease/condition.
  • the kit may further comprise at least one container having a predetermined quantity of another therapeutic agent (e.g. anti-infective agent or chemotherapy agent).
  • the kit may also comprise a second medicament or pharmaceutical composition such that the two medicaments or pharmaceutical compositions may be administered simultaneously or separately such that they provide a combined treatment for the specific disease or condition.
  • the therapeutic agent may also be formulated so as to be suitable for injection or infusion to a tumor or to the blood.
  • sequence identity refers to the percent of nucleotides/amino acid residues in a subject sequence that are identical to nucleotides/amino acid residues in a reference sequence, after aligning the sequences and, if necessary, introducing gaps, to achieve the maximum percent sequence identity between the sequences. Pairwise and multiple sequence alignment for the purposes of determining percent sequence identity between two or more amino acid or nucleic acid sequences can be achieved in various ways known to a person of skill in the art, for instance, using publicly available computer software such as ClustalOmega (Söding, J. 2005, Bioinformatics 21, 951-960), T-coffee (Notredame et al. 2000, J. Mol. Biol.
  • the invention includes the combination of the aspects and preferred features described except where such a combination is clearly impermissible or expressly avoided.
  • in vitro is intended to encompass procedures performed with cells in culture whereas the term “in vivo” is intended to encompass procedures with/on intact multi-cellular organisms.
  • FIG. 1 Ribbon diagram showing the 3D structure of interacting SIPRP ⁇ and CD47 domains, with regions used as immunogens for raising anti-CD47 antibodies overlain with spheres.
  • FIGS. 2A and 2B Sensorgrams showing affinity of binding of anti-CD47 antibodies to human CD47.
  • 2 A Sensorgram for 1-1-A1.
  • 2 B Sensorgram for 1-1-A1_BM.
  • FIGS. 3A to 3D Histograms showing staining of CD47-expressing cells by anti-CD47 antibodies as determined by flow cytometry.
  • 3 A Histogram showing staining of HEK293T cells (which express CD47), or HEK293T-derived CD47 knockout cells, by anti-CD47 antibody clone 1-1-A1 or isotype control antibody.
  • 3 B Histogram showing staining of HEK293T cells, or HEK293T-derived CD47 knockout cells, by anti-CD47 antibody clone 1-1-A1_BM or isotype control antibody.
  • FIG. 3 C Histogram showing staining of HEK293T cells, or HEK293T-derived CD47 knockout cells, by anti-CD47 antibody clone B6H12 or isotype control antibody.
  • 3 D Histogram showing staining of MM.1S cells, H929 cells, U226 cells, 8226 cells and RAJI cells by anti-CD47 antibody clone B6H12.
  • FIG. 4 Bar chart showing inhibition of interaction between human CD47 and human SIRP ⁇ by antigen-binding molecules as determined by ELISA.
  • FIG. 5 Graph showing binding to human CD47 (hCD47) and rhesus macaque CD47 (RhCD47) by the indicated antigen-binding molecules, as determined by ELISA.
  • FIG. 6 Histogram showing phagocytosis of CFSE-labelled Raji cells by macrophages in the presence of the indicated antigen-binding molecules or PBS, as determined by flow cytometry.
  • FIGS. 7A to 7C Fluorescence microscopy images and bar chart showing phagocytosis of CFSE-labelled HL-60 cells by macrophages in the presence of the indicated antigen-binding molecules.
  • 7 A and 7 B Images showing binding phagocytosis in the presence of ( 7 A) isotype control antibody (negative control), ( 7 B) anti-CD47 clone 1-1-A1_BM IgG1, ( 7 C) Bar chart summarising phagocytic indices for CFSE-labelled HL-60 cells by macrophages in the presence of the indicated antigen-binding molecules.
  • FIG. 8 Sensorgram showing affinity of binding of anti-CD47 antibody 1-1-A1_BM to human CD47.
  • FIG. 9 Graph showing binding to human CD47 by the indicated antigen-binding molecules, as determined by ELISA.
  • FIG. 10 Graph showing binding to human VISTA by the indicated antigen-binding molecules, as determined by ELISA.
  • FIGS. 11A to 11H Sensorgrams showing affinity of binding of anti-CD47 antibodies to human CD47.
  • 11 A Sensorgram for 11A1_BM.
  • 11 B Sensorgram for 11A1H3.
  • 11 C Sensorgram for 11A1H5.
  • 11 D Sensorgram for 11A1H6.
  • 11 E Sensorgram for 11A1H7.
  • 11 F Sensorgram for 11A1H9.
  • 11 G Sensorgram for 11A1H10.
  • 11 H Sensorgram for 11A1H11.
  • FIG. 12 Graph showing inhibition of interaction between human CD47 and SIRP ⁇ by the indicated antigen-binding molecules, as determined by ELISA.
  • FIG. 13 Images showing the results of analysis of hemagglutination by the indicated antigen-binding molecules.
  • Positive control anti-red blood cells antibody (ANTI RBC)
  • negative control isotype matched antibody specific for an irrelevant target antigen (Irrelevant Ag)
  • buffer only (BUFFER).
  • the inventors describe the generation of novel CD47-specific antibody clones targeted to specific regions of interest in the CD47 molecule, the biophysical and functional characterisation and the therapeutic evaluation of these antigen-binding molecules.
  • the inventors selected two regions in the Ig-like V region (SEQ ID NO:9) of the extracellular region 1 of human CD47 (SEQ ID NO:10) for raising CD47-binding monoclonal antibodies.
  • the inventors focused on regions of CD47 known to be involved in the interaction between CD47 and SIRP ⁇ ( FIG. 1 ).
  • mice Approximately 6 week old female BALB/c mice were obtained from InVivos (Singapore). Animals were housed under specific pathogen-free conditions and were treated in compliance with the Institutional Animal Care and Use Committee (IACUC) guidelines.
  • IACUC Institutional Animal Care and Use Committee
  • mice were immunized with proprietary mixtures of antigenic peptide for a total of 4 intraperitoneal injections with a 2 week interval between each injection.
  • Antigen for immunizations included one of the following:
  • mice Prior to harvesting the spleen for fusion, mice were boosted with antigen mixture for three consecutive days. 24 h after the final boost total splenocytes were isolated and fused with the myeloma cell line P3X63.Ag8.653 (ATCC, USA), with PEG using ClonaCell-HY Hybridoma Cloning Kit, in accordance with the manufacturer's instructions (Stemcell Technologies, Canada).
  • Fused cells were cultured in ClonaCell-HY Medium C (Stemcell Technologies, Canada) overnight at 37° C. in a 5% CO 2 incubator. The next day, fused cells were centrifuged and resuspended in 10 ml of ClonaCell-HY Medium C and then gently mixed with 90 ml of semisolid methylcellulose-based ClonaCell-HY Medium D (StemCell Technologies, Canada) containing HAT components, which combines the hybridoma selection and cloning into one step.
  • the fused cells were then plated into 96 well plates and allowed to grow at 37° C. in a 5% CO 2 incubator. After 7-10 days, single hybridoma clones were isolated and antibody producing hybridomas were selected by screening the supernatants by Enzyme-linked immunosorbent assay (ELISA) and Fluorescence-activated cell sorting (FACs).
  • ELISA Enzyme-linked immunosorbent assay
  • FACs Fluorescence-activated cell sorting
  • cDNA synthesis reactions contained: 5 ⁇ First-Strand Buffer, DTT (20 mM), dNTP Mix (10 mM), RNase Inhibitor (40 U/ ⁇ l) and SMARTScribe Reverse Transcriptase (100 U/ ⁇ l).
  • the race-ready cDNAs were amplified using SeqAmp DNA Polymerase (ClontechTM, USA).
  • Amplification reactions contained SeqAmp DNA Polymerase, 2 ⁇ Seq AMP buffer, 5′ universal primer provided in the 5′ SMARTer Race kit, that is complement to the adaptor sequence, and 3′ primers that anneal to respective heavy chain or light chain constant region primer.
  • the 5′ constant region were designed based on previously reported primer mix either by Krebber et al. J. Immunol. Methods 1997; 201: 35-55, Wang et al. Journal of Immunological Methods 2000, 233; 167-177 or Tiller et al. Journal of Immunological Methods 2009; 350:183-193.
  • VH and VL PCR products were cloned into pJET1.2/blunt vector using CloneJET PCR Cloning Kit (Thermo Scientific, USA) and used to transform highly competent E. coli DH5 ⁇ .
  • plasmid DNA was prepared using Miniprep Kit (Qiagene, Germany) and sequenced. DNA sequencing was carried out by AlTbiotech. These sequencing data were analyzed using the international IMGT (ImMunoGeneTics) information system (LeFranc et al., Nucleic Acids Res. (2015) 43 (Database issue):D413-22) to characterize the individual CDRs and framework sequences.
  • the signal peptide at 5′ end of the VH and VL was identified by SignalP (v 4.1; Nielsen, in Kihara, D (ed): Protein Function Prediction (Methods in Molecular Biology vol. 1611) 59-73, Springer 2017).
  • a humanised version of antibody clone 1-1-A1 was also prepared according to standard methods by cloning the CDRs of antibody clone 1-1-A1 into VH and VL comprising human antibody framework regions. This antibody clone was designated antibody clone 1-1-A1_BM.
  • VH SEQ ID NO: 23
  • VL SEQ ID NO: 31
  • 1-1-A1 VH SEQ ID NO: 39
  • VL SEQ ID NO: 44
  • 5-48-A6 VH SEQ ID NO: 49
  • VL SEQ ID NO: 57
  • 5-48-D2 VH SEQ ID NO: 65
  • VL SEQ ID NO: 73
  • Human IgG1 constant region encoded by pFUSE-CHIg-hG1 comprises the substitutions D356E, L358M (positions numbered according to EU numbering) in the CH3 region relative to Human IgG1 constant region (IGHG1; UniProt:P01857-1, v1).
  • pFUSE2ss-CLIg-hk encodes human IgG1 light chain kappa constant region (IGCK; UniProt: P01834-1, v2).
  • Variable regions along with the signal peptides were amplified from the cloning vector using SeqAmp enzyme (ClontechTM, USA) following the manufacturer's protocol. Forward and reverse primers having 15-20 bp overlap with the appropriate regions within VH or VL plus 6 bp at 5′ end as restriction sites were used.
  • the DNA insert and the pFuse vector were digested with restriction enzyme recommended by the manufacturer to ensure no frameshift was introduced (e.g., EcoRI and NheI for VH, AgeI and BsiWI for VL,) and ligated into its respective plasmid using T4 ligase enzyme (Thermo Scientific, USA). The molar ratio of 3:1 of DNA insert to vector was used for ligation.
  • Antibodies were expressed using either 1) Expi293 Transient Expression System Kit (Life Technologies, USA), or 2) HEK293-6E Transient Expression System (CNRC-NRC, Canada) following the manufacturer's instructions.
  • HEK293F cells (Expi293F) were obtained from Life Technologies, Inc (USA). Cells were cultured in serum-free, protein-free, chemically defined medium (Expi293 Expression Medium, Thermo Fisher, USA), supplemented with 50 IU/ml penicillin and 50 ⁇ g/ml streptomycine (Gibco, USA) at 37° C., in 8% CO 2 and 80% humidified incubators with shaking platform.
  • Expi293F cells were transfected with expression plasmids using ExpiFectamine 293 Reagent kit (Gibco, USA) according to its manufacturer's protocol. Briefly, cells at maintenance were subjected to a media exchange to remove antibiotics by spinning down the culture, cell pellets were re-suspended in fresh media without antibiotics at 1 day before transfection. On the day of transfection, 2.5 ⁇ 10 6 /ml of viable cells were seeded in shaker flasks for each transfection. DNA-ExpiFectamine complexes were formed in serum-reduced medium, Opti-MEM (Gibco, USA), for 25 min at room temperature before being added to the cells.
  • Opti-MEM serum-reduced medium
  • Enhancers were added to the transfected cells at 16-18 h post transfection. An equal amount of media was topped up to the transfectants at day 4 post-transfection to prevent cell aggregation. Transfectants were harvested at day 7 by centrifugation at 4000 ⁇ g for 15 min, and filtered through 0.22 ⁇ m sterile filter units.
  • HEK293-6E cells were obtained from National Research Council Canada. Cells were cultured in serum-free, protein-free, chemically defined Freestyle F17 Medium (Invitrogen, USA), supplemented with 0.1% Kolliphor-P188 and 4 mM L-Glutamine (Gibco, USA) and 25 ⁇ g/ml G-418 at 37° C., in 5% CO 2 and 80% humidified incubators with shaking platform.
  • HEK293-6E cells were transfected with expression plasmids using PEIproTM (Polyplus, USA) according to its manufacturer's protocol. Briefly, cells at maintenance were subjected to a media exchange to remove antibiotics by centrifugation, cell pellets were re-suspended with fresh media without antibiotics at 1 day before transfection. On the day of transfection, 1.5-2 ⁇ 10 6 cells/ml of viable cells were seeded in shaker flasks for each transfection. DNA and PEIproTM were mixed to a ratio of 1:1 and the complexes were allowed to form in F17 medium for 5 min at RT before adding to the cells. 0.5% (w/v) of Tryptone N1 was fed to transfectants at 24-48 h post transfection. Transfectants were harvested at day 6-7 by centrifugation at 4000 ⁇ g for 15 min and the supernatant was filtered through 0.22 ⁇ m sterile filter units.
  • PEIproTM Polyplus, USA
  • Antigen- binding molecule Polypeptides Antibody [1] 1-1-A1_BM anti-CD47 clone VH-CH1-CH2-CH3 1-1-A1_BM IgG1 (SEQ ID NO: 107) + 1-1-A1_BM VL-C K (SEQ ID NO: 108) [2] 1-1-A1 anti-CD47 clone VH-CH1-CH2-CH3 1-1-A1 IgG1 (SEQ ID NO: 109) + 1-1-A1 VL-C K (SEQ ID NO: 110) [3] 5-48-A6 anti-CD47 clone VH-CH1-CH2-CH3 5-48-A6 IgG1 (SEQ ID NO: 111) + 5-48-A6 VL-C K (SEQ ID NO: 112) [4] 5-48-D2 anti-CD47 clone VH-CH1-CH2-CH3 5-48-D2 IgG1 (SEQ ID NO: 113) + 5-48-D2 V
  • Antibodies secreted by the transfected cells into the culture supernatant were purified using liquid chromatography system AKTA Start (GE Healthcare, UK). Specifically, supernatants were loaded onto HiTrap Protein G column (GE Healthcare, UK) at a binding rate of 5 ml/min, followed by washing the column with 10 column volumes of washing buffer (20 mM sodium phosphate, pH 7.0). Bound mAbs were eluted with elution buffer (0.1 M glycine, pH 2.7) and the eluents were fractionated to collection tubes which contain appropriate amount of neutralization buffer (1 M Tris, pH 9).
  • Neutralised elution buffer containing purified mAb were exchanged into PBS using 30K MWCO protein concentrators (Thermo Fisher, USA) or 3.5K MWCO dialysis cassettes (Thermo Fisher, USA). Monoclonal antibodies were sterilized by passing through 0.22 ⁇ m filter, aliquoted and snap-frozen in ⁇ 80° C. for storage.
  • Antibody purity was analyzed by size exclusion chromatography (SEC) using HiLoad 16/600 Superdex 200 ⁇ g column (GE Healthcare, UK) on a AKTA Explorer liquid chromatography system (GE Healthcare, UK). Protein samples are injected to SEC column at concentrations ranging between 0.2-1.5 mg/ml and 1 ⁇ PBS was pumped to the column at a flow rate of 1 ml/min. Proteins were eluted according to their molecular weights.
  • SEC size exclusion chromatography
  • Antibody purity was also analysed by SDS-PAGE under reducing and non-reducing conditions according to standard methods. Briefly, 4%-20% TGX protein gels (Bio-Rad, USA) were used to resolve proteins using a Mini-Protean Electrophoresis System (Bio-Rad, USA). For non-reducing condition, protein samples were denatured by mixing with 2 ⁇ Laemmli sample buffer (Bio-Rad, USA) and boiled at 95° C. for 5-10 min before loading to the gel. For reducing conditions, 2 ⁇ sample buffer containing 5% of ⁇ -mercaptoethanol ( ⁇ ME), or 40 mM DTT (dithiothreitol) was used. Electrophoresis was carried out at a constant voltage of 150V for 1 h in SDS running buffer (25 mM Tris, 192 mM glycine, 1% SDS, pH 8.3).
  • Bio-Layer Interferometry (BLI) experiments were performed using a single channel BLItz system (ForteBio, Menlo Park, Calif.) using Anti-human immunoglobulin G (IgG) Fc (AHC) coated biosensor tips (Pall ForteBio, Menlo Park, Calif.) for capturing human IgGs.
  • Biosensors were first hydrated for at least 10 m in assay buffer (phosphate buffered saline) followed by buffer baseline for 30 s and loading of the human IgGs onto the biosensor tips at concentrations ranging from 25-50 nM for 120 s.
  • the tips were then washed briefly for 30 s with the assay buffer to remove nonspecifically bound proteins or unbound IgGs for obtaining a second buffer baseline.
  • the association phase of the IgGs with antigens 500 nM-0 nM was set up at 120 s which was followed by a dissociation phase (assay buffer alone) for 120 s.
  • All the BLITz runs were measured at room temperature at a stirring speed of 1000 rpm and AHC biosensors were regenerated using 10 mM of glycine (pH 2.7) after the assay. Binding affinity between the immobilized antibodies on the AHC sensors and human CD47 were determined by analyzing the binding kinetic curves using the software BLItz Pro.
  • the anti-CD47 antibody clones in IgG1 format were analyzed for binding affinity to human CD47.
  • FIGS. 2A and 2B Representative sensorgrams for the analysis are shown in FIGS. 2A and 2B .
  • Clone 1-1-A1 was found to have a K D of 9 nM
  • 1-1-A1_BM was found to have a K D of 16.1 nM.
  • HEK293T cells which express high levels of CD47
  • cells of a HEK293T cell-derived CD47 knockout cell line were incubated with 20 ⁇ g/ml of anti-CD47 antibody or isotype control antibody at 4° C. for 1 hr.
  • the anti-CD47 antibody clone B6H12 (Santa Cruz Biotechnology, cat no. sc-12730) was included in the analysis as a positive control.
  • the cells were washed thrice with FACS buffer (PBS with 5 mM EDTA and 0.5% BSA) and resuspended in FITC-conjugated anti-FC antibody (Invitrogen, USA) for 40 min at 2-8° C. Cells were washed again and resuspended in 200 ⁇ L of FACS flow buffer (PBS with 5 mM EDTA) for flow cytometric analysis using MACSQuant 10 (Miltenyi Biotec, Germany). After acquisition, all raw data were analyzed using Flowlogic software. Cells were gated using forward and side scatter profile and Median of Fluorescence Intensity (MFI) value was determined for native and overexpressing cell populations.
  • FACS buffer PBS with 5 mM EDTA and 0.5% BSA
  • FITC-conjugated anti-FC antibody Invitrogen, USA
  • FIGS. 3A and 3B show the results obtained using clones 1-1-A1 and 1-1-A1_BM
  • FIG. 3C shows results obtained using the commercially-available anti-CD47 antibody clone B6H12 (positive control).
  • ELISAs were used to determine the binding specificity of the antibodies.
  • the antibodies were tested against target peptide and protein as well as respective mouse, rat and monkey homologues (Sino Biological Inc., China).
  • ELISAs were carried out according to standard protocols. Briefly, 96-well plates (Nunc, Denmark) were coated with 1 ⁇ g/ml of Fc-tagged human CD47 in phosphate-buffered saline (PBS) for 16 h at 4° C. After blocking for 1 h with 1% BSA in Tris buffer saline (TBS) at room temperature, the candidate antigen-binding molecule was serially diluted with the highest conc. being 10 ⁇ g/ml and added to the plate.
  • PBS phosphate-buffered saline
  • TBS Tris buffer saline
  • 96-well plates (Nunc, Denmark) were coated with 1 ⁇ g/ml of untagged human CD47 protein (Sinobiological Inc, China) in 1 ⁇ PBS for 16 h at 4° C. After blocking for 1 h with 1% BSA in TBS at room temperature, 1 ⁇ g/ml of SIRP ⁇ /human His tagged fusion protein (Sinobiological Inc, China) was added either in the absence of antibody, or in the presence of increasing concentrations of anti-CD47 antibody at room temperature for 1 hr. Plates were subsequently washed three times with TBS-T and incubated with an HRP-conjugated anti-his secondary antibody (Thermo Scientific, USA) for 1 h at room temperature. After washing, plates were developed with colorimetric detection substrate Turbo-TMB (Pierce, USA). The reaction was stopped with 2M H2504, and OD was measured at 450 nM.
  • phagocytosis assays were performed according to standard protocols. Briefly, Raji or HL60 cells were cultured in RPMI-1640 supplemented with 10% fetal bovine serum (FBS) and 1% Pen/Strep at 37° C. in a 5% CO 2 incubator. HL-60 or Raji cells were then harvested and CFSE-labelled using CellTrace CFSE Cell Proliferation Kit (Thermo Scientific, USA), in accordance with the manufacturer's protocol. The labelled cells were then incubated with human peripheral blood-derived macrophages (Stemcell Technologies, Canada) in the presence of 20 ⁇ g/ml of anti-CD47 antibody, or an isotype control antibody for 2 h at 37° C.
  • FBS fetal bovine serum
  • Pen/Strep pen/Strep
  • HL-60 or Raji cells were then harvested and CFSE-labelled using CellTrace CFSE Cell Proliferation Kit (Thermo Scientific, USA), in accordance with the manufacturer's protocol.
  • antigen-binding molecules were analysed for their ability to promote phagocytosis of CSFE-labelled Raji cells by macrophages, compared to a negative control condition in which PBS was added instead of antibodies.
  • Anti-CD47 antibody clone B6H12 (Santa Cruz Biotechnology, cat no. sc-12730) was included as a positive control condition.
  • Anti-CD47 clone 1-1-A1_BM IgG1 was found to be extremely potent at promoting phagocytosis of Raji cells by macrophages.
  • antigen-binding molecules were analysed for their ability to promote phagocytosis of CSFE-labelled HL-60 cells by macrophages, as determined by fluorescence microscopy. Phagocytic index was calculated as the number of engulfed CFSE-labelled HL-60 cells per phagocyte, for 200 cells using the fluorescence microscope.
  • the anti-CD47 clone 1-1-A1_BM IgG1 ([1] of Example 2.2) was analysed in the experiment, and an isotype control condition was included as a negative control.
  • Anti-CD47 clone 1-1-A1_BM IgG1 was shown to be potent at inducing phagocytosis of HL-60 cells by macrophages.
  • the binding specificity of the humanised versions of anti-CD47 clone 1-1-A1 was analysed be ELISA.
  • 96-well plates (Nunc, Denmark) were coated with 1 ⁇ g/ml of human CD47 or VISTA protein in PBS, for 1 h at room temperature. Plates were blocked for 1 h at room temperature with 1% BSA in Tris buffer saline containing 0.05% Tween 20 (TBS-T). The test antigen-binding molecules were added at concentrations ranging from to 0.002 ⁇ g/ml to 200 ⁇ g/ml, and the plates were incubated at room temperature for 1 h. Plates were then washed three times with TBS-T, and were then incubated with a HRP-conjugated secondary antibody for 1 h at room temperature.
  • TBS-T Tris buffer saline containing 0.05% Tween 20
  • the results are shown in FIG. 9 .
  • the humanised antibodies displayed binding to human CD47.
  • EC50 values were calculated, and the fold increase in EC50 value relative to EC50 for 1-1-A1_BM are shown below.
  • Anti-human VISTA antibody VSTB112 (described e.g. in WO 2015/097536) was included as a positive control.
  • the results are shown in FIG. 10 .
  • the humanised antibodies were found not to cross-react with human VISTA.
  • the affinity of binding of humanised versions of anti-CD47 clone 1-1-A1 to human CD47 was in BLI experiments performed using a single channel BLItz system (ForteBio, Menlo Park, Calif.) using Anti-human immunoglobulin G (IgG) Fc (AHC) coated biosensor tips (Pall ForteBio, Menlo Park, Calif.) for capturing human IgGs.
  • Biosensors were first hydrated for at least 10 m in assay buffer (phosphate buffered saline) followed by buffer baseline for 60 s and loading of the human IgGs onto the biosensor tips at 25 nM for 120 s.
  • the tips were then washed briefly for 60 s with the assay buffer to remove nonspecifically bound proteins or unbound IgGs for obtaining a second buffer baseline.
  • the association phase of the IgGs with antigens 250 nM to 62.5 nM was set up at 120 s which was followed by a dissociation phase (assay buffer alone) for 120 s.
  • All the BLITz runs were measured at room temperature at a stirring speed of 1000 rpm and AHC biosensors were regenerated using 10 mM of glycine (pH 2.7) after the assay. Binding affinity between the immobilized antibodies on the AHC sensors and human CD47 were determined by analyzing the binding kinetic curves using the software BLItz Pro.
  • FIGS. 11A to 11H Representative sensorgrams are shown in FIGS. 11A to 11H , and the calculated kinetic and thermodynamic constants are shown below.
  • the hemagglutinating capacity of the humanised versions of anti-CD47 antibody clone 1-1-A1 was investigated using an in vitro hemagglutination assay.
  • human RBCs were prepared by extensively washing blood with 1 ⁇ PBS and centrifuging at 1500 rpm for 5 min, until a clear supernatant was observed.
  • 1% human RBCs were incubated for 1 hr at RT in presence or absence of increasing concentrations of the test antigen-binding molecules in a round bottom 96 well plate. Presence of hemagglutination was accessed by the presence of non-settled RBCs, appearing as a haze compared to a punctuated red dot of non-hemagglutinated RBCs.
  • An anti-red blood cells antibody (AbCam, cat. no. ab34858) condition was included as a positive control for hemagglutination, and an isotype control antibody condition was included as a negative control.

Abstract

CD47 antigen-binding molecules are disclosed. Also disclosed are nucleic acids and expression vectors encoding, compositions comprising, and methods using, the CD47 antigen-binding molecules.

Description

    RELATED APPLICATIONS
  • This application is a national stage filing under 35 U.S.C. 371 of International Patent Application Serial No. PCT/EP2018/079931, filed Nov. 1, 2018, which claims priority to British Application No. GB 1718101.7, filed Nov. 1, 2017, British Application No. GB 1720425.6, filed Dec. 7, 2017 and British Application No. GB 1720426.4, filed Dec. 7, 2017, the contents and elements of each of which are herein incorporated by reference for all purposes.
    • SEQUENCE LISTING
  • The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on May 6, 2022, is named H096970002US00-SUBSEQ-AZW and is 193,533 bytes in size.
    • FIELD OF THE INVENTION
  • The present invention relates to the fields of molecular biology, more specifically antibody technology. The present invention also relates to methods of medical treatment and prophylaxis.
    • BACKGROUND TO THE INVENTION
  • CD47 is the “don't-eat-me” signal and is ubiquitously expressed on normal cells where binding to SIRPα on macrophages inhibits phagocytosis. CD47 is commonly over-expressed in tumors where it correlates with immune evasion and poor prognosis. Blocking CD47-SIRPalpha interaction restores macrophage phagocytosis of tumor cells and anti-CD47 mAbs have shown anti-tumor efficacy in mouse models of solid tumors and hematological malignancies.
  • WO 2014/087248 A2 discloses monospecific anti-CD47 antibodies having an affinity for human CD47 as high as ˜23.6 nM. The high-affinity CD47 antibodies disclosed therein induce substantial hemagglutination (see e.g. Example 8 of WO 2014/087248 A2).
    • SUMMARY OF THE INVENTION
  • In a first aspect, the present invention provides an antigen-binding molecule, optionally isolated, which is capable of binding to CD47.
  • Also provided is an antigen-binding molecule, optionally isolated, which is capable of binding to CD47 in extracellular region 1.
  • In some embodiments the antigen-binding molecule is capable of binding to the V-type Ig-like domain of CD47. In some embodiments the antigen-binding molecule is capable of binding to a polypeptide comprising or consisting of the amino acid sequence shown in SEQ ID NO:9. In some embodiments the antigen-binding molecule is capable of inhibiting interaction between CD47 and SIRPα. In some embodiments the antigen-binding molecule is capable of increasing phagocytosis of CD47-expressing cells.
  • In some embodiments the antigen-binding molecule is capable of binding to a peptide or polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO:21. In some embodiments the antigen-binding molecule comprises:
      • (i) a heavy chain variable (VH) region incorporating the following CDRs:
        • HC-CDR1 having the amino acid sequence of SEQ ID NO:169
        • HC-CDR2 having the amino acid sequence of SEQ ID NO:170
        • HC-CDR3 having the amino acid sequence of SEQ ID NO:26,
      • or a variant thereof in which one or two or three amino acids in one or more of HC-CDR1, HC-CDR2, or HC-CDR3 are substituted with another amino acid; and
      • (ii) a light chain variable (VL) region incorporating the following CDRs:
        • LC-CDR1 having the amino acid sequence of SEQ ID NO:171
        • LC-CDR2 having the amino acid sequence of SEQ ID NO:172
        • LC-CDR3 having the amino acid sequence of SEQ ID NO:173;
          or a variant thereof in which one or two or three amino acids in one or more of LC-CDR1, LC-CDR2 or LC-CDR3 are substituted with another amino acid.
  • In some embodiments the antigen-binding molecule comprises:
  • (a)
      • (i) a heavy chain variable (VH) region incorporating the following CDRs:
        • HC-CDR1 having the amino acid sequence of SEQ ID NO:24
        • HC-CDR2 having the amino acid sequence of SEQ ID NO:25
        • HC-CDR3 having the amino acid sequence of SEQ ID NO:26,
      • or a variant thereof in which one or two or three amino acids in one or more of HC-CDR1, HC-CDR2, or HC-CDR3 are substituted with another amino acid; and
      • (ii) a light chain variable (VL) region incorporating the following CDRs:
        • LC-CDR1 having the amino acid sequence of SEQ ID NO:32
        • LC-CDR2 having the amino acid sequence of SEQ ID NO:33
        • LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
          or a variant thereof in which one or two or three amino acids in one or more of LC-CDR1, LC-CDR2 or LC-CDR3 are substituted with another amino acid;
          or
          (b)
      • (i) a heavy chain variable (VH) region incorporating the following CDRs:
        • HC-CDR1 having the amino acid sequence of SEQ ID NO:137
        • HC-CDR2 having the amino acid sequence of SEQ ID NO:138
        • HC-CDR3 having the amino acid sequence of SEQ ID NO:26,
      • or a variant thereof in which one or two or three amino acids in one or more of HC-CDR1, HC-CDR2, or HC-CDR3 are substituted with another amino acid; and
      • (ii) a light chain variable (VL) region incorporating the following CDRs:
        • LC-CDR1 having the amino acid sequence of SEQ ID NO:32
        • LC-CDR2 having the amino acid sequence of SEQ ID NO:33
        • LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
          or a variant thereof in which one or two or three amino acids in one or more of LC-CDR1, LC-CDR2 or LC-CDR3 are substituted with another amino acid;
          or
          (c)
      • (i) a heavy chain variable (VH) region incorporating the following CDRs:
        • HC-CDR1 having the amino acid sequence of SEQ ID NO:24
        • HC-CDR2 having the amino acid sequence of SEQ ID NO:25
        • HC-CDR3 having the amino acid sequence of SEQ ID NO:26,
      • or a variant thereof in which one or two or three amino acids in one or more of HC-CDR1, HC-CDR2, or HC-CDR3 are substituted with another amino acid; and
      • (ii) a light chain variable (VL) region incorporating the following CDRs:
        • LC-CDR1 having the amino acid sequence of SEQ ID NO:139
        • LC-CDR2 having the amino acid sequence of SEQ ID NO:141
        • LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
      • or a variant thereof in which one or two or three amino acids in one or more of LC-CDR1, LC-CDR2 or LC-CDR3 are substituted with another amino acid;
        or
        (d)
      • (i) a heavy chain variable (VH) region incorporating the following CDRs:
        • HC-CDR1 having the amino acid sequence of SEQ ID NO:137
        • HC-CDR2 having the amino acid sequence of SEQ ID NO:138
        • HC-CDR3 having the amino acid sequence of SEQ ID NO:26,
      • or a variant thereof in which one or two or three amino acids in one or more of HC-CDR1, HC-CDR2, or HC-CDR3 are substituted with another amino acid; and
      • (ii) a light chain variable (VL) region incorporating the following CDRs:
        • LC-CDR1 having the amino acid sequence of SEQ ID NO:139
        • LC-CDR2 having the amino acid sequence of SEQ ID NO:141
        • LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
  • or a variant thereof in which one or two or three amino acids in one or more of LC-CDR1, LC-CDR2 or LC-CDR3 are substituted with another amino acid;
  • or
    (e)
      • (i) a heavy chain variable (VH) region incorporating the following CDRs:
        • HC-CDR1 having the amino acid sequence of SEQ ID NO:24
        • HC-CDR2 having the amino acid sequence of SEQ ID NO:25
        • HC-CDR3 having the amino acid sequence of SEQ ID NO:26,
      • or a variant thereof in which one or two or three amino acids in one or more of HC-CDR1, HC-CDR2, or HC-CDR3 are substituted with another amino acid; and
      • (ii) a light chain variable (VL) region incorporating the following CDRs:
        • LC-CDR1 having the amino acid sequence of SEQ ID NO:140
        • LC-CDR2 having the amino acid sequence of SEQ ID NO:141
        • LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
  • or a variant thereof in which one or two or three amino acids in one or more of LC-CDR1, LC-CDR2 or LC-CDR3 are substituted with another amino acid;
  • or
    (f)
      • (i) a heavy chain variable (VH) region incorporating the following CDRs:
        • HC-CDR1 having the amino acid sequence of SEQ ID NO:137
        • HC-CDR2 having the amino acid sequence of SEQ ID NO:138
        • HC-CDR3 having the amino acid sequence of SEQ ID NO:26,
      • or a variant thereof in which one or two or three amino acids in one or more of HC-CDR1, HC-CDR2, or HC-CDR3 are substituted with another amino acid; and
      • (ii) a light chain variable (VL) region incorporating the following CDRs:
        • LC-CDR1 having the amino acid sequence of SEQ ID NO:140
        • LC-CDR2 having the amino acid sequence of SEQ ID NO:141
        • LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
      • or a variant thereof in which one or two or three amino acids in one or more of LC-CDR1, LC-CDR2 or LC-CDR3 are substituted with another amino acid;
        or
        (g)
      • (i) a heavy chain variable (VH) region incorporating the following CDRs:
        • HC-CDR1 having the amino acid sequence of SEQ ID NO:137
        • HC-CDR2 having the amino acid sequence of SEQ ID NO:138
        • HC-CDR3 having the amino acid sequence of SEQ ID NO:26,
      • or a variant thereof in which one or two or three amino acids in one or more of HC-CDR1, HC-CDR2, or HC-CDR3 are substituted with another amino acid; and
      • (ii) a light chain variable (VL) region incorporating the following CDRs:
        • LC-CDR1 having the amino acid sequence of SEQ ID NO:32
        • LC-CDR2 having the amino acid sequence of SEQ ID NO:141
        • LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
      • or a variant thereof in which one or two or three amino acids in one or more of LC-CDR1, LC-CDR2 or LC-CDR3 are substituted with another amino acid;
        or
        (h)
      • (i) a heavy chain variable (VH) region incorporating the following CDRs:
        • HC-CDR1 having the amino acid sequence of SEQ ID NO:137
        • HC-CDR2 having the amino acid sequence of SEQ ID NO:138
        • HC-CDR3 having the amino acid sequence of SEQ ID NO:26,
      • or a variant thereof in which one or two or three amino acids in one or more of HC-CDR1, HC-CDR2, or HC-CDR3 are substituted with another amino acid; and
      • (ii) a light chain variable (VL) region incorporating the following CDRs:
        • LC-CDR1 having the amino acid sequence of SEQ ID NO:32
        • LC-CDR2 having the amino acid sequence of SEQ ID NO:33
        • LC-CDR3 having the amino acid sequence of SEQ ID NO:142;
      • or a variant thereof in which one or two or three amino acids in one or more of LC-CDR1, LC-CDR2 or LC-CDR3 are substituted with another amino acid.
  • In some embodiments the antigen-binding molecule comprises:
  • (a)
      • (i) a heavy chain variable (VH) region incorporating the following CDRs:
        • HC-CDR1 having the amino acid sequence of SEQ ID NO:24
        • HC-CDR2 having the amino acid sequence of SEQ ID NO:25
        • HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and
      • (ii) a light chain variable (VL) region incorporating the following CDRs:
        • LC-CDR1 having the amino acid sequence of SEQ ID NO:32
        • LC-CDR2 having the amino acid sequence of SEQ ID NO:33
          LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
          or
          (b)
      • (i) a heavy chain variable (VH) region incorporating the following CDRs:
        • HC-CDR1 having the amino acid sequence of SEQ ID NO:137
        • HC-CDR2 having the amino acid sequence of SEQ ID NO:138
        • HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and
      • (ii) a light chain variable (VL) region incorporating the following CDRs:
        • LC-CDR1 having the amino acid sequence of SEQ ID NO:32
        • LC-CDR2 having the amino acid sequence of SEQ ID NO:33
        • LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
          or
          (c)
      • (i) a heavy chain variable (VH) region incorporating the following CDRs:
        • HC-CDR1 having the amino acid sequence of SEQ ID NO:24
        • HC-CDR2 having the amino acid sequence of SEQ ID NO:25
        • HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and
      • (ii) a light chain variable (VL) region incorporating the following CDRs:
        • LC-CDR1 having the amino acid sequence of SEQ ID NO:139
        • LC-CDR2 having the amino acid sequence of SEQ ID NO:141
        • LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
          or
          (d)
      • (i) a heavy chain variable (VH) region incorporating the following CDRs:
        • HC-CDR1 having the amino acid sequence of SEQ ID NO:137
        • HC-CDR2 having the amino acid sequence of SEQ ID NO:138
        • HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and
      • (ii) a light chain variable (VL) region incorporating the following CDRs:
        • LC-CDR1 having the amino acid sequence of SEQ ID NO:139
        • LC-CDR2 having the amino acid sequence of SEQ ID NO:141
        • LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
          or
          (e)
      • (i) a heavy chain variable (VH) region incorporating the following CDRs:
        • HC-CDR1 having the amino acid sequence of SEQ ID NO:24
        • HC-CDR2 having the amino acid sequence of SEQ ID NO:25
        • HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and
      • (ii) a light chain variable (VL) region incorporating the following CDRs:
        • LC-CDR1 having the amino acid sequence of SEQ ID NO:140
        • LC-CDR2 having the amino acid sequence of SEQ ID NO:141
        • LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
          or
          (f)
      • (i) a heavy chain variable (VH) region incorporating the following CDRs:
        • HC-CDR1 having the amino acid sequence of SEQ ID NO:137
        • HC-CDR2 having the amino acid sequence of SEQ ID NO:138
        • HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and
      • (ii) a light chain variable (VL) region incorporating the following CDRs:
        • LC-CDR1 having the amino acid sequence of SEQ ID NO:140
        • LC-CDR2 having the amino acid sequence of SEQ ID NO:141
        • LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
          or
          (g)
      • (i) a heavy chain variable (VH) region incorporating the following CDRs:
        • HC-CDR1 having the amino acid sequence of SEQ ID NO:137
        • HC-CDR2 having the amino acid sequence of SEQ ID NO:138
        • HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and
      • (ii) a light chain variable (VL) region incorporating the following CDRs:
        • LC-CDR1 having the amino acid sequence of SEQ ID NO:32
        • LC-CDR2 having the amino acid sequence of SEQ ID NO:141
        • LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
          or
          (h)
      • (i) a heavy chain variable (VH) region incorporating the following CDRs:
        • HC-CDR1 having the amino acid sequence of SEQ ID NO:137
        • HC-CDR2 having the amino acid sequence of SEQ ID NO:138
        • HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and
      • (ii) a light chain variable (VL) region incorporating the following CDRs:
        • LC-CDR1 having the amino acid sequence of SEQ ID NO:32
        • LC-CDR2 having the amino acid sequence of SEQ ID NO:33
        • LC-CDR3 having the amino acid sequence of SEQ ID NO:142.
  • In some embodiments the antigen-binding molecule comprises:
      • a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:23, 39, 178, 127, 129, 130, 131 or 132; and
      • a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:31, 44, 179, 128, 133, 134, 135 or 136.
  • In some embodiments the antigen-binding molecule comprises:
      • (i) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:23; and
        • a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:31;
          or
      • (ii) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:39; and
        • a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:44;
          or
      • (iii) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:178; and
        • a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:179;
          or
      • (iv) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:127; and
        • a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:128;
          or
      • (v) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:129; and
        • a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:128;
          or
      • (vi) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:130; and
        • a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:128;
          or
      • (vii) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:131; and
        • a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:128;
          or
      • (viii) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:132; and
        • a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:128;
          or
      • (ix) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:131; and
        • a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:133;
          or
      • (x) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:132; and
        • a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:133;
          or
      • (xi) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:131; and
        • a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:134;
          or
      • (xii) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:132; and
        • a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:134;
          or
      • (xiii) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:132; and
        • a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:135;
          or
      • (xiv) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:132; and
        • a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:136.
  • In some embodiments the antigen-binding molecule is capable of binding to a peptide or polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO:22.
  • In some embodiments the antigen-binding molecule comprises:
      • (i) a heavy chain variable (VH) region incorporating the following CDRs:
        • HC-CDR1 having the amino acid sequence of SEQ ID NO:50
        • HC-CDR2 having the amino acid sequence of SEQ ID NO:51
        • HC-CDR3 having the amino acid sequence of SEQ ID NO:52,
      • or a variant thereof in which one or two or three amino acids in one or more of HC-CDR1, HC-CDR2, or HC-CDR3 are substituted with another amino acid; and
      • (ii) a light chain variable (VL) region incorporating the following CDRs:
        • LC-CDR1 having the amino acid sequence of SEQ ID NO:58
        • LC-CDR2 having the amino acid sequence of SEQ ID NO:59
        • LC-CDR3 having the amino acid sequence of SEQ ID NO:60;
      • or a variant thereof in which one or two or three amino acids in one or more of LC-CDR1, LC-CDR2 or LC-CDR3 are substituted with another amino acid.
  • In some embodiments the antigen-binding molecule comprises:
      • (i) a heavy chain variable (VH) region incorporating the following CDRs:
        • HC-CDR1 having the amino acid sequence of SEQ ID NO:50
        • HC-CDR2 having the amino acid sequence of SEQ ID NO:51
        • HC-CDR3 having the amino acid sequence of SEQ ID NO:52; and
      • (ii) a light chain variable (VL) region incorporating the following CDRs:
        • LC-CDR1 having the amino acid sequence of SEQ ID NO:58
        • LC-CDR2 having the amino acid sequence of SEQ ID NO:59
        • LC-CDR3 having the amino acid sequence of SEQ ID NO:60.
  • In some embodiments the antigen-binding molecule comprises:
      • a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:49; and
      • a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:57.
  • In some embodiments the antigen-binding molecule comprises:
      • (i) a heavy chain variable (VH) region incorporating the following CDRs:
        • HC-CDR1 having the amino acid sequence of SEQ ID NO:66
        • HC-CDR2 having the amino acid sequence of SEQ ID NO:67
        • HC-CDR3 having the amino acid sequence of SEQ ID NO:68,
      • or a variant thereof in which one or two or three amino acids in one or more of HC-CDR1, HC-CDR2, or HC-CDR3 are substituted with another amino acid; and
      • (ii) a light chain variable (VL) region incorporating the following CDRs:
        • LC-CDR1 having the amino acid sequence of SEQ ID NO:74
        • LC-CDR2 having the amino acid sequence of SEQ ID NO:75
        • LC-CDR3 having the amino acid sequence of SEQ ID NO:76;
      • or a variant thereof in which one or two or three amino acids in one or more of LC-CDR1, LC-CDR2 or LC-CDR3 are substituted with another amino acid.
  • In some embodiments the antigen-binding molecule comprises:
      • (i) a heavy chain variable (VH) region incorporating the following CDRs:
        • HC-CDR1 having the amino acid sequence of SEQ ID NO:66
        • HC-CDR2 having the amino acid sequence of SEQ ID NO:67
        • HC-CDR3 having the amino acid sequence of SEQ ID NO:68; and
      • (ii) a light chain variable (VL) region incorporating the following CDRs:
        • LC-CDR1 having the amino acid sequence of SEQ ID NO:74
        • LC-CDR2 having the amino acid sequence of SEQ ID NO:75
        • LC-CDR3 having the amino acid sequence of SEQ ID NO:76.
  • In some embodiments the antigen-binding molecule comprises:
      • a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:65; and
      • a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:73.
  • In another aspect the present invention provides an antigen-binding molecule, optionally isolated, comprising (i) an antigen-binding molecule according to the invention, and (ii) an antigen-binding molecule capable of binding to an antigen other than CD47.
  • In some embodiments the antigen-binding molecule is capable of binding to cells expressing CD47 at the cell surface.
  • In some embodiments the antigen-binding molecule is capable of inhibiting interaction between CD47 and SIRPα.
  • In some embodiments the antigen-binding molecule is capable of increasing phagocytosis of CD47-expressing cells.
  • In another aspect the present invention provides a chimeric antigen receptor (CAR) comprising an antigen-binding molecule according to the invention.
  • In another aspect the present invention provides a nucleic acid, or a plurality of nucleic acids, optionally isolated, encoding an antigen-binding molecule or a CAR according to the invention.
  • In another aspect the present invention provides an expression vector, or a plurality of expression vectors, comprising a nucleic acid or a plurality of nucleic acids according to the invention.
  • In another aspect the present invention provides a cell comprising an antigen-binding molecule, a CAR, a nucleic acid or a plurality of nucleic acids, or an expression vector or a plurality of expression vectors according to the invention.
  • In another aspect the present invention provides a method comprising culturing a cell comprising a nucleic acid or a plurality of nucleic acids, or an expression vector or a plurality of expression vectors according to the invention, under conditions suitable for expression of the antigen-binding molecule or CAR from the nucleic acid(s) or expression vector(s).
  • In another aspect the present invention provides a composition comprising an antigen-binding molecule, a CAR, a nucleic acid or a plurality of nucleic acids, an expression vector or a plurality of expression vectors, or a cell according to the invention.
  • In another aspect the present invention provides an antigen-binding molecule, a CAR, a nucleic acid or a plurality of nucleic acids, an expression vector or a plurality of expression vectors, a cell, or a composition according to the invention for use in a method of medical treatment or prophylaxis.
  • In another aspect the present invention provides an antigen-binding molecule, a CAR, a nucleic acid or a plurality of nucleic acids, an expression vector or a plurality of expression vectors, a cell, or a composition according to the invention for use in a method of treatment or prevention of a cancer.
  • In another aspect the present invention provides the use of an antigen-binding molecule, a CAR, a nucleic acid or a plurality of nucleic acids, an expression vector or a plurality of expression vectors, a cell, or a composition according to the invention in the manufacture of a medicament for use in a method of treatment or prevention of a cancer.
  • In another aspect the present invention provides a method of treating or preventing a cancer, comprising administering to a subject a therapeutically or prophylactically effective amount of an antigen-binding molecule, a CAR, a nucleic acid or a plurality of nucleic acids, an expression vector or a plurality of expression vectors, a cell, or a composition according to the invention.
  • In another aspect the present invention provides a method for increasing phagocytosis of CD47-expressing cells, comprising contacting CD47-expressing cells with an antigen-binding molecule according to the invention.
  • In another aspect the present invention provides an in vitro complex, optionally isolated, comprising an antigen-binding molecule according to the invention bound to CD47.
  • In another aspect the present invention provides a method comprising contacting a sample containing, or suspected to contain, CD47 with an antigen-binding molecule according to the invention, and detecting the formation of a complex of the antigen-binding molecule with CD47.
  • In another aspect the present invention provides a subject for treatment with a CD47-targeted agent, the method comprising contacting, in vitro, a sample from the subject with an antigen-binding molecule according to the invention and detecting the formation of a complex of the antigen-binding molecule with CD47.
  • In another aspect the present invention provides the use of an antigen-binding molecule according to the invention as an in vitro or in vivo diagnostic or prognostic agent.
  • In some embodiments in connection with various aspects of the present invention the cancer is selected from: a hematologic malignancy, a myeloid hematologic malignancy, a lymphoblastic hematologic malignancy, myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma (NHL), multiple myeloma (MM), bladder cancer, brain cancer, glioblastoma, ovarian cancer, breast cancer, colon cancer, liver cancer, hepatocellular carcinoma, prostate cancer, lung cancer, Non-small Cell Lung Cancer (NSCLC), skin cancer and melanoma.
    • DESCRIPTION
  • The present invention provides antigen-binding molecules having combinations of desirable biophysical and/or functional properties as compared to antigen-binding molecules disclosed in the prior art.
  • Aspects of the present invention relate to antigen-binding molecules capable of binding to CD47.
  • In aspects described herein antigen-binding molecules are provided which bind to human CD47 with high affinity, which are cross-reactive with non-human primate CD47, and which display potent inhibition of interaction between CD47 and SIRPα.
  • In particular, the antigen-binding molecules described herein bind to CD47 with greater affinity than prior art anti-CD47 antibodies, and are more potent as a CD47-targeted therapeutic agents.
  • Also, the antigen-binding molecules described herein bind to a particular epitope of CD47 that provides for more effective inhibition of the interaction between CD47 and SIPRα as compared to prior art anti-CD47 antibodies. The antigen-binding molecules described herein are thus more effective at enhancing phagocytosis of cells expressing CD47 than prior art anti-CD47 antibodies.
  • CD47
  • Human CD47 (also known as IAP, MERG and OA3) is the protein identified by UniProt Q08722. Alternative splicing of mRNA encoded by the human CD47 gene yields four isoforms which differ in the sequence of the C-terminal cytoplasmic tail region: isoform OA3-323 (UniProt: Q08722-1, v1; SEQ ID NO:1); isoform OA3-293 (UniProt: Q08722-2; SEQ ID NO:2), which lacks the amino acid sequence corresponding to positions 293 to 323 of SEQ ID NO:1; isoform OA3-305 (UniProt: Q08722-3; SEQ ID NO:3), which comprises the substitutions K304N and A305N relative to SEQ ID NO:1, and which lacks the amino acid sequence corresponding to positions 306 to 323 of SEQ ID NO:1; and isoform OA3-312 (UniProt: Q08722-4; SEQ ID NO:4), which lacks the amino acid sequence corresponding to positions 312 to 323 of SEQ ID NO:1.
  • The N-terminal 18 amino acids of SEQ ID NOs:1 to 4 constitute a signal peptide, and so the mature form of isoforms OA3-323, OA3-293, OA3-305 and OA3-312 (i.e. after processing to remove the signal peptide) have the amino acid sequences shown in SEQ ID NOs:5 to 8, respectively.
  • The structure and function of CD47 is reviewed e.g. in Sick et al., Br J Pharmacol. (2012) 167(7): 1415-1430 and Willingham et al. Proc Natl Acad Sci USA. (2012) 109(17): 6662-6667, both of which are hereby incorporated by reference in its entirety. CD47 is a ubiquitously-expressed ˜50 kDa multi-pass membrane receptor that belongs to the immunoglobulin superfamily, comprising an N-terminal extracellular region (SEQ ID NO:10) having a V-type Ig-like domain (SEQ ID NO:9), five transmembrane domains (SEQ ID NOs:11, 13, 15, 17 and 19), and a short C-terminal intracellular tail (SEQ ID NO:20).
  • CD47 is involved in cell-to-cell communication through ligating to the transmembrane signal-regulatory proteins (SIRPs) SIRPα and SIRPγ and integrins (e.g. αvβ3 integrin), and also mediates cell-extracellular matrix interactions through binding to thrombospondin-1 (TSP-1). CD47 is involved in a wide range of cellular processes including adhesion, migration, proliferation and apoptosis, and plays a key role in immune processes and angiogenesis.
  • CD47 is the ligand for SIRPα, which expressed on macrophages and dendritic cells. Binding of CD47 to SIRPα on the surface of phagocytic cells, triggers SIRPα ITIM signalling, inhibiting phagocytosis of the CD47 expressing cell. CD47 is a multi-pass transmembrane protein, whereas SIRPα consists of 4 extracellular domains and an intracellular ITIM-domain. The terminal V-set domain of SIRPα interacts with the Ig V-like domain of CD47.
  • Upon binding CD47, SIRPα initiates a signalling cascade that results in the inhibition of phagocytosis of the CD47-expressing cell. This “don't eat me” signal is transmitted by phosphorylation by Src kinases of immunoreceptor tyrosine-based inhibitor motifs (ITIMs) in the cytoplasmic domain of SIRPα. Subsequent binding and activation of Src homology-2 (SH2) domain-containing tyrosine phosphatases SHP-1 and SHP-2 blocks phagocytosis, potentially through preventing the accumulation of myosin-IIA at the phagocytic synapse. Disrupting the interaction along the antiparallel beta sheets of CD47 prevents downstream ITIM-mediated signalling, enabling phagocytes to ‘eat’ and destroy cancer cells.
  • Aberrant CD47 expression/activity is implicated in the development and progression of many cancers, and accumulating evidence suggests that cell-surface expression of CD47 is a common mechanism by which cancer cells protect themselves from phagocytosis.
  • In this specification “CD47” refers to CD47 from any species and includes CD47 isoforms, fragments, variants or homologues from any species.
  • As used herein, a “fragment”, “variant” or “homologue” of a protein may optionally be characterised as having at least 60%, preferably one of 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of the reference protein (e.g. a reference isoform). In some embodiments fragments, variants, isoforms and homologues of a reference protein may be characterised by ability to perform a function performed by the reference protein.
  • A “fragment” generally refers to a fraction of the reference protein. A “variant” generally refers to a protein having an amino acid sequence comprising one or more amino acid substitutions, insertions, deletions or other modifications relative to the amino acid sequence of the reference protein, but retaining a considerable degree of sequence identity (e.g. at least 60%) to the amino acid sequence of the reference protein. An “isoform” generally refers to a variant of the reference protein expressed by the same species as the species of the reference protein (e.g. OA3-323, OA3-293, OA3-305 and OA3-312 are all isoforms of one another). A “homologue” generally refers to a variant of the reference protein produced by a different species as compared to the species of the reference protein. For example, human CD47 isoform OA3-323 (Q08722-1, v1; SEQ ID NO:1) and Rhesus macaque CD47 (UniProt: F7F5Y9-1, v2; SEQ ID NO:117) are homologues of one another. Homologues include orthologues.
  • A “fragment” of a reference protein may be of any length (by number of amino acids), although may optionally be at least 25% of the length of the reference protein (that is, the protein from which the fragment is derived) and may have a maximum length of one of 50%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the length of the reference protein.
  • A fragment of CD47 may have a minimum length of one of 10, 20, 30, 40, 50, 100, 150, 200, 250 or 300 amino acids, and may have a maximum length of one of 20, 30, 40, 50, 100, 150, 200, 250 or 300 amino acids.
  • In some embodiments, the CD47 is CD47 from a mammal (e.g. a primate (rhesus, cynomolgous, non-human primate or human) and/or a rodent (e.g. rat or murine) CD47). Isoforms, fragments, variants or homologues of CD47 may optionally be characterised as having at least 70%, preferably one of 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of an immature or mature CD47 isoform from a given species, e.g. human.
  • Isoforms, fragments, variants or homologues may optionally be functional isoforms, fragments, variants or homologues, e.g. having a functional property/activity of the reference CD47 (e.g. human CD47 isoform OA3-323), as determined by analysis by a suitable assay for the functional property/activity. For example, an isoform, fragment, variant or homologue of CD47 may display association with one or more of: SIRPα, SIRPγ, TSP-1 and αvβ3 integrin.
  • In some embodiments, the CD47 comprises, or consists of, an amino acid sequence having at least 70%, preferably one of 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to one of SEQ ID NOs:1 to 8.
  • In some embodiments, a fragment of CD47 comprises, or consists of, an amino acid sequence having at least 70%, preferably one of 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to one of SEQ ID NOs:9 or 10.
  • CD47 is an attractive therapeutic target. CD47 is usually expressed on the surface of normal healthy cells and migrating hematopoietic stem cells to prevent phagocytosis, and is upregulated in nearly all hematological and solid tumors, to evade immune surveillance and escape phagocytosis. Disrupting the interaction between CD47 and SIRPα enables phagocytes to “eat” and destroy cancer cells. CD47 blockade repolarises tumor-associated macrophages into a pro-inflammatory, anti-tumor state, and clearance of malignant cells by phagocytic cells offers an additional route for neo-antigen presentation to adaptive immune system.
  • Antigen-Binding Molecules
  • The present invention provides antigen-binding molecules capable of binding to CD47.
  • An “antigen-binding molecule” refers to a molecule which is capable of binding to a target antigen, and encompasses monoclonal antibodies, polyclonal antibodies, monospecific and multispecific antibodies (e.g., bispecific antibodies), and antibody fragments (e.g. Fv, scFv, Fab, scFab, F(ab′)2, Fab2, diabodies, triabodies, scFv-Fc, minibodies, single domain antibodies (e.g. VhH), etc.), as long as they display binding to the relevant target molecule(s).
  • The antigen-binding molecule of the present invention comprises a moiety or moieties capable of binding to a target antigen(s). In some embodiments, the moiety capable of binding to a target antigen comprises an antibody heavy chain variable region (VH) and an antibody light chain variable region (VL) of an antibody capable of specific binding to the target antigen. In some embodiments, the moiety capable of binding to a target antigen comprises or consists of an aptamer capable of binding to the target antigen, e.g. a nucleic acid aptamer (reviewed, for example, in Zhou and Rossi Nat Rev Drug Discov. 2017 16(3):181-202). In some embodiments, the moiety capable of binding to a target antigen comprises or consists of a antigen-binding peptide/polypeptide, e.g. a peptide aptamer, thioredoxin, monobody, anticalin, Kunitz domain, avimer, knottin, fynomer, atrimer, DARPin, affibody, nanobody (i.e. a single-domain antibody (sdAb)) affilin, armadillo repeat protein (ArmRP), OBody or fibronectin—reviewed e.g. in Reverdatto et al., Curr Top Med Chem. 2015; 15(12): 1082-1101, which is hereby incorporated by reference in its entirety (see also e.g. Boersma et al., J Biol Chem (2011) 286:41273-85 and Emanuel et al., Mabs (2011) 3:38-48).
  • The antigen-binding molecules of the present invention generally comprise an antigen-binding domain comprising a VH and a VL of an antibody capable of specific binding to the target antigen. The antigen-binding domain formed by a VH and a VL may also be referred to herein as an Fv region.
  • An antigen-binding molecule may be, or may comprise, an antigen-binding polypeptide, or an antigen-binding polypeptide complex. An antigen-binding molecule may comprise more than one polypeptide which together form an antigen-binding domain. The polypeptides may associate covalently or non-covalently. In some embodiments the polypeptides form part of a larger polypeptide comprising the polypeptides (e.g. in the case of scFv comprising VH and VL, or in the case of scFab comprising VH-CH1 and VL-CL).
  • An antigen-binding molecule may refer to a non-covalent or covalent complex of more than one polypeptide (e.g. 2, 3, 4, 6, or 8 polypeptides), e.g. an IgG-like antigen-binding molecule comprising two heavy chain polypeptides and two light chain polypeptides.
  • The antigen-binding molecules of the present invention may be designed and prepared using the sequences of monoclonal antibodies (mAbs) capable of binding to CD47. Antigen-binding regions of antibodies, such as single chain variable fragment (scFv), Fab and F(ab′)2 fragments may also be used/provided. An “antigen-binding region” is any fragment of an antibody which is capable of binding to the target for which the given antibody is specific.
  • Antibodies generally comprise six complementarity-determining regions CDRs; three in the heavy chain variable (VH) region: HC-CDR1, HC-CDR2 and HC-CDR3, and three in the light chain variable (VL) region: LC-CDR1, LC-CDR2, and LC-CDR3. The six CDRs together define the paratope of the antibody, which is the part of the antibody which binds to the target antigen.
  • The VH region and VL region comprise framework regions (FRs) either side of each CDR, which provide a scaffold for the CDRs. From N-terminus to C-terminus, VH regions comprise the following structure: N term-[HC-FR1]-[HC-CDR1]-[HC-FR2]-[HC-CDR2]-[HC-FR3]-[HC-CDR3]-[HC-FR4]-C term; and VL regions comprise the following structure: N term-[LC-FR1]-[LC-CDR1]-[LC-FR2]-[LC-CDR2]-[LC-FR3]-[LC-CDR3]-[LC-FR4]-C term.
  • There are several different conventions for defining antibody CDRs and FRs, such as those described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991), Chothia et al., J. Mol. Biol. 196:901-917 (1987), and VBASE2, as described in Retter et al., Nucl. Acids Res. (2005) 33 (suppl 1): D671-D674. The CDRs and FRs of the VH regions and VL regions of the antibody clones described herein were defined according to the international IMGT (ImMunoGeneTics) information system (LeFranc et al., Nucleic Acids Res. (2015) 43 (Database issue):D413-22), which uses the IMGT V-DOMAIN numbering rules as described in Lefranc et al., Dev. Comp. Immunol. (2003) 27:55-77.
  • In some embodiments, the antigen-binding molecule comprises the CDRs of an antigen-binding molecule which is capable of binding to CD47. In some embodiments, the antigen-binding molecule comprises the FRs of an antigen-binding molecule which is capable of binding to CD47. In some embodiments, the antigen-binding molecule comprises the CDRs and the FRs of an antigen-binding molecule which is capable of binding to CD47. That is, in some embodiments the antigen-binding molecule comprises the VH region and the VL region of an antigen-binding molecule which is capable of binding to CD47.
  • In some embodiments the antigen-binding molecule comprises a VH region and a VL region which is, or which is derived from, the VH/VL region of a CD47-binding antibody clone described herein (i.e. anti-CD47 antibody clones 1-1-A1_BM, 1-1-A1, 5-48-A6, 5-48-D2, 11A1H1, 11A1H2, 11A1H3, 11A1H4, 11A1H5, 11A1H6, 11A1H7, 11A1H8, 11A1H9, 11A1H10 or 11A1H11).
  • In some embodiments the antigen-binding molecule comprises a VH region according to one of (1) to (4) below:
  • (1) a VH region incorporating the following CDRs:
      • HC-CDR1 having the amino acid sequence of SEQ ID NO:24
      • HC-CDR2 having the amino acid sequence of SEQ ID NO:25
      • HC-CDR3 having the amino acid sequence of SEQ ID NO:26,
      • or a variant thereof in which one or two or three amino acids in one or more of HC-CDR1, HC-CDR2, or HC-CDR3 are substituted with another amino acid.
        (2) a VH region incorporating the following CDRs:
      • HC-CDR1 having the amino acid sequence of SEQ ID NO:50
      • HC-CDR2 having the amino acid sequence of SEQ ID NO:51
      • HC-CDR3 having the amino acid sequence of SEQ ID NO:52,
      • or a variant thereof in which one or two or three amino acids in one or more of HC-CDR1, HC-CDR2, or HC-CDR3 are substituted with another amino acid.
        (3) a VH region incorporating the following CDRs:
      • HC-CDR1 having the amino acid sequence of SEQ ID NO:66
      • HC-CDR2 having the amino acid sequence of SEQ ID NO:67
      • HC-CDR3 having the amino acid sequence of SEQ ID NO:68,
      • or a variant thereof in which one or two or three amino acids in one or more of HC-CDR1, HC-CDR2, or HC-CDR3 are substituted with another amino acid.
        (4) a VH region incorporating the following CDRs:
      • HC-CDR1 having the amino acid sequence of SEQ ID NO:169
      • HC-CDR2 having the amino acid sequence of SEQ ID NO:170
      • HC-CDR3 having the amino acid sequence of SEQ ID NO:26,
      • or a variant thereof in which one or two or three amino acids in one or more of HC-CDR1, HC-CDR2, or HC-CDR3 are substituted with another amino acid.
        (5) a VH region incorporating the following CDRs:
      • HC-CDR1 having the amino acid sequence of SEQ ID NO:137
      • HC-CDR2 having the amino acid sequence of SEQ ID NO:138
      • HC-CDR3 having the amino acid sequence of SEQ ID NO:26,
      • or a variant thereof in which one or two or three amino acids in one or more of HC-CDR1, HC-CDR2, or HC-CDR3 are substituted with another amino acid.
  • In some embodiments the antigen-binding molecule comprises a VH region according to one of (6) to (15) below:
  • (6) a VH region incorporating the following FRs:
      • HC-FR1 having the amino acid sequence of SEQ ID NO:27
      • HC-FR2 having the amino acid sequence of SEQ ID NO:28
      • HC-FR3 having the amino acid sequence of SEQ ID NO:29
      • HC-FR4 having the amino acid sequence of SEQ ID NO:30,
      • or a variant thereof in which one or two or three amino acids in one or more of HC-FR1, HC-FR2, HC-FR3, or HC-FR4 are substituted with another amino acid.
        (7) a VH region incorporating the following FRs:
      • HC-FR1 having the amino acid sequence of SEQ ID NO:40
      • HC-FR2 having the amino acid sequence of SEQ ID NO:41
      • HC-FR3 having the amino acid sequence of SEQ ID NO:42
      • HC-FR4 having the amino acid sequence of SEQ ID NO:43,
      • or a variant thereof in which one or two or three amino acids in one or more of HC-FR1, HC-FR2, HC-FR3, or HC-FR4 are substituted with another amino acid.
        (8) a VH region incorporating the following FRs:
      • HC-FR1 having the amino acid sequence of SEQ ID NO:53
      • HC-FR2 having the amino acid sequence of SEQ ID NO:54
      • HC-FR3 having the amino acid sequence of SEQ ID NO:55
      • HC-FR4 having the amino acid sequence of SEQ ID NO:56,
      • or a variant thereof in which one or two or three amino acids in one or more of HC-FR1, HC-FR2, HC-FR3, or HC-FR4 are substituted with another amino acid.
        (9) a VH region incorporating the following FRs:
      • HC-FR1 having the amino acid sequence of SEQ ID NO:69
      • HC-FR2 having the amino acid sequence of SEQ ID NO:70
      • HC-FR3 having the amino acid sequence of SEQ ID NO:71
      • HC-FR4 having the amino acid sequence of SEQ ID NO:72,
      • or a variant thereof in which one or two or three amino acids in one or more of HC-FR1, HC-FR2, HC-FR3, or HC-FR4 are substituted with another amino acid.
        (10) a VH region incorporating the following FRs:
      • HC-FR1 having the amino acid sequence of SEQ ID NO:143
      • HC-FR2 having the amino acid sequence of SEQ ID NO:174
      • HC-FR3 having the amino acid sequence of SEQ ID NO:175
      • HC-FR4 having the amino acid sequence of SEQ ID NO:176,
      • or a variant thereof in which one or two or three amino acids in one or more of HC-FR1, HC-FR2, HC-FR3, or HC-FR4 are substituted with another amino acid.
        (11) a VH region incorporating the following FRs:
      • HC-FR1 having the amino acid sequence of SEQ ID NO:143
      • HC-FR2 having the amino acid sequence of SEQ ID NO:144
      • HC-FR3 having the amino acid sequence of SEQ ID NO:147
      • HC-FR4 having the amino acid sequence of SEQ ID NO:152,
      • or a variant thereof in which one or two or three amino acids in one or more of HC-FR1, HC-FR2, HC-FR3, or HC-FR4 are substituted with another amino acid.
        (12) a VH region incorporating the following FRs:
      • HC-FR1 having the amino acid sequence of SEQ ID NO:143
      • HC-FR2 having the amino acid sequence of SEQ ID NO:144
      • HC-FR3 having the amino acid sequence of SEQ ID NO:148
      • HC-FR4 having the amino acid sequence of SEQ ID NO:152,
      • or a variant thereof in which one or two or three amino acids in one or more of HC-FR1, HC-FR2, HC-FR3, or HC-FR4 are substituted with another amino acid.
        (13) a VH region incorporating the following FRs:
      • HC-FR1 having the amino acid sequence of SEQ ID NO:143
      • HC-FR2 having the amino acid sequence of SEQ ID NO:145
      • HC-FR3 having the amino acid sequence of SEQ ID NO:149
      • HC-FR4 having the amino acid sequence of SEQ ID NO:153,
      • or a variant thereof in which one or two or three amino acids in one or more of HC-FR1, HC-FR2, HC-FR3, or HC-FR4 are substituted with another amino acid.
        (14) a VH region incorporating the following FRs:
      • HC-FR1 having the amino acid sequence of SEQ ID NO:143
      • HC-FR2 having the amino acid sequence of SEQ ID NO:146
      • HC-FR3 having the amino acid sequence of SEQ ID NO:150
      • HC-FR4 having the amino acid sequence of SEQ ID NO:153,
      • or a variant thereof in which one or two or three amino acids in one or more of HC-FR1, HC-FR2, HC-FR3, or HC-FR4 are substituted with another amino acid.
        (15) a VH region incorporating the following FRs:
      • HC-FR1 having the amino acid sequence of SEQ ID NO:143
      • HC-FR2 having the amino acid sequence of SEQ ID NO:146
      • HC-FR3 having the amino acid sequence of SEQ ID NO:151
      • HC-FR4 having the amino acid sequence of SEQ ID NO:152,
      • or a variant thereof in which one or two or three amino acids in one or more of HC-FR1, HC-FR2, HC-FR3, or HC-FR4 are substituted with another amino acid.
  • In some embodiments the antigen-binding molecule comprises a VH region comprising the CDRs according to one of (1), (2), (3), (4) or (5) above, and the FRs according to one of (5), (6), (7), (8), (9), (10), (11), (12), (13), (14) or (15) above.
  • In some embodiments the antigen-binding molecule comprises a VH region according to one of (16) to (25) below:
  • (16) a VH region comprising the CDRs according to (1) and the FRs according to (6).
    (17) a VH region comprising the CDRs according to (1) and the FRs according to (7).
    (18) a VH region comprising the CDRs according to (2) and the FRs according to (8).
    (19) a VH region comprising the CDRs according to (3) and the FRs according to (9).
    (20) a VH region comprising the CDRs according to (4) and the FRs according to (10).
    (21) a VH region comprising the CDRs according to (1) and the FRs according to (11).
    (22) a VH region comprising the CDRs according to (1) and the FRs according to (12).
    (23) a VH region comprising the CDRs according to (1) and the FRs according to (13).
    (24) a VH region comprising the CDRs according to (1) and the FRs according to (14).
    (25) a VH region comprising the CDRs according to (5) and the FRs according to (15).
  • In some embodiments the antigen-binding molecule comprises a VH region according to one of (26) to (34) below:
  • (26) a VH region comprising an amino acid sequence having at least 70% sequence identity more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO:23.
    (27) a VH region comprising an amino acid sequence having at least 70% sequence identity more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO:39.
    (28) a VH region comprising an amino acid sequence having at least 70% sequence identity more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO:49.
    (29) a VH region comprising an amino acid sequence having at least 70% sequence identity more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO:65.
    (31) a VH region comprising an amino acid sequence having at least 70% sequence identity more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO:178.
    (31) a VH region comprising an amino acid sequence having at least 70% sequence identity more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO:127.
    (32) a VH region comprising an amino acid sequence having at least 70% sequence identity more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO:129.
    (33) a VH region comprising an amino acid sequence having at least 70% sequence identity more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO:130.
    (34) a VH region comprising an amino acid sequence having at least 70% sequence identity more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO:131.
    (35) a VH region comprising an amino acid sequence having at least 70% sequence identity more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO:132.
  • In some embodiments the antigen-binding molecule comprises a VL region according to one of (36) to (43) below:
  • (36) a VL region incorporating the following CDRs:
      • LC-CDR1 having the amino acid sequence of SEQ ID NO:32
      • LC-CDR2 having the amino acid sequence of SEQ ID NO:33
      • LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
      • or a variant thereof in which one or two or three amino acids in one or more of LC-CDR1, LC-CDR2 or LC-CDR3 are substituted with another amino acid.
        (37) a VL region incorporating the following CDRs:
      • LC-CDR1 having the amino acid sequence of SEQ ID NO:58
      • LC-CDR2 having the amino acid sequence of SEQ ID NO:59
      • LC-CDR3 having the amino acid sequence of SEQ ID NO:60;
      • or a variant thereof in which one or two or three amino acids in one or more of LC-CDR1, LC-CDR2 or LC-CDR3 are substituted with another amino acid.
        (38) a VL region incorporating the following CDRs:
      • LC-CDR1 having the amino acid sequence of SEQ ID NO:74
      • LC-CDR2 having the amino acid sequence of SEQ ID NO:75
      • LC-CDR3 having the amino acid sequence of SEQ ID NO:76;
      • or a variant thereof in which one or two or three amino acids in one or more of LC-CDR1, LC-CDR2 or LC-CDR3 are substituted with another amino acid.
        (39) a VL region incorporating the following CDRs:
      • LC-CDR1 having the amino acid sequence of SEQ ID NO:171
      • LC-CDR2 having the amino acid sequence of SEQ ID NO:172
      • LC-CDR3 having the amino acid sequence of SEQ ID NO:173;
      • or a variant thereof in which one or two or three amino acids in one or more of LC-CDR1, LC-CDR2 or LC-CDR3 are substituted with another amino acid.
        (40) a VL region incorporating the following CDRs:
      • LC-CDR1 having the amino acid sequence of SEQ ID NO:139
      • LC-CDR2 having the amino acid sequence of SEQ ID NO:141
      • LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
      • or a variant thereof in which one or two or three amino acids in one or more of LC-CDR1, LC-CDR2 or LC-CDR3 are substituted with another amino acid.
        (41) a VL region incorporating the following CDRs:
      • LC-CDR1 having the amino acid sequence of SEQ ID NO:140
      • LC-CDR2 having the amino acid sequence of SEQ ID NO:141
      • LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
      • or a variant thereof in which one or two or three amino acids in one or more of LC-CDR1, LC-CDR2 or LC-CDR3 are substituted with another amino acid.
        (42) a VL region incorporating the following CDRs:
      • LC-CDR1 having the amino acid sequence of SEQ ID NO:32
      • LC-CDR2 having the amino acid sequence of SEQ ID NO:141
      • LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
      • or a variant thereof in which one or two or three amino acids in one or more of LC-CDR1, LC-CDR2 or LC-CDR3 are substituted with another amino acid.
        (43) a VL region incorporating the following CDRs:
      • LC-CDR1 having the amino acid sequence of SEQ ID NO:32
      • LC-CDR2 having the amino acid sequence of SEQ ID NO:33
      • LC-CDR3 having the amino acid sequence of SEQ ID NO:142;
      • or a variant thereof in which one or two or three amino acids in one or more of LC-CDR1, LC-CDR2 or LC-CDR3 are substituted with another amino acid.
  • In some embodiments the antigen-binding molecule comprises a VL region according to one of (44) to (50) below:
  • (44) a VL region incorporating the following FRs:
      • LC-FR1 having the amino acid sequence of SEQ ID NO:35
      • LC-FR2 having the amino acid sequence of SEQ ID NO:36
      • LC-FR3 having the amino acid sequence of SEQ ID NO:37
      • LC-FR4 having the amino acid sequence of SEQ ID NO:38,
      • or a variant thereof in which one or two or three amino acids in one or more of LC-FR1, LC-FR2, LC-FR3, or LC-FR4 are substituted with another amino acid.
        (45) a VL region incorporating the following FRs:
      • LC-FR1 having the amino acid sequence of SEQ ID NO:45
      • LC-FR2 having the amino acid sequence of SEQ ID NO:46
      • LC-FR3 having the amino acid sequence of SEQ ID NO:47
      • LC-FR4 having the amino acid sequence of SEQ ID NO:48,
      • or a variant thereof in which one or two or three amino acids in one or more of LC-FR1, LC-FR2, LC-FR3, or LC-FR4 are substituted with another amino acid.
        (46) a VL region incorporating the following FRs:
      • LC-FR1 having the amino acid sequence of SEQ ID NO:61
      • LC-FR2 having the amino acid sequence of SEQ ID NO:62
      • LC-FR3 having the amino acid sequence of SEQ ID NO:63
      • LC-FR4 having the amino acid sequence of SEQ ID NO:64,
      • or a variant thereof in which one or two or three amino acids in one or more of LC-FR1, LC-FR2, LC-FR3, or LC-FR4 are substituted with another amino acid.
        (47) a VL region incorporating the following FRs:
      • LC-FR1 having the amino acid sequence of SEQ ID NO:77
      • LC-FR2 having the amino acid sequence of SEQ ID NO:78
      • LC-FR3 having the amino acid sequence of SEQ ID NO:79
      • LC-FR4 having the amino acid sequence of SEQ ID NO:80,
      • or a variant thereof in which one or two or three amino acids in one or more of LC-FR1, LC-FR2, LC-FR3, or LC-FR4 are substituted with another amino acid.
        (48) a VL region incorporating the following FRs:
      • LC-FR1 having the amino acid sequence of SEQ ID NO:154
      • LC-FR2 having the amino acid sequence of SEQ ID NO:155
      • LC-FR3 having the amino acid sequence of SEQ ID NO:177
      • LC-FR4 having the amino acid sequence of SEQ ID NO:158,
      • or a variant thereof in which one or two or three amino acids in one or more of LC-FR1, LC-FR2, LC-FR3, or LC-FR4 are substituted with another amino acid.
        (49) a VL region incorporating the following FRs:
      • LC-FR1 having the amino acid sequence of SEQ ID NO:154
      • LC-FR2 having the amino acid sequence of SEQ ID NO:155
      • LC-FR3 having the amino acid sequence of SEQ ID NO:156
      • LC-FR4 having the amino acid sequence of SEQ ID NO:158,
      • or a variant thereof in which one or two or three amino acids in one or more of LC-FR1, LC-FR2, LC-FR3, or LC-FR4 are substituted with another amino acid.
        (50) a VL region incorporating the following FRs:
      • LC-FR1 having the amino acid sequence of SEQ ID NO:154
      • LC-FR2 having the amino acid sequence of SEQ ID NO:155
      • LC-FR3 having the amino acid sequence of SEQ ID NO:157
      • LC-FR4 having the amino acid sequence of SEQ ID NO:158,
      • or a variant thereof in which one or two or three amino acids in one or more of LC-FR1, LC-FR2, LC-FR3, or LC-FR4 are substituted with another amino acid.
  • In some embodiments the antigen-binding molecule comprises a VL region comprising the CDRs according to one of (36), (37), (38), (39), (40), (41), (42) or (43) above, and the FRs according to one of (44), (45), (46), (47), (48), (49) or (50) above.
  • In some embodiments the antigen-binding molecule comprises a VL region according to one of (51) to (60) below:
  • (51) a VL region comprising the CDRs according to (36) and the FRs according to (43).
    52) a VL region comprising the CDRs according to (36) and the FRs according to (44).
    (53) a VL region comprising the CDRs according to (37) and the FRs according to (45).
    (54) a VL region comprising the CDRs according to (38) and the FRs according to (46).
    (55) a VL region comprising the CDRs according to (39) and the FRs according to (48).
    (56) a VL region comprising the CDRs according to (36) and the FRs according to (49).
    (57) a VL region comprising the CDRs according to (40) and the FRs according to (50).
    (58) a VL region comprising the CDRs according to (41) and the FRs according to (50).
    (59) a VL region comprising the CDRs according to (42) and the FRs according to (50).
    (60) a VL region comprising the CDRs according to (43) and the FRs according to (49).
  • In some embodiments the antigen-binding molecule comprises a VL region according to one of (61) to (70) below:
  • (61) a VL region comprising an amino acid sequence having at least 70% sequence identity more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO:31.
    (62) a VL region comprising an amino acid sequence having at least 70% sequence identity more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO:44.
    (63) a VL region comprising an amino acid sequence having at least 70% sequence identity more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO:57.
    (64) a VL region comprising an amino acid sequence having at least 70% sequence identity more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO:73.
    (65) a VL region comprising an amino acid sequence having at least 70% sequence identity more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO:179.
    (66) a VL region comprising an amino acid sequence having at least 70% sequence identity more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO:128.
    (67) a VL region comprising an amino acid sequence having at least 70% sequence identity more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO:133.
    (68) a VL region comprising an amino acid sequence having at least 70% sequence identity more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO:134.
    (69) a VL region comprising an amino acid sequence having at least 70% sequence identity more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO:135.
    (70) a VL region comprising an amino acid sequence having at least 70% sequence identity more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO:136.
  • In some embodiments the antigen-binding molecule comprises a VH region according to any one of (1) to (35) above, and a VL region according to any one of (36) to (70) above.
  • In embodiments in accordance with the present invention in which one or more amino acids are substituted with another amino acid, the substitutions may conservative substitutions, for example according to the following Table. In some embodiments, amino acids in the same block in the middle column are substituted. In some embodiments, amino acids in the same line in the rightmost column are substituted:
  •
    ALIPHATIC Non-polar G A P
    I L V
    Polar - uncharged C S T M
    N Q
    Polar - charged D E
    K R
    AROMATIC H F W Y
  • In some embodiments, substitution(s) may be functionally conservative. That is, in some embodiments the substitution may not affect (or may not substantially affect) one or more functional properties (e.g. target binding) of the antigen-binding molecule comprising the substitution as compared to the equivalent unsubstituted molecule.
  • The VH and VL region of an antigen-binding region of an antibody together constitute the Fv region. In some embodiments, the antigen-binding molecule according to the present invention comprises, or consists of, an Fv region which binds to CD47. In some embodiments the VH and VL regions of the Fv are provided as single polypeptide joined by a linker region, i.e. a single chain Fv (scFv).
  • In some embodiments the antigen-binding molecule of the present invention comprises one or more regions of an immunoglobulin heavy chain constant sequence. In some embodiments the immunoglobulin heavy chain constant sequence is, or is derived from, the heavy chain constant sequence of an IgG (e.g. IgG1, IgG2, IgG3, IgG4), IgA (e.g. IgA1, IgA2), IgD, IgE or IgM.
  • In some embodiments the immunoglobulin heavy chain constant sequence is human immunoglobulin G 1 constant (IGHG1; UniProt: P01857-1, v1; SEQ ID NO:118). Positions 1 to 98 of SEQ ID NO:118 form the CH1 region (SEQ ID NO:119). Positions 99 to 110 of SEQ ID NO:118 form a hinge region between CH1 and CH2 regions (SEQ ID NO:120). Positions 111 to 223 of SEQ ID NO:118 form the CH2 region (SEQ ID NO:121). Positions 224 to 330 of SEQ ID NO:118 form the CH3 region (SEQ ID NO:122).
  • The exemplified antigen-binding molecules were prepared using pFUSE-CHIg-hG1, which comprises the substitutions D356E, L358M (positions numbered according to EU numbering) in the CH3 region relative to SEQ ID NO:118. The amino acid sequence of the CH3 region encoded by pFUSE-CHIg-hG1 is shown in SEQ ID NO:123. It will be appreciated that CH3 regions may be provided with further substitutions in accordance with modification to an Fc region of the antigen-binding molecule as described herein.
  • In some embodiments a CH1 region comprises or consists of the sequence of SEQ ID NO:119, or a sequence having at least 60%, preferably one of 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:119. In some embodiments a CH1-CH2 hinge region comprises or consists of the sequence of SEQ ID NO:120, or a sequence having at least 60%, preferably one of 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:120. In some embodiments a CH2 region comprises or consists of the sequence of SEQ ID NO:121, or a sequence having at least 60%, preferably one of 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:121. In some embodiments a CH3 region comprises or consists of the sequence of SEQ ID NO:122 or 123, or a sequence having at least 60%, preferably one of 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:122 or 123.
  • In some embodiments the antigen-binding molecule of the present invention comprises one or more regions of an immunoglobulin light chain constant sequence. In some embodiments the immunoglobulin light chain constant sequence is human immunoglobulin kappa constant (IGKC; Cκ; UniProt: P01834-1, v2; SEQ ID NO:124). In some embodiments the immunoglobulin light chain constant sequence is a human immunoglobulin lambda constant (IGLC; Cλ), e.g. IGLC1, IGLC2, IGLC3, IGLC6 or IGLC7. In some embodiments a CL region comprises or consists of the sequence of SEQ ID NO:124, or a sequence having at least 60%, preferably one of 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:124.
  • The VL and light chain constant (CL) region, and the VH region and heavy chain constant 1 (CH1) region of an antigen-binding region of an antibody together constitute the Fab region. In some embodiments the antigen-binding molecule comprises a Fab region comprising a VH, a CH1, a VL and a CL (e.g. Cκ or Cλ). In some embodiments the Fab region comprises a polypeptide comprising a VH and a CH1 (e.g. a VH-CH1 fusion polypeptide), and a polypeptide comprising a VL and a CL (e.g. a VL-CL fusion polypeptide). In some embodiments the Fab region comprises a polypeptide comprising a VH and a CL (e.g. a VH-CL fusion polypeptide) and a polypeptide comprising a VL and a CH (e.g. a VL-CH1 fusion polypeptide); that is, in some embodiments the Fab region is a CrossFab region. In some embodiments the VH, CH1, VL and CL regions of the Fab or CrossFab are provided as single polypeptide joined by linker regions, i.e. as a single chain Fab (scFab) or a single chain CrossFab (scCrossFab).
  • In some embodiments, the antigen-binding molecule of the present invention comprises, or consists of, a Fab region which binds to CD47.
  • In some embodiments, the antigen-binding molecule described herein comprises, or consists of, a whole antibody which binds to CD47. As used herein, “whole antibody” refers to an antibody having a structure which is substantially similar to the structure of an immunoglobulin (Ig). Different kinds of immunoglobulins and their structures are described e.g. in Schroeder and Cavacini J Allergy Clin Immunol. (2010) 125(202): S41-S52, which is hereby incorporated by reference in its entirety.
  • Immunoglobulins of type G (i.e. IgG) are ˜150 kDa glycoproteins comprising two heavy chains and two light chains. From N- to C-terminus, the heavy chains comprise a VH followed by a heavy chain constant region comprising three constant domains (CH1, CH2, and CH3), and similarly the light chain comprise a VL followed by a CL. Depending on the heavy chain, immunoglobulins may be classed as IgG (e.g. IgG1, IgG2, IgG3, IgG4), IgA (e.g. IgA1, IgA2), IgD, IgE, or IgM. The light chain may be kappa (κ) or lambda (λ).
  • In some embodiments, the antigen-binding molecule described herein comprises, or consists of, an IgG (e.g. IgG1, IgG2, IgG3, IgG4), IgA (e.g. IgA1, IgA2), IgD, IgE, or IgM which binds to CD47. Aspects of the present invention relate to multispecific antigen-binding molecules. By “multispecific” it is meant that the antigen-binding molecule displays specific binding to more than one target. In some embodiments the antigen-binding molecule is a bispecific antigen-binding molecule. In some embodiments the antigen-binding molecule comprises at least two different antigen-binding domains (i.e. at least two antigen-binding domains, e.g. comprising non-identical VHs and VLs).
  • In some embodiments the antigen-binding molecule binds to CD47 and an antigen other than CD47, and so is at least bispecific. The term “bispecific” means that the antigen-binding molecule is able to bind specifically to at least two distinct antigenic determinants.
  • It will be appreciated that an antigen-binding molecule according to the present invention (e.g. a multispecific antigen-binding molecule) may comprise antigen-binding molecules capable of binding to the targets for which the antigen-binding molecule is specific. For example, an antigen-binding molecule which is capable of binding to CD47 and an antigen other than CD47 may comprise: (i) an antigen-binding molecule which is capable of binding to CD47, and (ii) an antigen-binding molecule which is capable of binding to an antigen other than CD47. By way of illustration, an antigen-binding molecule which is capable of binding to CD47 and an antigen other than CD47 may comprise (i) an antigen-binding molecule which is capable of binding to CD47, (e.g. a CD47-binding Fab or scFv), and (ii) an antigen-binding molecule which is capable of binding to an antigen other than CD47 (e.g. a Fab or scFv specific for the antigen other than CD47).
  • It will also be appreciated that an antigen-binding molecule according to the present invention (e.g. a multispecific antigen-binding molecule) may comprise antigen-binding polypeptides or antigen-binding polypeptide complexes capable of binding to the targets for which the antigen-binding molecule is specific.
  • In some embodiments, a component antigen-binding molecule of a larger antigen-binding molecule (e.g. a multispecific antigen-binding molecule) may be referred to e.g. as an “antigen-binding domain” or “antigen-binding region” of the larger antigen-binding molecule.
  • In some embodiments the antigen-binding molecule comprises an antigen-binding molecule capable of binding to CD47, and an antigen-binding molecule capable of binding to an antigen other than CD47. In some embodiments, the antigen other than CD47 is an immune cell surface molecule. In some embodiments, the antigen other than CD47 is a cancer cell antigen. In some embodiments the antigen other than CD47 is a receptor molecule, e.g. a cell surface receptor. In some embodiments the antigen other than CD47 is a cell signalling molecule, e.g. a cytokine, chemokine, interferon, interleukin or lymphokine. In some embodiments the antigen other than CD47 is a growth factor or a hormone.
  • A cancer cell antigen is an antigen which is expressed or over-expressed by a cancer cell. A cancer cell antigen may be any peptide/polypeptide, glycoprotein, lipoprotein, glycan, glycolipid, lipid, or fragment thereof. A cancer cell antigen's expression may be associated with a cancer. A cancer cell antigen may be abnormally expressed by a cancer cell (e.g. the cancer cell antigen may be expressed with abnormal localisation), or may be expressed with an abnormal structure by a cancer cell. A cancer cell antigen may be capable of eliciting an immune response. In some embodiments, the antigen is expressed at the cell surface of the cancer cell (i.e. the cancer cell antigen is a cancer cell surface antigen). In some embodiments, the part of the antigen which is bound by the antigen-binding molecule described herein is displayed on the external surface of the cancer cell (i.e. is extracellular). The cancer cell antigen may be a cancer-associated antigen. In some embodiments the cancer cell antigen is an antigen whose expression is associated with the development, progression or severity of symptoms of a cancer. The cancer-associated antigen may be associated with the cause or pathology of the cancer, or may be expressed abnormally as a consequence of the cancer. In some embodiments, the cancer cell antigen is an antigen whose expression is upregulated (e.g. at the RNA and/or protein level) by cells of a cancer, e.g. as compared to the level of expression of by comparable non-cancerous cells (e.g. non-cancerous cells derived from the same tissue/cell type). In some embodiments, the cancer-associated antigen may be preferentially expressed by cancerous cells, and not expressed by comparable non-cancerous cells (e.g. non-cancerous cells derived from the same tissue/cell type). In some embodiments, the cancer-associated antigen may be the product of a mutated oncogene or mutated tumor suppressor gene. In some embodiments, the cancer-associated antigen may be the product of an overexpressed cellular protein, a cancer antigen produced by an oncogenic virus, an oncofetal antigen, or a cell surface glycolipid or glycoprotein.
  • An immune cell surface molecule may be any peptide/polypeptide, glycoprotein, lipoprotein, glycan, glycolipid, lipid, or fragment thereof expressed at or on the cell surface of an immune cell. In some embodiments, the part of the immune cell surface molecule which is bound by the antigen-binding molecule of the present invention is on the external surface of the immune cell (i.e. is extracellular). The immune cell surface molecule may be expressed at the cell surface of any immune cell. In some embodiments, the immune cell may be a cell of hematopoietic origin, e.g. a neutrophil, eosinophil, basophil, dendritic cell, lymphocyte, or monocyte. The lymphocyte may be e.g. a T cell, B cell, natural killer (NK) cell, NKT cell or innate lymphoid cell (ILC), or a precursor thereof (e.g. a thymocyte or pre-B cell).
  • In some embodiments the antigen other than CD47 is an antigen expressed by cells of a hematologic malignancy, a myeloid hematologic malignancy, a lymphoblastic hematologic malignancy, myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), chronic myeloid leukemia, acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma, multiple myeloma, bladder cancer or brain cancer.
  • In some embodiments the antigen other than CD47 is an antigen expressed by cells of AML, e.g. as described in Hoseini and Cheung Blood Cancer J. (2017) 7(2):e522, which is hereby incorporated by reference in its entirety. In some embodiments the antigen other than CD47 is selected from: CD33, CD123, Wilms' tumor protein (WT1), CD13, CD15, CD30, CD45, C-type lectin-like molecule 1 (CLL1), Fms-like tyrosine kinase 3 (FLT-3), VEGF and angiopoietin-2 (Ang-2). In some embodiments the antigen other than CD47 is CD33.
  • Multispecific antigen-binding molecules described herein display at least monovalent binding with respect to CD47, and also display at least monovalent binding with respect to the antigen other than CD47. In some embodiments the antigen-binding molecule comprises an antigen-binding region (e.g. an Fv, Fab or antibody) capable of binding to CD47, and an antigen-binding region (e.g. an Fv, Fab or antibody) capable of binding to an antigen other than CD47. In some embodiments the antigen-binding molecule comprises the VH and VL of an antibody capable of binding to CD47, and the VH and VL of an antibody capable of binding to an antigen other than CD47.
  • Binding valency refers to the number of binding sites in an antigen-binding molecule for a given antigenic determinant. For example, in the IgG1 format described herein the anti-CD47 antibody is bivalent with respect to binding to CD47.
  • Multispecific antigen-binding molecules according to the invention may be provided in any suitable format, such as those formats described in described in Brinkmann and Kontermann MAbs (2017) 9(2): 182-212, which is hereby incorporated by reference in its entirety. Suitable formats include those shown in FIG. 2 of Brinkmann and Kontermann MAbs (2017) 9(2): 182-212: antibody conjugates, e.g. IgG2, F(ab′)2 or CovX-Body; IgG or IgG-like molecules, e.g. IgG, chimeric IgG, κλ-body common HC; CH1/CL fusion proteins, e.g. scFv2-CH1/CL, VHH2-CH1/CL; ‘variable domain only’ bispecific antigen-binding molecules, e.g. tandem scFv (taFV), triplebodies, diabodies (db), dsDb, db(kih), DART, scDB, dsFv-dsFv, tandAbs, triple heads, tandem dAbNHH, tertravalent dAb.VHH; Non-Ig fusion proteins, e.g. scFv2-albumin, scDb-albumin, taFv-albumin, taFv-toxin, miniantibody, DNL-Fab2, DNL-Fab2-scFv, DNL-Fab2-IgG-cytokine2, ImmTAC (TCR-scFv); modified Fc and CH3 fusion proteins, e.g. scFv-Fc(kih), scFv-Fc(CH3 charge pairs), scFv-Fc (EW-RVT), scFv-fc (HA-TF), scFv-Fc (SEEDbody), taFv-Fc(kih), scFv-Fc(kih)-Fv, Fab-Fc(kih)-scFv, Fab-scFv-Fc(kih), Fab-scFv-Fc(BEAT), Fab-scFv-Fc (SEEDbody), DART-Fc, scFv-CH3(kih), TriFabs; Fc fusions, e.g. Di-diabody, scDb-Fc, taFv-Fc, scFv-Fc-scFv, HCAb-VHH, Fab-scFv-Fc, scFv4-Ig, scFv2-Fcab; CH3 fusions, e.g. Dia-diabody, scDb-CH3; IgE/IgM CH2 fusions, e.g. scFv-EHD2-scFv, scFvMHD2-scFv; Fab fusion proteins, e.g. Fab-scFv (bibody), Fab-scFv2 (tribody), Fab-Fv, Fab-dsFv, Fab-VHH, orthogonal Fab-Fab; non-Ig fusion proteins, e.g. DNL-Fab3, DNL-Fab2-scFv, DNL-Fab2-IgG-cytokine2; asymmetric IgG or IgG-like molecules, e.g. IgG(kih), IgG(kih) common LC, ZW1 IgG common LC, Biclonics common LC, CrossMab, CrossMab(kih), scFab-IgG(kih), Fab-scFab-IgG(kih), orthogonal Fab IgG(kih), DuetMab, CH3 charge pairs+CH1/CL charge pairs, hinge/CH3 charge pairs, SEED-body, Duobody, four-in-one-CrossMab(kih), LUZ-Y common LC; LUZ-Y scFab-IgG, FcFc*; appended and Fc-modified IgGs, e.g. IgG(kih)-Fv, IgG HA-TF-Fv, IgG(kih)scFab, scFab-Fc(kih)-scFv2, scFab-Fc(kih)-scFv, half DVD-Ig, DVI-Ig (four-in-one), CrossMab-Fab; modified Fc and CH3 fusion proteins, e.g. Fab-Fc(kih)-scFv, Fab-scFv-Fc(kih), Fab-scFv-Fc(BEAT), Fab-scFv-Fc-SEEDbody, Tri Fab; appended IgGs-HC fusions, e.g. IgG-HC, scFv, IgG-dAb, IgG-taFV, IgG-CrossFab, IgG-orthogonal Fab, IgG-(CαCβ) Fab, scFv-HC-IgG, tandem Fab-IgG (orthogonal Fab) Fab-IgG(CαCβ Fab), Fab-IgG(CR3), Fab-hinge-IgG(CR3); appended IgGs-LC fusions, e.g. IgG-scFv(LC), scFv(LC)-IgG, dAb-IgG; appended IgGs-HC and LC fusions, e.g. DVD-Ig, TVD-Ig, CODV-Ig, scFv4-IgG, Zybody; Fc fusions, e.g. Fab-scFv-Fc, scFv4-Ig; F(ab′)2 fusions, e.g. F(ab′)2-scFv2; CH1/CL fusion proteins e.g. scFv2-CH1-hinge/CL; modified IgGs, e.g. DAF (two-in one-IgG), DutaMab, Mabe; and non-Ig fusions, e.g. DNL-Fab4-IgG.
  • The skilled person is able to design and prepare bispecific antigen-binding molecules. Methods for producing bispecific antigen-binding molecules include chemically crosslinking of antigen-binding molecules or antibody fragments, e.g. with reducible disulphide or non-reducible thioether bonds, for example as described in Segal and Bast, 2001. Production of Bispecific Antigen-binding molecules. Current Protocols in Immunology. 14:IV:2.13:2.13.1-2.13.16, which is hereby incorporated by reference in its entirety. For example, N-succinimidyl-3-(-2-pyridyldithio)-propionate (SPDP) can be used to chemically crosslink e.g. Fab fragments via hinge region SH— groups, to create disulfide-linked bispecific F(ab)2 heterodimers.
  • Other methods for producing bispecific antigen-binding molecules include fusing antibody-producing hybridomas e.g. with polyethylene glycol, to produce a quadroma cell capable of secreting bispecific antibody, for example as described in D. M. and Bast, B. J. 2001. Production of Bispecific Antigen-binding molecules. Current Protocols in Immunology. 14:IV:2.13:2.13.1-2.13.16.
  • Bispecific antigen-binding molecules according to the present invention can also be produced recombinantly, by expression from e.g. a nucleic acid construct encoding polypeptides for the antigen-binding molecules, for example as described in Antibody Engineering: Methods and Protocols, Second Edition (Humana Press, 2012), at Chapter 40: Production of Bispecific Antigen-binding molecules: Diabodies and Tandem scFv (Hornig and Farber-Schwarz), or French, How to make bispecific antigen-binding molecules, Methods Mol. Med. 2000; 40:333-339, the entire contents of both of which are hereby incorporated by reference.
  • For example, a DNA construct encoding the light and heavy chain variable domains for the two antigen-binding fragments (i.e. the light and heavy chain variable domains for the antigen-binding fragment capable of binding CD47, and the light and heavy chain variable domains for the antigen-binding fragment capable of binding to another target protein), and including sequences encoding a suitable linker or dimerization domain between the antigen-binding fragments can be prepared by molecular cloning techniques. Recombinant bispecific antibody can thereafter be produced by expression (e.g. in vitro) of the construct in a suitable host cell (e.g. a mammalian host cell), and expressed recombinant bispecific antibody can then optionally be purified.
  • Fc Regions
  • In some embodiments the antigen-binding molecules of the present invention comprise an Fc region.
  • An Fc region is composed of CH2 and CH3 regions from one polypeptide, and CH2 and CH3 regions from another polypeptide. The CH2 and CH3 regions from the two polypeptides together form the Fc region.
  • In some embodiments, the antigen-binding molecule of the present invention comprises an Fc region comprising modification in one or more of the CH2 and CH3 regions promoting association of the Fc region. Recombinant co-expression of constituent polypeptides of an antigen-binding molecule and subsequent association leads to several possible combinations. To improve the yield of the desired combinations of polypeptides in antigen-binding molecules in recombinant production, it is advantageous to introduce in the Fc regions modification(s) promoting association of the desired combination of heavy chain polypeptides. Modifications may promote e.g. hydrophobic and/or electrostatic interaction between CH2 and/or CH3 regions of different polypeptide chains. Suitable modifications are described e.g. in Ha et al., Front. Immnol (2016) 7:394, which is hereby incorporated by reference in its entirety.
  • In some embodiments the antigen antigen-binding molecule of the present invention comprises an Fc region comprising paired substitutions in the CH3 regions of the Fc region according to one of the following formats, as shown in Table 1 of Ha et al., Front. Immnol (2016) 7:394: KiH, KiHs-s, HA-TF, ZW1, 7.8.60, DD-KK, EW-RVT, EW-RVTs-s, SEED or A107.
  • In some embodiments, the Fc region comprises the “knob-into-hole” or “KiH” modification, e.g. as described e.g. in U.S. Pat. No. 7,695,936 and Carter, J Immunol Meth 248, 7-15 (2001). In such embodiments, one of the CH3 regions of the Fc region comprises a “knob” modification, and the other CH3 region comprises a “hole” modification. The “knob” and “hole” modifications are positioned within the respective CH3 regions so that the “knob” can be positioned in the “hole” in order to promote heterodimerisation (and inhibit homodimerisation) of the polypeptides and/or stabilise heterodimers. Knobs are constructed by substituting amino acids having small chains with those having larger side chains (e.g. tyrosine or tryptophan). Holes are created by substituting amino acids having large side chains with those having smaller side chains (e.g. alanine or threonine).
  • In some embodiments, one of the CH3 regions of the Fc region of the antigen-binding molecule of the present invention comprises the substitution (numbering of positions/substitutions in the Fc, CH2 and CH3 regions herein is according to the EU numbering system as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991) T366W, and the other CH3 region of the Fc region comprises the substitution Y407V. In some embodiments, one of the CH3 regions of the Fc region of the antigen-binding molecule comprises the substitution T366W, and the other CH3 region of the Fc region comprises the substitutions T3665 and L368A. In some embodiments, one of the CH3 regions of the Fc region of the antigen-binding molecule comprises the substitution T366W, and the other CH3 region of the Fc region comprises the substitutions Y407V, T3665 and L368A.
  • In some embodiments, the Fc region comprises the “DD-KK” modification as described e.g. in WO 2014/131694 A1. In some embodiments, one of the CH3 regions comprises the substitutions K392D and K409D, and the other CH3 region of the Fc region comprises the substitutions E356K and D399K. The modifications promote electrostatic interaction between the CH3 regions.
  • In some embodiments, the antigen-binding molecule of the present invention comprises an Fc region modified as described in Labrijn et al., Proc Natl Acad Sci USA. (2013) 110(13):5145-50, referred to as ‘Duobody’ format. In some embodiments one of the CH3 regions comprises the substitution K409R, and the other CH3 region of the Fc region comprises the substitution K405L.
  • In some embodiments, the antigen-binding molecule of the present invention comprises an Fc region comprising the “EEE-RRR” modification as described in Strop et al., J Mol Biol. (2012) 420(3):204-19. In some embodiments one of the CH3 regions comprises the substitutions D221E, P228E and L368E, and the other CH3 region of the Fc region comprises the substitutions D221R, P228R and K409R.
  • In some embodiments, the antigen-binding molecule comprises an Fc region comprising the “EW-RVT” modification described in Choi et al., Mol Cancer Ther (2013) 12(12):2748-59. In some embodiments one of the CH3 regions comprises the substitutions K360E and K409W, and the other CH3 region of the Fc region comprises the substitutions Q347R, D399V and F405T.
  • In some embodiments, one of the CH3 regions comprises the substitution S354C, and the other CH3 region of the Fc region comprises the substitution Y349C. Introduction of these cysteine residues results in formation of a disulphide bridge between the two CH3 regions of the Fc region, further stabilizing the heterodimer (Carter (2001), J Immunol Methods 248, 7-15).
  • In some embodiments, the Fc region comprises the “KiHS-S” modification. In some embodiments one of the CH3 regions comprises the substitutions T366W and S354C, and the other CH3 region of the Fc region comprises the substitutions T3665, L368A, Y407V and Y349C.
  • In some embodiments, the antigen-binding molecule of the present invention comprises an Fc region comprising the “SEED” modification as described in Davis et al., Protein Eng Des Sel (2010) 23(4):195-202, in which β-strand segments of human IgG1 CH3 and IgA CH3 are exchanged.
  • In some embodiments, one of the CH3 regions comprises the substitutions S364H and F405A, and the other CH3 region of the Fc region comprises the substitutions Y349T and T394F (see e.g. Moore et al., MAbs (2011) 3(6):546-57).
  • In some embodiments, one of the CH3 regions comprises the substitutions T350V, L351Y, F405A and Y407V, and the other CH3 region of the Fc region comprises the substitutions T350V, T366L, K392L and T394W (see e.g. Von Kreudenstein et al., MAbs (2013) 5(5):646-54).
  • In some embodiments, one of the CH3 regions comprises the substitutions K360D, D399M and Y407A, and the other CH3 region of the Fc region comprises the substitutions E345R, Q347R, T366V and K409V (see e.g. Leaver-Fay et al., Structure (2016) 24(4):641-51).
  • In some embodiments, one of the CH3 regions comprises the substitutions K370E and K409W, and the other CH3 region of the Fc region comprises the substitutions E357N, D399V and F405T (see e.g. Choi et al., PLoS One (2015) 10(12):e0145349).
  • Polypeptides
  • The present invention also provides polypeptide constituents of antigen-binding molecules. The polypeptides may be provided in isolated or substantially purified form.
  • The antigen-binding molecule of the present invention may be, or may comprise, a complex of polypeptides.
  • In the present specification where a polypeptide comprises more than one domain or region, it will be appreciated that the plural domains/regions are preferably present in the same polypeptide chain. That is, the polypeptide comprises more than one domain or region is a fusion polypeptide comprising the domains/regions.
  • In some embodiments a polypeptide according to the present invention comprises, or consists of, a VH as described herein. In some embodiments a polypeptide according to the present invention comprises, or consists of, a VL as described herein.
  • In some embodiments, the polypeptide additionally comprises one or more antibody heavy chain constant regions (CH). In some embodiments, the polypeptide additionally comprises one or more antibody light chain constant regions (CL). In some embodiments, the polypeptide comprises a CH1, CH2 region and/or a CH3 region of an immunoglobulin (Ig).
  • In some embodiments the polypeptide comprises one or more regions of an immunoglobulin heavy chain constant sequence. In some embodiments the polypeptide comprises a CH1 region as described herein. In some embodiments the polypeptide comprises a CH1-CH2 hinge region as described herein. In some embodiments the polypeptide comprises a CH2 region as described herein. In some embodiments the polypeptide comprises a CH3 region as described herein.
  • In some embodiments the polypeptide comprises a CH3 region comprising any one of the following amino acid substitutions/combinations of amino acid substitutions (shown e.g. in Table 1 of Ha et al., Front. Immnol (2016) 7:394, incorporated by reference hereinabove): T366W; T3665, L368A and Y407V; T366W and S354C; T3665, L368A, Y407V and Y349C; S364H and F405A; Y349T and T394F; T350V, L351Y, F405A and Y407V; T350V, T366L, K392L and T394W; K360D, D399M and Y407A; E345R, Q347R, T366V and K409V; K409D and K392D; D399K and E356K; K360E and K409W; Q347R, D399V and F405T; K360E, K409W and Y349C; Q347R, D399V, F405T and S354C; K370E and K409W; and E357N, D399V and F405T.
  • In some embodiments the CH2 and/or CH3 regions of the polypeptide comprise one or more amino acid substitutions for promoting association of the polypeptide with another polypeptide comprising a CH2 and/or CH3 region.
  • In some embodiments the polypeptide comprises one or more regions of an immunoglobulin light chain constant sequence. In some embodiments the polypeptide comprises a CL region as described herein.
  • In some embodiments, the polypeptide according to the present invention comprises a structure from N- to C-terminus according to one of the following:
      • (i) VH
      • (ii) VL
      • (iii) VH-CH1
      • (iv) VL-CL
      • (v) VL-CH1
      • (vi) VH-CL
      • (vii) VH-CH1-CH2-CH3
      • (viii) VL-CL-CH2-CH3
      • (ix) VL-CH1-CH2-CH3
      • (x) VH-CL-CH2-CH3
  • Also provided by the present invention are antigen-binding molecules composed of the polypeptides of the present invention. In some embodiments, the antigen-binding molecule of the present invention comprises one of the following combinations of polypeptides:
      • (A) VH+VL
      • (B) VH-CH1+VL-CL
      • (C) VL-CH1+VH-CL
      • (D) VH-CH1-CH2-CH3+VL-CL
      • (E) VH-CL-CH2-CH3+VL-CH1
      • (F) VL-CH1-CH2-CH3+VH-CL
      • (G) VL-CL-CH2-CH3+VH-CH1
      • (H) VH-CH1-CH2-CH3+VL-CL-CH2-CH3
      • (I) VH-CL-CH2-CH3+VL-CH1-CH2-CH3
  • In some embodiments the antigen-binding molecule comprises more than one of a polypeptide of the combinations shown in (A) to (I) above. By way of example, with reference to (D) above, in some embodiments the antigen-binding molecule comprises two polypeptides comprising the structure VH-CH1-CH2-CH3, and two polypeptides comprising the structure VL-CL.
  • In some embodiments, the antigen-binding molecule of the present invention comprises one of the following combinations of polypeptides:
      • (J) VH (anti-CD47)+VL (anti-CD47)
      • (K) VH (anti-CD47)-CH1+VL (anti-CD47)-CL
      • (L) VL (anti-CD47)-CH1+VH (anti-CD47)-CL
      • (M) VH (anti-CD47)-CH1-CH2-CH3+VL (anti-CD47)-CL
      • (N) VH (anti-CD47)-CL-CH2-CH3+VL (anti-CD47)-CH1
      • (O) VL (anti-CD47)-CH1-CH2-CH3+VH (anti-CD47)-CL
      • (P) VL (anti-CD47)-CL-CH2-CH3+VH (anti-CD47)-CH1
      • (Q) VH (anti-CD47)-CH1-CH2-CH3+VL (anti-CD47)-CL-CH2-CH3
      • (R) VH (anti-CD47)-CL-CH2-CH3+VL (anti-CD47)-CH1-CH2-CH3
  • Wherein: “VH(anti-CD47)” refers to the VH of an antigen-binding molecule capable of binding to CD47 as described herein, e.g. as defined in one of (1) to (35); and “VL(anti-CD47)” refers to the VL of an antigen-binding molecule capable of binding to CD47 as described herein, e.g. as defined in one of (36) to (70); In some embodiments the polypeptide comprises or consists of an amino acid sequence having at least 70%, preferably one of 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of one of SEQ ID NOs:23, 31, 39, 44, 49, 57, 65, 73, 178, 179, 127, 128, 129, 130, 131, 132, 133, 134, 135 or 136.
  • In some embodiments the polypeptide comprises or consists of an amino acid sequence having at least 70%, preferably one of 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of one of SEQ ID NOs:107, 108, 109, 110, 111, 112, 113, 114, 159, 160, 161, 162, 163, 164, 165, 166, 167 or 168.
  • Linkers and Additional Sequences
  • In some embodiments the antigen-binding molecules and polypeptides of the present invention comprise a hinge region. In some embodiments a hinge region is provided between a CH1 region and a CH2 region. In some embodiments a hinge region is provided between a CL region and a CH2 region. In some embodiments the hinge region comprises, or consists of, an amino acid sequence having at least 70%, preferably one of 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:120.
  • In some embodiments the antigen-binding molecules and polypeptides of the present invention comprise one or more linker sequences between amino acid sequences. A linker sequence may be provided at one or both ends of one or more of a VH, VL, CH1-CH2 hinge region, CH2 region and a CH3 region of the antigen-binding molecule/polypeptide.
  • Linker sequences are known to the skilled person, and are described, for example in Chen et al., Adv Drug Deliv Rev (2013) 65(10): 1357-1369, which is hereby incorporated by reference in its entirety. In some embodiments, a linker sequence may be a flexible linker sequence. Flexible linker sequences allow for relative movement of the amino acid sequences which are linked by the linker sequence. Flexible linkers are known to the skilled person, and several are identified in Chen et al., Adv Drug Deliv Rev (2013) 65(10): 1357-1369. Flexible linker sequences often comprise high proportions of glycine and/or serine residues.
  • In some embodiments, the linker sequence comprises at least one glycine residue and/or at least one serine residue. In some embodiments the linker sequence consists of glycine and serine residues. In some embodiments, the linker sequence has a length of 1-2, 1-3, 1-4, 1-5 or 1-10 amino acids.
  • The antigen-binding molecules and polypeptides of the present invention may additionally comprise further amino acids or sequences of amino acids. For example, the antigen-binding molecules and polypeptides may comprise amino acid sequence(s) to facilitate expression, folding, trafficking, processing, purification or detection of the antigen-binding molecule/polypeptide. For example, the antigen-binding molecule/polypeptide may comprise a sequence encoding a His, (e.g. 6×His), Myc, GST, MBP, FLAG, HA, E, or Biotin tag, optionally at the N- or C-terminus of the antigen-binding molecule/polypeptide. In some embodiments the antigen-binding molecule/polypeptide comprises a detectable moiety, e.g. a fluorescent, lunminescent, immuno-detectable, radio, chemical, nucleic acid or enzymatic label.
  • The antigen-binding molecules and polypeptides of the present invention may additionally comprise a signal peptide (also known as a leader sequence or signal sequence). Signal peptides normally consist of a sequence of 5-30 hydrophobic amino acids, which form a single alpha helix. Secreted proteins and proteins expressed at the cell surface often comprise signal peptides.
  • The signal peptide may be present at the N-terminus of the antigen-binding molecule/polypeptide, and may be present in the newly synthesised antigen-binding molecule/polypeptide. The signal peptide provides for efficient trafficking and secretion of the antigen-binding molecule/polypeptide. Signal peptides are often removed by cleavage, and thus are not comprised in the mature antigen-binding molecule/polypeptide secreted from the cell expressing the antigen-binding molecule/polypeptide.
  • Signal peptides are known for many proteins, and are recorded in databases such as GenBank, UniProt, Swiss-Prot, TrEMBL, Protein Information Resource, Protein Data Bank, Ensembl, and InterPro, and/or can be identified/predicted e.g. using amino acid sequence analysis tools such as SignalP (Petersen et al., 2011 Nature Methods 8: 785-786) or Signal-BLAST (Frank and Sippl, 2008 Bioinformatics 24: 2172-2176).
  • In some embodiments, the signal peptide of the antigen-binding molecule/polypeptide of the present invention comprises, or consists of, an amino acid sequence having at least 80%, 85% 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of one of SEQ ID NOs:81 to 86.
  • Labels and Conjugates
  • In some embodiments the antigen-binding molecules of the present invention additionally comprise a detectable moiety.
  • In some embodiments the antigen-binding molecule comprises a detectable moiety, e.g. a fluorescent label, phosphorescent label, luminescent label, immuno-detectable label (e.g. an epitope tag), radiolabel, chemical, nucleic acid or enzymatic label. The antigen-binding molecule may be covalently or non-covalently labelled with the detectable moiety.
  • Fluorescent labels include e.g. fluorescein, rhodamine, allophycocyanin, eosine and NDB, green fluorescent protein (GFP) chelates of rare earths such as europium (Eu), terbium (Tb) and samarium (Sm), tetramethyl rhodamine, Texas Red, 4-methyl umbelliferone, 7-amino-4-methyl coumarin, Cy3, and Cy5. Radiolabels include radioisotopes such as lodine123, lodine125, lodine126, lodine131, lodine133, Bromine77, Technetium99m, Indium111, Indium113m, Gallium67, Gallium68, Ruthenium95, Ruthenium97, Ruthenium103, Ruthenium105, Mercury207, Mercury203, Rhenium99m, Rhenium101, Rhenium105, Scandium47, Tellurium121m, Tellurium122m, Tellurium125m, Thulium165, Thuliuml167, Thulium168, Copper67, Fluorine18, Yttrium90, Palladium100, Bismuth217 and Antimon211. Luminescent labels include as radioluminescent, chemiluminescent (e.g. acridinium ester, luminol, isoluminol) and bioluminescent labels. Immuno-detectable labels include haptens, peptides/polypeptides, antibodies, receptors and ligands such as biotin, avidin, streptavidin or digoxigenin. Nucleic acid labels include aptamers. Enzymatic labels include e.g. peroxidase, alkaline phosphatase, glucose oxidase, beta-galactosidase and luciferase.
  • In some embodiments the antigen-binding molecules of the present invention are conjugated to a chemical moiety. The chemical moiety may be a moiety for providing a therapeutic effect. Antibody-drug conjugates are reviewed e.g. in Parslow et al., Biomedicines. 2016 September; 4(3):14. In some embodiments, the chemical moiety may be a drug moiety (e.g. a cytotoxic agent). In some embodiments, the drug moiety may be a chemotherapeutic agent. In some embodiments, the drug moiety is selected from calicheamicin, DM1, DM4, monomethylauristatin E (MMAE), monomethylauristatin F (MMAF), SN-38, doxorubicin, duocarmycin, D6.5 and PBD.
  • Particular Exemplary Embodiments of the Antigen-Binding Molecules
  • In some embodiments the antigen-binding molecule comprises, or consists of:
      • (i) two polypeptides comprising, or consisting of, an amino acid sequence having at least 70%, preferably one of 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:107; and
      • (ii) two polypeptides comprising, or consisting of, an amino acid sequence having at least 70%, preferably one of 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:108.
  • In some embodiments the antigen-binding molecule comprises, or consists of:
      • (i) two polypeptides comprising, or consisting of, an amino acid sequence having at least 70%, preferably one of 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:109; and
      • (ii) two polypeptides comprising, or consisting of, an amino acid sequence having at least 70%, preferably one of 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:110.
  • In some embodiments the antigen-binding molecule comprises, or consists of:
      • (i) two polypeptides comprising, or consisting of, an amino acid sequence having at least 70%, preferably one of 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:111; and
      • (ii) two polypeptides comprising, or consisting of, an amino acid sequence having at least 70%, preferably one of 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:112.
  • In some embodiments the antigen-binding molecule comprises, or consists of:
      • (i) two polypeptides comprising, or consisting of, an amino acid sequence having at least 70%, preferably one of 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:113; and
      • (ii) two polypeptides comprising, or consisting of, an amino acid sequence having at least 70%, preferably one of 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:114.
  • In some embodiments the antigen-binding molecule comprises, or consists of:
      • (i) two polypeptides comprising, or consisting of, an amino acid sequence having at least 70%, preferably one of 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:159; and
      • (ii) two polypeptides comprising, or consisting of, an amino acid sequence having at least 70%, preferably one of 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:160.
  • In some embodiments the antigen-binding molecule comprises, or consists of:
      • (i) two polypeptides comprising, or consisting of, an amino acid sequence having at least 70%, preferably one of 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:161; and
      • (ii) two polypeptides comprising, or consisting of, an amino acid sequence having at least 70%, preferably one of 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:160.
  • In some embodiments the antigen-binding molecule comprises, or consists of:
      • (i) two polypeptides comprising, or consisting of, an amino acid sequence having at least 70%, preferably one of 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:162; and
      • (ii) two polypeptides comprising, or consisting of, an amino acid sequence having at least 70%, preferably one of 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:160.
  • In some embodiments the antigen-binding molecule comprises, or consists of:
      • (i) two polypeptides comprising, or consisting of, an amino acid sequence having at least 70%, preferably one of 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:163; and
      • (ii) two polypeptides comprising, or consisting of, an amino acid sequence having at least 70%, preferably one of 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:160.
  • In some embodiments the antigen-binding molecule comprises, or consists of:
      • (i) two polypeptides comprising, or consisting of, an amino acid sequence having at least 70%, preferably one of 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:164; and
      • (ii) two polypeptides comprising, or consisting of, an amino acid sequence having at least 70%, preferably one of 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:160.
  • In some embodiments the antigen-binding molecule comprises, or consists of:
      • (i) two polypeptides comprising, or consisting of, an amino acid sequence having at least 70%, preferably one of 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:163; and
      • (ii) two polypeptides comprising, or consisting of, an amino acid sequence having at least 70%, preferably one of 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:165.
  • In some embodiments the antigen-binding molecule comprises, or consists of:
      • (i) two polypeptides comprising, or consisting of, an amino acid sequence having at least 70%, preferably one of 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:164; and
      • (ii) two polypeptides comprising, or consisting of, an amino acid sequence having at least 70%, preferably one of 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:165.
  • In some embodiments the antigen-binding molecule comprises, or consists of:
      • (i) two polypeptides comprising, or consisting of, an amino acid sequence having at least 70%, preferably one of 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:163; and
      • (ii) two polypeptides comprising, or consisting of, an amino acid sequence having at least 70%, preferably one of 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:166.
  • In some embodiments the antigen-binding molecule comprises, or consists of:
      • (i) two polypeptides comprising, or consisting of, an amino acid sequence having at least 70%, preferably one of 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:164; and
      • (ii) two polypeptides comprising, or consisting of, an amino acid sequence having at least 70%, preferably one of 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:166.
  • In some embodiments the antigen-binding molecule comprises, or consists of:
      • (i) two polypeptides comprising, or consisting of, an amino acid sequence having at least 70%, preferably one of 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:164; and
      • (ii) two polypeptides comprising, or consisting of, an amino acid sequence having at least 70%, preferably one of 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:167.
  • In some embodiments the antigen-binding molecule comprises, or consists of:
      • (i) two polypeptides comprising, or consisting of, an amino acid sequence having at least 70%, preferably one of 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:164; and
      • (ii) two polypeptides comprising, or consisting of, an amino acid sequence having at least 70%, preferably one of 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:168.
  • Functional Properties of the Antigen-Binding Molecules
  • The antigen-binding molecules described herein may be characterised by reference to certain functional properties. In some embodiments, the antigen-binding molecule described herein may possess one or more of the following properties:
      • binds to CD47;
      • binds to CD47-expressing cells;
      • inhibits interaction between CD47 and SIRPα;
      • inhibits SIRPα-mediated signalling;
      • increases phagocytosis of CD47-expressing cells by phagocytic cells (e.g. macrophages);
      • increases the number/proportion of cancer antigen-specific immune cells
      • does not cause substantial hemagglutination;
      • causes less hemagglutination as compared to a reference anti-CD47 antibody;
      • increases killing of cancer cells;
      • inhibits the development/progression of cancer.
  • The antigen-binding molecules and antigen-binding domains described herein preferably display specific binding to the relevant target antigen(s) (e.g. CD47). As used herein, “specific binding” refers to binding which is selective for the antigen, and which can be discriminated from non-specific binding to non-target antigen. An antigen-binding molecule/domain that specifically binds to a target molecule preferably binds the target with greater affinity, and/or with greater duration than it binds to other, non-target molecules.
  • The ability of a given polypeptide to bind specifically to a given molecule can be determined by analysis according to methods known in the art, such as by ELISA, Surface Plasmon Resonance (SPR; see e.g. Hearty et al., Methods Mol Biol (2012) 907:411-442), Bio-Layer Interferometry (see e.g. Lad et al., (2015) J Biomol Screen 20(4): 498-507), flow cytometry, or by a radiolabeled antigen-binding assay (RIA) enzyme-linked immunosorbent assay. Through such analysis binding to a given molecule can be measured and quantified. In some embodiments, the binding may be the response detected in a given assay.
  • In some embodiments, the extent of binding of the antigen-binding molecule to an non-target molecule is less than about 10% of the binding of the antibody to the target molecule as measured, e.g. by ELISA, SPR, Bio-Layer Interferometry or by RIA. Alternatively, binding specificity may be reflected in terms of binding affinity where the antigen-binding molecule binds with a dissociation constant (KD) that is at least 0.1 order of magnitude (i.e. 0.1×10n, where n is an integer representing the order of magnitude) greater than the KD of the antigen-binding molecule towards a non-target molecule. This may optionally be one of at least 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.5, or 2.0.
  • In some embodiments, the antigen-binding molecule described herein binds to CD47 with a KD of 10 μM or less, preferably one of ≤5 μM, ≤2 μM, ≤1 μM, ≤500 nM, ≤100 nM, ≤75 nM, ≤50 nM, ≤40 nM, ≤30 nM, ≤20 nM, ≤15 nM, ≤12.5 nM, ≤10 nM, ≤9 nM, ≤8 nM, ≤7 nM, ≤6 nM, ≤5 nM, ≤4 nM ≤3 nM, ≤2 nM, ≤1 nM or ≤500 μM. In some embodiments, the antigen-binding molecule binds to CD47 with an affinity of KD=≤10 nM, ≤9 nM, ≤8 nM, ≤7 nM or ≤6 nM, e.g. ˜5 nM.
  • In some embodiments, the antigen-binding molecule binds to CD47 with an affinity of binding (e.g. as determined by ELISA) of EC50=100 μg/ml or less, preferably one of ≤90 μg/ml, ≤80 μg/ml, ≤70 μg/ml, ≤60 μg/ml, ≤50 μg/ml, ≤40 μg/ml, ≤30 μg/ml, ≤20 μg/ml, ≤10 μg/ml, ≤9 μg/ml, ≤8 μg/ml, ≤7 μg/ml, ≤6 μg/ml, ≤5 μg/ml, ≤4 μg/ml, ≤3 μg/ml, ≤2 μg/ml, ≤1.5 μg/ml, ≤1 μg/ml, ≤0.5 μg/ml, ≤0.25 μg/ml, or ≤0.1 μg/ml.
  • The antigen-binding molecules of the present invention may bind to a particular region of interest of the target antigen(s). The antigen-binding region of an antigen-binding molecule according to the present domain may bind to linear epitope of a target antigen (e.g. CD47), consisting of a contiguous sequence of amino acids (i.e. an amino acid primary sequence). In some embodiments, the antigen-binding region molecule may bind to a conformational epitope of a target antigen (i.e. CD47), consisting of a discontinuous sequence of amino acids of the amino acid sequence.
  • In some embodiments, the antigen-binding molecule of the present invention is capable of binding to CD47. In some embodiments, the antigen-binding molecule is capable of binding to CD47 in an extracellular region of CD47. In some embodiments, the antigen-binding molecule is capable of binding to CD47 in extracellular region 1 of CD47 (e.g. the region shown in SEQ ID NO:10). In some embodiments, the antigen-binding molecule is capable of binding to the V-type Ig-like domain of CD47 (e.g. the region shown in SEQ ID NO:9).
  • In some embodiments the antigen-binding molecule is capable of binding to a polypeptide comprising or consisting of the amino acid sequence shown in SEQ ID NO:10. In some embodiments the antigen-binding molecule is capable of binding to a polypeptide comprising or consisting of the amino acid sequence shown in SEQ ID NO:9. In some embodiments the antigen-binding molecule is capable of binding to a polypeptide comprising or consisting of the amino acid sequence shown in SEQ ID NO:9. In some embodiments the antigen-binding molecule is capable of binding to a peptide or polypeptide comprising or consisting of the amino acid sequence shown in SEQ ID NO:21. In some embodiments the antigen-binding molecule is capable of binding to a peptide or polypeptide comprising or consisting of the amino acid sequence shown in SEQ ID NO:22.
  • As used herein, a “peptide” refers to a chain of two or more amino acid monomers linked by peptide bonds. A peptide typically has a length in the region of about 2 to 50 amino acids. A “polypeptide” is a polymer chain of two or more peptides. Polypeptides typically have a length greater than about 50 amino acids.
  • The ability of an antigen-binding molecule to bind to a given peptide/polypeptide can be analysed by methods well known to the skilled person, including analysis by ELISA, immunoblot (e.g. western blot), immunoprecipitation, surface plasmon resonance and biolayer interferometry.
  • In some embodiments the antigen-binding molecule is capable of binding the same region of CD47, or an overlapping region of CD47, to the region of CD47 which is bound by an antibody comprising the VH and VL sequences of one of clones 1-1-A1_BM, 1-1-A1, 5-48-A6, 5-48-D2, 11A1H1, 11A1H2, 11A1H3, 11A1H4, 11A1H5, 11A1H6, 11A1H7, 11A1H8, 11A1H9, 11A1H10 or 11A1H11.
  • The region of a peptide/polypeptide to which an antibody binds can be determined by the skilled person using various methods well known in the art, including X-ray co-crystallography analysis of antibody-antigen complexes, peptide scanning, mutagenesis mapping, hydrogen-deuterium exchange analysis by mass spectrometry, phage display, competition ELISA and proteolysis-based ‘protection’ methods. Such methods are described, for example, in Gershoni et al., BioDrugs, 2007, 21(3):145-156, which is hereby incorporated by reference in its entirety.
  • In some embodiments the antigen-binding molecule of the present invention displays cross-reactivity with CD47 of a non-human primate. That is, in some embodiments the antigen-binding molecule binds to both human CD47 and CD47 from a non-human primate. In some embodiments the non-human primate is rhesus macaque (Macaca mulatta).
  • In some embodiments the antigen-binding molecule of the present invention binds to CD47 in a region which is accessible to an antigen-binding molecule (i.e., an extracellular antigen-binding molecule) when CD47 is expressed at the cell surface (i.e. in or at the cell membrane). In some embodiments the antigen-binding molecule is capable of binding to CD47 expressed at the cell surface of a cell expressing CD47. In some embodiments the antigen-binding molecule is capable of binding to CD47-expressing cells (e.g. myeloid cells, myeloid leukemia cells, HL-60 cells, HMC-1 cells, HEL cells or Raji cells).
  • The ability of an antigen-binding molecule to bind to a given cell type can be analysed by contacting cells with the antigen-binding molecule, and detecting antigen-binding molecule bound to the cells, e.g. after a washing step to remove unbound antigen-binding molecule. The ability of an antigen-binding molecule to bind to immune cell surface molecule-expressing cells and/or cancer cell antigen-expressing cells can be analysed by methods such as flow cytometry and immunofluorescence microscopy.
  • The antigen-binding molecule of the present invention may be an antagonist of CD47. In some embodiments, the antigen-binding molecule is capable of inhibiting a function or process (e.g. interaction, signalling or other activity) mediated by CD47. Herein, ‘inhibition’ refers to a reduction, decrease or lessening relative to a control condition.
  • In some embodiments the antigen-binding molecule of the present invention is capable of inhibiting interaction between CD47 and a ligand for CD47. In some embodiments the antigen-binding molecule of the present invention is capable of inhibiting interaction between CD47 and SIRPα.
  • The ability of an antigen-binding molecule to inhibit interaction between two factors can be determined for example by analysis of interaction in the presence of, or following incubation of one or both of the interaction partners with, the antibody/fragment. An example of a suitable assay to determine whether a given antigen-binding molecule is capable of inhibiting interaction between two interaction partners is a competition ELISA assay.
  • An antigen-binding molecule which is capable of inhibiting a given interaction (e.g. between CD47 and SIRPα) is identified by the observation of a reduction/decrease in the level of interaction between the interaction partners in the presence of—or following incubation of one or both of the interaction partners with—the antigen-binding molecule, as compared to the level of interaction in the absence of the antigen-binding molecule (or in the presence of an appropriate control antigen-binding molecule). Suitable analysis can be performed in vitro, e.g. using recombinant interaction partners or using cells expressing the interaction partners. Cells expressing interaction partners may do so endogenously, or may do so from nucleic acid introduced into the cell. For the purposes of such assays, one or both of the interaction partners and/or the antigen-binding molecule may be labelled or used in conjunction with a detectable entity for the purposes of detecting and/or measuring the level of interaction.
  • The ability of an antigen-binding molecule to inhibit interaction between two binding partners can also be determined by analysis of the downstream functional consequences of such interaction. For example, downstream functional consequences of interaction between CD47 and SIRPα may include SIRPα-mediated signalling. For example, the ability of an antigen-binding molecule to inhibit interaction of CD47 and SIRPα may be determined by analysis of SIRPα ITIM phosphorylation, or analysis of phagocytosis of CD47-expressing cell by a SIRPα-expressing cell.
  • In some embodiments, the antigen-binding molecule of the present invention is capable of inhibiting interaction between CD47 and SIRPα to less than less than 1 times, e.g. ≤0.99 times, ≤0.95 times, ≤0.9 times, ≤0.85 times, ≤0.8 times, ≤0.75 times, ≤0.7 times, ≤0.65 times, ≤0.6 times, ≤0.55 times, ≤0.5 times, ≤0.45 times, ≤0.4 times, ≤0.35 times, ≤0.3 times, ≤0.25 times, ≤0.2 times, ≤0.15 times, ≤0.1 times, ≤0.05 times, or ≤0.01 times the level of interaction between CD47 and SIRPα in the absence of the antigen-binding molecule (or in the presence of an appropriate control antigen-binding molecule).
  • In some embodiments, the antigen-binding molecule inhibits interaction between CD47 and SIRPα with an IC50 (e.g. as determined by ELISA) of 100 μg/ml or less, preferably one of ≤90 μg/ml, ≤80 μg/ml, ≤70 μg/ml, ≤60 μg/ml, ≤50 μg/ml, ≤40 μg/ml, ≤30 μg/ml, ≤20 μg/ml, ≤10 μg/ml, ≤9 μg/ml, ≤8 μg/ml, ≤7 μg/ml, ≤6 μg/ml, ≤5 μg/ml, ≤4 μg/ml, ≤3 μg/ml, ≤2 μg/ml, ≤1.5 μg/ml, ≤1 μg/ml, ≤0.5 μg/ml, ≤0.25 μg/ml, or ≤0.1 μg/ml.
  • In some embodiments the antigen-binding molecule inhibits SIRPα-mediated signalling. SIRPα-mediated signalling can be analysed using SIRPα-expressing cells e.g. using an assay for detecting and/or quantifying SIRPα ITIM phosphorylation, or using in vitro assay of phagocytosis of CD47-expressing cells (e.g. Raji cells) by SIRPα-expressing cells (e.g. macrophages). For example, an in vitro assay of phagocytosis of CD47-expressing cells by SIRPα-expressing cells may be performed as described in Feng et al., Proc Natl Acad Sci USA. (2015) 112(7): 2145-2150 (hereby incorporated by reference in its entirety), or as described in the experimental examples herein.
  • In some embodiments, the antigen-binding molecule of the present invention is capable of inhibiting SIRPα-mediated signalling to less than 1 times, e.g. ≤0.99 times, ≤0.95 times, ≤0.9 times, ≤0.85 times, ≤0.8 times, ≤0.75 times, ≤0.7 times, ≤0.65 times, ≤0.6 times, ≤0.55 times, ≤0.5 times, ≤0.45 times, ≤0.4 times, ≤0.35 times, ≤0.3 times, ≤0.25 times, ≤0.2 times, ≤0.15 times, ≤0.1 times, ≤0.05 times, or ≤0.01 times the level of SIRPα-mediated signalling in the absence of the antigen-binding molecule (or in the presence of an appropriate control antigen-binding molecule).
  • In some embodiments, the antigen-binding molecule of the present invention is capable of increasing phagocytosis of CD47-expressing cells. In some embodiments, the antigen-binding molecule of the present invention is capable of increasing phagocytosis of CD47-expressing cells (e.g. Raji cells) by SIRPα-expressing cells (e.g. macrophages).
  • An antigen-binding molecule which is capable of increasing phagocytosis of CD47-expressing cells by SIRPα-expressing cells is identified by the observation of an increased level of phagocytosis of the CD47-expressing cells by the SIRPα-expressing cells in the presence of—or following incubation of the CD47-expressing cells with—the antigen-binding molecule, as compared to the level of phagocytosis detected in the absence of the antigen-binding molecule (or in the presence of an appropriate control antigen-binding molecule).
  • In some embodiments, the antigen-binding molecule of the present invention is capable of increasing phagocytosis of CD47-expressing cells (e.g. Raji cells) by SIRPα-expressing cells (e.g. macrophages) to more than 1 times, e.g. ≥1.01 times, ≥1.02 times, ≥1.03 times, ≥1.04 times, ≥1.05 times, ≥1.1 times, ≥1.2 times, ≥1.3 times, ≥1.4 times, ≥1.5 times, ≥1.6 times, ≥1.7 times, ≥1.8 times, ≥1.9 times, ≥2 times, ≥3 times, ≥4 times, ≥5 times, ≥6 times, ≥7 times, ≥8 times, ≥9 times or ≥10 times the level phagocytosis of the CD47-expressing cells by the SIRPα-expressing cells in the absence of the antigen-binding molecule (or in the presence of an appropriate control antigen-binding molecule).
  • In some embodiments, the antigen-binding molecule of the present invention is capable of increasing the number/proportion of cancer antigen-specific immune cells (e.g. CD8+ T cells or CD8+ CTLs) relative to a negative control condition, e.g. in an appropriate in vitro assay, or in vivo. Tseng et al., Proc Natl Acad Sci USA. (2013) 110(27): 11103-11108 (hereby incorporated by reference in its entirety) demonstrated that increased phagocytosis of CD47-expressing cancer cells by macrophages in the presence of an anti-CD47 antibody was associated with increased priming of cancer antigen-specific CD8+ T cells. Antigen-binding molecules capable of causing an increase in the number/proportion of cancer antigen-specific immune cells can be identified using a T cell priming assay e.g. as described in Tseng et al., Proc Natl Acad Sci USA. (2013) 110(27): 11103-11108.
  • In some embodiments, the antigen-binding molecule of the present invention does not cause substantial hemagglutination (e.g. at concentrations of up to 400 μg/ml). Hemagglutination refers to agglutination of red blood cells (erythrocytes).
  • An agent which causes hemagglutination may be referred to as a hemagglutinin. In some embodiments the antigen-binding molecule of the present invention is not a hemagglutinin.
  • The ability of an antibody to cause hemagglutination can be analysed e.g. using an in vitro hemagglutination assay. A suitable assay of hemagglutination for the purposes of such analysis is described e.g. in Example 5 of WO 2013/119714 A1 (hereby incorporated by reference in its entirety), or the assay of hemagglutination described in the experimental examples herein. “Substantial” hemagglutination may be a level of hemagglutination which is more than 2 times, e.g. more than 3, 4, 5, 6, 7, 8, 9 or 10 times the level of hemagglutination detected in the absence of the antigen-binding molecule (or in the presence of an appropriate control antigen-binding molecule which does not cause hemagglutination).
  • In some embodiments, the antigen-binding molecule of the present invention causes less hemagglutination as compared to a reference anti-CD47 antibody (e.g. a prior art anti-CD47 antibody). In some embodiments, the antigen-binding molecule of the present invention causes less than 1 times, e.g. ≤0.99 times, ≤0.95 times, ≤0.9 times, ≤0.85 times, ≤0.8 times, ≤0.75 times, ≤0.7 times, ≤0.65 times, ≤0.6 times, ≤0.55 times, ≤0.5 times, ≤0.45 times, ≤0.4 times, ≤0.35 times, ≤0.3 times, ≤0.25 times, ≤0.2 times, ≤0.15 times, ≤0.1 times, ≤0.05 times, or ≤0.01 times the level of hemagglutination as compared to a reference anti-CD47 antibody (e.g. a prior art anti-CD47 antibody), e.g. as determined using an in vitro assay of hemagglutination.
  • In some embodiments the antigen-binding molecule of the present invention increases killing of cancer cells. In some embodiments the antigen-binding molecule of the present invention causes a reduction in the number of cancer cells in vivo, e.g. as compared to an appropriate control condition. The cancer may be a cancer expressing CD47, or may comprise cells expressing CD47 (e.g. the CD47+ AML cell line, HL-60). The antigen-binding molecule of the present invention may be analysed for anticancer activity in an appropriate in vivo model, e.g. an AML cell line-derived xenograft model.
  • In some embodiments the antigen-binding molecule of the present invention causes a greater reduction of the number of cancer cells in vivo in a AML cell line-derived xenograft model as compared to a reference anti-CD47 antibody (e.g. a prior art anti-CD47 antibody).
  • In some embodiments, administration of an antigen-binding molecule according to the present invention may cause one or more of: inhibition of the development/progression of the cancer, a delay to/prevention of onset of the cancer, a reduction in/delay to/prevention of tumor growth, a reduction in/delay to/prevention of metastasis, a reduction in the severity of the symptoms of the cancer, a reduction in the number of cancer cells, a reduction in tumour size/volume, and/or an increase in survival (e.g. progression free survival), e.g. as determined in an AML cell line-derived xenograft model.
  • Chimeric Antigen Receptors (CARs)
  • The present invention also provides Chimeric Antigen Receptors (CARs) comprising the antigen-binding polypeptides or polypeptides of the present invention.
  • CARs are recombinant receptors that provide both antigen-binding and T cell activating functions. CAR structure and engineering is reviewed, for example, in Dotti et al., Immunol Rev (2014) 257(1), hereby incorporated by reference in its entirety. CARs comprise an antigen-binding region linked to a cell membrane anchor region and a signalling region. An optional hinge region may provide separation between the antigen-binding region and cell membrane anchor region, and may act as a flexible linker.
  • The CAR of the present invention comprises an antigen-binding region which comprises or consists of the antigen-binding molecule of the present invention, or which comprises or consists of a polypeptide according to the invention.
  • The cell membrane anchor region is provided between the antigen-binding region and the signalling region of the CAR and provides for anchoring the CAR to the cell membrane of a cell expressing a CAR, with the antigen-binding region in the extracellular space, and signalling region inside the cell. In some embodiments, the CAR comprises a cell membrane anchor region comprising or consisting of an amino acid sequence which comprises, consists of, or is derived from, the transmembrane region amino acid sequence for one of CD3-ζ, CD4, CD8 or CD28. As used herein, a region which is ‘derived from’ a reference amino acid sequence comprises an amino acid sequence having at least 60%, e.g. one of at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the reference sequence.
  • The signalling region of a CAR allows for activation of the T cell. The CAR signalling regions may comprise the amino acid sequence of the intracellular domain of CD3-, which provides immunoreceptor tyrosine-based activation motifs (ITAMs) for phosphorylation and activation of the CAR-expressing T cell. Signalling regions comprising sequences of other ITAM-containing proteins such as FcγRI have also been employed in CARs (Haynes et al., 2001 J Immunol 166(1):182-187). Signalling regions of CARs may also comprise co-stimulatory sequences derived from the signalling region of co-stimulatory molecules, to facilitate activation of CAR-expressing T cells upon binding to the target protein. Suitable co-stimulatory molecules include CD28, OX40, 4-1BB, ICOS and CD27. In some cases CARs are engineered to provide for co-stimulation of different intracellular signalling pathways. For example, signalling associated with CD28 costimulation preferentially activates the phosphatidylinositol 3-kinase (P13K) pathway, whereas the 4-1BB-mediated signalling is through TNF receptor associated factor (TRAF) adaptor proteins. Signalling regions of CARs therefore sometimes contain co-stimulatory sequences derived from signalling regions of more than one co-stimulatory molecule. In some embodiments, the CAR of the present invention comprises one or more co-stimulatory sequences comprising or consisting of an amino acid sequence which comprises, consists of, or is derived from, the amino acid sequence of the intracellular domain of one or more of CD28, OX40, 4-1BB, ICOS and CD27.
  • An optional hinge region may provide separation between the antigen-binding domain and the transmembrane domain, and may act as a flexible linker. Hinge regions may be derived from IgG1. In some embodiments, the CAR of the present invention comprises a hinge region comprising or consisting of an amino acid sequence which comprises, consists of, or is derived from, the amino acid sequence of the hinge region of IgG1.
  • Also provided is a cell comprising a CAR according to the invention. The CAR according to the present invention may be used to generate CAR-expressing immune cells, e.g. CAR-T or CAR-NK cells. Engineering of CARs into immune cells may be performed during culture, in vitro.
  • The antigen-binding region of the CAR of the present invention may be provided with any suitable format, e.g. scFv, scFab, etc.
  • Nucleic Acids and Vectors
  • The present invention provides a nucleic acid, or a plurality of nucleic acids, encoding an antigen-binding molecule, polypeptide or CAR according to the present invention.
  • In some embodiments, the nucleic acid is purified or isolated, e.g. from other nucleic acid, or naturally-occurring biological material. In some embodiments the nucleic acid(s) comprise or consist of DNA and/or RNA.
  • The present invention also provides a vector, or plurality of vectors, comprising the nucleic acid or plurality of nucleic acids according to the present invention.
  • The nucleotide sequence may be contained in a vector, e.g. an expression vector. A “vector” as used herein is a nucleic acid molecule used as a vehicle to transfer exogenous nucleic acid into a cell. The vector may be a vector for expression of the nucleic acid in the cell. Such vectors may include a promoter sequence operably linked to the nucleotide sequence encoding the sequence to be expressed. A vector may also include a termination codon and expression enhancers. Any suitable vectors, promoters, enhancers and termination codons known in the art may be used to express a peptide or polypeptide from a vector according to the invention.
  • The term “operably linked” may include the situation where a selected nucleic acid sequence and regulatory nucleic acid sequence (e.g. promoter and/or enhancer) are covalently linked in such a way as to place the expression of nucleic acid sequence under the influence or control of the regulatory sequence (thereby forming an expression cassette). Thus a regulatory sequence is operably linked to the selected nucleic acid sequence if the regulatory sequence is capable of effecting transcription of the nucleic acid sequence. The resulting transcript(s) may then be translated into a desired peptide(s)/polypeptide(s).
  • Suitable vectors include plasmids, binary vectors, DNA vectors, mRNA vectors, viral vectors (e.g. gammaretroviral vectors (e.g. murine Leukemia virus (MLV)-derived vectors), lentiviral vectors, adenovirus vectors, adeno-associated virus vectors, vaccinia virus vectors and herpesvirus vectors), transposon-based vectors, and artificial chromosomes (e.g. yeast artificial chromosomes).
  • In some embodiments, the vector may be a eukaryotic vector, e.g. a vector comprising the elements necessary for expression of protein from the vector in a eukaryotic cell. In some embodiments, the vector may be a mammalian vector, e.g. comprising a cytomegalovirus (CMV) or SV40 promoter to drive protein expression.
  • Constituent polypeptides of an antigen-binding molecule according to the present invention may be encoded by different nucleic acids of the plurality of nucleic acids, or by different vectors of the plurality of vectors.
  • Cells Comprising/Expressing the Antigen-Binding Molecules and Polypeptides
  • The present invention also provides a cell comprising or expressing an antigen-binding molecule, polypeptide or CAR according to the present invention. Also provided is a cell comprising or expressing a nucleic acid, a plurality of nucleic acids, a vector or a plurality of vectors according to the invention.
  • The cell may be a eukaryotic cell, e.g. a mammalian cell. The mammal may be a primate (rhesus, cynomolgous, non-human primate or human) or a non-human mammal (e.g. rabbit, guinea pig, rat, mouse or other rodent (including any animal in the order Rodentia), cat, dog, pig, sheep, goat, cattle (including cows, e.g. dairy cows, or any animal in the order Bos), horse (including any animal in the order Equidae), donkey, and non-human primate).
  • The present invention also provides a method for producing a cell comprising a nucleic acid(s) or vector(s) according to the present invention, comprising introducing a nucleic acid, a plurality of nucleic acids, a vector or a plurality of vectors according to the present invention into a cell. In some embodiments, introducing an isolated nucleic acid(s) or vector(s) according to the invention into a cell comprises transformation, transfection, electroporation or transduction (e.g. retroviral transduction).
  • The present invention also provides a method for producing a cell expressing/comprising an antigen-binding molecule, polypeptide or CAR according to the present invention, comprising introducing a nucleic acid, a plurality of nucleic acids, a vector or a plurality of vectors according to the present invention in a cell. In some embodiments, the methods additionally comprise culturing the cell under conditions suitable for expression of the nucleic acid(s) or vector(s) by the cell. In some embodiments, the methods are performed in vitro.
  • The present invention also provides cells obtained or obtainable by the methods according to the present invention.
  • Producing the Antigen-Binding Molecules and Polypeptides
  • Antigen-binding molecules and polypeptides according to the invention may be prepared according to methods for the production of polypeptides known to the skilled person.
  • Polypeptides may be prepared by chemical synthesis, e.g. liquid or solid phase synthesis. For example, peptides/polypeptides can by synthesised using the methods described in, for example, Chandrudu et al., Molecules (2013), 18: 4373-4388, which is hereby incorporated by reference in its entirety.
  • Alternatively, antigen-binding molecules and polypeptides may be produced by recombinant expression. Molecular biology techniques suitable for recombinant production of polypeptides are well known in the art, such as those set out in Green and Sambrook, Molecular Cloning: A Laboratory Manual (4th Edition), Cold Spring Harbor Press, 2012, and in Nat Methods. (2008); 5(2): 135-146 both of which are hereby incorporated by reference in their entirety. Methods for the recombinant production of antigen-binding molecules are also described in Frenzel et al., Front Immunol. (2013); 4: 217 and Kunert and Reinhart, Appl Microbiol Biotechnol. (2016) 100: 3451-3461, both of which are hereby incorporated by reference in their entirety.
  • In some cases the antigen-binding molecule of the present invention are comprised of more than one polypeptide chain. In such cases, production of the antigen-binding molecules may comprise transcription and translation of more than one polypeptide, and subsequent association of the polypeptide chains to form the antigen-binding molecule.
  • For recombinant production according to the invention, any cell suitable for the expression of polypeptides may be used. The cell may be a prokaryote or eukaryote. In some embodiments the cell is a prokaryotic cell, such as a cell of archaea or bacteria. In some embodiments the bacteria may be Gram-negative bacteria such as bacteria of the family Enterobacteriaceae, for example Escherichia coli. In some embodiments, the cell is a eukaryotic cell such as a yeast cell, a plant cell, insect cell or a mammalian cell, e.g. CHO, HEK (e.g. HEK293), HeLa or COS cells.
  • In some cases the cell is not a prokaryotic cell because some prokaryotic cells do not allow for the same folding or post-translational modifications as eukaryotic cells. In addition, very high expression levels are possible in eukaryotes and proteins can be easier to purify from eukaryotes using appropriate tags. Specific plasmids may also be utilised which enhance secretion of the protein into the media.
  • In some embodiments polypeptides may be prepared by cell-free-protein synthesis (CFPS), e.g. according using a system described in Zemella et al. Chembiochem (2015) 16(17): 2420-2431, which is hereby incorporated by reference in its entirety.
  • Production may involve culture or fermentation of a eukaryotic cell modified to express the polypeptide(s) of interest. The culture or fermentation may be performed in a bioreactor provided with an appropriate supply of nutrients, air/oxygen and/or growth factors. Secreted proteins can be collected by partitioning culture media/fermentation broth from the cells, extracting the protein content, and separating individual proteins to isolate secreted polypeptide(s). Culture, fermentation and separation techniques are well known to those of skill in the art, and are described, for example, in Green and Sambrook, Molecular Cloning: A Laboratory Manual (4th Edition; incorporated by reference herein above).
  • Bioreactors include one or more vessels in which cells may be cultured. Culture in the bioreactor may occur continuously, with a continuous flow of reactants into, and a continuous flow of cultured cells from, the reactor. Alternatively, the culture may occur in batches. The bioreactor monitors and controls environmental conditions such as pH, oxygen, flow rates into and out of, and agitation within the vessel such that optimum conditions are provided for the cells being cultured.
  • Following culturing the cells that express the antigen-binding molecule/polypeptide(s), the polypeptide(s) of interest may be isolated. Any suitable method for separating proteins from cells known in the art may be used. In order to isolate the polypeptide it may be necessary to separate the cells from nutrient medium. If the polypeptide(s) are secreted from the cells, the cells may be separated by centrifugation from the culture media that contains the secreted polypeptide(s) of interest. If the polypeptide(s) of interest collect within the cell, protein isolation may comprise centrifugation to separate cells from cell culture medium, treatment of the cell pellet with a lysis buffer, and cell disruption e.g. by sonification, rapid freeze-thaw or osmotic lysis.
  • It may then be desirable to isolate the polypeptide(s) of interest from the supernatant or culture medium, which may contain other protein and non-protein components. A common approach to separating protein components from a supernatant or culture medium is by precipitation. Proteins of different solubilities are precipitated at different concentrations of precipitating agent such as ammonium sulfate. For example, at low concentrations of precipitating agent, water soluble proteins are extracted. Thus, by adding different increasing concentrations of precipitating agent, proteins of different solubilities may be distinguished. Dialysis may be subsequently used to remove ammonium sulfate from the separated proteins.
  • Other methods for distinguishing different proteins are known in the art, for example ion exchange chromatography and size chromatography. These may be used as an alternative to precipitation, or may be performed subsequently to precipitation.
  • Once the polypeptide(s) of interest have been isolated from culture it may be desired or necessary to concentrate the polypeptide(s). A number of methods for concentrating proteins are known in the art, such as ultrafiltration or lyophilisation.
  • Compositions
  • The present invention also provides compositions comprising the antigen-binding molecules, polypeptides, CARs, nucleic acids, expression vectors and cells described herein.
  • The antigen-binding molecules, polypeptides, CARs, nucleic acids, expression vectors and cells described herein may be formulated as pharmaceutical compositions or medicaments for clinical use and may comprise a pharmaceutically acceptable carrier, diluent, excipient or adjuvant. The composition may be formulated for topical, parenteral, systemic, intracavitary, intravenous, intra-arterial, intramuscular, intrathecal, intraocular, intraconjunctival, intratumoral, subcutaneous, intradermal, intrathecal, oral or transdermal routes of administration which may include injection or infusion.
  • Suitable formulations may comprise the antigen-binding molecule in a sterile or isotonic medium. Medicaments and pharmaceutical compositions may be formulated in fluid, including gel, form. Fluid formulations may be formulated for administration by injection or infusion (e.g. via catheter) to a selected region of the human or animal body.
  • In some embodiments the composition is formulated for injection or infusion, e.g. into a blood vessel or tumor.
  • In accordance with the invention described herein methods are also provided for the production of pharmaceutically useful compositions, such methods of production may comprise one or more steps selected from: producing an antigen-binding molecule, polypeptide, CAR, nucleic acid (or plurality thereof), expression vector (or plurality thereof) or cell described herein; isolating an antigen-binding molecule, polypeptide, CAR, nucleic acid (or plurality thereof), expression vector (or plurality thereof) or cell described herein; and/or mixing antigen-binding molecule, polypeptide, CAR, nucleic acid (or plurality thereof), expression vector (or plurality thereof) or cell described herein with a pharmaceutically acceptable carrier, adjuvant, excipient or diluent.
  • For example, a further aspect the invention described herein relates to a method of formulating or producing a medicament or pharmaceutical composition for use in the treatment of a disease/condition (e.g. a cancer), the method comprising formulating a pharmaceutical composition or medicament by mixing an antigen-binding molecule, polypeptide, CAR, nucleic acid (or plurality thereof), expression vector (or plurality thereof) or cell described herein with a pharmaceutically acceptable carrier, adjuvant, excipient or diluent.
  • Therapeutic and Prophylactic Applications
  • The antigen-binding molecules, polypeptides, CARs, nucleic acids, expression vectors, cells and compositions described herein find use in therapeutic and prophylactic methods.
  • The present invention provides an antigen-binding molecule, polypeptide, CAR, nucleic acid (or plurality thereof), expression vector (or plurality thereof), cell or composition described herein for use in a method of medical treatment or prophylaxis. Also provided is the use of an antigen-binding molecule, polypeptide, CAR, nucleic acid (or plurality thereof), expression vector (or plurality thereof), cell or composition described herein in the manufacture of a medicament for treating or preventing a disease or condition. Also provided is a method of treating or preventing a disease or condition, comprising administering to a subject a therapeutically or prophylactically effective amount of an antigen-binding molecule, polypeptide, CAR, nucleic acid (or plurality thereof), expression vector (or plurality thereof), cell or composition described herein.
  • The methods may be effective to reduce the development or progression of a disease/condition, alleviation of the symptoms of a disease/condition or reduction in the pathology of a disease/condition. The methods may be effective to prevent progression of the disease/condition, e.g. to prevent worsening of, or to slow the rate of development of, the disease/condition. In some embodiments the methods may lead to an improvement in the disease/condition, e.g. a reduction in the symptoms of the disease/condition or reduction in some other correlate of the severity/activity of the disease/condition. In some embodiments the methods may prevent development of the disease/condition a later stage (e.g. a chronic stage or metastasis).
  • It will be appreciated that the articles of the present invention may be used for the treatment/prevention of any disease/condition that would derived therapeutic or prophylactic benefit from a reduction in the number and/or activity of cells expressing CD47. For example, the disease/condition may be a disease/condition in which cells expressing CD47 are pathologically implicated, e.g. a disease/condition in which an increased number/proportion of cells expressing CD47 is positively associated with the onset, development or progression of the disease/condition, and/or severity of one or more symptoms of the disease/condition, or for which an increased number/proportion of cells expressing CD47, is a risk factor for the onset, development or progression of the disease/condition.
  • In some embodiments, the disease/condition to be treated/prevented in accordance with the present invention is a disease/condition characterised by an increase in the number/proportion/activity of cells expressing CD47, e.g. as compared to the number/proportion/activity of cells expressing CD47 in the absence of the disease/condition.
  • In some embodiments the disease/condition to be treated/prevented is a cancer. CD47 has been proposed to be a cell-surface marker expressed by all human cancers (Willingham et al. Proc Natl Acad Sci USA. (2012) 109(17): 6662-6667)
  • The cancer may be any unwanted cell proliferation (or any disease manifesting itself by unwanted cell proliferation), neoplasm or tumor. The cancer may be benign or malignant and may be primary or secondary (metastatic). A neoplasm or tumor may be any abnormal growth or proliferation of cells and may be located in any tissue. The cancer may be of tissues/cells derived from e.g. the adrenal gland, adrenal medulla, anus, appendix, bladder, blood, bone, bone marrow, brain, breast, cecum, central nervous system (including or excluding the brain) cerebellum, cervix, colon, duodenum, endometrium, epithelial cells (e.g. renal epithelia), gallbladder, oesophagus, glial cells, heart, ileum, jejunum, kidney, lacrimal glad, larynx, liver, lung, lymph, lymph node, lymphoblast, maxilla, mediastinum, mesentery, myometrium, nasopharynx, omentum, oral cavity, ovary, pancreas, parotid gland, peripheral nervous system, peritoneum, pleura, prostate, salivary gland, sigmoid colon, skin, small intestine, soft tissues, spleen, stomach, testis, thymus, thyroid gland, tongue, tonsil, trachea, uterus, vulva, white blood cells.
  • Tumors to be treated may be nervous or non-nervous system tumors. Nervous system tumors may originate either in the central or peripheral nervous system, e.g. glioma, medulloblastoma, meningioma, neurofibroma, ependymoma, Schwannoma, neurofibrosarcoma, astrocytoma and oligodendroglioma. Non-nervous system cancers/tumors may originate in any other non-nervous tissue, examples include melanoma, mesothelioma, lymphoma, myeloma, leukemia, Non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma, chronic myelogenous leukemia (CML), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), cutaneous T-cell lymphoma (CTCL), chronic lymphocytic leukemia (CLL), hepatoma, epidermoid carcinoma, prostate carcinoma, breast cancer, lung cancer, colon cancer, ovarian cancer, pancreatic cancer, thymic carcinoma, NSCLC, hematologic cancer and sarcoma.
  • The treatment/prevention may be aimed at one or more of: delaying/preventing the onset/progression of symptoms of the cancer, reducing the severity of symptoms of the cancer, reducing the survival/growth/invasion/metastasis of cells of the cancer, reducing the number of cells of the cancer and/or increasing survival of the subject.
  • In some embodiments, the cancer to be treated/prevented comprises cells expressing CD47. In some embodiments, the cancer to be treated/prevented is a cancer which is positive for CD47. In some embodiments, the cancer over-expresses CD47. Overexpression of CD47 can be determined by detection of a level of expression of CD47 which is greater than the level of expression by equivalent non-cancerous cells/non-tumor tissue.
  • CD47 expression may be determined by any suitable means. Expression may be gene expression or protein expression. Gene expression can be determined e.g. by detection of mRNA encoding CD47, for example by quantitative real-time PCR (qRT-PCR). Protein expression can be determined e.g. by detection of CD47, for example by antibody-based methods, for example by western blot, immunohistochemistry, immunocytochemistry, flow cytometry, or ELISA.
  • In some embodiments, a patient may be selected for treatment described herein based on the detection of a cancer expressing CD47, or overexpressing CD47, e.g. in a sample obtained from the subject.
  • The role of CD47 in the development and progression of various cancers is reviewed e.g. in Sick et al. Br J Pharmacol. (2012) 167(7): 1415-1430 and Chao et al., Curr Opin Immunol. 2012 April; 24(2): 225-232 (hereby incorporated by reference in its entirety). Elevated CD47 expression is a negative prognostic indicator for several cancers, and may contribute to cancer development/progression by reducing killing of cancer cells and by increasing proliferation, migration and/or invasion of cancer cells. CD47 has been shown to suppress innate macrophage and NK cell-mediated anticancer responses (Soto-Pantoja et al., Expert Opin Ther Targets. (2013) 17(1): 89-103, which is hereby incorporated by reference in its entirety).
  • CD47 is expressed by acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma (NHL), multiple myeloma (MM), bladder cancer, brain cancer and ovarian cancer cells. Willingham et al. Proc Natl Acad Sci USA. (2012) 109(17): 6662-6667 reported expression of CD47 on cells of ovarian, breast, colon, bladder, glioblastoma, hepatocellular carcinoma, and prostate tumors, and CD47 has recently been shown to promote tumor invasion and metastasis in Non-small Cell Lung Cancer (NSCLC; Zhao et al., Sci Rep. (2016) 6: 29719) and melanoma (Ngo et al., Cell Reports (2016) 16, 1701-1716).
  • Accordingly, in some embodiments the cancer to be treated/prevented in accordance with the present invention is selected from: a hematologic malignancy, a myeloid hematologic malignancy, a lymphoblastic hematologic malignancy, myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma (NHL), multiple myeloma (MM), bladder cancer, brain cancer, glioblastoma, ovarian cancer, breast cancer, colon cancer, liver cancer, hepatocellular carcinoma, prostate cancer, lung cancer, Non-small Cell Lung Cancer (NSCLC), skin cancer and melanoma.
  • CD47 is a particularly attractive therapeutic targets for AML because it is highly expressed in all characterised AML cell lines, and play functional roles which therefore reduce risk of antigen loss. The large population of tissue-resident macrophages in the liver (Kupffer cells) represents an attractive therapeutic mechanism for hematological malignancies, and macrophage-driven clearance of malignant cells offers a further route for neo-antigen presentation to adaptive immune system.
  • CD47 is also implicated in the pathogenesis of autoimmune diseases, inflammatory diseases, ischemia-reperfusion injury (IRI) and cardiovascular diseases (see e.g. Soto-Pantoja et al., Expert Opin Ther Targets. (2013) 17(1): 89-103). The CD47-SIRPα axis has been implicated in type I diabetes (Dugas et al., J Autoimmun. (2010) 35(1):23-32). Thrombospondin-1 has been shown to act via CD47 to inhibit nitric oxide signaling throughout the vascular system, and blocking TSP1-CD47 interaction alleviates tissue ischemia (Isenberg et al., Arterioscler Thromb Vasc Biol. (2008) 28(4): 615-621) and reduces ischemia-reperfusion injury (IRI) (Xiao et al., Liver Transpl. (2015) 21(4): 468-477).
  • Accordingly, in some embodiments the disease/disorder to be treated/prevented is a cancer, an autoimmune disease (e.g. type I diabetes), an inflammatory disease, ischemia-reperfusion injury (IRI) or cardiovascular disease.
  • Administration of the articles of the present invention is preferably in a “therapeutically effective” or “prophylactically effective” amount, this being sufficient to show therapeutic or prophylactic benefit to the subject. The actual amount administered, and rate and time-course of administration, will depend on the nature and severity of the disease/condition and the particular article administered. Prescription of treatment, e.g. decisions on dosage etc., is within the responsibility of general practitioners and other medical doctors, and typically takes account of the disease/disorder to be treated, the condition of the individual subject, the site of delivery, the method of administration and other factors known to practitioners. Examples of the techniques and protocols mentioned above can be found in Remington's Pharmaceutical Sciences, 20th Edition, 2000, pub. Lippincott, Williams & Wilkins.
  • Administration may be alone or in combination with other treatments, either simultaneously or sequentially dependent upon the condition to be treated. The antigen-binding molecule or composition described herein and a therapeutic agent may be administered simultaneously or sequentially.
  • In some embodiments, the methods comprise additional therapeutic or prophylactic intervention, e.g. for the treatment/prevention of a cancer. In some embodiments, the therapeutic or prophylactic intervention is selected from chemotherapy, immunotherapy, radiotherapy, surgery, vaccination and/or hormone therapy. In some embodiments, the therapeutic or prophylactic intervention comprises leukapheresis. In some embodiments the therapeutic or prophylactic intervention comprises a stem cell transplant.
  • The antigen-binding molecules of the present invention are particularly suitable for use in conjunction with radiotherapy. Antagonism of CD47 has previously been shown to help maintain the viability of normal tissues after irradiation, while increasing the radiosensitivity of tumors (Maxhimer et al., Science Translational Medicine (2009) 1(3): 3ra7).
  • Simultaneous administration refers to administration of the antigen-binding molecule, polypeptide, CAR, nucleic acid (or plurality thereof), expression vector (or plurality thereof), cell or composition and therapeutic agent together, for example as a pharmaceutical composition containing both agents (combined preparation), or immediately after each other and optionally via the same route of administration, e.g. to the same artery, vein or other blood vessel. Sequential administration refers to administration of one of the antigen-binding molecule/composition or therapeutic agent followed after a given time interval by separate administration of the other agent. It is not required that the two agents are administered by the same route, although this is the case in some embodiments. The time interval may be any time interval.
  • Chemotherapy and radiotherapy respectively refer to treatment of a cancer with a drug or with ionising radiation (e.g. radiotherapy using X-rays or γ-rays). The drug may be a chemical entity, e.g. small molecule pharmaceutical, antibiotic, DNA intercalator, protein inhibitor (e.g. kinase inhibitor), or a biological agent, e.g. antibody, antibody fragment, aptamer, nucleic acid (e.g. DNA, RNA), peptide, polypeptide, or protein. The drug may be formulated as a pharmaceutical composition or medicament. The formulation may comprise one or more drugs (e.g. one or more active agents) together with one or more pharmaceutically acceptable diluents, excipients or carriers.
  • A treatment may involve administration of more than one drug. A drug may be administered alone or in combination with other treatments, either simultaneously or sequentially dependent upon the condition to be treated. For example, the chemotherapy may be a co-therapy involving administration of two drugs, one or more of which may be intended to treat the cancer.
  • The chemotherapy may be administered by one or more routes of administration, e.g. parenteral, intravenous injection, oral, subcutaneous, intradermal or intratumoral.
  • The chemotherapy may be administered according to a treatment regime. The treatment regime may be a pre-determined timetable, plan, scheme or schedule of chemotherapy administration which may be prepared by a physician or medical practitioner and may be tailored to suit the patient requiring treatment. The treatment regime may indicate one or more of: the type of chemotherapy to administer to the patient; the dose of each drug or radiation; the time interval between administrations; the length of each treatment; the number and nature of any treatment holidays, if any etc. For a co-therapy a single treatment regime may be provided which indicates how each drug is to be administered.
  • Chemotherapeutic drugs may be selected from: Abemaciclib, Abiraterone Acetate, Abitrexate (Methotrexate), Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation), ABVD, ABVE, ABVE-PC, AC, Acalabrutinib, AC-T, Adcetris (Brentuximab Vedotin), ADE, Ado-Trastuzumab Emtansine, Adriamycin (Doxorubicin Hydrochloride), Afatinib Dimaleate, Afinitor (Everolimus), Akynzeo (Netupitant and Palonosetron Hydrochloride), Aldara (Imiquimod), Aldesleukin, Alecensa (Alectinib), Alectinib, Alemtuzumab, Alimta (Pemetrexed Disodium), Aliqopa (Copanlisib Hydrochloride), Alkeran for Injection (Melphalan Hydrochloride), Alkeran Tablets (Melphalan), Aloxi (Palonosetron Hydrochloride), Alunbrig (Brigatinib), Ambochlorin (Chlorambucil), Amboclorin (Chlorambucil), Amifostine, Aminolevulinic Acid, Anastrozole, Aprepitant, Aredia (Pamidronate Disodium), Arimidex (Anastrozole), Aromasin (Exemestane), Arranon (Nelarabine), Arsenic Trioxide, Arzerra (Ofatumumab), Asparaginase Erwinia chrysanthemi, Atezolizumab, Avastin (Bevacizumab), Avelumab, Axicabtagene Ciloleucel, Axitinib, Azacitidine, Bavencio (Avelumab), BEACOPP, Becenum (Carmustine), Beleodaq (Belinostat), Belinostat, Bendamustine Hydrochloride, BEP, Besponsa (Inotuzumab Ozogamicin), Bevacizumab, Bexarotene, Bexxar (Tositumomab and Iodine I 131 Tositumomab), Bicalutamide, BiCNU (Carmustine), Bleomycin, Blinatumomab, Blincyto (Blinatumomab), Bortezomib, Bosulif (Bosutinib), Bosutinib, Brentuximab Vedotin, Brigatinib, BuMel, Busulfan, Busulfex (Busulfan), Cabazitaxel, Cabometyx (Cabozantinib-S-Malate), Cabozantinib-S-Malate, CAF, Calquence (Acalabrutinib), Campath (Alemtuzumab), Camptosar (Irinotecan Hydrochloride), Capecitabine, CAPDX, Carac (Fluorouracil—Topical), Carboplatin, CARBOPLATIN-TAXOL, Carfilzomib, Carmubris (Carmustine), Carmustine, Carmustine Implant, Casodex (Bicalutamide), CEM, Ceritinib, Cerubidine (Daunorubicin Hydrochloride), Cervarix (Recombinant HPV Bivalent Vaccine), Cetuximab, CEV, Chlorambucil, CHLORAMBUCIL-PREDNISONE, CHOP, Cisplatin, Cladribine, Clafen (Cyclophosphamide), Clofarabine, Clofarex (Clofarabine), Clolar (Clofarabine), CMF, Cobimetinib, Cometriq (Cabozantinib-S-Malate), Copanlisib Hydrochloride, COPDAC, COPP, COPP-ABV, Cosmegen (Dactinomycin), Cotellic (Cobimetinib), Crizotinib, CVP, Cyclophosphamide, Cyfos (Ifosfamide), Cyramza (Ramucirumab), Cytarabine, Cytarabine Liposome, Cytosar-U (Cytarabine), Cytoxan (Cyclophosphamide), Dabrafenib, Dacarbazine, Dacogen (Decitabine), Dactinomycin, Daratumumab, Darzalex (Daratumumab), Dasatinib, Daunorubicin Hydrochloride, Daunorubicin Hydrochloride and Cytarabine Liposome, Decitabine, Defibrotide Sodium, Defitelio (Defibrotide Sodium), Degarelix, Denileukin Diftitox, Denosumab, DepoCyt (Cytarabine Liposome), Dexamethasone, Dexrazoxane Hydrochloride, Dinutuximab, Docetaxel, Doxil (Doxorubicin Hydrochloride Liposome), Doxorubicin Hydrochloride, Doxorubicin Hydrochloride Liposome, Dox-SL (Doxorubicin Hydrochloride Liposome), DTIC-Dome (Dacarbazine), Durvalumab, Efudex (Fluorouracil—Topical), Elitek (Rasburicase), Ellence (Epirubicin Hydrochloride), Elotuzumab, Eloxatin (Oxaliplatin), Eltrombopag Olamine, Emend (Aprepitant), Empliciti (Elotuzumab), Enasidenib Mesylate, Enzalutamide, Epirubicin Hydrochloride, EPOCH, Erbitux (Cetuximab), Eribulin Mesylate, Erivedge (Vismodegib), Erlotinib Hydrochloride, Erwinaze (Asparaginase Erwinia chrysanthemi), Ethyol (Amifostine), Etopophos (Etoposide Phosphate), Etoposide, Etoposide Phosphate, Evacet (Doxorubicin Hydrochloride Liposome), Everolimus, Evista (Raloxifene Hydrochloride), Evomela (Melphalan Hydrochloride), Exemestane, 5-FU (Fluorouracil Injection), 5-FU (Fluorouracil—Topical), Fareston (Toremifene), Farydak (Panobinostat), Faslodex (Fulvestrant), FEC, Femara (Letrozole), Filgrastim, Fludara (Fludarabine Phosphate), Fludarabine Phosphate, Fluoroplex (Fluorouracil—Topical), Fluorouracil Injection, Fluorouracil—Topical, Flutamide, Folex (Methotrexate), Folex PFS (Methotrexate), FOLFIRI, FOLFIRI-BEVACIZUMAB, FOLFIRI-CETUXIMAB, FOLFIRINOX, FOLFOX, Folotyn (Pralatrexate), FU-LV, Fulvestrant, Gardasil (Recombinant HPV Quadrivalent Vaccine), Gardasil 9 (Recombinant HPV Nonavalent Vaccine), Gazyva (Obinutuzumab), Gefitinib, Gemcitabine Hydrochloride, GEMCITABINE-CISPLATIN, GEMCITABINE-OXALIPLATIN, Gemtuzumab Ozogamicin, Gemzar (Gemcitabine Hydrochloride), Gilotrif (Afatinib Dimaleate), Gleevec (Imatinib Mesylate), Gliadel (Carmustine Implant), Gliadel wafer (Carmustine Implant), Glucarpidase, Goserelin Acetate, Halaven (Eribulin Mesylate), Hemangeol (Propranolol Hydrochloride), Herceptin (Trastuzumab), HPV Bivalent Vaccine, Recombinant, HPV Nonavalent Vaccine, Recombinant, HPV Quadrivalent Vaccine, Recombinant, Hycamtin (Topotecan Hydrochloride), Hydrea (Hydroxyurea), Hydroxyurea, Hyper-CVAD, Ibrance (Palbociclib), Ibritumomab Tiuxetan, Ibrutinib, ICE, Iclusig (Ponatinib Hydrochloride), Idamycin (Idarubicin Hydrochloride), Idarubicin Hydrochloride, Idelalisib, Idhifa (Enasidenib Mesylate), Ifex (Ifosfamide), Ifosfamide, Ifosfamidum (Ifosfamide), IL-2 (Aldesleukin), Imatinib Mesylate, Imbruvica (Ibrutinib), Imfinzi (Durvalumab), Imiquimod, Imlygic (Talimogene Laherparepvec), Inlyta (Axitinib), Inotuzumab Ozogamicin, Interferon Alfa-2b, Recombinant, Interleukin-2 (Aldesleukin), Intron A (Recombinant Interferon Alfa-2b), Iodine I 131 Tositumomab and Tositumomab, Ipilimumab, Iressa (Gefitinib), Irinotecan Hydrochloride, Irinotecan Hydrochloride Liposome, Istodax (Romidepsin), Ixabepilone, Ixazomib Citrate, Ixempra (Ixabepilone), Jakafi (Ruxolitinib Phosphate), JEB, Jevtana (Cabazitaxel), Kadcyla (Ado-Trastuzumab Emtansine), Keoxifene (Raloxifene Hydrochloride), Kepivance (Palifermin), Keytruda (Pembrolizumab), Kisqali (Ribociclib), Kymriah (Tisagenlecleucel), Kyprolis (Carfilzomib), Lanreotide Acetate, Lapatinib Ditosylate, Lartruvo (Olaratumab), Lenalidomide, Lenvatinib Mesylate, Lenvima (Lenvatinib Mesylate), Letrozole, Leucovorin Calcium, Leukeran (Chlorambucil), Leuprolide Acetate, Leustatin (Cladribine), Levulan (Aminolevulinic Acid), Linfolizin (Chlorambucil), LipoDox (Doxorubicin Hydrochloride Liposome), Lomustine, Lonsurf (Trifluridine and Tipiracil Hydrochloride), Lupron (Leuprolide Acetate), Lupron Depot (Leuprolide Acetate), Lupron Depot-Ped (Leuprolide Acetate), Lynparza (Olaparib), Marciibo (Vincristine Sulfate Liposome), Matulane (Procarbazine Hydrochloride), Mechlorethamine Hydrochloride, Megestrol Acetate, Mekinist (Trametinib), Melphalan, Melphalan Hydrochloride, Mercaptopurine, Mesna, Mesnex (Mesna), Methazolastone (Temozolomide), Methotrexate, Methotrexate LPF (Methotrexate), Methylnaltrexone Bromide, Mexate (Methotrexate), Mexate-AQ (Methotrexate), Midostaurin, Mitomycin C, Mitoxantrone Hydrochloride, Mitozytrex (Mitomycin C), MOPP, Mozobil (Plerixafor), Mustargen (Mechlorethamine Hydrochloride), Mutamycin (Mitomycin C), Myleran (Busulfan), Mylosar (Azacitidine), Mylotarg (Gemtuzumab Ozogamicin), Nanoparticle Paclitaxel (Paclitaxel Albumin-stabilized Nanoparticle Formulation), Navelbine (Vinorelbine Tartrate), Necitumumab, Nelarabine, Neosar (Cyclophosphamide), Neratinib Maleate, Nerlynx (Neratinib Maleate), Netupitant and Palonosetron Hydrochloride, Neulasta (Pegfilgrastim), Neupogen (Filgrastim), Nexavar (Sorafenib Tosylate), Nilandron (Nilutamide), Nilotinib, Nilutamide, Ninlaro (Ixazomib Citrate), Niraparib Tosylate Monohydrate, Nivolumab, Nolvadex (Tamoxifen Citrate), Nplate (Romiplostim), Obinutuzumab, Odomzo (Sonidegib), OEPA, Ofatumumab, OFF, Olaparib, Olaratumab, Omacetaxine Mepesuccinate, Oncaspar (Pegaspargase), Ondansetron Hydrochloride, Onivyde (Irinotecan Hydrochloride Liposome), Ontak (Denileukin Diftitox), Opdivo (Nivolumab), OPPA, Osimertinib, Oxaliplatin, Paclitaxel, Paclitaxel Albumin-stabilized Nanoparticle Formulation, PAD, Palbociclib, Palifermin, Palonosetron Hydrochloride, Palonosetron Hydrochloride and Netupitant, Pamidronate Disodium, Panitumumab, Panobinostat, Paraplat (Carboplatin), Paraplatin (Carboplatin), Pazopanib Hydrochloride, PCV, PEB, Pegaspargase, Pegfilgrastim, Peginterferon Alfa-2b, PEG-Intron (Peginterferon Alfa-2b), Pembrolizumab, Pemetrexed Disodium, Perjeta (Pertuzumab), Pertuzumab, Platinol (Cisplatin), Platinol-AQ (Cisplatin), Plerixafor, Pomalidomide, Pomalyst (Pomalidomide), Ponatinib Hydrochloride, Portrazza (Necitumumab), Pralatrexate, Prednisone, Procarbazine Hydrochloride, Proleukin (Aldesleukin), Prolia (Denosumab), Promacta (Eltrombopag Olamine), Propranolol Hydrochloride, Provenge (Sipuleucel-T), Purinethol (Mercaptopurine), Purixan (Mercaptopurine), [No Entries], Radium 223 Dichloride, Raloxifene Hydrochloride, Ramucirumab, Rasburicase, R-CHOP, R-CVP, Recombinant Human Papillomavirus (HPV) Bivalent Vaccine, Recombinant Human Papillomavirus (HPV) Nonavalent Vaccine, Recombinant Human Papillomavirus (HPV) Quadrivalent Vaccine, Recombinant Interferon Alfa-2b, Regorafenib, Relistor (Methylnaltrexone Bromide), R-EPOCH, Revlimid (Lenalidomide), Rheumatrex (Methotrexate), Ribociclib, R-ICE, Rituxan (Rituximab), Rituxan Hycela (Rituximab and Hyaluronidase Human), Rituximab, Rituximab and Hyaluronidase Human, Rolapitant Hydrochloride, Romidepsin, Romiplostim, Rubidomycin (Daunorubicin Hydrochloride), Rubraca (Rucaparib Camsylate), Rucaparib Camsylate, Ruxolitinib Phosphate, Rydapt (Midostaurin), Sclerosol Intrapleural Aerosol (Talc), Siltuximab, Sipuleucel-T, Somatuline Depot (Lanreotide Acetate), Sonidegib, Sorafenib Tosylate, Sprycel (Dasatinib), STANFORD V, Sterile Talc Powder (Talc), Steritalc (Talc), Stivarga (Regorafenib), Sunitinib Malate, Sutent (Sunitinib Malate), Sylatron (Peginterferon Alfa-2b), Sylvant (Siltuximab), Synribo (Omacetaxine Mepesuccinate), Tabloid (Thioguanine), TAC, Tafinlar (Dabrafenib), Tagrisso (Osimertinib), Talc, Talimogene Laherparepvec, Tamoxifen Citrate, Tarabine PFS (Cytarabine), Tarceva (Erlotinib Hydrochloride), Targretin (Bexarotene), Tasigna (Nilotinib), Taxol (Paclitaxel), Taxotere (Docetaxel), Tecentriq (Atezolizumab), Temodar (Temozolomide), Temozolomide, Temsirolimus, Thalidomide, Thalomid (Thalidomide), Thioguanine, Thiotepa, Tisagenlecleucel, Tolak (Fluorouracil—Topical), Topotecan Hydrochloride, Toremifene, Torisel (Temsirolimus), Tositumomab and Iodine I 131 Tositumomab, Totect (Dexrazoxane Hydrochloride), TPF, Trabectedin, Trametinib, Trastuzumab, Treanda (Bendamustine Hydrochloride), Trifluridine and Tipiracil Hydrochloride, Trisenox (Arsenic Trioxide), Tykerb (Lapatinib Ditosylate), Unituxin (Dinutuximab), Uridine Triacetate, VAC, Valrubicin, Valstar (Valrubicin), Vandetanib, VAMP, Varubi (Rolapitant Hydrochloride), Vectibix (Panitumumab), VeIP, Velban (Vinblastine Sulfate), Velcade (Bortezomib), Velsar (Vinblastine Sulfate), Vemurafenib, Venclexta (Venetoclax), Venetoclax, Verzenio (Abemaciclib), Viadur (Leuprolide Acetate), Vidaza (Azacitidine), Vinblastine Sulfate, Vincasar PFS (Vincristine Sulfate), Vincristine Sulfate, Vincristine Sulfate Liposome, Vinorelbine Tartrate, VIP, Vismodegib, Vistogard (Uridine Triacetate), Voraxaze (Glucarpidase), Vorinostat, Votrient (Pazopanib Hydrochloride), Vyxeos (Daunorubicin Hydrochloride and Cytarabine Liposome), Wellcovorin (Leucovorin Calcium), Xalkori (Crizotinib), Xeloda (Capecitabine), XELIRI, XELOX, Xgeva (Denosumab), Xofigo (Radium 223 Dichloride), Xtandi (Enzalutamide), Yervoy (Ipilimumab), Yescarta (Axicabtagene Ciloleucel), Yondelis (Trabectedin), Zaltrap (Ziv-Aflibercept), Zarxio (Filgrastim), Zejula (Niraparib Tosylate Monohydrate), Zelboraf (Vemurafenib), Zevalin (Ibritumomab Tiuxetan), Zinecard (Dexrazoxane Hydrochloride), Ziv-Aflibercept, Zofran (Ondansetron Hydrochloride), Zoladex (Goserelin Acetate), Zoledronic Acid, Zolinza (Vorinostat), Zometa (Zoledronic Acid), Zydelig (Idelalisib), Zykadia (Ceritinib) and Zytiga (Abiraterone Acetate).
  • In some embodiments the chemotherapeutic agent is selected from one or more of: cytarabine, 5-azacytidine (5-AZA), valproic acid (VPA), all-trans retinoic acid (ATRA), decitabine, sodium phenylbutyrate, hydrozyurea, 6-mercaptopurine (6-MP), 6-thioguanine (6-TG), Mocetinostat (MGCD0103), Panobinostat (LBH-589), romidepsin, an antracycline, daunorubicin, daunomycin, idarubicin, cladribine (Leustatin, 2-CdA), midostaurin, fludarabine (Fludara) and topotecan.
  • In some embodiments the chemotherapeutic agent is histone deacetylase (HDAC) inhibitor, e.g. a HDAC inhibitor described in Fredly et al., Clin Epigenetics. (2013) 5(1):12 (hereby incorporated by reference in its entirety). In some embodiments the chemotherapeutic agent is cytarabine.
  • Multiple doses of the producing an antigen-binding molecule, polypeptide, CAR, nucleic acid (or plurality thereof), expression vector (or plurality thereof), cell or composition may be provided. One or more, or each, of the doses may be accompanied by simultaneous or sequential administration of another therapeutic agent.
  • Multiple doses may be separated by a predetermined time interval, which may be selected to be one of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or 31 days, or 1, 2, 3, 4, 5, or 6 months. By way of example, doses may be given once every 7, 14, 21 or 28 days (plus or minus 3, 2, or 1 days).
  • Methods of Detection
  • The invention also provides the articles of the present invention for use in methods for detecting, localizing or imaging CD47, or cells expressing CD47.
  • The antigen-binding molecules described herein may be used in methods that involve the antigen-binding molecule to CD47. Such methods may involve detection of the bound complex of the antigen-binding molecule and CD47.
  • As such, a method is provided, comprising contacting a sample containing, or suspected to contain, CD47, and detecting the formation of a complex of the antigen-binding molecule and CD47. Also provided is a method comprising contacting a sample containing, or suspected to contain, a cell expressing CD47, and detecting the formation of a complex of the antigen-binding molecule and a cell expressing CD47.
  • Suitable method formats are well known in the art, including immunoassays such as sandwich assays, e.g. ELISA. The methods may involve labelling the antigen-binding molecule, or target(s), or both, with a detectable moiety, e.g. a fluorescent label, phosphorescent label, luminescent label, immuno-detectable label, radiolabel, chemical, nucleic acid or enzymatic label as described herein. Detection techniques are well known to those of skill in the art and can be selected to correspond with the labelling agent.
  • Methods of this kind may provide the basis of methods for the diagnostic and/or prognostic evaluation of a disease or condition, e.g. a cancer. Such methods may be performed in vitro on a patient sample, or following processing of a patient sample. Once the sample is collected, the patient is not required to be present for the in vitro method to be performed, and therefore the method may be one which is not practised on the human or animal body. In some embodiments the method is performed in vivo.
  • Detection in a sample may be used for the purpose of diagnosis of a disease/condition (e.g. a cancer), predisposition to a disease/condition, or for providing a prognosis (prognosticating) for a disease/condition, e.g. a disease/condition described herein. The diagnosis or prognosis may relate to an existing (previously diagnosed) disease/condition.
  • Such methods may involve detecting or quantifying one or more of CD47 or cells expressing CD47, e.g. in a patient sample. Where the method comprises quantifying the relevant factor, the method may further comprise comparing the determined amount against a standard or reference value as part of the diagnostic or prognostic evaluation. Other diagnostic/prognostic tests may be used in conjunction with those described herein to enhance the accuracy of the diagnosis or prognosis or to confirm a result obtained by using the tests described herein.
  • A sample may be taken from any tissue or bodily fluid. The sample may comprise or may be derived from: a quantity of blood; a quantity of serum derived from the individual's blood which may comprise the fluid portion of the blood obtained after removal of the fibrin clot and blood cells; a tissue sample or biopsy; pleural fluid; cerebrospinal fluid (CSF); or cells isolated from said individual. In some embodiments, the sample may be obtained or derived from a tissue or tissues which are affected by the disease/condition (e.g. tissue or tissues in which symptoms of the disease manifest, or which are involved in the pathogenesis of the disease/condition).
  • The present invention also provides methods for selecting/stratifying a subject for treatment with a CD47-targeted agent. In some embodiments a subject is selected for treatment/prevention in accordance with the invention, or is identified as a subject which would benefit from such treatment/prevention, based on detection/quantification of CD47, or cells expressing CD47, e.g. in a sample obtained from the individual.
  • Subjects
  • The subject in accordance with aspects the invention described herein may be any animal or human. The subject is preferably mammalian, more preferably human. The subject may be a non-human mammal, but is more preferably human. The subject may be male or female. The subject may be a patient. A subject may have been diagnosed with a disease or condition requiring treatment (e.g. a cancer), may be suspected of having such a disease/condition, or may be at risk of developing/contracting such a disease/condition.
  • In embodiments according to the present invention the subject is preferably a human subject. In some embodiments, the subject to be treated according to a therapeutic or prophylactic method of the invention herein is a subject having, or at risk of developing, a cancer. In embodiments according to the present invention, a subject may be selected for treatment according to the methods based on characterisation for certain markers of such disease/condition.
  • Kits
  • In some aspects of the invention described herein a kit of parts is provided. In some embodiments the kit may have at least one container having a predetermined quantity of an antigen-binding molecule, polypeptide, CAR, nucleic acid (or plurality thereof), expression vector (or plurality thereof), cell or composition described herein.
  • In some embodiments, the kit may comprise materials for producing an antigen-binding molecule, polypeptide, CAR, nucleic acid (or plurality thereof), expression vector (or plurality thereof), cell or composition described herein.
  • The kit may provide the antigen-binding molecule, polypeptide, CAR, nucleic acid (or plurality thereof), expression vector (or plurality thereof), cell or composition together with instructions for administration to a patient in order to treat a specified disease/condition.
  • In some embodiments the kit may further comprise at least one container having a predetermined quantity of another therapeutic agent (e.g. anti-infective agent or chemotherapy agent). In such embodiments, the kit may also comprise a second medicament or pharmaceutical composition such that the two medicaments or pharmaceutical compositions may be administered simultaneously or separately such that they provide a combined treatment for the specific disease or condition. The therapeutic agent may also be formulated so as to be suitable for injection or infusion to a tumor or to the blood.
  • Sequence Identity
  • As used herein, “sequence identity” refers to the percent of nucleotides/amino acid residues in a subject sequence that are identical to nucleotides/amino acid residues in a reference sequence, after aligning the sequences and, if necessary, introducing gaps, to achieve the maximum percent sequence identity between the sequences. Pairwise and multiple sequence alignment for the purposes of determining percent sequence identity between two or more amino acid or nucleic acid sequences can be achieved in various ways known to a person of skill in the art, for instance, using publicly available computer software such as ClustalOmega (Söding, J. 2005, Bioinformatics 21, 951-960), T-coffee (Notredame et al. 2000, J. Mol. Biol. (2000) 302, 205-217), Kalign (Lassmann and Sonnhammer 2005, BMC Bioinformatics, 6(298)) and MAFFT (Katoh and Standley 2013, Molecular Biology and Evolution, 30(4) 772-780 software. When using such software, the default parameters, e.g. for gap penalty and extension penalty, are preferably used.
  • SEQUENCES
    SEQ ID
    NO: DESCRIPTION SEQUENCE
    1 Human CD47 MWPLVAALLLGSACCGSAQLLFNKTKSVEFTFCNDTVVIPCFVTNMEAQNTTEVYVKWKFKGRDI
    isoform YTFDGALNKSTVPTDFSSAKIEVSQLLKGDASLKMDKSDAVSHTGNYTCEVTELTREGETIIELK
    OA3-323 YRVVSWFSPNENILIVIFPIFAILLFWGQFGIKTLKYRSGGMDEKTIALLVAGLVITVIVIVGAI
    (UniProt: LFVPGEYSLKNATGLGLIVTSTGILILLHYYVFSTAIGLTSFVIAILVIQVIAYILAVVGLSLCI
    Q08722-1, v1) AACIPMHGPLLISGLSILALAQLLGLVYMKFVASNQKTIQPPRKAVEEPLNAFKESKGMMNDE
    2 Human CD47 MWPLVAALLLGSACCGSAQLLFNKTKSVEFTFCNDTVVIPCFVTNMEAQNTTEVYVKWKFKGRDI
    isoform YTFDGALNKSTVPTDFSSAKIEVSQLLKGDASLKMDKSDAVSHTGNYTCEVTELTREGETIIELK
    OA3-293 YRVVSWFSPNENILIVIFPIFAILLFWGQFGIKTLKYRSGGMDEKTIALLVAGLVITVIVIVGAI
    (UniProt: LFVPGEYSLKNATGLGLIVTSTGILILLHYYVFSTAIGLTSFVIAILVIQVIAYILAVVGLSLCI
    Q08722-2) AACIPMHGPLLISGLSILALAQLLGLVYMKFV
    3 Human CD47 MWPLVAALLLGSACCGSAQLLFNKTKSVEFTFCNDTVVIPCFVTNMEAQNTTEVYVKWKFKGRDI
    isoform YTFDGALNKSTVPTDFSSAKIEVSQLLKGDASLKMDKSDAVSHTGNYTCEVTELTREGETIIELK
    OA3-305 YRVVSWFSPNENILIVIFPIFAILLFWGQFGIKTLKYRSGGMDEKTIALLVAGLVITVIVIVGAI
    (UniProt: LFVPGEYSLKNATGLGLIVTSTGILILLHYYVFSTAIGLTSFVIAILVIQVIAYILAVVGLSLCI
    Q08722-3) AACIPMHGPLLISGLSILALAQLLGLVYMKFVASNQKTIQPPRNN
    4 Human CD47 MWPLVAALLLGSACCGSAQLLFNKTKSVEFTFCNDTVVIPCFVTNMEAQNTTEVYVKWKFKGRDI
    isoform YTFDGALNKSTVPTDFSSAKIEVSQLLKGDASLKMDKSDAVSHTGNYTCEVTELTREGETIIELK
    OA3-312 YRVVSWFSPNENILIVIFPIFAILLFWGQFGIKTLKYRSGGMDEKTIALLVAGLVITVIVIVGAI
    (UniProt: LFVPGEYSLKNATGLGLIVTSTGILILLHYYVFSTAIGLTSFVIAILVIQVIAYILAVVGLSLCI
    Q08722-4) AACIPMHGPLLISGLSILALAQLLGLVYMKFVASNQKTIQPPRKAVEEPLN
    5 Mature human QLLFNKTKSVEFTFCNDTVVIPCFVTNMEAQNTTEVYVKWKFKGRDIYTFDGALNKSTVPTDFSSA
    CD47 isoform KIEVSQLLKGDASLKMDKSDAVSHTGNYTCEVTELTREGETIIELKYRVVSWFSPNENILIVIFPI
    OA3-323 FAILLFWGQFGIKTLKYRSGGMDEKTIALLVAGLVITVIVIVGAILFVPGEYSLKNATGLGLIVTS
    (UniProt: TGILILLHYYVFSTAIGLTSFVIAILVIQVIAYILAVVGLSLCIAACIPMHGPLLISGLSILALAQ
    Q08722-1, v1 LLGLVYMKFVASNQKTIQPPRKAVEEPLNAFKESKGMMNDE
    positions
    19-323)
    6 Mature human QLLFNKTKSVEFTFCNDTVVIPCFVTNMEAQNTTEVYVKWKFKGRDIYTFDGALNKSTVPTDFSSA
    CD47 isoform KIEVSQLLKGDASLKMDKSDAVSHTGNYTCEVTELTREGETIIELKYRVVSWFSPNENILIVIFPI
    OA3-293 FAILLFWGQFGIKTLKYRSGGMDEKTIALLVAGLVITVIVIVGAILFVPGEYSLKNATGLGLIVTS
    (UniProt: TGILILLHYYVFSTAIGLTSFVIAILVIQVIAYILAVVGLSLCIAACIPMHGPLLISGLSILALAQ
    Q08722-2 LLGLVYMKFV
    positions
    19-292)
    7 Mature human QLLFNKTKSVEFTFCNDTVVIPCFVTNMEAQNTTEVYVKWKFKGRDIYTFDGALNKSTVPTDFSSA
    CD47 isoform KIEVSQLLKGDASLKMDKSDAVSHTGNYTCEVTELTREGETIIELKYRVVSWFSPNENILIVIFPI
    OA3-305 FAILLFWGQFGIKTLKYRSGGMDEKTIALLVAGLVITVIVIVGAILFVPGEYSLKNATGLGLIVTS
    (UniProt: TGILILLHYYVFSTAIGLTSFVIAILVIQVIAYILAVVGLSLCIAACIPMHGPLLISGLSILALAQ
    Q08722-3, LLGLVYMKFVASNQKTIQPPRNN
    positions
    19-305)
    8 Mature human QLLFNKTKSVEFTFCNDTVVIPCFVTNMEAQNTTEVYVKWKFKGRDIYTFDGALNKSTVPTDFSSA
    CD47 isoform KIEVSQLLKGDASLKMDKSDAVSHTGNYTCEVTELTREGETIIELKYRVVSWFSPNENILIVIFPI
    OA3-312 FAILLFWGQFGIKTLKYRSGGMDEKTIALLVAGLVITVIVIVGAILFVPGEYSLKNATGLGLIVTS
    (UniProt: TGILILLHYYVFSTAIGLTSFVIAILVIQVIAYILAVVGLSLCIAACIPMHGPLLISGLSILALAQ
    Q08722-4 LLGLVYMKFVASNQKTIQPPRKAVEEPLN
    positions
    19-311)
    9 V-type QLLFNKTKSVEFTFCNDTVVIPCFVTNMEAQNTTEVYVKWKFKGRDIYTFDGALNKSTVPTDFSSA
    Ig-like KIEVSQLLKGDASLKMDKSDAVSHTGNYTCEVTELTREGETII
    domain
    (UniProt:
    Q08722-1
    positions
    19-127)
    10 Human CD47 QLLFNKTKSVEFTFCNDTVVIPCFVTNMEAQNTTEVYVKWKFKGRDIYTFDGALNKSTVPTDFSSA
    extracellular KIEVSQLLKGDASLKMDKSDAVSHTGNYTCEVTELTREGETIIELKYRVVSWFSPNE
    region 1
    (UniProt:
    Q08722-1
    positions
    19-141)
    11 Human CD47 NILIVIFPIFAILLFWGQFGI
    transmembrane
    region 1
    (UniProt:
    Q08722-1
    positions
    142-162)
    12 Human CD47 KTLKYRSGGMDEKT
    cytoplasmic
    region 1
    (UniProt:
    Q08722-1
    positions
    163-176)
    13 Human CD47 IALLVAGLVITVIVIVGAILF
    transmembrane
    region 2
    (UniProt:
    Q08722-1
    positions
    177-197)
    14 Human CD47 VPGEYSLKNA
    extracellular
    region 2
    (UniProt:
    Q08722-1
    positions
    198-207)
    15 Human CD47 TGLGLIVTSTGILILLHYYVF
    transmembrane
    region 3
    (UniProt:
    Q08722-1
    positions
    208-228)
    16 Human CD47 STAIGLT
    cytoplasmic
    region 2
    (UniProt:
    Q08722-1
    positions
    229-235)
    17 Human CD47 SFVIAILVIQVIAYILAVVGL
    transmembrane
    region 4
    (UniProt:
    Q08722-1
    positions
    236-256)
    18 Human CD47 SLCIAACIPMHG
    extracellular
    region 3
    (UniProt:
    Q08722-1
    positions
    257-268)
    19 Human CD47 PLLISGLSILALAQLLGLVYM
    transmembrane
    region 5
    (UniProt:
    Q08722-1
    positions
    269-289)
    20 Human CD47 KFVASNQKTIQPPRKAVEEPLNAFKESKGMMNDE
    cytoplasmic
    region 3
    (UniProt:
    Q08722-1
    positions
    290-323)
    21 Region of VKWKFKGRDI
    human CD47
    targeted by
    1-1-A1 and
    1-1-A1_BM
    (UniProt:
    Q08722-1
    positions
    56-65)
    22 Region of KTKSVEFTFCN
    human CD47
    targeted by
    5-48-A6 and
    5-48-D2
    (UniProt:
    Q08722-1
    positions
    24-34)
    23 1-1-A1_BM QVQLQQSGPDLKKPGASVKVSCKVSGYTFTNYVIHWVRQKPGQGLEWMGYINPYNDGTKSNEKFKG
    heavy chain KATLTSDKSSTSAYMELSSLTSEDTAVYYCASGGYYTMDYWGQGTSVTVSS
    variable
    region
    24 1-1-A1_BM, GYTFTNYV
    1-1-A1, 11A1H1,
    11A1H2, 11A1H3,
    11A1H4, 11A1H6,
    11A1 H8 heavy
    chain CDR1
    25 1-1-A1_BM, INPYNDGT
    1-1-A1, 11A1H1,
    11A1H2, 11A1H3,
    11A1H4, 11A1H6,
    11A1 H8 heavy
    chain CDR2
    26 1-1-A1_BM, ASGGYYTMDY
    1-1-A1, 11A1H1,
    11A1H2, 11A1H3,
    11A1H4, 11A1H6,
    11A1H8, 11A1H5,
    11A1H7, 11A1H9,
    11A1H10,
    11A1H11 heavy
    chain CDR3
    27 1-1-A1_BM heavy QVQLQQSGPDLKKPGASVKVSCKVS
    chain FR1
    28 1-1-A1_BM heavy IHWVRQKPGQGLEWMGY
    chain FR2
    29 1-1-A1_BM heavy KSNEKFKGKATLTSDKSSTSAYMELSSLTSEDTAVYYC
    chain FR3
    30 1-1-A1_BM heavy WGQGTSVTVSS
    chain FR4
    31 1-1-A1_BM light DVVMTQTPLSLPVTLGDQASISCRSSQHLEYSNGYSYLHWYQQRPGQSPQLLIYKISNRFSGVPDR
    chain variable FSGSGSGTDFTLKISRVEAEDLGVYYCSQSTHVPYTFGGGTKLEIK
    region
    32 1-1-A1_BM, QHLEYSNGYSY
    1-1-A1, 11A1H1,
    11A1H2, 11A1H3,
    11A1H4, 11A1H5,
    11A1H10,
    11A1H11 light
    chain CDR1
    33 1-1-A1_13M, KIS
    1-1-A1, 11A1H1,
    11A1H2, 11A1H3,
    11A1H4, 11A1H5,
    11A1H11 light
    chain CDR2
    34 1-1-A1_BM, SQSTHVPYT
    1-1-A1, 11A1H1,
    11A1H2, 11A1H3,
    11A1H4, 11A1H5
    11A1H6, 11A1H7
    11A1H8, 11A1H9
    11A1H10 light
    chain CDR3
    35 1-1-A1_BM light DVVMTQTPLSLPVTLGDQASISCRSS
    chain FR1
    36 1-1-A1_BM light LHWYQQRPGQSPQLLIY
    chain FR2
    37 1-1-A1_BM light NRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYC
    chain FR3
    38 1-1-A1_BM light FGGGTKLEIK
    chain FR4
    39 1-1-A1 heavy EVQLQQSGPDLVKPGASVKMSCKASGYTFTNYVIHWVKQKPGQGLEWIGYINPYNDGTKSNEKFKG
    chain variable KATLTSDKSSTSAYMELSSLTSEDSAVYYCASGGYYTMDYWGQGTSVTVSS
    region
    40 1-1-A1 heavy EVQLQQSGPDLVKPGASVKMSCKAS
    chain FR1
    41 1-1-A1 heavy IHWVKQKPGQGLEWIGY
    chain FR2
    42 1-1-A1 heavy KSNEKFKGKATLTSDKSSTSAYMELSSLTSEDSAVYYC
    chain FR3
    43 1-1-A1 heavy WGQGTSVTVSS
    chain FR4
    44 1-1-A1 DVVMTQTPLSLPVSLGDQASISCRSSQHLEYSNGYSYLHWYLQKPGQSPQLLIYKISNRFSGVPDR
    light chain FSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPYTFGGGTKLEIK
    variable
    region
    45 1-1-A1 light DVVMTQTPLSLPVSLGDQASISCRSS
    chain FR1
    46 1-1-A1 light LHWYLQKPGQSPQLLIY
    chain FR2
    47 1-1-A1 light NRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFC
    chain FR3
    48 1-1-A1 light FGGGTKLEIK
    chain FR4
    49 5-48-A6 QVQLKESGPGLVAPSQSLSITCTVSGFSLTSYGVHWVRQPPGKGLEWLGVIWAGGSTNYNSALMSR
    heavy chain LSISKDNSKSQVFLKMNSLQTDDTAMYYCARVPTGRIKSYFYAMDYWGQGTSVTVSS
    variable
    region
    50 5-48-A6 heavy GFSLTSYG
    chain CDR1
    51 5-48-A6 heavy IWAGGST
    chain CDR2
    52 5-48-A6 heavy ARVPTGRIKSYFYAMDY
    chain CDR3
    53 5-48-A6 heavy QVQLKESGPGLVAPSQSLSITCTVS
    chain FR1
    54 5-48-A6 heavy VHWVRQPPGKGLEWLGV
    chain FR2
    55 5-48-A6 heavy NYNSALMSRLSISKDNSKSQVFLKMNSLQTDDTAMYYC
    chain FR3
    56 5-48-A6 heavy WGQGTSVTVSS
    chain FR4
    57 5-48-A6 light DIKMTQSPSSMYSSLGERVTITCKASQDISSYLSWFQQKPGKSPKTLIYRANRLVDGVPSRFSGSG
    chain variable SGQDYSLTISSLEYEDMGIYYCLQYDEFPYTFGGGTKLEIK
    region
    58 5-48-A6 light QDISSY
    chain CDR1
    59 5-48-A6 light RAN
    chain CDR2
    60 5-48-A6 light LQYDEFPYT
    chain CDR3
    61 5-48-A6 light DIKMTQSPSSMYSSLGERVTITCKAS
    chain FR1
    62 5-48-A6 light LSWFQQKPGKSPKTLIY
    chain FR2
    63 5-48-A6 light RLVDGVPSRFSGSGSGQDYSLTISSLEYEDMGIYYC
    chain FR3
    64 5-48-A6 light FGGGTKLEIK
    chain FR4
    65 5-48-D2 heavy EVKLLESGGGLVQPGGSLKLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPDSSTINYTPSLKD
    chain variable KFIISRDNAKNTLYLQMSKVRSEDTALYYCATGTGFAYWGQGTLVTVSA
    region
    66 5-48-D2 heavy GFDFSRYW
    chain CDR1
    67 5-48-D2 heavy INPDSSTI
    chain CDR2
    68 5-48-D2 heavy ATGTGFAY
    chain CDR3
    69 5-48-D2 heavy EVKLLESGGGLVQPGGSLKLSCAAS
    chain FR1
    70 5-48-D2 heavy MSWVRQAPGKGLEWIGE
    chain FR2
    71 5-48-D2 heavy NYTPSLKDKFI ISRDNAKNTLYLQMSKVRSEDTALYYC
    chain FR3
    72 5-48-D2 heavy WGQGTLVTVSA
    chain FR4
    73 5-48-D2 light DIQMTQSPASLSASVGETVTITCRASENIYSYLAWYQQKQGKSPQLLVYNAKTLAEGVPSRFSGSG
    chain variable SGTQFSLKINSLQPEDFGSYYCQHHYVTPWTFGGVTKLEIK
    region
    74 5-48-D2 light ENIYSY
    chain CDR1
    75 5-48-D2 light NAK
    chain CDR2
    76 5-48-D2 light QHHYVTPWT
    chain CDR3
    77 5-48-D2 light DIQMTQSPASLSASVGETVTITCRAS
    chain FR1
    78 5-48-D2 light LAWYQQKQGKSPQLLVY
    chain FR2
    79 5-48-D2 light TLAEGVPSRFSGSGSGTQFSLKINSLQPEDFGSYYC
    chain FR3
    80 5-48-D2 light FGGVTKLEIK
    chain FR4
    81 1-1-A1 heavy MEWSWIFLFLLSGTAGVHS
    chain SignalP
    82 1-1-A1 light MKLPVRLLVLMFWIPASSS
    chain SignalP
    83 5-48-A6 heavy MAVLVLFLCLVAFPSCVLS
    chain SignalP
    84 5-48-A6 light MRTPAQFLGILLLWFPGIKC
    chain SignalP
    85 5-48-D2 heavy MDFGLIFFIVALLKGVQC
    chain SignalP
    86 5-48-D2 light MSVPTQVLGLLLLWLTGARC
    chain SignalP
    87 1-1-A1_BM CAGGTGCAGCTGCAGCAGTCTGGACCAGACCTGAAGAAGCCTGGAGCCAGCGTGAAGGTGTCCTGT
    heavy chain AAGGTGTCCGGCTACACCTTCACAAACTATGTGATCCACTGGGTGAGGCAGAAGCCAGGACAGGGC
    DNA CTGGAGTGGATGGGCTACATCAACCCCTATAATGACGGCACCAAGTCTAATGAGAAGTTTAAGGGC
    AAGGCCACCCTGACATCTGATAAGAGCAGCACCAGCGCCTACATGGAGCTGTCTAGCCTGACCAGC
    GAGGACACAGCCGTGTACTATTGCGCTTCCGGCGGCTACTATACAATGGATTATTGGGGCCAGGGC
    ACCAGCGTGACAGTGTCCTCT
    88 1-1-A1_BM GACGTGGTCATGACCCAGACACCACTGTCCCTGCCTGTGACCCTGGGCGATCAGGCCTCTATCAGC
    light chain TGTAGAAGCTCCCAGCACCTGGAGTACAGCAACGGCTACTCCTATCTGCACTGGTATCAGCAGCGC
    DNA CCAGGACAGTCTCCACAGCTGCTGATCTACAAGATCTCTAATCGGTTCAGCGGCGTGCCTGACAGG
    TTTTCCGGCTCTGGCAGCGGCACCGATTTCACACTGAAGATCAGCAGAGTGGAGGCTGAGGACCTG
    GGCGTGTACTATTGCTCCCAGTCTACCCACGTGCCCTATACATTTGGCGGCGGCACCAAGCTGGAG
    ATCAAG
    89 1-1-A1 heavy GAGGTCCAGCTGCAGCAGTCTGGACCTGACCTAGTAAAGCCTGGGGCTTCAGTGAAGATGTCCTGC
    chain DNA AAGGCTTCTGGATACACATTCACTAATTATGTTATACACTGGGTGAAGCAGAAGCCTGGGCAGGGC
    CTTGAGTGGATTGGATATATTAATCCTTACAATGATGGTACTAAGTCCAATGAGAAGTTCAAAGGC
    AAGGCCACACTGACTTCAGACAAATCCTCCACCTCAGCCTACATGGAGCTCAGCAGCCTGACCTCT
    GAGGACTCTGCGGTCTATTACTGTGCAAGCGGAGGGTACTATACTATGGACTATTGGGGTCAAGGA
    ACCTCAGTCACCGTCTCCTCG
    90 1-1-A1 GATGTTGTGATGACCCAAACTCCACTCTCCCTGCCTGTCAGTCTTGGAGATCAAGCCTCCATCTCT
    light chain TGCAGATCTAGTCAACACCTTGAATACAGTAATGGATACTCCTATTTGCATTGGTACCTGCAGAAG
    DNA CCAGGCCAGTCTCCACAGCTCCTGATCTACAAAATTTCCAACCGATTTTCTGGGGTCCCAGACAGG
    TTCAGTGGCAGTGGATCAGGGACAGATTTCACACTCAAGATCAGCAGAGTGGAGGCTGAGGATCTG
    GGGGTTTATTTCTGCTCTCAAAGTACACATGTTCCGTACACATTCGGAGGGGGGACCAAGCTGGAA
    ATAAAA
    91 5-48-A6 CAGGTGCAGCTGAAGGAGTCAGGACCTGGCCTGGTGGCGCCCTCACAGAGCCTGTCCATCACTTGC
    heavy chain ACTGTCTCTGGGTTTTCATTAACCAGTTATGGTGTACACTGGGTTCGCCAGCCTCCAGGAAAGGGT
    DNA CTGGAGTGGCTGGGAGTAATATGGGCTGGTGGAAGCACAAATTATAATTCGGCTCTCATGTCCAGA
    CTGAGCATCAGCAAAGACAACTCCAAGAGCCAAGTTTTCTTAAAAATGAACAGTCTGCAAACTGAT
    GACACAGCCATGTACTACTGTGCCAGAGTTCCGACAGGTCGGATTAAATCTTATTTCTATGCTATG
    GACTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCG
    92 5-48-A6 GACATCAAGATGACCCAGTCTCCATCTTCCATGTATTCATCTCTTGGAGAGAGAGTCACTATCACT
    light chain TGCAAGGCGAGTCAGGACATTAGTAGCTATTTAAGCTGGTTCCAGCAGAAACCAGGGAAGTCTCCT
    DNA AAGACCCTGATCTATCGTGCAAACAGATTGGTGGATGGGGTCCCATCAAGGTTCAGTGGCAGTGGA
    TCTGGGCAAGATTATTCTCTCACCATCAGCAGCCTGGAGTATGAAGATATGGGAATTTATTATTGT
    CTACAGTATGATGAGTTTCCGTACACGTTCGGAGGGGGGACCAAGCTGGAAATAAAA
    93 5-48-D2 GAGGTGAAGCTTCTCGAGTCTGGAGGTGGCCTGGTGCAGCCTGGAGGATCCCTGAAACTCTCCTGT
    heavy chain GCAGCCTCAGGATTCGATTTTAGTAGATACTGGATGAGTTGGGTCCGGCAGGCTCCAGGGAAAGGG
    DNA CTAGAATGGATTGGAGAAATTAATCCAGATAGCAGTACGATAAACTATACGCCATCTCTAAAGGAT
    AAATTCATCATCTCCAGAGACAACGCCAAAAATACGCTGTACCTGCAAATGAGCAAAGTGAGATCT
    GAGGACACAGCCCTTTATTACTGTGCAACTGGGACGGGGTTTGCTTACTGGGGCCAAGGGACTCTG
    GTCACTGTCTCTGCG
    94 5-48-D2 GACATCCAGATGACTCAGTCTCCAGCTTCCCTATCTGCATCTGTGGGAGAAACTGTCACCATCACA
    light chain TGTCGAGCAAGTGAGAATATTTACAGTTATTTAGCATGGTATCAGCAGAAACAGGGAAAATCTCCT
    DNA CAGCTCCTGGTCTATAATGCAAAAACCTTAGCAGAAGGTGTGCCCTCAAGGTTCAGTGGCAGTGGA
    TCAGGCACACAGTTTTCTCTGAAGATCAACAGCCTGCAGCCTGAAGATTTTGGGAGTTATTACTGT
    CAACATCATTATGTTACTCCGTGGACGTTCGGTGGAGTCACCAAGCTGGAAATCAAA
    95 Human SIRPA MEPAGPAPGRLGPLLCLLLAASCAWSGVAGEEELQVIQPDKSVLVAAGETATLRCTATSLIPVGPI
    isoform 1 QWFRGAGPGRELIYNQKEGHFPRVTTVSDLTKRNNMDFSIRIGNITPADAGTYYCVKFRKGSPDDV
    (UniProt: EFKSGAGTELSVRAKPSAPVVSGPAARATPQHTVSFTCESHGFSPRDITLKWFKNGNELSDFQTNV
    P78324-1, DPVGESVSYSIHSTAKVVLTREDVHSQVICEVAHVTLQGDPLRGTANLSETIRVPPTLEVTQQPVR
    v2) AENQVNVTCQVRKFYPQRLQLTWLENGNVSRTETASTVTENKDGTYNWMSWLLVNVSAHRDDVKLT
    CQVEHDGQPAVSKSHDLKVSAHPKEQGSNTAAENTGSNERNIYIVVGVVCTLLVALLMAALYLVRI
    RQKKAQGSTSSTRLHEPEKNAREITQDTNDITYADLNLPKGKKPAPQAAEPNNHTEYASIQTSPQP
    ASEDTLTYADLDMVHLNRTPKQPAPKPEPSFSEYASVQVPRK
    96 Human SIRPA MEPAGPAPGRLGPLLCLLLAASCAWSGVAGEEELQVIQPDKSVLVAAGETATLRCTATSLIPVGPI
    isoform 2 QWFRGAGPGRELIYNQKEGHFPRVTTVSDLTKRNNMDFSIRIGNITPADAGTYYCVKFRKGSPDD
    (UniProt: VEFKSGAGTELSVRAKPSAPVVSGPAARATPQHTVSFTCESHGFSPRDITLKWFKNGNELSDFQT
    P78324-2) NVDPVGESVSYSIHSTAKVVLTREDVHSQVICEVAHVTLQGDPLRGTANLSETIRVPPTLEVTQQP
    VRAENQVNVTCQVRKFYPQRLQLTWLENGNVSRTETASTVTENKDGTYNWMSWLLVNVSAHRD
    DVKLTCQVEHDGQPAVSKSHDLKVSAHPKEQGSNTAAENTGSNERNIYIVVGVVCTLLVALLMAA
    LYLVRIRQKKAQGSTSSTRLHEPEKNAREITQVQSLDTNDITYADLNLPKGKKPAPQAAEPNNHTE
    YASIQTSPQPASEDTLTYADLDMVHLNRTPKQPAPKPEPSFSEYASVQVPRK
    97 Human SIRPA MEPAGPAPGRLGPLLCLLLAASCAWSGVAGEEELQVIQPDKSVLVAAGETATLRCTATSLIPVGPI
    isoform 4 QWFRGAGPGRELIYNQKEGHFPRVTTVSDLTKRNNMDFSIRIGNITPADAGTYYCVKFRKGSPDVE
    (UniProt: FKSGAGTELSVRAKPSAPVVSGPAARATPQHTVSFTCESHGFSPRDITLKWFKNGNELSDFQTNVD
    P78324-4) PVGESVSYSIHSTAKVVLTREDVHSQVICEVAHVTLQGDPLRGTANLSETIRVPPTLEVTQQPVRA
    ENQVNVTCQVRKFYPQRLQLTWLENGNVSRTETASTVTENKDGTYNWMSWLLVNVSAHRDDVKLTC
    QVEHDGQPAVSKSHDLKVSAHPKEQGSNTAAENTGSNERNIYIVVGVVCTLLVALLMAALYLVRIR
    QKKAQGSTSSTRLHEPEKNAREITQDTNDITYADLNLPKGKKPAPQAAEPNNHTEYASIQTSPQPA
    SEDTLTYADLDMVHLNRTPKQPAPKPEPSFSEYASVQVPRK
    98 Mature EEELQVIQPDKSVLVAAGETATLRCTATSLIPVGPIQWFRGAGPGRELIYNQKEGHFPRVTTVSDL
    human SIRPA TKRNNMDFSIRIGNITPADAGTYYCVKFRKGSPDDVEFKSGAGTELSVRAKPSAPVVSGPAARATP
    isoform 1 QHTVSFTCESHGFSPRDITLKWFKNGNELSDFQTNVDPVGESVSYSIHSTAKVVLTREDVHSQVIC
    (UniProt: EVAHVTLQGDPLRGTANLSETIRVPPTLEVTQQPVRAENQVNVTCQVRKFYPQRLQLTWLENGNVS
    P20138-1 RTETASTVTENKDGTYNWMSWLLVNVSAHRDDVKLTCQVEHDGQPAVSKSHDLKVSAHPKEQGSNT
    positions AAENTGSNERNIYIVVGVVCTLLVALLMAALYLVRIRQKKAQGSTSSTRLHEPEKNAREITQDTND
    31-504) ITYADLNLPKGKKPAPQAAEPNNHTEYASIQTSPQPASEDTLTYADLDMVHLNRTPKQPAPKPEPS
    FSEYASVQVPRK
    99 Mature EEELQVIQPDKSVLVAAGETATLRCTATSLIPVGPIQWFRGAGPGRELIYNQKEGHFPRVTTVSDL
    human SIRPA TKRNNMDFSIRIGNITPADAGTYYCVKFRKGSPDDVEFKSGAGTELSVRAKPSAPVVSGPAARATP
    isoform 2 QHTVSFTCESHGFSPRDITLKWFKNGNELSDFQTNVDPVGESVSYSIHSTAKVVLTREDVHSQVIC
    (UniProt: EVAHVTLQGDPLRGTANLSETIRVPPTLEVTQQPVRAENQVNVTCQVRKFYPQRLQLTWLENGNVS
    P78324-2 RTETASTVTENKDGTYNWMSWLLVNVSAHRDDVKLTCQVEHDGQPAVSKSHDLKVSAHPKEQGSNT
    positions AAENTGSNERNIYIVVGVVCTLLVALLMAALYLVRIRQKKAQGSTSSTRLHEPEKNAREITQVQSL
    31-478) DTNDITYADLNLPKGKKPAPQAAEPNNHTEYASIQTSPQPASEDTLTYADLDMVHLNRTPKQPAPK
    PEPSFSEYASVQVPRK
    100 Mature EEELQVIQPDKSVLVAAGETATLRCTATSLIPVGPIQWFRGAGPGRELIYNQKEGHFPRVTTVSDL
    human SIRPA TKRNNMDFSIRIGNITPADAGTYYCVKFRKGSPDVEFKSGAGTELSVRAKPSAPVVSGPAARATPQ
    isoform 4 HTVSFTCESHGFSPRDITLKWFKNGNELSDFQTNVDPVGESVSYSIHSTAKVVLTREDVHSQVICE
    (UniProt: VAHVTLQGDPLRGTANLSETIRVPPTLEVTQQPVRAENQVNVTCQVRKFYPQRLQLTWLENGNVSR
    P78324-4 TETASTVTENKDGTYNWMSWLLVNVSAHRDDVKLTCQVEHDGQPAVSKSHDLKVSAHPKEQGSNTA
    positions AENTGSNERNIYIVVGVVCTLLVALLMAALYLVRIRQKKAQGSTSSTRLHEPEKNAREITQDTNDI
    31-473) TYADLNLPKGKKPAPQAAEPNNHTEYASIQTSPQPASEDTLTYADLDMVHLNRTPKQPAPKPEPSF
    SEYASVQVPRK
    101 Human SIRPA EEELQVIQPDKSVLVAAGETATLRCTATSLIPVGPIQWFRGAGPGRELIYNQKEGHFPRVTTVSDL
    extra TKRNNMDFSIRIGNITPADAGTYYCVKFRKGSPDDVEFKSGAGTELSVRAKPSAPVVSGPAARATP
    cellular QHTVSFTCESHGFSPRDITLKWFKNGNELSDFQTNVDPVGESVSYSIHSTAKVVLTREDVHSQVIC
    domain EVAHVTLQGDPLRGTANLSETIRVPPTLEVTQQPVRAENQVNVTCQVRKFYPQRLQLTWLENGNVS
    (UniProt: RTETASTVTENKDGTYNWMSWLLVNVSAHRDDVKLTCQVEHDGQPAVSKSHDLKVSAHPKEQGSNT
    P78324-1 AAENTGSNERNIY
    positions
    31-373)
    102 Human SIRPA IVVGVVCTLLVALLMAALYLV
    transmembrane
    domain
    (UniProt:
    P78324-1
    positions
    374-394)
    103 Human SIRPA RIRQKKAQGSTSSTRLHEPEKNAREITQDTNDITYADLNLPKGKKPAPQAAEPNNHTEYASIQTSP
    cytoplasmic QPASEDTLTYADLDMVHLNRTPKQPAPKPEPSFSEYASVQVPRK
    domain
    (UniProt:
    P78324-1
    positions
    395-504)
    104 Human SIRPA EELQVIQPDKSVLVAAGETATLRCTATSLIPVGPIQWFRGAGPGRELIYNQKEGHFPRVTTVSDLT
    V-type KRNNMDFSIRIGNITPADAGTYYCVKFRKGSPDDVEFKSG
    Ig-like
    domain
    (UniProt:
    P78324-1
    positions
    32-137)
    105 Human SIRPA PSAPVVSGPAARATPQHTVSFTCESHGFSPRDITLKWFKNGNELSDFQTNVDPVGESVSYSIHSTA
    C1-type KVVLTREDVHSQVICEVAHVTLQGDPLRGTANLS
    Ig-like
    domain 1
    (UniProt:
    P78324-1
    positions
    148-247)
    106 Human SIRPA PTLEVTQQPVRAENQVNVTCQVRKFYPQRLQLTWLENGNVSRTETASTVTENKDGTYNWMSWLLVN
    C1-type VSAHRDDVKLTCQVEHDGQPAVSKSHDLK
    Ig-like
    domain 2
    (UniProt:
    P78324-1
    positions
    254-348)
    107 1-1-A1_BM QVQLQQSGPDLKKPGASVKVSCKVSGYTFTNYVI HWVRQKPGQGLEWMGYINPYNDGTKSNEKFK
    VH-CH1-CH2- GKATLTSDKSSTSAYMELSSLTSEDTAVYYCASGGYYTMDYWGQGTSVTVSSASTKGPSVFPLAPS
    CH3 SKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV
    VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP
    APIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTP
    PVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
    108 1-1-A1_BM DVVMTQTPLSLPVTLGDQASISCRSSQHLEYSNGYSYLHWYQQRPGQSPQLLIYKISNRFSGVPDR
    VL-Cκ FSGSGSGTDFTLKISRVEAEDLGVYYCSQSTHVPYTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKS
    GTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYA
    CEVTHQGLSSPVTKSFNRGEC
    109 1-1-A1 EVQLQQSGPDLVKPGASVKMSCKASGYTFTNYVIHWVKQKPGQGLEWIGYINPYNDGTKSNEKFKG
    VH-CH1-CH2- KATLTSDKSSTSAYMELSSLTSEDSAVYYCASGGYYTMDYWGQGTSVTVSSASTKGPSVFPLAPSS
    CH3 KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY
    ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVV
    DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA
    PIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP
    VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
    110 1-1-A1 DVVMTQTPLSLPVSLGDQASISCRSSQHLEYSNGYSYLHWYLQKPGQSPQLLIYKISNRFSGVPDR
    VL-Cκ FSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPYTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKS
    GTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYA
    CEVTHQGLSSPVTKSFNRGEC
    111 5-48-A6 QVQLKESGPGLVAPSQSLSITCTVSGFSLTSYGVHWVRQPPGKGLEWLGVIWAGGSTNYNSALMSR
    VH-CH1-CH2- LSISKDNSKSQVFLKMNSLQTDDTAMYYCARVPTGRIKSYFYAMDYWGQGTSVTVSSASTKGPSVF
    CH3 PLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS
    LGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPE
    VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS
    NKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN
    YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
    112 5-48-A6 DIKMTQSPSSMYSSLGERVTITCKASQDISSYLSWFQQKPGKSPKTLIYRANRLVDGVPSRFSGSG
    VL-Cκ SGQDYSLTISSLEYEDMGIYYCLQYDEFPYTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASV
    VCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTH
    QGLSSPVTKSFNRGEC
    113 5-48-D2 EVKLLESGGGLVQPGGSLKLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPDSSTINYTPSLKD
    VH-CH1-CH2- KFIISRDNAKNTLYLQMSKVRSEDTALYYCATGTGFAYWGQGTLVTVSAASTKGPSVFPLAPSSKS
    CH3 TSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC
    NVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV
    SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPI
    EKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL
    DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
    114 5-48-D2 DIQMTQSPASLSASVGETVTITCRASENIYSYLAWYQQKQGKSPQLLVYNAKTLAEGVPSRFSGSG
    VL-Cκ SGTQFSLKINSLQPEDFGSYYCQHHYVTPWTFGGVTKLEIKRTVAAPSVFIFPPSDEQLKSGTASV
    VCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTH
    QGLSSPVTKSFNRGEC
    115 anti-CD33 QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYNMHWVRQAPGQGLEWIGYIYPYNGGTGYNQKFKS
    VH-CH1-CH2- KATITADESTNTAYMELSSLRSEDTAVYYCARGRPAMDYWGQGTLVTVSSASTKGPSVFPLAPSSK
    CH3 STSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYI
    CNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD
    VSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP
    IEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV
    LDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
    116 anti-CD33 DIQMTQSPSSLSASVGDRVTITCRASESVDNYGISFMNWFQQKPGKAPKLLIYAASNQGSGVPSRF
    VL-Cκ SGSGSGTDFTLTISSLQPDDFATYYCQQSKEVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSG
    TASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYAC
    EVTHQGLSSPVTKSFNRGEC
    117 Rhesus MWPLVAALLLGSACCGSAQLLFNKTKSVEFTFCNDTVVIPCFVTNMEAQNTTEVYVKWKFKGRDIY
    macaque TFDGALNKSTAPANFSSAKIEVSQLLKGDASLKMDKSDAVSHTGNYTCEVTELTREGETIIELKYR
    CD47 VVSWFSPNENILIVIFPIFAILLFWGQFGIKTLKYRSGGMDEKTIALLVAGLMITVIVIVGAILFV
    (UniProt: PGEYSLKNATGLGLIVTSTGILILLHYYVFSTAIGLTSFVIAILVIQVIAYILAVVGLSLCIAACI
    F7F5Y9-1, PMHGPLLISGLSILALAQLLGLVYMKFVASNQKTIQPPRNDNFRLKNEEKFILN
    v2)
    118 Human IgG1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS
    constant SVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD
    region TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLN
    (IGHG1; GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEW
    UniProt: ESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
    P01857-1,
    v1)
    119 CH1 IgG1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS
    (positions SVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV
    1-98 of
    P01857-1,
    v1)
    120 Hinge IgG1 EPKSCDKTHTCP
    (positions
    99-110 of
    P01857-1,
    v1)
    121 CH2 IgG1 PCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE
    (positions EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK
    111-223 of
    P01857-1,
    v1)
    122 CH3 IgG1 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL
    (positions YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
    224-330 of
    P01857-1,
    v1)
    123 CH3 (D356E, GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL
    L358M; YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
    positions
    numbered
    according
    to EU
    numbering)
    124 Cκ CL (IGCK; RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTY
    UniProt: SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
    P01834-1,
    v2)
    125 J6M0 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYWMHWVRQAPGQGLEWMGATYRGHSDTYYNQKFKG
    VH-CH1-CH2- RVTITADKSTSTAYMELSSLRSEDTAVYYCARGAIYDGYDVLDNWGQGTLVTVSSASTKGPSVFPL
    CH3 APSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLG
    TQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT
    CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNK
    ALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK
    TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
    126 J6M0 VL-Cκ DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKLLIYYTSNLHSGVPSRFSGSG
    SGTDFTLTISSLQPEDFATYYCQQYRKLPWTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASV
    VCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTH
    QGLSSPVTKSFNRGEC
    127 11A1H1 VH QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYVIHWVRQAPGKGLEWMGYINPYNDGTKSNEKFKG
    RVTLTSDKSSTSAYMELSSLRSEDTAVYYCASGGYYTMDYWGQGTLVTVSS
    128 11A1H1, 11A1H2, DVVMTQSPLSLPVTLGQPASISCRSSQHLEYSNGYSYLHWYQQRPGQSPRLLIYKISNRFSGVPDR
    11A1H3, 11A1H4, FSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPYTFGGGTKVEIK
    11A1H5 VL
    129 11A1H2 VH QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYVIHWVRQAPGKGLEWMGYINPYNDGTKSNEKFKG
    RVTLTSDTSTTTAYMELSSLRSEDTAVYYCASGGYYTMDYWGQGTLVTVSS
    130 11A1 H3 VH QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYVMHWVRQAPGQGLEWMGYINPYNDGTKSNEKFQG
    RVTLTSDTSTSTAYMELSSLRSEDTAVYYCASGGYYTMDYWGQGTLV
    131 11A1H4, 11A1H6, QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYVIHWVRQAPGQGLEWMGYINPYNDGTKYNQKFKG
    11A1H8 VH RVTLTSDTSTTTAYMELSRLRSDDTAVYYCASGGYYTMDYWGQGTLV
    132 11A1H5, 11A1H7, QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYVIHWVRQAPGQGLEWMGYINPYNGGTNYAQKFKG
    11A1H9, 11A1H10, RVTLTSDTSTTTAYMELSRLRSEDTAVYYCASGGYYTMDYWGQGTLVTVSS
    11A1H11 VH
    133 11A1H6, 11A1H7 DVVMTQSPLSLPVTLGQPASISCRSSQHLEYSQGYSYLHWYQQRPGQSPRLLIYKVSNRDSGVPDR
    VL FSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPYTFGGGTKVEIK
    134 11A1H8, 11A1H9 DVVMTQSPLSLPVTLGQPASISCRSSQHLEYSTGYSYLHWYQQRPGQSPRLLIYKVSNRDSGVPDR
    VL FSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPYTFGGGTKVEIK
    135 11A1H10 VL DVVMTQSPLSLPVTLGQPASISCRSSQHLEYSNGYSYLHWYQQRPGQSPRLLIYKVSNRDSGVPDR
    FSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPYTFGGGTKVEIK
    136 11A1H11 VL DVVMTQSPLSLPVTLGQPASISCRSSQHLEYSNGYSYLHWYQQRPGQSPRLLIYKISNRFSGVPDR
    FSGSGSGTDFTLKISRVEAEDVGVYYCSQGTHVPYTFGGGTKVEIK
    137 11A1H5, 11A1H7, GYTFTGYV
    11A1H9, 11A1H10,
    11A1H11 HC-CDR1
    138 11A1H5, 11A1H7, INPYNGGT
    11A1H9, 11A1H10,
    11A1H11 HC-CDR2
    139 11A1H6, 11A1H7 QHLEYSQGYSY
    LC-CDR1
    140 11A1 H8, 11A1H9 QHLEYSTGYSY
    LC-CDR1
    141 11A1H6, 11A1H7, KVS
    11A1H8, 11A1H9,
    11A1H10 LC-CDR2
    142 11A1H11 LC-CDR3 SQGTHVPYT
    143 11A1H1, 11A1H2, QVQLVQSGAEVKKPGASVKVSCKAS
    11A1H3, 11A1H4,
    11A1H5, 11A1H6,
    11A1H7, 11A1H8,
    11A1H9, 11A1H10,
    11A1H11 HC-FR1
    144 11A1H1, 11A1H2, IHWVRQAPGKGLEWMGY
    HC-FR2
    145 11A1H3 HC-FR2 MHWVRQAPGQGLEWMGY
    146 11A1H4, 11A1H5, IHWVRQAPGQGLEWMGY
    11A1H6, 11A1H7,
    11A1H8, 11A1H9,
    11A1H10, 11A1H11
    HC-FR2
    147 11A1H1 HC-FR3 KSNEKFKGRVTLTSDKSSTSAYMELSSLRSEDTAVYYC
    148 11A1H2 HC-FR3 KSNEKFKGRVTLTSDTSTTTAYMELSSLRSEDTAVYYC
    149 11A1H3 HC-FR3 KSNEKFQGRVTLTSDTSTSTAYMELSSLRSEDTAVYYC
    150 11A1H4, 11A1H6, KYNQKFKGRVTLTSDTSTTTAYMELSRLRSDDTAVYYC
    11A1H8 HC-FR3
    151 11A1H5, 11A1H7, NYAQKFKGRVTLTSDTSTTTAYMELSRLRSEDTAVYYC
    11A1H9, 11A1H10,
    11A1H11 HC-FR3
    152 11A1H1, 11A1H2, WGQGTLVTVSS
    11A1H5, 11A1H7,
    11A1H9, 11A1H10,
    11A1H11 HC-FR4
    153 11A1H3, 11A1H4, WGQGTLV
    11A1H6, 11A1H8
    HC-FR4
    154 11A1H1, 11A1H2, DVVMTQSPLSLPVTLGQPASISCRSS
    11A1H3, 11A1H4,
    11A1H5, 11A1H6,
    11A1H7, 11A1H8,
    11A1H9, 11A1H10,
    11A1H11 LC-FR1
    155 11A1H1, 11A1H2, LHWYQQRPGQSPRLLIY
    11A1H3, 11A1H4,
    11A1H5, 11A1H6,
    11A1H7, 11A1H8,
    11A1H9, 11A1H10,
    11A1H11 LC-FR2
    156 11A1H1, 11A1H2, NRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYC
    11A1H3, 11A1H4,
    11A1H5, 11A1H11
    LC-FR3
    157 11A1H6, 11A1H7, NRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYC
    11A1H8, 11A1H9,
    11A1H10 LC-FR3
    158 11A1H1, 11A1H2, FGGGTKVEIK
    11A1H3, 11A1H4,
    11A1H5, 11A1H6,
    11A1H7, 11A1H8,
    11A1H9, 11A1H10,
    11A1H11 LC-FR4
    159 11A1H1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYVIHWVRQAPGKGLEWMGYINPYNDGTKSNEKFKG
    VH-CH1-CH2- RVTLTSDKSSTSAYMELSSLRSEDTAVYYCASGGYYTMDYWGQGTLVTVSSASTKGPSVFPLAPSS
    CH3 KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY
    ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVV
    DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA
    PIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP
    VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
    160 11A1H1, 11A1H2, DVVMTQSPLSLPVTLGQPASISCRSSQHLEYSNGYSYLHWYQQRPGQSPRLLIYKISNRFSGVPDR
    11A1H3, 11A1H4, FSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPYTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKS
    11A1H5 VL-CK GTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYA
    CEVTHQGLSSPVTKSFNRGEC
    161 11A1H2 QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYVIHWVRQAPGKGLEWMGYINPYNDGTKSNEKFKG
    VH-CH1-CH2- RVTLTSDTSTTTAYMELSSLRSEDTAVYYCASGGYYTMDYWGQGTLVTVSSASTKGPSVFPLAPSS
    CH3 KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY
    ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVV
    DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA
    PIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP
    VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
    162 11A1H3 QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYVMHWVRQAPGQGLEWMGYINPYNDGTKSNEKFQG
    VH-CH1-CH2- RVTLTSDTSTSTAYMELSSLRSEDTAVYYCASGGYYTMDYWGQGTLVASTKGPSVFPLAPSSKSTS
    CH3 GGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNV
    NHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH
    EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK
    TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS
    DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
    163 11A1H4, 11A1H6, QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYVIHWVRQAPGQGLEWMGYINPYNDGTKYNQKFKG
    11A1H8 VH-CH1- RVTLTSDTSTTTAYMELSRLRSDDTAVYYCASGGYYTMDYWGQGTLVASTKGPSVFPLAPSSKSTS
    CH2-CH3 GGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNV
    NHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH
    EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK
    TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS
    DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
    164 11A1H5, 11A1H7, QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYVIHWVRQAPGQGLEWMGYINPYNGGTNYAQKFKG
    11A1H9, 11A1H10, RVTLTSDTSTTTAYMELSRLRSEDTAVYYCASGGYYTMDYWGQGTLVTVSSASTKGPSVFPLAPSS
    11A1H11 KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY
    VH-CH1-CH2- ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVV
    CH3 DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA
    PIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP
    VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
    165 11A1H6, 11A1H7 DVVMTQSPLSLPVTLGQPASISCRSSQHLEYSQGYSYLHWYQQRPGQSPRLLIYKVSNRDSGVPDR
    VL-CK FSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPYTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKS
    GTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYA
    CEVTHQGLSSPVTKSFNRGEC
    166 11A1H8, 11A1H9 DVVMTQSPLSLPVTLGQPASISCRSSQHLEYSTGYSYLHWYQQRPGQSPRLLIYKVSNRDSGVPDR
    VL-CK FSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPYTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKS
    GTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYA
    CEVTHQGLSSPVTKSFNRGEC
    167 11A1H10 VL-CK DVVMTQSPLSLPVTLGQPASISCRSSQHLEYSNGYSYLHWYQQRPGQSPRLLIYKVSNRDSGVPDR
    FSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPYTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKS
    GTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYA
    CEVTHQGLSSPVTKSFNRGEC
    168 11A1H11 VL-CK DVVMTQSPLSLPVTLGQPASISCRSSQHLEYSNGYSYLHWYQQRPGQSPRLLIYKISNRFSGVPDR
    FSGSGSGTDFTLKISRVEAEDVGVYYCSQGTHVPYTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKS
    GTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYA
    CEVTHQGLSSPVTKSFNRGEC
    169 11A1H_CHC-CDR1 GYTFTX1YV
    X1 = N or G
    170 11A1H_CHC-CDR2 INPYNX2GT
    X2 = D or G
    171 11A1H_CLC-CDR1 QHLEYSX3GYSY
    X3 = N, Q or T
    172 11A1H_CLC-CDR2 KX4S
    X4 = I or V
    173 11A1H_CLC-CDR3 SQX5THVPYT
    X5 = S or G
    174 11A1H_CHC-FR2 X6HWVRQAPGX7GLEWMGY
    X6 = I or M
    X7 = Q or K
    175 11A1H_CHC-FR3 X8X9X10X11KFX12GRVTLTSDX13SX14SX15AYMELSX16LRSX17DTAVYYC
    X8 = K or N
    X9 = S or Y
    X10 = N or A
    X11 = E or Q
    X12 = K or Q
    X13 = T or K
    X14 = T or S
    X15 = T or S
    X16 = S or R
    X17 = E or D
    176 11A1H_CHC-FR4 WGQGTLVX18X19X20X21
    X18 = T or absent
    X19 = V or absent
    X20 = S or absent
    X21 = S or absent
    177 11A1H_CLC-FR3 NRX22SGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYC
    X22 = D or F
    178 11A1H_CVH QVQLVQSGAEVKKPGASVKVSCKASGYTFTX22YVX23HVVVRQAPGX24GLEWMGYINPYNX25G
    TX26X27X28X29KFX30GRVTLTSDX3iSX32SX33AYMELSX34LRSX35DTAVYYCASGGYYT
    MDYWGQGTLVX36X37X38X39
    X22 = N or G
    X23 = I or M
    X24 = Q or K
    X25 = D or G
    X26 = K or N
    X27 = S or Y
    X28 = N or A
    X29 = E or Q
    X30 = K or Q
    X31 = T or K
    X32 = T or S
    X33 = T or S
    X34 = S or R
    X35 = E or D
    X36 = T or absent
    X37 = V or absent
    X38 = S or absent
    X39 = S or absent
    179 11A1H_CVL DVVMTQSPLSLPVTLGQPASISCRSSQHLEYSX40GYSYLHWYQQRPGQSPRLLIYKX41SNRX42
    SGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQX43THVPYTFGGGTKVEIK
    X40 = N, Q or T
    X41 = I or V
    X42 = D or F
    X43 = S or G
  • The invention includes the combination of the aspects and preferred features described except where such a combination is clearly impermissible or expressly avoided.
  • The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
  • Aspects and embodiments of the present invention will now be illustrated, by way of example, with reference to the accompanying figures. Further aspects and embodiments will be apparent to those skilled in the art. All documents mentioned in this text are incorporated herein by reference.
  • Throughout this specification, including the claims which follow, unless the context requires otherwise, the word “comprise,” and variations such as “comprises” and “comprising,” will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.
  • It must be noted that, as used in the specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Ranges may be expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, another embodiment includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by the use of the antecedent “about,” it will be understood that the particular value forms another embodiment.
  • Where a nucleic acid sequence is disclosed herein, the reverse complement thereof is also expressly contemplated.
  • Methods described herein may preferably performed in vitro. The term “in vitro” is intended to encompass procedures performed with cells in culture whereas the term “in vivo” is intended to encompass procedures with/on intact multi-cellular organisms.
    • BRIEF DESCRIPTION OF THE FIGURES
  • Embodiments and experiments illustrating the principles of the invention will now be discussed with reference to the accompanying figures.
  • FIG. 1. Ribbon diagram showing the 3D structure of interacting SIPRPα and CD47 domains, with regions used as immunogens for raising anti-CD47 antibodies overlain with spheres.
  • FIGS. 2A and 2B. Sensorgrams showing affinity of binding of anti-CD47 antibodies to human CD47. (2A) Sensorgram for 1-1-A1. (2B) Sensorgram for 1-1-A1_BM.
  • FIGS. 3A to 3D. Histograms showing staining of CD47-expressing cells by anti-CD47 antibodies as determined by flow cytometry. (3A) Histogram showing staining of HEK293T cells (which express CD47), or HEK293T-derived CD47 knockout cells, by anti-CD47 antibody clone 1-1-A1 or isotype control antibody. (3B) Histogram showing staining of HEK293T cells, or HEK293T-derived CD47 knockout cells, by anti-CD47 antibody clone 1-1-A1_BM or isotype control antibody. (3C) Histogram showing staining of HEK293T cells, or HEK293T-derived CD47 knockout cells, by anti-CD47 antibody clone B6H12 or isotype control antibody. (3D) Histogram showing staining of MM.1S cells, H929 cells, U226 cells, 8226 cells and RAJI cells by anti-CD47 antibody clone B6H12.
  • FIG. 4. Bar chart showing inhibition of interaction between human CD47 and human SIRPα by antigen-binding molecules as determined by ELISA.
  • FIG. 5. Graph showing binding to human CD47 (hCD47) and rhesus macaque CD47 (RhCD47) by the indicated antigen-binding molecules, as determined by ELISA.
  • FIG. 6. Histogram showing phagocytosis of CFSE-labelled Raji cells by macrophages in the presence of the indicated antigen-binding molecules or PBS, as determined by flow cytometry.
  • FIGS. 7A to 7C. Fluorescence microscopy images and bar chart showing phagocytosis of CFSE-labelled HL-60 cells by macrophages in the presence of the indicated antigen-binding molecules. (7A and 7B) Images showing binding phagocytosis in the presence of (7A) isotype control antibody (negative control), (7B) anti-CD47 clone 1-1-A1_BM IgG1, (7C) Bar chart summarising phagocytic indices for CFSE-labelled HL-60 cells by macrophages in the presence of the indicated antigen-binding molecules.
  • FIG. 8. Sensorgram showing affinity of binding of anti-CD47 antibody 1-1-A1_BM to human CD47.
  • FIG. 9. Graph showing binding to human CD47 by the indicated antigen-binding molecules, as determined by ELISA.
  • FIG. 10. Graph showing binding to human VISTA by the indicated antigen-binding molecules, as determined by ELISA.
  • FIGS. 11A to 11H. Sensorgrams showing affinity of binding of anti-CD47 antibodies to human CD47. (11A) Sensorgram for 11A1_BM. (11B) Sensorgram for 11A1H3. (11C) Sensorgram for 11A1H5. (11D) Sensorgram for 11A1H6. (11E) Sensorgram for 11A1H7. (11F) Sensorgram for 11A1H9. (11G) Sensorgram for 11A1H10. (11H) Sensorgram for 11A1H11.
  • FIG. 12. Graph showing inhibition of interaction between human CD47 and SIRPα by the indicated antigen-binding molecules, as determined by ELISA.
  • FIG. 13. Images showing the results of analysis of hemagglutination by the indicated antigen-binding molecules. Positive control=anti-red blood cells antibody (ANTI RBC), negative control=isotype matched antibody specific for an irrelevant target antigen (Irrelevant Ag), and buffer only (BUFFER).
    •  EXAMPLES
  • In the following Examples, the inventors describe the generation of novel CD47-specific antibody clones targeted to specific regions of interest in the CD47 molecule, the biophysical and functional characterisation and the therapeutic evaluation of these antigen-binding molecules.
    • Example 1: CD47 Target Design and Anti-CD47 Antibody Hybridoma Production
  • The inventors selected two regions in the Ig-like V region (SEQ ID NO:9) of the extracellular region 1 of human CD47 (SEQ ID NO:10) for raising CD47-binding monoclonal antibodies. The inventors focused on regions of CD47 known to be involved in the interaction between CD47 and SIRPα (FIG. 1).
  • 1.1 Hybridoma Production
  • Approximately 6 week old female BALB/c mice were obtained from InVivos (Singapore). Animals were housed under specific pathogen-free conditions and were treated in compliance with the Institutional Animal Care and Use Committee (IACUC) guidelines.
  • For hybridoma production, mice were immunized with proprietary mixtures of antigenic peptide for a total of 4 intraperitoneal injections with a 2 week interval between each injection. Antigen for immunizations included one of the following:
      • i) Up to 50 μg of synthetic peptide conjugated with KLH (China Peptides Co. Ltd, China)
      • ii) Up to 50 μg of commercially available recombinant Fc-tagged human CD47 (Sinobiological Inc, China)
      • iii) Up to 20×106 isogenic cells overexpressing human CD47.
  • Prior to harvesting the spleen for fusion, mice were boosted with antigen mixture for three consecutive days. 24 h after the final boost total splenocytes were isolated and fused with the myeloma cell line P3X63.Ag8.653 (ATCC, USA), with PEG using ClonaCell-HY Hybridoma Cloning Kit, in accordance with the manufacturer's instructions (Stemcell Technologies, Canada).
  • Fused cells were cultured in ClonaCell-HY Medium C (Stemcell Technologies, Canada) overnight at 37° C. in a 5% CO2 incubator. The next day, fused cells were centrifuged and resuspended in 10 ml of ClonaCell-HY Medium C and then gently mixed with 90 ml of semisolid methylcellulose-based ClonaCell-HY Medium D (StemCell Technologies, Canada) containing HAT components, which combines the hybridoma selection and cloning into one step.
  • The fused cells were then plated into 96 well plates and allowed to grow at 37° C. in a 5% CO2 incubator. After 7-10 days, single hybridoma clones were isolated and antibody producing hybridomas were selected by screening the supernatants by Enzyme-linked immunosorbent assay (ELISA) and Fluorescence-activated cell sorting (FACs).
  • 1.2 Antibody Variable Region Amplification and Sequencing
  • Total RNA was extracted from hybridoma cells using TRIzol reagent (Life Technologies, Inc., USA) using manufacturer's protocol. Double-stranded cDNA was synthesized using SMARTer RACE 573′ Kit (Clontech™, USA) in accordance with the manufacturer's instructions. Briefly, 1 μg total RNA was used to generate full-length cDNA using 5′-RACE CDS primer (provided in the kit), and the 5′ adaptor (SMARTer II A primer) was then incorporated into each cDNA according to manufacturer's instructions. cDNA synthesis reactions contained: 5× First-Strand Buffer, DTT (20 mM), dNTP Mix (10 mM), RNase Inhibitor (40 U/μl) and SMARTScribe Reverse Transcriptase (100 U/μl).
  • The race-ready cDNAs were amplified using SeqAmp DNA Polymerase (Clontech™, USA). Amplification reactions contained SeqAmp DNA Polymerase, 2×Seq AMP buffer, 5′ universal primer provided in the 5′ SMARTer Race kit, that is complement to the adaptor sequence, and 3′ primers that anneal to respective heavy chain or light chain constant region primer. The 5′ constant region were designed based on previously reported primer mix either by Krebber et al. J. Immunol. Methods 1997; 201: 35-55, Wang et al. Journal of Immunological Methods 2000, 233; 167-177 or Tiller et al. Journal of Immunological Methods 2009; 350:183-193. The following thermal protocol was used: pre-denature cycle at 94° C. for 1 min; 35 cycles of 94° C., 30 s, 55° C., 30 s and 72° C., 45 s; final extension at 72° C. for 3 min.
  • The resulting VH and VL PCR products, approximately 550 bp, were cloned into pJET1.2/blunt vector using CloneJET PCR Cloning Kit (Thermo Scientific, USA) and used to transform highly competent E. coli DH5α. From the resulting transformants, plasmid DNA was prepared using Miniprep Kit (Qiagene, Germany) and sequenced. DNA sequencing was carried out by AlTbiotech. These sequencing data were analyzed using the international IMGT (ImMunoGeneTics) information system (LeFranc et al., Nucleic Acids Res. (2015) 43 (Database issue):D413-22) to characterize the individual CDRs and framework sequences. The signal peptide at 5′ end of the VH and VL was identified by SignalP (v 4.1; Nielsen, in Kihara, D (ed): Protein Function Prediction (Methods in Molecular Biology vol. 1611) 59-73, Springer 2017).
  • Three monoclonal anti-CD47 antibody clones were selected for further development: 1-1-A1, 5-48-A6 and 5-48-D2.
  • A humanised version of antibody clone 1-1-A1 was also prepared according to standard methods by cloning the CDRs of antibody clone 1-1-A1 into VH and VL comprising human antibody framework regions. This antibody clone was designated antibody clone 1-1-A1_BM.
  • Peptide immunogen used
    Antibody clone VH/VL sequence to raise the antibody
    1-1-A1_BM VH = SEQ ID NO: 23 SEQ ID NO: 21
    VL = SEQ ID NO: 31
    1-1-A1 VH = SEQ ID NO: 39
    VL = SEQ ID NO: 44
    5-48-A6 VH = SEQ ID NO: 49 SEQ ID NO: 22
    VL = SEQ ID NO: 57
    5-48-D2 VH = SEQ ID NO: 65
    VL = SEQ ID NO: 73
    • Example 2: Antibody Production and Purification
  • 2.1 Cloning VH and VL into Expression Vectors:
  • DNA sequence encoding the heavy and light chain variable regions of the anti-CD47 antibody clones were subcloned into the pFUSE-CHIg-hG1 and pFUSE2ss-CLIg-hk (InvivoGen, USA) eukaryotic expression vectors for construction of human-mouse chimeric antibodies. Human IgG1 constant region encoded by pFUSE-CHIg-hG1 comprises the substitutions D356E, L358M (positions numbered according to EU numbering) in the CH3 region relative to Human IgG1 constant region (IGHG1; UniProt:P01857-1, v1). pFUSE2ss-CLIg-hk encodes human IgG1 light chain kappa constant region (IGCK; UniProt: P01834-1, v2).
  • Variable regions along with the signal peptides were amplified from the cloning vector using SeqAmp enzyme (Clontech™, USA) following the manufacturer's protocol. Forward and reverse primers having 15-20 bp overlap with the appropriate regions within VH or VL plus 6 bp at 5′ end as restriction sites were used. The DNA insert and the pFuse vector were digested with restriction enzyme recommended by the manufacturer to ensure no frameshift was introduced (e.g., EcoRI and NheI for VH, AgeI and BsiWI for VL,) and ligated into its respective plasmid using T4 ligase enzyme (Thermo Scientific, USA). The molar ratio of 3:1 of DNA insert to vector was used for ligation.
  • 2.2 Expression of Antibodies in Mammalian Cells
  • Antibodies were expressed using either 1) Expi293 Transient Expression System Kit (Life Technologies, USA), or 2) HEK293-6E Transient Expression System (CNRC-NRC, Canada) following the manufacturer's instructions.
  • 1) Expi293 Transient Expression System:
  • Cell Line Maintenance:
  • HEK293F cells (Expi293F) were obtained from Life Technologies, Inc (USA). Cells were cultured in serum-free, protein-free, chemically defined medium (Expi293 Expression Medium, Thermo Fisher, USA), supplemented with 50 IU/ml penicillin and 50 μg/ml streptomycine (Gibco, USA) at 37° C., in 8% CO2 and 80% humidified incubators with shaking platform.
  • Transfection:
  • Expi293F cells were transfected with expression plasmids using ExpiFectamine 293 Reagent kit (Gibco, USA) according to its manufacturer's protocol. Briefly, cells at maintenance were subjected to a media exchange to remove antibiotics by spinning down the culture, cell pellets were re-suspended in fresh media without antibiotics at 1 day before transfection. On the day of transfection, 2.5×106/ml of viable cells were seeded in shaker flasks for each transfection. DNA-ExpiFectamine complexes were formed in serum-reduced medium, Opti-MEM (Gibco, USA), for 25 min at room temperature before being added to the cells. Enhancers were added to the transfected cells at 16-18 h post transfection. An equal amount of media was topped up to the transfectants at day 4 post-transfection to prevent cell aggregation. Transfectants were harvested at day 7 by centrifugation at 4000×g for 15 min, and filtered through 0.22 μm sterile filter units.
  • 2) HEK293-6E Transient Expression System
  • Cell Line Maintenance:
  • HEK293-6E cells were obtained from National Research Council Canada. Cells were cultured in serum-free, protein-free, chemically defined Freestyle F17 Medium (Invitrogen, USA), supplemented with 0.1% Kolliphor-P188 and 4 mM L-Glutamine (Gibco, USA) and 25 μg/ml G-418 at 37° C., in 5% CO2 and 80% humidified incubators with shaking platform.
  • Transfection:
  • HEK293-6E cells were transfected with expression plasmids using PEIpro™ (Polyplus, USA) according to its manufacturer's protocol. Briefly, cells at maintenance were subjected to a media exchange to remove antibiotics by centrifugation, cell pellets were re-suspended with fresh media without antibiotics at 1 day before transfection. On the day of transfection, 1.5-2×106 cells/ml of viable cells were seeded in shaker flasks for each transfection. DNA and PEIpro™ were mixed to a ratio of 1:1 and the complexes were allowed to form in F17 medium for 5 min at RT before adding to the cells. 0.5% (w/v) of Tryptone N1 was fed to transfectants at 24-48 h post transfection. Transfectants were harvested at day 6-7 by centrifugation at 4000×g for 15 min and the supernatant was filtered through 0.22 μm sterile filter units.
  • Cells were transfected with vectors encoding the following combinations of polypeptides:
  • Antigen-
    binding
    molecule Polypeptides Antibody
    [1] 1-1-A1_BM anti-CD47 clone
    VH-CH1-CH2-CH3 1-1-A1_BM IgG1
    (SEQ ID NO: 107) +
    1-1-A1_BM VL-CK
    (SEQ ID NO: 108)
    [2] 1-1-A1 anti-CD47 clone
    VH-CH1-CH2-CH3 1-1-A1 IgG1
    (SEQ ID NO: 109) +
    1-1-A1 VL-CK
    (SEQ ID NO: 110)
    [3] 5-48-A6 anti-CD47 clone
    VH-CH1-CH2-CH3 5-48-A6 IgG1
    (SEQ ID NO: 111) +
    5-48-A6 VL-CK
    (SEQ ID NO: 112)
    [4] 5-48-D2 anti-CD47 clone
    VH-CH1-CH2-CH3 5-48-D2 IgG1
    (SEQ ID NO: 113) +
    5-48-D2 VL-CK
    (SEQ ID NO: 114)
    [5] anti-CD33 anti-CD33 IgG1
    VH-CH1-CH2-CH3
    (SEQ ID NO: 115) +
    anti-CD33 VL-CK
    (SEQ ID NO: 116)
  • 2.3 Antibody Purification
  • Affinity Purification, Buffer Exchange and Storage:
  • Antibodies secreted by the transfected cells into the culture supernatant were purified using liquid chromatography system AKTA Start (GE Healthcare, UK). Specifically, supernatants were loaded onto HiTrap Protein G column (GE Healthcare, UK) at a binding rate of 5 ml/min, followed by washing the column with 10 column volumes of washing buffer (20 mM sodium phosphate, pH 7.0). Bound mAbs were eluted with elution buffer (0.1 M glycine, pH 2.7) and the eluents were fractionated to collection tubes which contain appropriate amount of neutralization buffer (1 M Tris, pH 9). Neutralised elution buffer containing purified mAb were exchanged into PBS using 30K MWCO protein concentrators (Thermo Fisher, USA) or 3.5K MWCO dialysis cassettes (Thermo Fisher, USA). Monoclonal antibodies were sterilized by passing through 0.22 μm filter, aliquoted and snap-frozen in −80° C. for storage.
  • 2.4 Antibody-Purity Analysis
  • Size Exclusion Chromatography (SEC):
  • Antibody purity was analyzed by size exclusion chromatography (SEC) using HiLoad 16/600 Superdex 200 μg column (GE Healthcare, UK) on a AKTA Explorer liquid chromatography system (GE Healthcare, UK). Protein samples are injected to SEC column at concentrations ranging between 0.2-1.5 mg/ml and 1×PBS was pumped to the column at a flow rate of 1 ml/min. Proteins were eluted according to their molecular weights.
  • Sodium-Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE):
  • Antibody purity was also analysed by SDS-PAGE under reducing and non-reducing conditions according to standard methods. Briefly, 4%-20% TGX protein gels (Bio-Rad, USA) were used to resolve proteins using a Mini-Protean Electrophoresis System (Bio-Rad, USA). For non-reducing condition, protein samples were denatured by mixing with 2× Laemmli sample buffer (Bio-Rad, USA) and boiled at 95° C. for 5-10 min before loading to the gel. For reducing conditions, 2× sample buffer containing 5% of β-mercaptoethanol (βME), or 40 mM DTT (dithiothreitol) was used. Electrophoresis was carried out at a constant voltage of 150V for 1 h in SDS running buffer (25 mM Tris, 192 mM glycine, 1% SDS, pH 8.3).
    • Example 3: Biophysical Characterisation
  • 3.1 Global Affinity Study Using BLITz System
  • Bio-Layer Interferometry (BLI) experiments were performed using a single channel BLItz system (ForteBio, Menlo Park, Calif.) using Anti-human immunoglobulin G (IgG) Fc (AHC) coated biosensor tips (Pall ForteBio, Menlo Park, Calif.) for capturing human IgGs. Biosensors were first hydrated for at least 10 m in assay buffer (phosphate buffered saline) followed by buffer baseline for 30 s and loading of the human IgGs onto the biosensor tips at concentrations ranging from 25-50 nM for 120 s. The tips were then washed briefly for 30 s with the assay buffer to remove nonspecifically bound proteins or unbound IgGs for obtaining a second buffer baseline. The association phase of the IgGs with antigens (500 nM-0 nM) was set up at 120 s which was followed by a dissociation phase (assay buffer alone) for 120 s. All the BLITz runs were measured at room temperature at a stirring speed of 1000 rpm and AHC biosensors were regenerated using 10 mM of glycine (pH 2.7) after the assay. Binding affinity between the immobilized antibodies on the AHC sensors and human CD47 were determined by analyzing the binding kinetic curves using the software BLItz Pro. All the sensorgrams were reference subtracted and globally fitted into a 1:1 model which analysed the binding curves at different concentrations of antigens and generated kinetic constants (KD/Ka/Kd) for the globally fitted data. All the binding curves were subjected to step correction which corrects the misalignment between association and dissociation steps and only the curves with R2 values greater than 0.9 were used for analysis.
  • The anti-CD47 antibody clones in IgG1 format were analyzed for binding affinity to human CD47.
  • Representative sensorgrams for the analysis are shown in FIGS. 2A and 2B. Clone 1-1-A1 was found to have a KD of 9 nM, and 1-1-A1_BM was found to have a KD of 16.1 nM.
  • In a separate experiment, the affinity of 1-1-A1_BM ([1] of Example 2.2) for human CD47 was analysed by BLI using an anti-Penta-HIS (HIS1K) Octet sensors. Buffer baseline was obtained for 30 s, and then sensors were loaded with his-tagged human CD47 (1.2 μM) for 120 s. A second buffer baseline was obtained for 60 s, followed by an association phase with 1-1-A1_BM at concentrations ranging from 15.6 M to 500 nM for 120 s, and a dissociation phase in buffer for 120 s.
  • The results are shown in FIG. 8. 1-1-A1_BM was found to bind to human CD47 in this assay with a KD=10.4 nM.
  • 3.2 Analysis of Cell Surface Antigen-Binding by Flow Cytometry
  • HEK293T cells (which express high levels of CD47) and cells of a HEK293T cell-derived CD47 knockout cell line were incubated with 20 μg/ml of anti-CD47 antibody or isotype control antibody at 4° C. for 1 hr. The anti-CD47 antibody clone B6H12 (Santa Cruz Biotechnology, cat no. sc-12730) was included in the analysis as a positive control.
  • The cells were washed thrice with FACS buffer (PBS with 5 mM EDTA and 0.5% BSA) and resuspended in FITC-conjugated anti-FC antibody (Invitrogen, USA) for 40 min at 2-8° C. Cells were washed again and resuspended in 200 μL of FACS flow buffer (PBS with 5 mM EDTA) for flow cytometric analysis using MACSQuant 10 (Miltenyi Biotec, Germany). After acquisition, all raw data were analyzed using Flowlogic software. Cells were gated using forward and side scatter profile and Median of Fluorescence Intensity (MFI) value was determined for native and overexpressing cell populations.
  • The anti-CD47 antibodies were shown to bind to human CD47 with high specificity. FIGS. 3A and 3B show the results obtained using clones 1-1-A1 and 1-1-A1_BM, and FIG. 3C shows results obtained using the commercially-available anti-CD47 antibody clone B6H12 (positive control).
  • Multiple myeloma and Burkitt's lymphoma cell lines were analysed for CD47 expression by flow cytometry using anti-CD47 antibody clone B6H12. Briefly, 0.5×106 cells were fixed by treatment with 4% paraformaldehyde for 10 min at room temperature, and subsequently stained with APC-conjugated anti-CD47 antibody at a 1:11 dilution, for 30 min at 4° C. The results of the analysis are shown in FIG. 3D and in the table below:
  • Cell Line % cells positive for CD47
    MM.1S 99.9
    H929 2.23
    U226 93.3
    8226 99.4
    RAJI 97.9
  • 3.3 ELISAs for Determining Antibody Specificity
  • ELISAs were used to determine the binding specificity of the antibodies. The antibodies were tested against target peptide and protein as well as respective mouse, rat and monkey homologues (Sino Biological Inc., China).
  • ELISAs were carried out according to standard protocols. Briefly, 96-well plates (Nunc, Denmark) were coated with 1 μg/ml of Fc-tagged human CD47 in phosphate-buffered saline (PBS) for 16 h at 4° C. After blocking for 1 h with 1% BSA in Tris buffer saline (TBS) at room temperature, the candidate antigen-binding molecule was serially diluted with the highest conc. being 10 μg/ml and added to the plate. Post 1 h incubation at RT, plates were washed three times with TBS containing 0.05% Tween 20 (TBS-T) and were then incubated with a HRP-conjugated anti-His antibody (Life Technologies, Inc., USA) for 1 h at room temperature. After washing, plates were developed with colorimetric detection substrate 3,3′,5,5′-tetramethylbenzidine (Turbo-TMB; Pierce, USA). The reaction was stopped with 2M H2SO4, and OD was measured at 450 nM.
  • Binding of anti-CD47 clone 1-1-A1_BM IgG1 ([1] of Example 2.2) to rhesus macaque CD47 (RhCD47) was compared to binding to human CD47 (hCD47).
  • The results are shown in FIG. 5.
    • Example 4: Functional Characterisation
  • 4.1 Analysis of Ability to Block CD47-SIRPα Interaction
  • 96-well plates (Nunc, Denmark) were coated with 1 μg/ml of untagged human CD47 protein (Sinobiological Inc, China) in 1×PBS for 16 h at 4° C. After blocking for 1 h with 1% BSA in TBS at room temperature, 1 μg/ml of SIRPα/human His tagged fusion protein (Sinobiological Inc, China) was added either in the absence of antibody, or in the presence of increasing concentrations of anti-CD47 antibody at room temperature for 1 hr. Plates were subsequently washed three times with TBS-T and incubated with an HRP-conjugated anti-his secondary antibody (Thermo Scientific, USA) for 1 h at room temperature. After washing, plates were developed with colorimetric detection substrate Turbo-TMB (Pierce, USA). The reaction was stopped with 2M H2504, and OD was measured at 450 nM.
  • Percent inhibition of CD47-SIRPα interaction calculated relative to the signal in the absence of SIRPα (100%).
  • In a first experiment, inhibition of interaction between CD47 and SIRPα was evaluated for the following antigen-binding molecules:
      • anti-CD47 clone 1-1-A1 IgG1 ([2] of Example 2.2)
      • anti-CD47 clone 5-48-A6 IgG1 ([3] of Example 2.2)
      • anti-CD47 clone 5-48-D2 IgG1 ([4] of Example 2.2)
  • The results are shown in FIG. 4. Several of the anti-CD47 binding antibodies were found to be potent inhibitors of CD47-SIRPα interaction.
  • 4.2 In Vitro Phagocytosis Assay
  • In vitro phagocytosis assays were performed according to standard protocols. Briefly, Raji or HL60 cells were cultured in RPMI-1640 supplemented with 10% fetal bovine serum (FBS) and 1% Pen/Strep at 37° C. in a 5% CO2 incubator. HL-60 or Raji cells were then harvested and CFSE-labelled using CellTrace CFSE Cell Proliferation Kit (Thermo Scientific, USA), in accordance with the manufacturer's protocol. The labelled cells were then incubated with human peripheral blood-derived macrophages (Stemcell Technologies, Canada) in the presence of 20 μg/ml of anti-CD47 antibody, or an isotype control antibody for 2 h at 37° C. Cells were washed thrice with 1×PBS to remove all the non-phagocytosed labelled cells and resuspended in 200 μL of FACS flow buffer (PBS with 5 mM EDTA) for flow cytometric analysis using MACSQuant 10 (Miltenyi Biotec, Germany). After acquisition, all raw data were analyzed using Flowlogic software. Cells were gated using forward and side scatter profile and percentage of the engulfed effector cells were calculated.
  • In a first experiment, antigen-binding molecules were analysed for their ability to promote phagocytosis of CSFE-labelled Raji cells by macrophages, compared to a negative control condition in which PBS was added instead of antibodies.
  • The following antigen-binding molecules were analysed in the experiment:
      • anti-CD47 clone 1-1-A1_BM IgG1 ([1] of Example 2.2)
  • Anti-CD47 antibody clone B6H12 (Santa Cruz Biotechnology, cat no. sc-12730) was included as a positive control condition.
  • The results are shown in FIG. 6. Anti-CD47 clone 1-1-A1_BM IgG1 was found to be extremely potent at promoting phagocytosis of Raji cells by macrophages.
  • In a separate experiment, antigen-binding molecules were analysed for their ability to promote phagocytosis of CSFE-labelled HL-60 cells by macrophages, as determined by fluorescence microscopy. Phagocytic index was calculated as the number of engulfed CFSE-labelled HL-60 cells per phagocyte, for 200 cells using the fluorescence microscope.
  • The anti-CD47 clone 1-1-A1_BM IgG1 ([1] of Example 2.2) was analysed in the experiment, and an isotype control condition was included as a negative control.
  • The results are shown in FIGS. 7A to 7C. Anti-CD47 clone 1-1-A1_BM IgG1 was shown to be potent at inducing phagocytosis of HL-60 cells by macrophages.
    • Example 5: Production of Humanised Versions of Anti-CD47 Clone 1-1-A1
  • Humanised versions of anti-CD47 antibody clone 1-1-A1 were produced and purified as described in Example 2.
  • Antigen-
    binding
    molecule Polypeptides Antibody
     [6] SEQ ID NO: 159 + SEQ ID NO: 160 11A1H1-IgG1 
     [7] SEQ ID NO: 161 + SEQ ID NO: 160 11A1H2-IgG1 
     [8] SEQ ID NO: 162 + SEQ ID NQ: 160 11A1H3-IgG1 
     [9] SEQ ID NO: 163 + SEQ ID NQ: 160 11A1H4-IgG1 
    [10] SEQ ID NO: 164 + SEQ ID NQ: 160 11A1H5-IgG1 
    [11] SEQ ID NO: 163 + SEQ ID NO: 165 11A1H6-IgG1 
    [12] SEQ ID NO: 164 + SEQ ID NO: 165 11A1H7-IgG1 
    [13] SEQ ID NO: 163 + SEQ ID NO: 166 11A1H8-IgG1 
    [14] SEQ ID NO: 164 + SEQ ID NO: 166 11A1H9-IgG1 
    [15] SEQ ID NO: 164 + SEQ ID NO: 167 11A1H10-IgG1
    [16] SEQ ID NO: 164 + SEQ ID NO: 168 11A1H11-IgG1
  • The CDRs of the humanised versions of anti-CD47 antibody clone 1-1-A1 are shown below:
  • Clone HC-CDR1 HC-CDR2 HC-CDR3 LC-CDR1 LC-CDR2 LC-CDR3
    1A11H1 GYTFTNYV INPYNDGT ASGGYYTMDY QHLEYSNGYSY KIS SQSTHVPYT
    (SEQ ID (SEQ ID (SEQ ID (SEQ ID NO: (SEQ ID (SEQ ID
    NO: 24) NO: 25) NO: 26) 32) NO: 33) NO: 34)
    1A11H2
    1A11H3
    1A11H4
    1A11H5 GYTFTGYV INPYNGGT
    (SEQ ID (SEQ ID
    NO: 137) NO: 138)
    1A11H6 GYTFTNYV INPYNDGT QHLEYSQGYSY KVS
    (SEQ ID (SEQ ID (SEQ ID NO: (SEQ ID
    NO: 24) NO: 25) 139) NO: 141)
    1A11H7 GYTFTGYV INPYNGGT
    (SEQ ID (SEQ ID
    NO: 137) NO: 138)
    1A11H8 GYTFTNYV INPYNDGT QHLEYSTGYSY
    (SEQ ID (SEQ ID (SEQ ID NO:
    NO: 24) NO: 25) 140)
    1A11H9 GYTFTGYV INPYNGGT
    (SEQ ID (SEQ ID
    NO: 137) NO: 138)
    1A11H10 QHLEYSNGYSY
    (SEQ ID
    NO: 32)
    1A11H11 KIS SQGTHVPYT
    (SEQ ID (SEQ ID
    NO: 33) NO: 142)
    Consensus GYTFTX1YV INPYNX2GT ASGGYYTMDY QHLEYSX3GYSY KX4S SQX5THVPYT
    X1 = N or X2 = D or (SEQ ID X3 = N, Q X4 = I X5 = S or
    G (SEQ G (SEQ NO: 26) or T (SEQ or V G (SEQ ID
    ID NO: ID NO: ID NO: 171) (SEQ ID NO: 173)
    169) 170) NO: 172)
  • The FRs of the humanised versions of anti-CD47 antibody clone 1-1-A1 are shown below:
  •
    Clone HC-FR1 HC-FR2 HC-FR3 HC-FR4
    1A11H1 QVQLVQSGAEVKK IHWVRQAPGKG KSNEKFKGRVTLTS WGQGTLVTVSS
    PGASVKVSCKAS LEWMGY DKSSTSAYMELSSL (SEQ ID NO:
    (SEQ ID NO: (SEQ ID RSEDTAVYYC 152)
    143) NO: 144) (SEQ ID NO:
    147)
    1A11H2 KSNEKFKGRVTLTS
    DTSTTTAYMELSSL
    RSEDTAVYYC
    (SEQ ID NO:
    148)
    1A11H3 MHWVRQAPGQG KSNEKFQGRVTLTS WGQGTLV
    LEWMGY DTSTSTAYMELSSL (SEQ ID NO:
    (SEQ ID RSEDTAVYYC 153)
    NO: 145) (SEQ ID NO:
    149)
    1A11H4 IHWVRQAPGQG KYNQKFKGRVTLTS
    LEWMGY DTSTTTAYMELSRL
    (SEQ ID RSDDTAVYYC
    NO: 146) (SEQ ID NO:
    150)
    1A11H5 NYAQKFKGRVTLTS WGQGTLVTVSS
    DTSTTTAYMELSRL (SEQ ID NO:
    RSEDTAVYYC 152)
    (SEQ ID NO:
    151)
    1A11H6 KYNQKFKGRVTLTS WGQGTLV
    DTSTTTAYMELSRL (SEQ ID NO:
    RSDDTAVYYC 153)
    (SEQ ID NO:
    150)
    1A11H7 NYAQKFKGRVTLTS WGQGTLVTVSS
    DTSTTTAYMELSRL (SEQ ID NO:
    RSEDTAVYYC 152)
    (SEQ ID NO:
    151)
    1A11H8 KYNQKFKGRVTLTS WGQGTLV 
    DTSTTTAYMELSRL (SEQ ID NO:
    RSDDTAVYYC 153)
    (SEQ ID NO:
    150)
    1A11H9 NYAQKFKGRVTLTS WGQGTLVTVSS
    DTSTTTAYMELSRL (SEQ ID NO:
    RSEDTAVYYC 152)
    (SEQ ID NO:
    151)
    1A11H10
    1A11H11
    Consensus QVQLVQSGAEVKK X6HWVRQAPG X8X9X10X11KFX12 WGQGTLVX18
    PGASVKVSCKAS X7GLEWMGY GRVTLTSDX13SX14 X19X20X21
    (SEQ ID NO: X6 = I or M SX15AYMELSX16LR X18 = T or
    143) X7 = Q or K SX17DTAVYYC absent
    (SEQ ID NO: X8 = K or N X19 = V or
    174) X9 = S or Y absent
    X10 = N or A X20 = S or
    X11 = E or Q absent
    X12 = K or Q X21 = S or
    X13 = T or K absent
    X14 = T or S (SEQ ID NO:
    X15 = T or S 176)
    X16 = S or R
    X17 = E or D
    (SEQ ID NO:
    175)
    Clone LC-FR1 LC-FR2 LC-FR3 LC-FR4
    1A11H1 DVVMTQSPLSLP LHWYQQRPGQS NRFSGVPDRFSGSG
    VTLGQPASISCR PRLLIY (SEQ SGTDFTLKISRVEA
    SS (SEQ ID ID NO: 155) EDVGVYYC (SEQ
    NO: 154) ID NO: 156)
    1A11H2
    1A11H3
    1A11H4
    1A11H5
    1A11H6 NRDSGVPDRFSGSG FGGGTKVEIK
    SGTDFTLKISRVEA (SEQ ID NO:
    EDVGVYYC (SEQ 158)
    ID NO: 157)
    1A11H7
    1A11H8
    1A11H9
    1A11H10
    1A11H11 NRFSGVPDRFSGSG
    SGTDFTLKISRVEA
    EDVGVYYC (SEQ
    ID NO: 156)
    Consensus DVVMTQSPLSLP LHWYQQRPGQS NRX22SGVPDRFSG FGGGTKVEIK
    VTLGQPASISCR PRLLIY SGSGTDFTLKISRV (SEQ ID NO:
    SS (SEQ ID (SEQ ID NO: EAEDVGVYYC 158)
    NO: 154) 155) X22 = D or F
    (SEQ ID NO:
    177)
    • Example 6: Biophysical Characterisation of Humanised Versions of Anti-CD47 Antibody Clone 1-1-A1
  • 6.1 ELISAs for Determining Antibody Specificity
  • The binding specificity of the humanised versions of anti-CD47 clone 1-1-A1 was analysed be ELISA.
  • 96-well plates (Nunc, Denmark) were coated with 1 μg/ml of human CD47 or VISTA protein in PBS, for 1 h at room temperature. Plates were blocked for 1 h at room temperature with 1% BSA in Tris buffer saline containing 0.05% Tween 20 (TBS-T). The test antigen-binding molecules were added at concentrations ranging from to 0.002 μg/ml to 200 μg/ml, and the plates were incubated at room temperature for 1 h. Plates were then washed three times with TBS-T, and were then incubated with a HRP-conjugated secondary antibody for 1 h at room temperature. After washing, plates were developed with colorimetric detection substrate 3,3′,5,5′-tetramethylbenzidine (Turbo-TMB; Pierce, USA). The reaction was stopped after 3.5 min with 2M H2504, and OD was measured at 450 nM.
  • The following antigen-binding molecules were analysed in the experiment:
      • 11A1H3-IgG1 ([8] of Example 5).
      • 11A1H4-IgG1 ([9] of Example 5).
      • 11A1H5-IgG1 ([10] of Example 5).
      • 11A1H6-IgG1 ([11] of Example 5).
      • 11A1H7-IgG1 ([12] of Example 5).
      • 11A1H9-IgG1 ([14] of Example 5).
      • 11A1H10-IgG1 ([15] of Example 5).
      • 11A1H11-IgG1 ([16] of Example 5).
      • anti-CD47 clone 1-1-A1_BM IgG1 ([1] of Example 2.2).
      • anti-CD33 IgG1 ([5] of Example 2.2) (negative control)—referred to as ‘M195’ in FIG. 9.
  • The results are shown in FIG. 9. The humanised antibodies displayed binding to human CD47. EC50 values were calculated, and the fold increase in EC50 value relative to EC50 for 1-1-A1_BM are shown below.
  • Fold increase in EC50 relative
    Antibody EC50 (μg/mL) to 1-1-A1_BM
    11A1H3  0.00022 0.12
    11A1H4  0.00018 0.10
    11A1H5  0.00015 0.08
    11A1H6  13.4 7444
    11A1H7  36.8 20444
    11A1H9  23.5 13056
    11A1H10 38.1 21167
    11A1H11 0.0021 1.17
    11A1BM 0.0018 1.0
  • In a separate ELISA, the antigen-binding molecules were evaluated for binding to human VISTA. Anti-human VISTA antibody VSTB112 (described e.g. in WO 2015/097536) was included as a positive control.
  • The results are shown in FIG. 10. The humanised antibodies were found not to cross-react with human VISTA.
  • 6.2 Global Affinity Study Using BLITz System
  • The affinity of binding of humanised versions of anti-CD47 clone 1-1-A1 to human CD47 was in BLI experiments performed using a single channel BLItz system (ForteBio, Menlo Park, Calif.) using Anti-human immunoglobulin G (IgG) Fc (AHC) coated biosensor tips (Pall ForteBio, Menlo Park, Calif.) for capturing human IgGs. Biosensors were first hydrated for at least 10 m in assay buffer (phosphate buffered saline) followed by buffer baseline for 60 s and loading of the human IgGs onto the biosensor tips at 25 nM for 120 s. The tips were then washed briefly for 60 s with the assay buffer to remove nonspecifically bound proteins or unbound IgGs for obtaining a second buffer baseline. The association phase of the IgGs with antigens (250 nM to 62.5 nM) was set up at 120 s which was followed by a dissociation phase (assay buffer alone) for 120 s. All the BLITz runs were measured at room temperature at a stirring speed of 1000 rpm and AHC biosensors were regenerated using 10 mM of glycine (pH 2.7) after the assay. Binding affinity between the immobilized antibodies on the AHC sensors and human CD47 were determined by analyzing the binding kinetic curves using the software BLItz Pro. All the sensorgrams were reference subtracted and globally fitted into a 1:1 model which analysed the binding curves at different concentrations of antigens and generated kinetic constants (KD/Ka/Kd) for the globally fitted data. All the binding curves were subjected to step correction which corrects the misalignment between association and dissociation steps and only the curves with R2 values greater than 0.9 were used for analysis.
  • Representative sensorgrams are shown in FIGS. 11A to 11H, and the calculated kinetic and thermodynamic constants are shown below.
  • Antibody KD (nM) Kon (M−1s−1) Kdis (s−1)
    11A1BM 9.31 1.30 × 105 1.21 × 10−3
    11A1H3  3.39 2.66 × 105 9.04 × 10−4
    11A1H5  9.28 1.29 × 105 1.20 × 10−3
    11A1H6  134 1.08 × 105 1.44 × 10−2
    11A1H7  232 3.24 × 105 7.50 × 10−3
    11A1H9  23.3 2.73 × 105 6.35 × 10−3
    11A1H10 111 8.09 × 104 8.98 × 10−3
    11A1H11 13.8 1.18 × 105 4.28 × 10−3
    • Example 7: Functional Characterisation of Humanised Versions of Anti-CD47 Antibody Clone 1-1-A1
  • 7.1 Analysis of Ability to Block CD47-SIRPα Interaction
  • The ability of humanised versions of anti-CD47 antibody clone 1-1-A1 to inhibit interaction between human CD47 and SIRPα was investigated by ELISA, as described in Example 4.1.
  • The following antigen-binding molecules were analysed in the experiment:
      • 11A1H4-IgG1 ([9] of Example 5).
      • 11A1H5-IgG1 ([10] of Example 5).
      • 11A1H6-IgG1 ([11] of Example 5).
      • 11A1H7-IgG1 ([12] of Example 5).
      • 11A1H9-IgG1 ([14] of Example 5).
      • 11A1H10-IgG1 ([15] of Example 5).
      • 11A1H11-IgG1 ([16] of Example 5).
      • anti-CD47 clone 1-1-A1_BM IgG1 ([1] of Example 2.2).
      • anti-CD33 IgG1 ([5] of Example 2.2) (negative control)—referred to as ‘M195’ in FIG. 12.
      • J6M0-IgG1 ([17] below) (negative control).
      • Isotype control hlgG (negative control).
  • Antigen-
    binding
    molecule Polypeptides Antibody
    [17] J6M0 VH-CH1-CH2-CH3 J6M0-IgG1
    (SEQ ID NO: 125) +
    J6M0 VL-CK (SEQ ID NO: 126),
  • The results are shown in FIG. 12. IC50 values were calculated, and the fold increase in IC50 value for the inhibition of interaction between CD47 and SIRPα relative to IC50 for 1-1-A1_BM are shown below.
  • Fold increase in IC50 relative
    Antibody IC50 (μg/mL) to 1-1-A1_BM
    11A1H4  0.150 0.32
    11A1H5  0.201 0.42
    11A1H6  >100 >200
    11A1H7  >100 >200
    11A1H9  >100 >200
    11A1H10 >100 >200
    11A1H11 0.483 1.02
    11A1BM 0.474 1.00
  • 7.2 In Vitro Hemagglutination Assay
  • The hemagglutinating capacity of the humanised versions of anti-CD47 antibody clone 1-1-A1 was investigated using an in vitro hemagglutination assay.
  • To evaluate the hemagglutinating capacity of the test antigen-binding molecules, human RBCs were prepared by extensively washing blood with 1×PBS and centrifuging at 1500 rpm for 5 min, until a clear supernatant was observed. For the assay, 1% human RBCs were incubated for 1 hr at RT in presence or absence of increasing concentrations of the test antigen-binding molecules in a round bottom 96 well plate. Presence of hemagglutination was accessed by the presence of non-settled RBCs, appearing as a haze compared to a punctuated red dot of non-hemagglutinated RBCs.
  • An anti-red blood cells antibody (AbCam, cat. no. ab34858) condition was included as a positive control for hemagglutination, and an isotype control antibody condition was included as a negative control.
  • The following antigen-binding molecules were analysed in the experiment:
      • 11A1H1-IgG1 ([6] of Example 5).
      • 11A1H2-IgG1 ([7] of Example 5).
      • 11A1H3-IgG1 ([7] of Example 5).
      • 11A1H4-IgG1 ([8] of Example 5).
      • 11A1H5-IgG1 ([10] of Example 5).
      • 11A1H6-IgG1 ([11] of Example 5).
      • 11A1H7-IgG1 ([12] of Example 5).
      • 11A1H9-IgG1 ([14] of Example 5).
      • 11A1H10-IgG1 ([15] of Example 5).
      • 11A1H11-IgG1 ([16] of Example 5).
      • anti-CD47 clone 1-1-A1_BM IgG1 ([1] of Example 2.2).
      • anti-CD33 IgG1 ([5] of Example 2.2) (negative control)—referred to as ‘M195’ in FIG. 13.
      • J6M0-IgG1 ([17] of Example 7.1) (negative control)—referred to as ‘Irrelevant Ag’ in FIG. 13.
      • An anti-red blood cells antibody (AbCam, cat. no. ab34858)— referred to as ‘ANTI RBC’ in FIG. 13.
  • The results are shown in FIG. 13.

Claims (20)

1.-39. (canceled)
40. An antigen-binding molecule which binds to CD47, comprising:
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:169
HC-CDR2 having the amino acid sequence of SEQ ID NO:170
HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:171
LC-CDR2 having the amino acid sequence of SEQ ID NO:172
LC-CDR3 having the amino acid sequence of SEQ ID NO:173.
41. The antigen-binding molecule according to claim 40, wherein the antigen-binding molecule comprises:
(a)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:137
HC-CDR2 having the amino acid sequence of SEQ ID NO:138
HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:32
LC-CDR2 having the amino acid sequence of SEQ ID NO:33
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
or
(b)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:24
HC-CDR2 having the amino acid sequence of SEQ ID NO:25
HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:32
LC-CDR2 having the amino acid sequence of SEQ ID NO:33
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
or
(c)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:24
HC-CDR2 having the amino acid sequence of SEQ ID NO:25
HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:139
LC-CDR2 having the amino acid sequence of SEQ ID NO:141
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
or
(d)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:137
HC-CDR2 having the amino acid sequence of SEQ ID NO:138
HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:139
LC-CDR2 having the amino acid sequence of SEQ ID NO:141
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
or
(e)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:24
HC-CDR2 having the amino acid sequence of SEQ ID NO:25
HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:140
LC-CDR2 having the amino acid sequence of SEQ ID NO:141
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
or
(f)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:137
HC-CDR2 having the amino acid sequence of SEQ ID NO:138
HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:140
LC-CDR2 having the amino acid sequence of SEQ ID NO:141
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
or
(g)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:137
HC-CDR2 having the amino acid sequence of SEQ ID NO:138
HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:32
LC-CDR2 having the amino acid sequence of SEQ ID NO:141
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
or
(h)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:137
HC-CDR2 having the amino acid sequence of SEQ ID NO:138
HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:32
LC-CDR2 having the amino acid sequence of SEQ ID NO:33
LC-CDR3 having the amino acid sequence of SEQ ID NO:142.
42. The antigen-binding molecule according to claim 40, wherein the antigen-binding molecule comprises:
a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:132, 23, 39, 178, 127, 129, 130 or 131; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:128, 31, 44, 179, 133, 134, 135 or 136.
43. The antigen-binding molecule according to claim 40, wherein the antigen-binding molecule comprises:
(i) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:132; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:128;
or
(ii) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:23; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:31;
or
(iii) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:39; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:44;
or
(iv) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:178; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:179;
or
(v) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:127; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:128;
or
(vi) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:129; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:128;
or
(vii) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:130; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:128;
or
(viii) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:131; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:128;
or
(ix) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:131; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:133;
or
(x) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:132; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:133;
or
(xi) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:131; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:134;
or
(xii) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:132; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:134;
or
(xiii) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:132; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:135;
or
(xiv) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:132; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:136.
44. The antigen-binding molecule according to claim 40, wherein the antigen-binding molecule inhibits interaction between CD47 and SIRPα.
45. The antigen-binding molecule according to claim 40, wherein the antigen-binding molecule is a multispecific antigen-binding molecule, and further comprises an antigen-binding domain specific for a target antigen other than CD47.
46. A nucleic acid, or a plurality of nucleic acids, encoding an antigen-binding molecule which binds to CD47, comprising:
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:169
HC-CDR2 having the amino acid sequence of SEQ ID NO:170
HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:171
LC-CDR2 having the amino acid sequence of SEQ ID NO:172
LC-CDR3 having the amino acid sequence of SEQ ID NO:173.
47. The nucleic acid or plurality of nucleic acids according to claim 46, wherein the antigen-binding molecule comprises:
(a)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:137
HC-CDR2 having the amino acid sequence of SEQ ID NO:138
HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:32
LC-CDR2 having the amino acid sequence of SEQ ID NO:33
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
or
(b)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:24
HC-CDR2 having the amino acid sequence of SEQ ID NO:25
HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:32
LC-CDR2 having the amino acid sequence of SEQ ID NO:33
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
or
(c)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:24
HC-CDR2 having the amino acid sequence of SEQ ID NO:25
HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:139
LC-CDR2 having the amino acid sequence of SEQ ID NO:141
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
or
(d)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:137
HC-CDR2 having the amino acid sequence of SEQ ID NO:138
HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:139
LC-CDR2 having the amino acid sequence of SEQ ID NO:141
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
or
(e)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:24
HC-CDR2 having the amino acid sequence of SEQ ID NO:25
HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:140
LC-CDR2 having the amino acid sequence of SEQ ID NO:141
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
or
(f)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:137
HC-CDR2 having the amino acid sequence of SEQ ID NO:138
HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:140
LC-CDR2 having the amino acid sequence of SEQ ID NO:141
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
or
(g)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:137
HC-CDR2 having the amino acid sequence of SEQ ID NO:138
HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:32
LC-CDR2 having the amino acid sequence of SEQ ID NO:141
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
or
(h)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:137
HC-CDR2 having the amino acid sequence of SEQ ID NO:138
HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:32
LC-CDR2 having the amino acid sequence of SEQ ID NO:33
LC-CDR3 having the amino acid sequence of SEQ ID NO:142.
48. The nucleic acid or plurality of nucleic acids according to claim 46, wherein the antigen-binding molecule comprises:
a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:132, 23, 39, 178, 127, 129, 130 or 131; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:128, 31, 44, 179, 133, 134, 135 or 136
49. The nucleic acid or plurality of nucleic acids according to claim 46, wherein the antigen-binding molecule comprises:
(i) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:132; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:128;
or
(ii) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:23; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:31;
or
(iii) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:39; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:44;
or
(iv) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:178; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:179;
or
(v) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:127; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:128;
or
(vi) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:129; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:128;
or
(vii) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:130; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:128;
or
(viii) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:131; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:128;
or
(ix) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:131; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:133;
or
(x) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:132; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:133;
or
(xi) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:131; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:134;
or
(xii) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:132; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:134;
or
(xiii) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:132; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:135;
or
(xiv) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:132; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:136.
50. The nucleic acid or plurality of nucleic acids according to claim 46, wherein the antigen-binding molecule inhibits interaction between CD47 and SIRPα.
51. The nucleic acid or plurality of nucleic acids according to claim 46, wherein the antigen-binding molecule is a multispecific antigen-binding molecule, and further comprises an antigen-binding domain specific for a target antigen other than CD47.
52. A method of treating or preventing a cancer, comprising administering to a subject a therapeutically or prophylactically effective amount of an antigen-binding molecule which binds to CD47, comprising:
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:169
HC-CDR2 having the amino acid sequence of SEQ ID NO:170
HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:171
LC-CDR2 having the amino acid sequence of SEQ ID NO:172
LC-CDR3 having the amino acid sequence of SEQ ID NO:173.
53. The method according to claim 52, wherein the antigen-binding molecule comprises:
(a)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:137
HC-CDR2 having the amino acid sequence of SEQ ID NO:138
HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:32
LC-CDR2 having the amino acid sequence of SEQ ID NO:33
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
or
(b)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:24
HC-CDR2 having the amino acid sequence of SEQ ID NO:25
HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:32
LC-CDR2 having the amino acid sequence of SEQ ID NO:33
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
or
(c)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:24
HC-CDR2 having the amino acid sequence of SEQ ID NO:25
HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:139
LC-CDR2 having the amino acid sequence of SEQ ID NO:141
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
or
(d)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:137
HC-CDR2 having the amino acid sequence of SEQ ID NO:138
HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:139
LC-CDR2 having the amino acid sequence of SEQ ID NO:141
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
or
(e)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:24
HC-CDR2 having the amino acid sequence of SEQ ID NO:25
HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:140
LC-CDR2 having the amino acid sequence of SEQ ID NO:141
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
or
(f)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:137
HC-CDR2 having the amino acid sequence of SEQ ID NO:138
HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:140
LC-CDR2 having the amino acid sequence of SEQ ID NO:141
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
or
(g)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:137
HC-CDR2 having the amino acid sequence of SEQ ID NO:138
HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:32
LC-CDR2 having the amino acid sequence of SEQ ID NO:141
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
or
(h)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:137
HC-CDR2 having the amino acid sequence of SEQ ID NO:138
HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:32
LC-CDR2 having the amino acid sequence of SEQ ID NO:33
LC-CDR3 having the amino acid sequence of SEQ ID NO:142.
54. The method according to claim 52, wherein the antigen-binding molecule comprises:
a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:132, 23, 39, 178, 127, 129, 130 or 131; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:128, 31, 44, 179, 133, 134, 135 or 136.
55. The method according to claim 52, wherein the antigen-binding molecule comprises:
(i) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:132; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:128;
or
(ii) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:23; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:31;
or
(iii) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:39; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:44;
or
(iv) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:178; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:179;
or
(v) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:127; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:128;
or
(vi) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:129; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:128;
or
(vii) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:130; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:128;
or
(viii) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:131; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:128;
or
(ix) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:131; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:133;
or
(x) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:132; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:133;
or
(xi) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:131; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:134;
or
(xii) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:132; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:134;
or
(xiii) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:132; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:135;
or
(xiv) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:132; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:136.
56. The method according to claim 52, wherein the antigen-binding molecule inhibits interaction between CD47 and SIRPα.
57. The method according to claim 52, wherein the antigen-binding molecule is a multispecific antigen-binding molecule, and further comprises an antigen-binding domain specific for a target antigen other than CD47.
58. The method according to claim 52, wherein the cancer is selected from: a hematologic malignancy, a myeloid hematologic malignancy, a lymphoblastic hematologic malignancy, myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma (NHL), multiple myeloma (MM), bladder cancer, brain cancer, glioblastoma, ovarian cancer, breast cancer, colon cancer, liver cancer, hepatocellular carcinoma, prostate cancer, lung cancer, Non-small Cell Lung Cancer (NSCLC), skin cancer and melanoma.
US16/760,899 2017-11-01 2018-11-01 Cd47 antigen-binding molecules Pending US20220298254A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1718101.7A GB201718101D0 (en) 2017-11-01 2017-11-01 CD47 and CD33 Antigen-binding molecules
GB1718101.7 2017-11-01
GBGB1720425.6A GB201720425D0 (en) 2017-12-07 2017-12-07 CD47 and CD33 antigen-binding molecules
GBGB1720426.4A GB201720426D0 (en) 2017-12-07 2017-12-07 CD47 and BCMA antigen-binding molecules
GB1720426.4 2017-12-07
GB1720425.6 2017-12-07
PCT/EP2018/079931 WO2019086573A1 (en) 2017-11-01 2018-11-01 Cd47 antigen-binding molecules

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2018/079931 A-371-Of-International WO2019086573A1 (en) 2017-11-01 2018-11-01 Cd47 antigen-binding molecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/847,020 Continuation US11685789B2 (en) 2017-11-01 2022-06-22 CD47 antigen-binding molecules

Publications (1)

Publication Number Publication Date
US20220298254A1 true US20220298254A1 (en) 2022-09-22

Family

ID=64316482

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/760,899 Pending US20220298254A1 (en) 2017-11-01 2018-11-01 Cd47 antigen-binding molecules
US17/847,020 Active US11685789B2 (en) 2017-11-01 2022-06-22 CD47 antigen-binding molecules

Family Applications After (1)

Application Number Title Priority Date Filing Date
US17/847,020 Active US11685789B2 (en) 2017-11-01 2022-06-22 CD47 antigen-binding molecules

Country Status (9)

Country Link
US (2) US20220298254A1 (en)
EP (1) EP3704157A1 (en)
JP (1) JP2021500926A (en)
KR (1) KR20200079511A (en)
CN (1) CN111417653A (en)
AU (1) AU2018358004A1 (en)
CA (1) CA3080860A1 (en)
SG (1) SG11202003943YA (en)
WO (1) WO2019086573A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11685789B2 (en) 2017-11-01 2023-06-27 Hummingbird Bioscience Pte. Ltd. CD47 antigen-binding molecules

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114761041A (en) 2019-07-16 2022-07-15 吉利德科学公司 HIV vaccines and methods of making and using the same
WO2021032174A1 (en) * 2019-08-21 2021-02-25 和铂医药(上海)有限责任公司 Anti-cd47 antigen binding protein, and application thereof
KR20220085796A (en) 2019-10-18 2022-06-22 포티 세븐, 인코포레이티드 Combination Therapy to Treat Myelodysplastic Syndrome and Acute Myelogenous Leukemia
CA3153636A1 (en) 2019-10-31 2021-05-06 Forty Seven, Inc. Anti-cd47 and anti-cd20 based treatment of blood cancer
PE20230376A1 (en) 2019-12-24 2023-03-06 Carna Biosciences Inc DIACYL GLYCEROL KINASE MODULATING COMPOUNDS
IL295023A (en) 2020-02-14 2022-09-01 Jounce Therapeutics Inc Antibodies and fusion proteins that bind to ccr8 and uses thereof
KR102557016B1 (en) * 2020-09-22 2023-07-20 비피진 주식회사 CD47 binder and liposome complex for treatment cancer
TW202233677A (en) 2020-11-02 2022-09-01 新加坡商蜂鳥生物科技私人有限公司 Bcma/taci antigen-binding molecules
EP4304633A1 (en) 2021-03-12 2024-01-17 Mendus B.V. Methods of vaccination and use of cd47 blockade
TW202302145A (en) 2021-04-14 2023-01-16 美商基利科學股份有限公司 Co-inhibition of cd47/sirpα binding and nedd8-activating enzyme e1 regulatory subunit for the treatment of cancer
US20230046340A1 (en) 2021-06-23 2023-02-16 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
CA3222595A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022299051A1 (en) 2021-06-23 2023-12-07 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2023051674A1 (en) * 2021-09-30 2023-04-06 正大天晴药业集团南京顺欣制药有限公司 Anti-cd47 antibody for combined treatment of blood tumor
US20230183216A1 (en) 2021-10-28 2023-06-15 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
WO2023077030A1 (en) 2021-10-29 2023-05-04 Gilead Sciences, Inc. Cd73 compounds
WO2023122581A2 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US20230242508A1 (en) 2021-12-22 2023-08-03 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (en) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Parp7 inhibitors
US20230373950A1 (en) 2022-03-17 2023-11-23 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US20230355796A1 (en) 2022-03-24 2023-11-09 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TW202345901A (en) 2022-04-05 2023-12-01 美商基利科學股份有限公司 Combination therapy for treating colorectal cancer
WO2023205719A1 (en) 2022-04-21 2023-10-26 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
WO2024015741A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
CN116004636B (en) * 2023-01-10 2024-03-12 广西师范大学 Differential CD47 aptamer not binding red blood cells and application thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2477648T1 (en) 2009-09-15 2022-09-30 The Board Of Trustees Of The Leland Stanford Junior University Synergistic anti-cd47 therapy for hematologic cancers
CN106279418A (en) 2011-05-27 2017-01-04 葛兰素集团有限公司 BCMA(CD269/TNFRSF17) associated proteins
MY169341A (en) 2012-02-06 2019-03-21 Inhibrx Inc Cd47 antibodies and methods of use thereof
CN110183534A (en) 2012-12-03 2019-08-30 诺夫免疫股份有限公司 Anti-cd 47 antibody and its application method
EP2931751B1 (en) 2012-12-12 2020-02-05 Arch Oncology, Inc. Therapeutic cd47 antibodies
WO2014121093A1 (en) 2013-01-31 2014-08-07 Thomas Jefferson University Fusion proteins that facilitate cancer cell destruction
AU2015221933B2 (en) 2014-02-27 2019-09-12 Autolus Limited APRIL variants
CN104804093A (en) 2015-05-27 2015-07-29 江苏春申堂药业有限公司 Single-domain antibody for CD47
UA126146C2 (en) * 2015-09-18 2022-08-25 Арч Онколоджі, Інк. Therapeutic cd47 antibodies
EP3165536A1 (en) * 2015-11-09 2017-05-10 Ludwig-Maximilians-Universität München Trispecific molecule combining specific tumor targeting and local immune checkpoint inhibition
KR102472087B1 (en) * 2016-01-11 2022-11-29 포티 세븐, 인코포레이티드 Humanized, mouse or chimeric anti-CD47 monoclonal antibody
WO2017196793A1 (en) 2016-05-09 2017-11-16 Celgene Corporation Cd47 antibodies and methods of use thereof
CN105950561A (en) 2016-05-26 2016-09-21 江苏杰晟生物科技有限公司 Products and preparation method of double chimeric antigen receptor gene modified T lymphocyte targeting breast cancer stem cells
KR102136742B1 (en) * 2016-10-20 2020-07-23 아이-맵 바이오파마 유에스 리미티드 New CD47 monoclonal antibodies and uses
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2019086573A1 (en) 2017-11-01 2019-05-09 Hummingbird Bioscience Holdings Pte. Ltd. Cd47 antigen-binding molecules

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Almagro JC, Fransson J. Humanization of antibodies. Front Biosci. 2008 Jan 1;13:1619-33. (Year: 2008) *
Chen et al. Enhancement and destruction of antibody function by somatic mutation: unequal occurrence is controlled by V gene combinatorial associations.EMBO J.1995 Jun 15; 14(12): 2784-94. (Year: 1995) *
Koenig et al. Mutational landscape of antibody variable domains reveals a switch modulating the interdomain conformational dynamics and antigen binding.PNAS January 24, 2017 114(4)E486-E495;f irstpublished January 5, 2017. (Year: 2017) *
Kussie et al. A single engineered amino acid substitution changes antibody fine specificity.J Immunol.1994 Jan 1;152(1):146-52. (Year: 1994) *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11685789B2 (en) 2017-11-01 2023-06-27 Hummingbird Bioscience Pte. Ltd. CD47 antigen-binding molecules

Also Published As

Publication number Publication date
JP2021500926A (en) 2021-01-14
EP3704157A1 (en) 2020-09-09
SG11202003943YA (en) 2020-05-28
KR20200079511A (en) 2020-07-03
WO2019086573A1 (en) 2019-05-09
AU2018358004A1 (en) 2020-05-28
CN111417653A (en) 2020-07-14
US11685789B2 (en) 2023-06-27
US20220356250A1 (en) 2022-11-10
CA3080860A1 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
US11685789B2 (en) CD47 antigen-binding molecules
US11208498B2 (en) Treatment and prevention of cancer using HER3 antigen-binding molecules
EP3645570B1 (en) Vista antigen-binding molecules
US11873346B2 (en) VISTA antigen-binding molecules
US11780933B2 (en) HER3 antigen-binding molecules
WO2019086574A1 (en) Cd47 and cd33 antigen-binding molecules
WO2019185163A1 (en) Vista antigen-binding molecules
WO2019110209A1 (en) Cd47 and bcma/taci antigen-binding molecules
US20230374147A1 (en) Bcma/taci antigen-binding molecules

Legal Events

Date Code Title Description
AS Assignment

Owner name: HUMMINGBIRD BIOSCIENCE HOLDINGS PTE. LTD., SINGAPORE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BOYD-KIRKUP, JEROME;BRAUER, PETER;INGRAM, PIERS;AND OTHERS;SIGNING DATES FROM 20200114 TO 20200120;REEL/FRAME:056501/0964

AS Assignment

Owner name: HUMMINGBIRD BIOSCIENCE HOLDINGS LIMITED, SINGAPORE

Free format text: CHANGE OF NAME;ASSIGNOR:HUMMINGBIRD BIOSCIENCE HOLDINGS PTE. LTD.;REEL/FRAME:056832/0875

Effective date: 20210514

AS Assignment

Owner name: HUMMINGBIRD BIOSCIENCE PTE. LTD., SINGAPORE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HUMMINGBIRD BIOSCIENCE HOLDINGS LIMITED;REEL/FRAME:059519/0410

Effective date: 20220101

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION